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Abstract 
Background 
Medicines optimisation is a key role for hospital pharmacists, but with ever-increasing 
demands on services, there is a need to increase efficiency while maintaining patient 
safety. The aim of this study was to use prognostic modelling to develop a prediction 
tool, the Medicines Optimisation Assessment Tool (MOATTM), to target patients most in 
need of pharmacists’ input while in hospital.   
Methods and analysis 
Patients from adult medical wards at two UK hospitals were prospectively included into 
this cohort study between April and November 2016. Data on medication related 
problems (MRPs) were collected by pharmacists at the study sites as part of their 
routine daily clinical assessment of patients. Data on potential risk factors, such as 
polypharmacy and use of ‘high-risk’ medicines, were collected retrospectively from the 
information departments at the study sites, laboratory reporting systems and patient 
medical records. Multivariable logistic regression was used to determine the 
relationship between potential risk factors and the study outcome, namely preventable 
MRPs that were at least moderate in severity. A simplified electronic scoring system 
(the MOAT) was then developed. 
Results 
Among 1,503 eligible patient admissions, 610 (40.6%) experienced the study outcome. 
Eighteen risk factors were pre-selected for MOAT development, with 11 variables 
retained in the final model. The MOAT demonstrated fair predictive performance 
(concordance index 0.66), and good calibration. The decision threshold between ‘low’ 
and ‘medium-risk’ patients has a sensitivity of 90% (specificity 30%). The sensitivity for 
the threshold between ‘medium’ and ‘high-risk’ patients is 66% (specificity 61%). 
Decision curve analysis suggests that the MOAT has potential to be clinically useful 
across a wide range of predicted risk probabilities (from approximately 15% to 70%).  
Conclusions 
The MOAT has potential to predict those patients most at risk of moderate or severe 
preventable MRPs. External validation will be required to establish predictive accuracy 
in a new group of patients. 
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Impact statement  
The work presented in this thesis has the potential to be put to beneficial use both 
outside and inside academia. Each of these is discussed below, together with 
proposed timescales and methods for impact realisation. 
Impact on clinical practice 
In terms of potential impact of this research outside academia, the main output is the 
Medicines Optimisation Assessment Tool (MOATTM) itself, which was developed with 
the aim of increasing the efficiency of hospital pharmacy services, reducing risks and 
improving patient outcomes. Once fully validated, the MOAT has the potential to impact 
on professional practice and patient safety.  
The intention was for the MOAT to be adopted widely into clinical practice, therefore if 
generalisability and clinical effectiveness are demonstrated, the MOAT has the 
potential to be used across the UK, and potentially more widely; I have already 
received an expression of interest from a pharmacist in Australia regarding external 
validation of the MOAT within her clinical setting.  
Impact within this research area 
This study has also created knowledge that may inform future research in this field. 
This includes: 
 consensus views on potential risk factors associated with medication related 
problems (MRPs) in hospitalised patients; 
 data on MRP occurrence in adult medical patients in UK hospitals. More 
specifically, the prevalence of MRPs and moderate or severe preventable MRPs, 
and their breakdown by MRP sub-categories;  
 quantification of the potential variability in MRP identification by hospital 
pharmacists; 
 the views of practising pharmacy clinicians on the requirements of a predictive tool, 
including presentation and usability. 
My academic supervisors at UCL have offered a place to a prospective PhD candidate 
to progress work in this area; if accepted, I have been asked to be a clinical advisor. 
Realisation of impact 
While the academic knowledge created by this research has potential to be used 
immediately, further research will be required prior to implementation of the MOAT into 
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routine practice. This will include external validation to assess predictive accuracy in a 
new sample of patients, and impact and implementation studies. I estimate this will 
take three to four years, dependant on funding opportunities. 
Initially I intend to raise awareness of the findings of this study through dissemination 
via presentations at professional, academic and scientific meetings and conferences, 
and submission for publication in peer-reviewed journals. I also plan to present at 
relevant patient / public meetings at the study sites, and to work with the patient and 
public members of the project steering group to develop a wider public dissemination 
strategy. I hope to secure further funding to validate the MOAT, and once fully 
validated I would aim to work with key decision makers, such as the Head of Research 
at the Royal Pharmaceutical Society, and Medication Safety Team at NHS England to 
advise on further dissemination and adoption of the MOAT into practice. There is also 
potential to work with software developers to integrate the MOAT into automated 
systems such as electronic health records systems, permitting automated risk 
assessments in ‘real-time’, further supporting implementation into clinical 
environments. 
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Chapter 1: Overview 
This thesis describes the development of a prediction tool, the Medicines Optimisation 
Assessment Tool (MOATTM), to identify patients at highest risk of moderate or severe 
preventable medication related problems (MRPs) during admission to a hospital 
medical ward. The thesis is presented in 11 chapters; each is briefly described below. 
Chapter 1 – Overview 
This comprises a brief summary of each subsequent chapter. 
Chapter 2 – Background 
The background provides the medical context and rationale for development of the 
MOAT. It comprises evidence supporting the need to reduce avoidable medication-
related harm, the role played by hospital clinical pharmacists in medicines optimisation, 
the need for clinical prioritisation, and the potential use of ‘prediction research’ to permit 
effective targeting of patients.  
Chapter 3 – Literature review 
The literature review summarises existing evidence related to the prediction of adverse 
medication-related outcomes. This includes the identification of potential risk factors, 
known as prognostic factors, and a critical appraisal of existing prediction tools. The 
review resulted in the identification of 59 possible prognostic factors. It also suggested 
that the currently available prediction tools are not suitably robust for routine clinical 
use in terms of validated predictive accuracy, and/or generalisability. 
Chapter 4 – Aim and objectives 
The aim and objectives for the research were developed to address the gap in the 
evidence base identified in the preceding chapters. In summary, the aim was to 
develop an evidence-based prediction tool (using prognostic modelling), which has 
potential to increase the efficiency of hospital pharmacy services, reduce risks and 
improve patient outcomes. 
Chapter 5 – Selection of candidate predictors 
Chapter 5 describes the selection of potential prognostic factors (known as candidate 
predictors) to be used for MOAT development. This involved consideration of evidence 
from previous research, consensus of clinical experts and patient / public 
representatives, and a review of suitability in terms of the methodological requirements 
for prognostic modelling. One hundred and eighteen potential predictors were 
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considered, 59 from previous research and 59 suggested by clinical experts; 18 were 
pre-selected for use in MOAT development. 
Chapter 6 – Data collection for model development 
Chapter 6 describes the methodology, methods, and results of data collection. This 
includes the selection of study participants, flow of patients through the study, key 
characteristics of study admissions, analysis of missing data, data entry checks, 
descriptive analysis of MRP data, and ethical considerations.   
Chapter 7 – Pharmacists’ identification of MRPs: a validation exercise 
A potential limitation of MRP data collection, identified in chapter 6, was the possible 
impact of knowledge, experience and skills of pharmacists on their ability to identify 
potential MRPs. Chapter 7 describes the assessment of this potential variability 
through use of a simulated MRP identification assessment exercise. 
Chapter 8 – Analysis of outcome events 
Chapter 8 describes the severity assessment of MRPs, which was undertaken to 
identify patients with the outcome event of interest, namely at least one moderate or 
severe preventable MRP. Chapter 8 also includes descriptive analyses of the outcome 
events identified.  
Chapter 9 – Modelling 
Chapter 9 describes the use of multivariable logistic regression modelling to develop 
the MOAT. This chapter includes sample size calculation, exploratory data analysis, 
use of multiple imputation, model development, assessment of model performance, 
adjustment for optimism (to reduce potential for overconfident predictions when applied 
to a new group of patients), and development of an electronic decision aid.  
Chapter 10 – Assessment of the MOAT’s clinical credibility 
Assessment of the potential usability of the MOAT in clinical practice is described in 
chapter 10. This includes a review of the content validity, ease of use, potential 
workload implications, and potential clinical risk associated with false negative 
predictions. 
Chapter 11 – Overall discussion 
The overall discussion considers the key results of this research with reference to the 
study’s objectives. Previous literature and limitations are also discussed. This is 
followed by implications for future research, and an overall conclusion. 
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Chapter 2: Background 
Medication-related harm 
Medicines play a crucial role in maintaining health and are the most common 
intervention in healthcare. However, in the United Kingdom (UK), as elsewhere, there 
is a growing body of evidence that there is a need to improve medicines use1-7. This 
includes the Francis and Berwick reports1 2, which call for a number of actions to 
improve patient safety and reduce avoidable harm, and the World Health 
Organization’s Global Patient Safety Challenge: Medication Without Harm7, which was 
published in 2017, and outlines their global initiative to reduce the level of severe, 
avoidable medication-related harm by 50% over five years. 
Various terms are used for adverse medication-related outcomes, including adverse 
drug reactions (ADRs), adverse drug events (ADEs), and medication errors (MEs). The 
relationship between each of these is shown in Figure 1i (produced by Otero et al8), 
which shows that ADRs are effectively a subset of ADEs, representing non-preventable 
medicines-related harm. MEs span all preventable events, and may or may not result in 
harm. 
 
Figure 1 – Relationships between adverse drug events, adverse drug reactions 
and medication errors 
Research in the UK has shown that 1 in 20 prescription items in general practice 
contain either a prescribing or monitoring error9; 5-8% of all hospital admissions are 
due to preventable adverse effects of medicines10; 30-70% of patients have an error or 
unintentional change to their medicines when care is transferred3; and there is a 
prescribing error rate in hospitals of almost nine errors per 100 medication orders11.  
                                                          
i
 Permission to use this image obtained from Annals of Internal Medicine 
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This has human and financial costs5 12-14. Research has shown that admissions related 
to ADEs cost the National Health Service (NHS) up to £466m annually, with most being 
avoidable10. Focusing specifically on hospitalised patients, it is estimated that the 
annual cost to treat preventable ADEs in a 400-bed acute hospital in the UK is £0.3m-
£1m15, and a systematic review found that ADEs in hospitalised patients prolong 
hospitalisation by 3.4 days16. 
Medicines optimisation 
Historically, ADEs have been the focus of studies on medication-related harm12, but 
problems can also result from suboptimal medicines use, such as ineffective 
treatments or subtherapeutic doses. It is estimated that only 4-21% of patients in 
primary care receive optimum benefit from their medicines17, and it has been 
suggested that research efforts should also identify patients with unrealised benefits18. 
A term that encompasses both aspects is medication related problems (MRPs), defined 
as all circumstances involving a patient’s drug treatment that actually, or potentially, 
interfere with the achievement of an optimal outcome (from prescribing to 
administration)12 16 19 20. This also shifts the focus from ‘medicine-related harm’ to 
‘medicines optimisation’, which can be described as the safe and effective use of 
medicines to enable the best possible outcomes5. Medicines optimisation is high on the 
English national agenda, with guidance issued by the Royal Pharmaceutical Society 
and the National Institute for Health and Care Excellence4 5. 
Hospital clinical pharmacists 
Medicines optimisation is a key function of pharmacists21-24, and a number of 
systematic reviews conclude that addition of clinical pharmacist services to the care of 
hospital inpatients generally improves the quality, safety, and efficiency of patient 
care16 25 26. Ideally, pharmacists would see every patient daily, but medicines 
optimisation is not the only goal for hospital pharmacy services in England21 27. Other 
service developments are required, such as the delivery of 7-day services28 and the 
Hospital Pharmacy Transformation Programme, as set out in the recent review by Lord 
Carter on improving productivity and performance in English NHS acute hospitals29. 
Owing to the financial challenges that face the NHS, these developments often have to 
be achieved within existing funding through increased efficiency and innovation5 30 31. 
There have therefore been calls from international government organisations and 
professional bodies for effective ways for pharmacy services to target patients most in 
need23 32-36. 
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Prioritisation / prediction tools 
Clinical prioritisation has been proposed as a way to permit pharmacy services to focus 
on the greatest need and where clinical pharmacy input is likely to have greatest 
impact. This requires a method to triage patients to assign ‘pharmaceutical acuity’36 37. 
There are recognised risk factors for MRPs, for example polypharmacy, renal 
impairment, and the use of ‘high-risk’ medicines38, but to target patients appropriately 
pharmacists need to be able to apply this knowledge effectively and consistently within 
their routine clinical practice. 
Predicting clinical risk is well established in medicine. Tools such as cardiac-risk 
calculators39, and the Waterlow score40 (shown in Appendix A2.1), which assesses the 
risk of pressure ulcers, are both used daily across the NHS. Prediction tools to identify 
hospitalised patients at risk of adverse medication-related outcomes have been 
developed41-52, but the majority identify patients at risk of ADRs41-43, ADEs44 45, or 
MEs47, rather than MRPs, or are based on ‘expert opinion’ rather than statistical 
determination46 48-51. 
Prediction research 
Interest in prediction research (also known as prognosis research), has developed 
rapidly in recent years. It involves use of statistical methods to predict future health 
outcomes among people with a given baseline health status, and therefore has 
potential to inform clinical decision making, improve patient care, and make healthcare 
more efficient53 54. Prognostic modelling is one component of prognosis research, in 
which multiple risk (prognostic) factors are statistically combined to predict future 
clinical risk for an individual patient55. However, many published prognostic model 
studies have been criticised in terms of methodological shortcomings, limiting their 
reliability and applicability55 56, as well as poor reporting, which limits the ability to 
effectively assess the risk of bias54 57. Both problems ultimately limit the usefulness of 
the prognostic models. The perceived inadequacies in prognostic model research 
prompted the recent publication of recommendations for prognosis research by the 
PROGnosis RESearch Strategy (PROGRESS) partnership53 55 58 59, together with 
specific guidelines for reporting54 57 and critically appraising60 prognostic model 
research.  
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Gap in the evidence base 
An initial review of the literature suggested that a methodologically sound prognostic 
model that can target hospital patients most in need of pharmacists’ input, based on 
their risk of MRPs, does not yet exist. My aim was, therefore, to address this gap in the 
evidence base by developing a suitable model, the Medicines Optimisation 
Assessment Tool (MOATTM). This was driven by my desire to reduce risk, improve 
outcomes, and increase efficiency of hospital clinical pharmacy services, thereby 
supporting delivery of national targets related to patient safety, medicines optimisation, 
and service provision. 
The next stage was to review the literature to: (1) review previous research into the 
development of prediction tools to identify hospitalised patients at risk of adverse 
medication-related outcomes; and (2) identify potential prognostic factors. This is 
described in the next chapter. 
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Chapter 3: Literature review 
3.1 Introduction 
As described in the previous chapter, the aim of this study was to develop a prediction 
tool, the Medicines Optimisation Assessment Tool (MOATTM), using prognosis research 
methods. Prognosis research can be subdivided into distinct, but interrelated themes48. 
These include the identification of factors associated with prognosis, known as 
prognostic factor research, and prognostic model research, where prognostic factors 
are combined to predict future clinical risk for individual patients53 55.  
A key purpose of this literature review was to critically appraise the existing prediction 
tools41-52. In 2014 Stevenson et al61 published a systematic review of adverse drug 
reaction (ADR) and adverse drug event (ADE) prediction models for hospitalised older 
adults. My aim, therefore, was to update Stevenson’s review, and broaden it to include 
prediction tools for other adverse medication-related outcomes, those developed using 
‘expert opinion’, and those developed for adult patients irrespective of age, as these 
were excluded in Stevenson’s review.  
Prognostic factor research can guide model development by informing the selection of 
potential prognostic factors62 63, therefore the second purpose was to inform the 
selection of potential prognostic factors for the MOAT (discussed further in chapter 5, 
section 5.2.1). After undertaking my initial database searches, Suggett et al64 published 
a systematic review of risk factors associated with the need for pharmaceutical 
interventions in a hospital setting. Our research question and eligibility criteria were 
broadly similar, but our reviews differ in search close date (Suggett’s search closed in 
July 2013). My review therefore provides an update, and an opportunity to compare 
and contrast findings. 
In summary, the objectives were to review studies that:  
 developed prediction tools for adverse medication-related outcomes for adult 
patients admitted to hospital medical wards, to appraise the quality, applicability 
and limitations of existing prediction tools; 
 assessed the association between prognostic / risk factors and this outcome event, 
to identify potential prognostic factors to be used in MOAT development. 
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3.2 Methods 
To minimise bias, I established the research question and inclusion criteria a priori65 
using PICOS criteria (participants, interventions, comparators, outcomes, and study 
design)66. Three elements of the PICOS criteria were relevant to this review 
(participants, outcomes, and study design). I also followed the guidance developed by 
Moons et al60 for the critical appraisal and data extraction for systematic reviews of 
prediction modelling studies (shown in Appendix A3.1). This provides advice on 
framing the review question, search strategy, and eligibility criteria. 
The format and content of the review are based on the Preferred Reporting Items for 
Systematic reviews and Meta-Analysis (PRISMA) guidelines67.  
3.2.1 Eligibility criteria 
The eligibility criteria, with rationale, are summarised below:  
Type of studies: Existing research in this field includes a wide range of study types, I 
therefore included observational studies (cohort, case-control, and cross sectional 
studies), and consensus studies (expert opinion, Delphi method, and nominal group 
technique). No types of study were excluded. I restricted the search to published 
studies, hence excluded grey literature (reports, theses, opinion pieces, and 
conference proceedings)68. 
Types of participants: To reflect the proposed target population for the MOAT I 
selected studies of adult inpatients (defined as 18 years and over) on general medical 
wards. Studies that only included the following specialised groups / treatments were 
excluded:  
 patients on specialised units, including intensive care and cardiology; 
 patients with specific conditions, including renal disease, human immunodeficiency 
virus (HIV) infection, diabetes, cancer, depression, and dementia; 
 patients treated with a single group of medicines, such as antibiotics. 
Studies that included specialised patients as part of a wider group, including those on 
general medical wards, were included in the review. 
Type of outcome measures: I included studies that identified prognostic factors, 
and/or developed prediction tools, for patients at risk of adverse medication-related 
outcomes during hospital admission. Studies related to medication problems causing 
admission to hospital, or occurring following discharge, were excluded as they fall 
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outside the scope of the current research. Various outcomes measures have been 
used in these studies, including ADRs, ADEs, medication related problems (MRPs), 
and medication errors (MEs). A range of definitions are also used for each outcome, 
making direct comparison among studies difficult. I therefore included studies of all the 
above outcomes events.   
Language/publication date: For practical reasons I restricted studies to those 
published in English. No publication date restriction was applied. 
3.2.2 Information sources 
As the identification and resolution of adverse medication-related outcomes is a multi-
professional discipline I searched a range of databases: Excerpta Medica dataBASE 
(EMBASE); Medical Literature Analysis and Retrieval System Online (MEDLINE); 
Cumulative Index of Nursing and Allied Health Literature (CINAHL), and International 
Pharmaceutical Abstracts (IPA). Reference lists of relevant studies were also scanned 
and experts in the field consulted to check for other relevant studies. 
The database searches were initially completed between August and November 2015, 
with weekly electronic update alerts checked to identify subsequent publications.  
3.2.3 Search 
To allow for variation in index terms, I searched each database separately. The 
research question was divided into facets, with synonyms used to account for the 
different terminology, and truncation symbols to retrieve variant spellings and word 
endings. The facets were then added together using the Boolean AND operator. Three 
facets were used, the first included the outcome measure (MRPs, ADRs, ADEs, and 
MEs), the second covered risk prediction, so included risk factor, predictor variable, 
prediction tool, clinical decision rule, prioritisation tool and prognostic model. The third 
was used to capture studies of hospitalised patients. The full electronic search strategy 
used for EMBASE is shown in Appendix A3.2.  
3.2.4 Study selection 
I screened the titles of all records identified by each database search and excluded 
records according to the eligibility criteria. Abstracts and full-text publications were 
reviewed for potentially relevant records. Duplicate records were removed, and 
duplicate publications identified (i.e. studies published more than once). All reports 
from duplicate publications were considered and only the paper related to the original 
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study to develop the prediction tool or identify prognostic factors selected for the 
review.   
3.2.5 Data collection  
I developed and piloted data extraction records for six sets of data. The extraction 
records and data items are listed below. 
All studies: 
1. General data. This included: research method (consensus or statistical); country 
where study undertaken; sample size; age of participants; patient group (i.e. 
speciality / specialities studied); whether study was carried out prospectively or 
retrospectively; type of outcome event (MRP, ADE, ADR, ME); whether the 
outcomes were rated for severity and preventability (for the purposes of selecting 
the outcomes for statistical analysis); whether a prediction tool was developed. 
2. Data on the risk / prognostic factors studied. For consensus studies this 
included which factors were initially considered, and which were subsequently 
selected as being associated with the outcome event. For statistical studies it 
included details of all factors studied, and whether a univariable and/or 
multivariable association was found between the prognostic factor and outcome 
event.  
Consensus studies: 
3. A summary of study purpose (identification of risk factors or development of a 
prediction tool); study method (expert opinion, Delphi method, nominal group 
technique); details of the expert group; results of testing / validation. 
Statistical studies: 
4. Prognostic factor studies: data on the six domains of the Quality In Prognostic 
Studies (QUIPS) tool69. 
5. Prognostic modelling studies: data on the 11 domains of the ‘CHecklist for 
critical Appraisal and data extraction for systematic Reviews of prediction Modelling 
Studies’ (CHARMS)60. 
Prediction tool studies (consensus and statistical): 
6. Method of development; type of tool developed; prognostic / risk factors included in 
the prediction tool; scoring system; results of testing / validation. 
There was overlap between data required to assess the risk of bias within individual 
studies, and for the overall synthesis of results. For example, testing / validation of 
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prediction tools forms part of the risk of bias review for prognostic model and 
consensus studies individually, but also forms part of the overall synthesis of results. 
For ease of reference I reported these data in each relevant section of the results. 
3.2.6 Risk of bias in individual studies 
To assess the risk of methodological bias within individual studies I used the QUIPS 
tool69 and CHARMS60 checklist to assess the prognostic factor and modelling studies 
respectively. The consensus studies were assessed based on consideration of the 
appropriateness of the method, expert group, and results from testing / validation 
where available. The results were used when summarising the available evidence. 
The QUIPS tool (Appendix A3.3) permits prognostic factor studies to be rated as high, 
moderate or low bias for each of six domains (study participation, study attrition, 
prognostic factor measurement, outcome measurement, study confounding, and 
statistical analysis and reporting) using explicit criteria for each domain. As the purpose 
of this literature review was to identify potential prognostic factors to include in 
development of the MOAT rather than provide a definitive answer as to which factors 
are prognostic, I chose to use the QUIPS tool to provide a high-level overview of the 
included studies rather than a detailed critique.  
The CHARMS checklist (Appendix A3.4) lists the key data items to extract for 
systematic reviews of prediction model studies to identify potential sources of bias, and 
issues that may affect the applicability of the model. The checklist is grouped into 11 
domains (source of data, participants, outcome, candidate predictors, sample size, 
missing data, model development, model performance, model evaluation, results, 
interpretation and discussion). I chose to use the CHARMS checklist to complete a 
detailed review because of the importance of fully understanding the strengths and 
limitations of prognostic models currently available in this field. 
3.2.7 Summary measures / synthesis of results 
The analysis of individual studies was split into two sections, prognostic factor, and 
prediction tool development studies, as described below.  
Prognostic factor studies 
To inform the selection of prognostic factors for the MOAT I performed a simple count 
of the number of studies where an association was found between the factor and 
outcome event, a method recommended by Steyerberg70. Correlation between 
variables can affect the results of univariable analysis, either increasing or decreasing 
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the association70, I therefore chose to use univariable and/or multivariable associations 
as the outcome event of primary interest. Statistical combination of data was not 
performed due to differences in study design and outcome event measures. Steyerberg 
also advises caution when combining data due to publication bias70, in which authors 
only report results when associations are found, so biasing effects to more extreme 
values. 
For each study I recorded the prognostic factors studied, and whether an association 
was found. I categorised some prognostic factors into groups to simplify the analysis, 
for example where individual diagnoses were studied I recorded this under the group 
‘diagnosis’. I then combined studies by study method (statistical and consensus), and 
outcome measure (MRP, ME, ADE, ADR) to establish the number of studies within 
each category that found an association. I also combined the results from all studies to 
give an overall indication of the level of association, in terms of the proportion of 
studies that found an association between the prognostic factor / group and the 
outcome event.  
Prediction tool development studies 
For each prediction tool development study, I recorded the method of development 
(consensus or statistical), type of tool developed (electronic scoring algorithm, or risk 
model / score), prognostic / risk factors included in the prediction tool, scoring system, 
and results of testing / validation.  
3.2.8 Risk of bias across studies 
Assessing bias across prognosis research studies is challenging as there is currently 
no requirement for study registration, making it difficult to assess publication or 
selective reporting bias54. Assessment of selective reporting bias is also hampered by 
deficiencies in the quality of reporting of prognosis research, with key details often 
missing, such as which prognostic factors were examined57. For these reasons the risk 
of bias across studies was not considered as part of this literature review. 
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3.3 Results 
3.3.1 Study selection 
Figure 2 shows the PRISMA flow diagram of study selection. The database searches 
identified 5,020 records. The initial numbers identified from each database were: 
 EMBASE  2724 records; 
 MEDLINE 1280 records; 
 CINAHL  185 records; 
 IPA  831 records. 
An additional record was identified through a report in the pharmaceutical press71, and 
six records from subsequent weekly electronic update alerts43 46 47 51 72 73. Titles / 
abstracts were screened and the potentially relevant records combined (total 387). 
Thirty nine duplicates records were removed, leaving 348 records. Each record was 
reviewed and a further 276 excluded. The majority of these reports (274) did not meet 
the eligibility criteria. Two reports were potentially eligible but were not retrievable (from 
the UCL Library Service or NHS Evidence)74 75. Full-text for 79 articles were retrieved 
and reviewed. Duplicate publications were identified and the paper related to the 
original study selected for the review. A further assessment against the eligibility 
criteria was then made.  
A total of 31 studies were identified for inclusion in the literature review. Twelve of the 
studies involved the development of a prediction tool (in addition to identifying 
prognostic factors); the remaining 19 involved the identification of prognostic factors 
only. 
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Figure 2 – PRISMA flow diagram showing the stages of the literature review 
5,020 records identified 
through database searching 
7 additional records identified 
through other sources 
31 studies included in descriptive synthesis  
48 excluded: 
Duplicate publications (6) 
Review articles (8) 
Paediatrics (11)  
Specialised units (4) 
Specific conditions (6) 
Not restricted to hospitalised 
patients (3) 
Not prediction modelling (10) 
 
Records screened for 
eligibility 
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prognostic factor studies 
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3.3.2 Study characteristics 
The characteristics of studies selected for the review are shown in Appendix A3.5, and 
summarised below. All studies identified risk / prognostic factors, with a subset (12 
studies) also developing prediction tools. I have therefore separated this section into a 
review of all studies, followed by a review of prediction tool studies only. 
3.3.2.1 All studies 
Type of studies: Six of the 31 studies used consensus methods. Of these, five 
developed prediction tools for medication-related harm, and the other identified risk 
factors only. The remaining 25 used statistical methods; seven were prognostic model 
studies, and 18 identified prognostic factors only (summarised in Table 1).  
Of the 25 statistical studies, 19 were prospective and six retrospective. Twenty two 
used logistic regression. Log-linear, Cox, and Poisson regression were used in the 
remaining three. 
Types of participants: All 31 studies included patients on hospital medical wards / 
specialities, but 18 also included patients from other specialities (surgery, orthopaedics, 
maternity, intensive care, cardiology, gynaecology, and urology). All studies included 
only adult patients, with six restricted to older adults (aged 65 years and over). The 
number of patients involved in each of the statistical studies ranged from 131 to 
68,835, with a total of 250,585 patients included in the 25 studies.  
The majority of the studies (22) involved research carried out in Europe (four in the 
Netherlands; four in England; two in Ireland, Spain, Switzerland, France  and Germany; 
one in Scotland, Italy, Denmark and Norway). Five studies were conducted in North 
America (three in the USA and two in Canada); two in Africa (Ethiopia and Uganda); 
one in Asia (Israel), and one in Australasia (New Zealand).  
The studies were published between 1997 and 2017. 
Type of outcome measures: All studies involved the identification of risk / prognostic 
factors, and 12 also developed prediction tools. Nine studies used MRPs as the 
outcome measure, eight used ADEs, eight ADRs, five MEs, and the remaining study 
used ADEs and MEs (see Table 1). 
Seven studies used severity ratings to select outcome events for statistical analysis. 
Two used a preventability assessment.  
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Table 1 – Summary of included studies 
Source 
Outcome 
event 
Risk / prognostic 
factor identified? 
Prediction tool 
developed? 
Consensus studies 
Roten et al. (2010)
50
 MRP   
Cottrell et al. (2013)
48
 MRP   
Falconer et al. (2014)
49
 ADE & ME   
Kaufmann et al. (2015)
38
 MRP   
Saedder et al. (2016)
46
 ME   
Hickson et al. (2016)
51
 MRP   
Statistical studies 
Onder et al. (2010)
41
 ADR   
Tangiisuran et al. (2014)
42
 ADR   
Kiguba et al.(2017)
43
 ADR   
McElnay et al. (1997)
44
 ADE   
Trivalle et al. (2011)
45
 ADE   
Nguyen et al. (2017)
47
 ME   
Urbina et al. (2014)
52
 MRP   
Bates et al. (1999)
76
 ADE   
Van den Bemt et al. (2000)
77
 ADE   
Blix et al. (2004)
78
 MRP   
Evans et al. (2005)
79
 ADE   
Johnston et al. (2006)
80
 ADE   
Zopf et al. (2008)
81
 ADR   
Davies et al. (2009)
82
 ADR   
Zaal et al. (2010)
83
 ME*   
Munoz-Torrero et al. (2010)
84
 ADR   
Dequito et al. (2011)
85
 ADE   
Ben-Yehuda et al. (2011)
86
 ME*   
Beckett et al. (2012)
87
 ADE   
O’Connor et al. (2012)
88
 ADR   
Sikdar et al. (2012)
89
 ADR   
Wilmer et al. (2015)
90
 MRP   
Ashcroft et al. (2015)
91
 ME
†
   
Ayalew et al. (2015)
72
 MRP   
Lenssen et al. (2016)
73
 MRP   
*  Prescribing and transcribing errors only 
†
  
Prescribing errors only 
ADR = adverse drug reaction, ADE = adverse drug event, ME = medication error, MRP = 
medication related problem  
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3.3.2.2 Prediction tool studies 
Type of studies: Of the 12 prediction tool studies, five used consensus methods and 
seven used statistical methods (see Table 1). Of the statistical studies, six were 
prospective and one retrospective. All used logistic regression.  
Types of participants: All 12 studies included patients on hospital medical wards / 
specialities, but nine also included patients from other specialities (surgery, 
orthopaedics, maternity, cardiology, and gynaecology). All studies included only adult 
patients, with four restricted to older adults (aged 65 years and over). The number of 
patients involved in each of the statistical studies ranged from 526 to 8,713, with a total 
of 18,964 patients included in the seven studies.  
The majority of the studies (ten) involved research carried out in Europe (two in 
England and France, and one in Ireland, Scotland, Spain, Switzerland, Italy and 
Denmark). One study was conducted in Africa (Uganda), and one in Australasia (New 
Zealand).  
The studies were published between 1997 and 2017. 
Type of outcome measures: Four studies used MRPs as the outcome measure, three 
used ADRs, two used ADEs, two used MEs, and the remaining study used ADEs and 
MEs (see Table 1).   
One study used severity ratings to select outcome events for statistical analysis. None 
used a preventability assessment.  
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3.3.3 Risk of bias in individual studies 
The risk of bias was assessed for all 31 studies, and the results are separated into 
three sections due to the different methods used. The statistical studies are split by 
whether they identified prognostic factors only (18 studies), or developed prognostic 
models (seven studies). The six consensus studies are considered separately. 
3.3.3.1 Prognostic factor studies  
The results of the QUIPS review are shown in Appendix A3.6, and a summary for each 
of the six domains is given below. 
Study participation: Eleven of the 18 studies lacked a clear description of how the 
study wards / sites were selected, which prevents an assessment of whether the study 
samples were representative of the source population. In addition, one study did not 
specify the dates / duration of data collection (limiting an assessment of the 
applicability of the results), and one did not specify whether or not patients were 
recruited consecutively. Although the adequacy of the sample size is dependent on the 
number of events per variable used for analysis92 (as discussed in section 9.2.3),  
seven of the studies had fewer than 500 patients, which may affect the reliability of the 
findings. 
Study attrition: As the included studies were linked to a defined hospital admission of 
limited duration this was not a significant source of bias in any of the studies. 
Prognostic factor measurement: Definitions for one or more of the prognostic factors 
were not given in five of the 18 studies, and ten did not give details of the timing of 
prognostic factor data collection in relation to the patients’ admission, which is a 
particular issue with prognostic factors that are likely to alter during the course of a 
patient’s admission, such as the number of medicines prescribed and laboratory 
results. Continuous variables were categorised or cut-points used in 12 of the 18 
studies, which is not recommended as it has the potential to skew the results58. In 
addition, 14 of the 18 studies did not give details of the proportion of patients with 
missing data, or the method used to impute any missing data.  
Outcome measure: The method of measuring the outcome event was well described 
in 17 of the 18 studies. Regarding the validity and reliability of outcome event 
measurement, two studies relied on voluntary reporting systems, and one used data 
that were not collected for study purposes. One study used patient interviews as part of 
their assessment of the outcome event, which may introduce a degree of variability 
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(due to patients’ ability to correctly recognise the outcome and attribute it to their 
medication, severity of illness / ability to communicate, and whether patients agree to 
be interviewed). In addition, one study used hospital coding data to identify the 
outcome event, resulting in identification of only the most severe outcomes, and one 
relied on twice weekly reviews by the investigators. This has the potential to result in 
missing data due to patient discharges, events that occur between scheduled review 
visits, or poor documentation in nursing / medical records.  
Study confounding: All studies were exploratory and study confounding was therefore 
not relevant. 
Statistical analysis and reporting: Five of the 18 studies gave insufficient information 
to judge the adequacy of the analytic strategy, and eight reported that they selected 
prognostic factors for inclusion in the final multivariable analysis based on initial 
univariable analysis. This is not recommended as it can lead to selection bias62, and 
result in prognostic factors being wrongly excluded from the model63. In addition, four 
studies categorised data or used cut-points for continuous variables during the 
statistical analysis.  
 
In summary, this review found that all of the prognostic factor studies have some 
degree of bias, which has the potential to over or underestimate the relationship 
between the prognostic factors and outcome events.  
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3.3.3.2 Prognostic model studies  
The results of the CHARMS review are shown in Appendix A3.7, and a summary for 
each of the 11 domains is given below. 
Source of data 
All studies41-45 47 52 used data collected specifically for research purposes, with six of the 
seven studies using a prospective cohort design, the preferred method for model 
development as it enables optimal measurement of prognostic factors and outcome 
events60. Onder et al41 analysed data from a historical database.     
Participants 
Appropriate recruitment methods were used by all studies, so reducing the risk of 
selective sampling bias. One study used systematic random sampling43, and all others 
used consecutive recruitment. All studies also clearly described the study setting and 
age of included participants, permitting an assessment of applicability and 
generalisability, although two44 45 did not specify study dates.  
It was not possible to assess the risk of selective inclusion bias for two studies as the 
exclusion criteria were not stated43 47. In addition, McElnay et al44 gave the total number 
excluded, but no breakdown of reasons, and Tangiisuran et al42 listed five exclusion 
criteria (self-poisoning suspected, patient transferred to another ward during weekend, 
admitted and discharged during weekend, died within 24 hours of admission, and 
medical notes not available for further investigation) but only gave details of the 
number who were discharged or died before end of study, which does not correspond 
to the initial criteria. Similarly, written consent was required for four studies41-44, but no 
details given for the number, or description, of the patients who refused consent. One 
study did not state whether or not consent was required45.  
Outcome event 
The outcome event and method of measurement were well defined in all studies. 
Urbina et al52 used electronic alerts to identify the outcome event, ensuring reliability of 
data collection, but it is not clear whether all alerts were used as outcomes, or just 
those subsequently verified by pharmacists. All other studies used manual data 
collection. In one study all data were collected by one principal investigator42, but no 
details of inter-rater reliability were given for the remaining studies. A consensus 
method to confirm and classify the outcome events was used in four studies42 43 45 47. 
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A single outcome event (ADR or ADE) was used for five studies41-43 45 47. McElnay et 
al44 and Urbina et al52 used a combined outcome (ADR plus compliance, and MRPs 
respectively), but McElnay et al44 did not state the frequency of the individual 
components, which could make comparison with other studies difficult given that 
prevalence may differ between populations. 
Blinding, that is the assessment of the outcome event without knowledge of the 
predictors, occurred in one study52 due to the use of electronically generated alerts. It 
was not possible to determine if blinding was used in the remaining studies. 
Candidate predictors 
Candidate predictors are the potential prognostic factors selected for a prognostic 
modelling study. The studies used a wide range of predictors, including patient 
demographics, clinical history, physical examination, disease characteristics, test 
results, and medication details, although none justified reasons for selection. 
Definitions, for example liver disease and heart failure, were poorly defined in all 
studies, as were the timing and method of predictor measurements. Some studies also 
used predictors with subjective definitions, which may lead to poor reproducibility93. For 
example, McElnay44 used ‘patient thinks drugs were responsible for hospitalisation’ as 
a predictor in his final risk-score. 
Categorisation of some continuous variables occurred in all studies apart from Nguyen 
et al47, despite this being associated with reduced model reliability due to loss of 
statistical power, selection of spurious predictors, and overoptimistic predictive 
performance60. Ideally data on candidate predictors should be collected blindly, in 
terms of knowledge of the outcome event and other predictors60 94, but it was not 
possible to determine if this occurred in any of the studies. 
Sample size 
A key consideration when assessing sample size for prognostic model studies is the 
number of outcome events relative to the number of variables used (which includes all 
candidate predictors chosen to be studied, and not just those included in the 
multivariable analysis, transformations for continuous predictors, and indicator 
variables for categorical predictors)60. A commonly used ‘rule of thumb’ is that there 
should be at least ten ‘events per variable’ (EPV)92 but it was not possible to establish 
the EPV for any of the studies due to lack of information on the number of candidate 
predictors / variables. From the data available it appears that only three studies used 
an EPV of ten or more41 43 52.  
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Missing data 
It is recommended that prognostic studies report the frequency and type of missing 
data, and whether any data were imputed, or complete-case analysis used60. This was 
poorly reported in all studies. Only two studies gave details of missing data. McElnay et 
al44 reported the number of participants who did not take part in a structured interview, 
but no details were given on the impact on data collection, or how missing data were 
handled. Kiguba et al43 stated that they used the missing-assigned approach to 
categorise missing data for two categorical variables, but no details were given 
regarding how much data were missing. 
Model development 
All studies used logistic regression. The modelling assumptions for logistic regression 
include the need for: (1) observations to be independent of each other (i.e. no paired 
data); (2) little or no multicollinearity between predictors; and (3) predictors should be 
linearly related to the log odds of the outcome event70. In one study patients were 
eligible for recruitment more than once, meaning all observations were not 
independent; this did not appear to be accounted for in the analysis52. Only three 
studies stated that they performed checks for multicollinearity42 44 45, of which McElnay 
et al44 did not report the results. Similarly, only three studies reported checking 
linearity43 45 47. Nguyen et al47 reported the non-linear relationship between age and 
outcome event,  but Trivalle et al45 and Kiguba et al43 did not report results for their 
linearity analyses. 
A potential source of bias in prognostic model studies is the method used to select 
predictors, both for initial inclusion in the multivariable modelling, and during 
modelling60. The use of univariable analysis to select predictors for modelling is known 
to cause prediction selection bias60, but was used in six studies41 42 44 45 47 52, with the 
remaining study not specifying how predictors were selected43. It is also known that 
inclusion of predictors that occur infrequently in the study population can lead to 
inaccurate results63 95, but only two studies reported excluding predictors on this basis42 
44. Bias also occurs when predictors are categorised60. Although proposed as a way to 
deal with non-linearity, Harrell96 describes this as ‘disastrous’, as it leads to ‘low 
predictive accuracy, serious lack of model fit, residual confounding, and overestimation 
of effects of remaining variables’. Despite this, categorisation was used in six studies41-
45 52. 
There is no consensus on the best method to select predictors during modelling, but 
forward selection has been shown to be less reliable than a full model or backwards 
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elimination approach60. All methods have limitations, with substantive prior knowledge 
being needed for the full model approach, and a risk of omitting potentially important 
predictors with backward elimination60. It is therefore recommended that researchers 
clearly state their modelling approach60, but a clear description of both the modelling 
strategy and criteria for predictor inclusion were only provided for two studies42 44.  
It is also recommended that shrinkage techniques are used to adjust for model 
overfitting60,  but only Nguyen et al47 reported applying shrinkage to their model. 
Model performance 
It is recommended that all prognostic model studies report calibration and 
discrimination60, but both measures were reported in only three studies42 47 52. 
Calibration, which shows the agreement between observed and expected predictions, 
was assessed in three studies42 47 52. Two used the Hosmer-Lemeshow test, although 
this has been criticised for lack of statistical power, oversensitivity in large samples, 
and inability to show the direction or magnitude of the miscalibration60. Calibration plots 
are preferred, but were used only by Nguyen et al47. Discrimination, which is the ability 
to differentiate between those who do or do not experience the outcome event, was 
assessed using the area under the receiver operating characteristic (ROC) curve in five 
studies41 42 45 47 52. Results ranged from 0.70 to 0.78, suggesting modest discrimination. 
Two studies created risk groups, therefore were able to report sensitivity and 
specificity41 42, although both used a probability threshold based on study data rather 
than being predefined, which is associated with producing overoptimistic and biased 
results60. In addition neither study gave confidence intervals (CIs) for the sensitivity or 
specificity despite the recognised value of doing so97 98. Tangiisuran’s model had the 
highest senstivity42 (80%), but this was based on a detection score of one of a total 
score of five, hence one would expect high sensitivity at the expense of lower 
specificity, which was only 55%. Onder’s model had poorer sensitivity (68%) but better 
specificity (65%)41, which may be due to using a relatively higher detection score (four 
of a possible total of ten).  
Model evaluation 
Measuring the predictive performance of prognostic models using the same data used 
to develop the model, known as ‘apparent performance’, often overestimates the 
results found in a new set of patients, known as overfitting or optimism60. The risk is 
increased when using small samples, low EPV, data-driven modelling techniques, or 
when shrinkage techniques are not used. It is therefore recommended that 
performance is assessed using new data, known as model validation60. Internal 
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validation involves data-resampling, often bootstrapping or splitting the original sample. 
External validation involves using new data, and is therefore the preferred method60. 
Six of the studies performed model evaluation, two used external validation in a 
separate dataset41 42, two used bootstrap resampling of the developmental data45 47, 
and one used a non-random split of the original sample (based on the date of 
admission)52. McElnay et al44 used patients from the same study site to validate their 
model, but did not specify whether they used a split sample, or temporal validation. 
Kiguba et al43 did not perform model evaluation, therefore it was not possible to assess 
how well their model may perform in a new sample of patients. 
When studies include validation in a new group of patients it is recommended that 
authors report the differences in the frequency / distribution of predictors and outcome 
events between the development and validation datasets, as it is known that case-mix 
may influence model performance60. This was reported by Tangiisuran et al42, although 
not for all predictors. Onder et al41 reported that there were differences between the 
two groups, but the frequencies / distributions were not given for the predictors. 
McElnay et al44 reported that the groups were similar, but gave no further details. 
Urbina et al52 reported the difference in outcome event prevalence only. 
Onder et al41, Tangiisuran et al42 and Urbina et al52 reported similar predictive 
performance in their development and validation samples. McElnay et al44 reported the 
sensitivity and specificity of their model in the validation dataset only, but despite 
selecting a probability threshold to produce optimal results, concluded that their model 
had insufficient  sensitivity (40.5%) to be a satisfactory predictor of ADEs.  
Trivalle et al45 and Nguyen et al47 used bootstrap validation. Nguyen et al47 used the 
results to calculate a shrinkage factor. Trivalle et al45 used bootstrapping, but did not 
report using this to shrink the model. Instead it was used to estimate the risk of ADE for 
various categories of risk scores, as discussed below (under results domain).  
Results 
All studies reported the odds ratios and 95% CIs for predictors included in the final 
model, but the intercept and/or regression coefficients were not given by Onder et al41 
or Trivalle et al45, therefore it would not be possible to use these models to estimate 
outcome event probabilities for individual patients.  
Risk scores were developed by Onder et al41, Tangiisuran et al42, Trivalle et al45, and 
Urbina et al52. Different methods were used to assign the risk scores to each variable. 
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Onder et al41 and Urbina et al52 assigned a score to each variable based on odds 
ratios. Although this method is commonly used to assign risk scores, it has been 
criticised by Moons et al99, who advise that the use of regression coefficients is 
‘algebraically the only correct approach’. Urbina et al52 may have created additional 
bias by dichotomising continuous predictors using cut-points that gave the highest 
sensitivity and specificity. An alternative approach recommended by Sullivan et al100 is 
to use ‘meaningful categories’, for example quintiles, select a base category, then 
calculate the risk score based on how far each category is from the base category in 
terms of regression units.  Trivalle et al45 used regression coefficients to develop his 
risk score, but gave no further details on how these were used to create the score, 
therefore it is not possible to assess appropriateness. Tangiisuran et al42 chose to 
assign an equal weight to each variable retained in the final model, irrespective of the 
regression coefficients / odds ratios. While this was chosen for simplicity, it takes no 
account of the strength of association between each predictor and the outcome event, 
therefore is unlikely to accurately reflect individual risk estimates obtained from the 
regression model. 
As discussed above, Onder et al41 and Tangiisuran et al42 used their risk scores to 
create risk groups based on the selection of a probability threshold. Trivalle et al45 and 
Urbina et al52 did not create risk groups, but Trivalle et al used bootstrapping to 
estimate the risk of ADE for four risk score categories, for example a score of over 18 
(out of maximum score of 34) corresponded to an estimated risk of 52% (95% CI 40-
62%). Despite providing a useful way to interpret scores, the confidence intervals for 
each category were wide, and overlapped in three of the four categories, which 
reduces certainty and may limit clinical usefulness. 
A range of predictors were included in the final prediction models. Although it is not 
possible to directly compare studies, due to lack of information on which predictors 
were included43-45, and the use of unclear definitions (as stated above), Table 2 shows 
the predictors selected for each of the final models, and which other studies assessed 
the same predictors. This shows the variability in both the choice of candidate 
predictors, and in the associations found. Only three predictors (comorbidities, number 
of medicines prescribed, and age) appear in more than one model, despite many being 
assessed in two or more studies.  
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Table 2 – Predictors included in prognostic modelling studies 
Predictor included in final model

 Selected for final model 
x  Assessed but not included in final model 
Type of adverse medication-
related outcome 
ADR ADE ME MRP 
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Number of comorbid conditions / comorbidity index  x   x   
Heart failure  x   x   
Liver disease     x  x 
Number of medicines    x    
Previous ADR  x  x    
Renal failure  x   x  x 
Hyperlipidaemia         
Length of stay    x    
Use of anti-diabetic agents / diabetes x   x    
High white cell count on admission        
Age x x  x x   
Gender  x  x  x x 
Self-reported herbal medicine use        
HIV-positive serostatus        
Hospitalisation in 3 months prior to admission        
Gynaecology ward        
Prescribed antidepressants / depression x    x   
Prescribed digoxin        
Gastrointestinal problems         
Abnormal serum potassium        
Thinks drugs were responsible for hospitalisation        
Angina         
Congestive obstructive pulmonary disease x       
Prescribed antipsychotics        
Recent anticoagulation        
Treatment initiated before admission        
Best possible medication history available        
Psycholeptics (ATC code N05)        
Blood substitutes / perfusion solutions (ATC code B05)        
Cardiovascular medicines (ATC group C)        
Hormone therapy medicines (ATC group H)        
Systemic anti-infective therapy (ATC group J)        
Sensory organ medicines (ATC group S)        
Medicines from ATC group V (various)*        
Admission to surgical versus medical ward        
Hospital admission within  30 days        
Admission from emergency room        
Admission time (day versus night)        
Admission from outside institution        
MDC groups: other, nervous system, circulatory, 
digestive, musculoskeletal, kidney and urinary tract 
       
* Full details not given, but predominance of drugs from V03 subgroup 
ADR = adverse drug reaction, ADE = adverse drug event, ME = medication error, MRP = 
medication related problem, HIV = human immunodeficiency virus, ATC = Anatomical 
Therapeutic Chemical, MDC = major diagnostic category 
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Interpretation and discussion 
Six of the studies41-43 45 47 52 concluded that they had produced an effective method to 
identify adverse medication-related outcomes, with only McElnay et al44 stating that 
their model did not satisfactorily predict ADEs. All authors concluded that further work 
was needed prior to the introduction of their prediction tool into routine clinical practice. 
For McElnay et al44 this was due to the poor predictive performance of their model44, for 
other studies it was to validate the model in different populations and settings41 43 45 47 52. 
Tangiisuran et al42 recommended further research prior to routine use, including the 
need to compare the model with clinical judgement, and to assess the usability, impact 
on patient safety, and associated humanistic and cost implications. 
 
In summary, this review found that all of the prognostic modelling studies have some 
degree of bias, and are subject to selective reporting, which has the potential to impact 
both their predictive accuracy and clinical credibility.  
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3.3.3.3 Consensus studies  
The consensus studies include one risk factor study38, and five prediction tool studies46 
48-51. The results of the review are summarised below, with a detailed description of 
each study in Appendix A3.8. 
Five of the six studies used literature review to identify risk factors38 46 49-51, but all 
incorporated expert opinion, either for identification38 46 48 50 51, and/or to allocate 
scores48 49. Two studies used the Delphi method38 46, with Kaufmann et al38 using both 
the nominal group technique (NGT) and Delphi method, although the use of the same 
participants in both may have biased the results due to familiarity with the topic. The 
size and composition of the Delphi and NGT groups were acceptable101, with both 
using representation from physicians and pharmacists. The expert groups in the 
remaining four studies comprised pharmacists only, with each only using staff from 
within the base hosptial48-51. The results may therefore not reflect those of a 
multidisciplinary group, or be generalisable to other hospitals. Three of these studies 
also gave limited details on the method of expert involvement / number of experts49 50 
51
.  
A potential source of bias for the studies that developed risk scores was the selection 
of the cut-off scores for risk groups. Scores were developed by Cottrell et al48, Falconer 
et al49 and Saedder et al46. Cottrell et al did not describe how cut-offs were selected, 
and both Falconer et al and Saedder et al used arbitrary cut-points. Falconer et al 
based this on staffing constraints, with the high-risk score chosen to restrict this 
category to the top 10% of patients. Saedder et al selected the score that gave the 
highest precision. While being a pragmatic approach, Falconer’s method could be 
criticised for identifying patients based on workload capacity rather than actual risk, and 
Saedder’s for the potential for overoptimistic and biased results60. 
Saedder et al46 used statistical modelling to allocate risk factors scores, but may have 
introduced bias by the use of relatively small samples (four groups were used, ranging 
from 50 to 146 patients per group), and correspondingly small number of outcome 
events (9 to 33 per group). There were also differences in the characteristics of the 
groups, for example two populations were restricted to adults over the age of 65 years, 
whereas two included adults of all ages, and differences in the number of medicines 
prescribed, average number of MEs, and number of patients who experienced a ME. 
Finally, they used categorisation for all variables in the risk score, but it was unclear 
how these categories were selected.  
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Roten et al50 and Saedder et al46 reported performance measures (sensitivity and 
specificity), but as noted above, Saedder et al selected the threshold score to produce 
optimal performance. Roten’s tool had good sensitivity (85.1%), but a correspondingly 
lower specificity (60.4%)50. Saedder’s tool had better specificity (75%), but lower 
sensitivity (64%). Neither reported CIs. Cottrell et al48 compared their algorithm with 
identification by traditional methods, and reported a match, but no further details were 
given. No details of validation testing were given by Falconer et al49 or Hickson et al51, 
although Hickson et al did quantify the agreement between the scores allocated by 
pharmacists using the tool in practice, and the per-guidance scores. No studies 
reported external validation. 
 
In summary, Kaufmann’s study appears to have the lowest risk of bias, but the results 
of all other studies may be biased due to their choice of expert group, or the method of 
selection for risk scores and/or groups. 
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3.3.4 Results of individual studies / synthesis of results 
The results will be presented in two sections: prognostic factor identification, and 
prediction tool development studies.  
3.3.4.1 Prognostic factor identification 
From the 31 studies included in the review I identified 59 possible prognostic factors / 
groups. Table 3 provides a summary of the prognostic factor analysis, showing the 
proportion of studies where an association was found between the prognostic factor 
and outcome event. Each prognostic factor / group is shown, with the proportion of 
studies where an association was found, split by study method (statistical and 
consensus), and outcome measure. It also shows the combined proportion for all 
studies that included that prognostic factor or group of factors. For example, gender 
was associated with adverse medication-related outcomes in six of the 22 studies 
where it was assessed. Of these it was positively associated with the outcome event in 
one of the five studies of MRPs, none of the studies on MEs, and so on. 
Additional information on which studies investigated each prognostic factor or group of 
factors is given in Table 4. This shows the prognostic factor associations by study, and 
is sub-divided by outcome type. For the statistical studies it gives the level of the 
association (none, univariable or multivariable association). For consensus studies it 
shows whether each prognostic factor / group was selected, or considered but not 
selected. 
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Table 3 – Summary of prognostic factor analysis 
Prognostic factor 
Study method / outcome event 
Total Statistical analysis 
E
x
p
e
rt
 
o
p
in
io
n
 
MRPs MEs ADEs ADRs 
Demographics 
Gender 1/5*  0/2 2/7 3/8 - 6/22 
Ethnicity - - 0/2 0/1 1/1 1/4 
Non-native speaker - 0/1 - - 2/2  2/3 
Age 3/5 2/3 5/7 3/9  2/4  15/28  
Marital status - - 0/1 - - 0/1  
Patient characteristics 
Weight / height related factors 2/2 - 1/3 0/2  0/1  3/8  
Swallowing problems - - 0/1 - 1/1  1/2  
Allergy / previous ADR - - 1/1 1/2  2/2  4/5  
Non-compliance with medication - - - - 2/2  2/2  
Dependent living situation - - 0/2 1/3  0/1  1/6 
Disability - 0/1 - 0/1  - 0/2  
Ability to sign consent form - 0/1 - - - 0/1  
Smoking status / nicotine use - - 0/1 0/3  - 0/4  
Social deprivation - - - 0/1  - 0/1  
Alcohol related - - 0/1 1/2  - 1/3  
Falls risk - - - 0/1  0/1  0/2  
Impaired manual skills - - - - 1/1  1/1  
Visual impairment - - 0/1  - 1/1  1/2  
Medicines related factors 
Number of medicines prescribed 5/5 3/3 4/7  7/8  3/3 22/26  
Number of potentially 
inappropriate medicines 
prescribed 
- - - 1/1  - 1/1  
Cessation of medicines used 
before admission 
- - 1/1  - - 1/1  
Prescription of new medicines 
during / before admission 
- 1/1  1/1  - - 2/2  
Admission details / past admissions & outpatient appointments 
Elective versus unplanned 
admission 
0/1 - - - - 0/1  
Readmission to hospital  1/1 0/2 1/1  1/1  1/2  4/7 
Number of past hospital 
admissions 
- - 0/1  - - 0/1  
Number of past outpatient 
appointments 
- - 0/1  - 1/1  1/2  
Administrative factors  
Length of stay 0/1  2/2 2/4  5/5  - 9/12  
Time of day prescribed - 0/1  1/1  - - 1/2  
Month of stay - - 1/1  - - 1/1 
Stage of patient stay (admission 
/ during stay / discharge) 
- 1/1 - - - 1/1 
Type of hospital department / 
speciality 
3/4 1/2 3/4  3/3  - 10/13 
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Continued from previous page… 
Prognostic factor 
Study method / outcome event 
Total Statistical analysis 
E
x
p
e
rt
 
o
p
in
io
n
 
MRPs MEs ADEs ADRs 
Medical condition 
Diagnosis / reason for admission 1/2 1/1  2/4  1/3  - 5/10  
Comorbidities 1/2 1/1 3/4  5/6  4/4  14/17  
Comorbidity index 2/3 1/1 3/5  4/7 1/2 11/18 
DRG weight 1/1 - 0/1 - - 1/2 
Results 
Anaemia / haemoglobin - - - 1/2 1/1 2/3 
Temperature - - 0/1 1/1 - 1/2 
Heart rate / blood pressure - - 0/1 0/1 - 0/2 
Renal function 1/2 1/1 1/4 5/6 5/5 13/18 
Liver function 1/1 - 0/2 2/3 2/2 5/8 
Serum albumin - - 1/2 1/3 - 2/5 
Serum amylase - - - 1/1 - 1/1 
Thyroid function - - - 1/1 - 1/1 
Hyperlipidaemia - - - 1/2 - 1/2 
White blood cell count - - - 1/2 1/1 2/3 
Platelet count - - 1/1 1/1 - 2/2 
Serum potassium - - 1/1 1/1 1/1 3/3 
Serum sodium - - - 1/1 1/1 2/2 
Serum calcium - - - 1/1 - 1/1 
Prothrombin time / INR - - - 1/1 1/1 2/2  
Blood glucose / HbA1c  - - 1/1 1/1 1/1 3/3 
Serum C-reactive protein - - - 1/1 - 1/1 
Medicine use 
Individual medicines / groups 1/2 3/3 7/7 3/4 5/5  19/21 
‘ISMP high-alert medication’ / 
risk of harm 
- - 1/1  - 1/1 2/2 
‘Narrow therapeutic index’ 
medicines 
0/1 - - 0/1  3/3  3/5  
Drug interactions - - - 1/1  1/1  2/2  
Route of administration of 
medication 
- 2/2 2/2  -  4/4  
Dosing frequency of medication - 1/1 1/2  - - 2/3  
Drug dose (high versus low) - - 1/1  - - 1/1  
*  Number of studies where an association found / total number of studies which assessed 
the prognostic factor or group 
MRP = medication related problem, ME = medication error, ADE = adverse drug event, ADR = 
adverse drug reaction, DRG = Diagnosis-related group, HbA1c = Haemoglobin A1c / glycated 
haemoglobin test, ISMP = Institute for Safe Medication Practices 
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Table 4 – Detailed summary of prognostic factor analysis (showing associations 
by study) 
Prognostic 
factor 
Outcome 
event 
Positive 
univariable 
correlation 
Positive 
multivaria-
ble 
correlation 
Selected 
by expert 
opinion / 
theoretical 
modelling 
No 
correlation / 
considered 
by experts & 
not selected 
Gender MRPs Urbina
52
 
   Blix
78
  
Wilmer
90
  
Lenssen
73
 
 
Ayalew
72
  
MEs    Zaal
83
 
 
Nguyen
47
  
ADEs Beckett
87
 Evans
79
  Van den Bemt
77
 
Bates
76
 
Dequito
85
 
McElnay
44
   
Johnston
80
 
ADRs Davies
82
 
 
Dequito
85
 
Zopf
81
 
 O’Connor
88
  
Tangiisuran
42
 
Munoz-Torrero
84
 
Sikdar
89
 
 
Kiguba
43
  
Ethnicity ADEs     Bates
76
 
Johnston
80
 
ADRs    Tangiisuran
42
 
Expert opinion 
(ME/MRPs) 
  Falconer
49
   
Non-native 
speaker 
MEs    Ben-Yehuda
86
  
Expert opinion 
(ME/MRPs) 
  Falconer
49
 
Kaufmann
38
 
 
Age MRPs Blix
78
 
Lenssen
73
 
Urbina
52
  Wilmer
90
 
Ayalew
72
 
MEs Zaal
83
 Nguyen
47
  Ashcroft
91
 
 
ADEs Beckett
87
 
Bates
76
 
Johnston
80
 
Van den 
Bemt
77
 
Dequito
85
 
 Evans
79 
McElnay
44
 
ADRs Dequito
85
 
Davies
82
 
 
O’Connor
88
 
 
 Onder
41
 
Tangiisuran
42
 
Munoz-Torrero
84
 
Sikdar
89
 
Zopf
81
 
Kiguba
43
 
Expert opinion 
(ME/MRPs) 
  Cottrell
48
 
Falconer
49
 
Kaufmann
38
 
Saedder
46
 
Marital status ADEs    McElnay
44
 
Weight / height 
related factors 
MRPs Urbina
52
 
Wilmer
90
 
   
ADEs  Evans
79
  Beckett
87
 
McElnay
44
 
ADRs    Onder
41
 
Munoz-Torrero
84
 
Expert opinion 
(ME/MRPs) 
   Kaufmann
38
 
Swallowing 
problems 
 
ADEs    McElnay
44
 
Expert opinion 
(ME/MRPs) 
  Kaufmann
38
  
Allergy / 
previous ADR 
ADEs McElnay
44
    
ADRs  Onder
41
  Tangiisuran
42
 
Expert opinion 
(ME/MRPs) 
  Cottrell
48
 
Kaufmann
38
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Continued from previous page… 
Prognostic 
factor 
Outcome 
event 
Positive 
univariable 
correlation 
Positive 
multivariable 
correlation 
Selected by 
expert 
opinion / 
theoretical 
modelling 
No correlation / 
considered by 
experts & not 
selected 
Non-compliance 
with medication 
Expert opinion 
(ME/MRPs) 
  Falconer
49
 
Kaufmann
38
 
 
Dependent living 
situation 
ADEs    Bates
76
 
McElnay
44
 
ADRs O’Connor
88
   Onder
41
 
Tangiisuran
42
 
Expert opinion 
(ME/MRPs) 
   Kaufmann
38
 
Disability MEs    Ben-Yehuda
86
 
ADRs    Tangiisuran
42
 
Ability to sign 
consent form 
MEs    Ben-Yehuda
86
 
Smoking status / 
nicotine use 
ADEs    McElnay
44
 
ADRs    Onder
41
 
Tangiisuran
42
 
Zopf
81
 
Social 
deprivation 
ADRs    Sikdar
89
 
Alcohol related ADEs    McElnay
44
 
ADRs  Zopf
81
  Tangiisuran
42
 
Falls risk ADRs    Onder
41
 
Expert opinion 
(ME/MRPs) 
   Kaufmann
38
 
Impaired manual 
skills 
Expert opinion 
(ME/MRPs) 
  Kaufmann
38
  
Visual 
impairment 
ADEs    McElnay
44
 
Expert opinion 
(ME/MRPs) 
  Kaufmann
38
  
Number of 
medicines 
prescribed 
MRPs Wilmer
90
 Blix
78
 
Urbina
52
 
Lenssen
73
 
Ayalew
72
 
  
MEs  Zaal
83
 
Ben-Yehuda
86
 
Nguyen
47
 
  
ADEs Bates
76
 Van den 
Bemt
77
 
Trivalle
45
 
Dequito
85
 
 Beckett
87
 
Evans
79
 
McElnay
44
 
ADRs  Dequito
85
 
Onder
41
 
O’Connor
88
 
Davies
82
 
Zopf
81
 
Tangiisuran
42
 
Kiguba
43
 
 Munoz-Torrero
84
 
 
Expert opinion 
(ME/MRPs) 
  Falconer
49
 
Kaufmann
38
 
Saedder
46
 
 
Number of 
potentially 
inappropriate 
medicines 
prescribed 
ADRs  O’Connor
88
   
Cessation of 
medicines used 
before 
admission 
ADEs  Van den 
Bemt
77
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Continued from previous page… 
Prognostic 
factor 
Outcome 
event 
Positive 
univariable 
correlation 
Positive 
multivariable 
correlation 
Selected by 
expert 
opinion / 
theoretical 
modelling 
No correlation / 
considered by 
experts & not 
selected 
Prescription of 
new medicines 
during / before 
admission 
MEs Nguyen
47
    
ADEs  Van den 
Bemt
77
 
  
Elective versus 
unplanned 
admission 
MRPs    Urbina
52
 
Readmission to 
hospital 
MRPs Urbina
52
    
MEs    Zaal
83 
Nguyen
47
 
ADEs Beckett
87
    
ADRs  Kiguba
43
   
Expert opinion 
(ME/MRPs) 
  Falconer
49
 Kaufmann
38
 
Number of past 
hospital 
admissions 
ADEs    McElnay
44
 
 
Number of past 
outpatient 
appointments 
ADEs    McElnay
44
 
 
Expert opinion 
(ME/MRPs) 
  Falconer
49
  
Length of stay MRPs    Ayalew
72
 
MEs  Zaal
83
 
Ben-Yehuda
86
 
  
ADEs Bates
76
 Dequito
85
 
 
 Beckett
87
 
McElnay
44
 
ADRs O’Connor
88
 
Davies
82
 
Dequito
85
 
Tangiisuran
42
 
Munoz-
Torrero
84
 
  
Time of day 
prescribed 
MEs    Nguyen
47
 
ADEs  Beckett
87
   
Month of stay ADEs  Beckett
87
   
Stage of patient 
stay (admission / 
during stay / 
discharge) 
MEs  Ashcroft
91
   
Type of hospital 
department / 
speciality 
MRPs Urbina
52
 Blix
78
 
Wilmer
90
 
 Lenssen
73
 
MEs  Zaal
83
  Nguyen
47
 
ADEs  Evans
79
 
Bates
76
 
Dequito
85
 
 Beckett
87
 
ADRs Davies
82
 Dequito
85 
Kiguba
43
 
  
Diagnosis / 
reason for 
admission 
MRPs  Urbina
52
  Wilmer
90
 
MEs Ben-Yehuda
86
    
ADEs  McElnay
44
 
Johnston
80
 
 Beckett
87
 
Bates
76
 
ADRs  Onder
41
  O’Connor
88
 
Munoz-Torrero
84
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Continued from previous page… 
Prognostic 
factor 
Outcome 
event 
Positive 
univariable 
correlation 
Positive 
multivariable 
correlation 
Selected by 
experts / 
theoretical 
modelling 
No correlation / 
considered by 
experts & not 
selected 
Comorbidities MRPs Urbina
52
   Wilmer
90
 
MEs Ben-Yehuda
86
    
ADEs Bates
76
 
McElnay
44
 
Trivalle
45
 
  Evans
79
 
ADRs O’Connor
88
 
Tangiisuran
42
 
Munoz-
Torrero
84
 
Onder
41
 
Sikdar
89
 
 Kiguba
43
 
Expert opinion 
(ME/MRPs) 
  Cottrell
48
 
Falconer
49
 
Kaufmann
38
 
Hickson
51
 
 
Comorbidity 
index 
MRPs  Urbina
52
 
Wilmer
90
 
 Ayalew
72
 
MEs  Ben-Yehuda
86
   
ADEs Trivalle
45
 Evans
79
 
Dequito
85
 
 Bates
76
 
McElnay
44
 
ADRs Munoz-
Torrero
84
 
 
Dequito
85
 
Onder
41
 
Sikdar
89
 
 O’Connor
88
 
Tangiisuran
42 
Kiguba
43
 
Expert opinion 
(ME/MRPs) 
  Kaufmann
38
 Saedder
46
 
DRG weight MRPs Urbina
52
    
ADEs    Bates
76
 
Anaemia / 
haemoglobin 
ADRs  Zopf
81
  Onder
41
 
Expert opinion 
(ME/MRPs) 
  Falconer
49
  
Temperature ADEs    McElnay
44
 
ADRs  Zopf
81
   
Heart rate / 
blood pressure 
ADEs    McElnay
44
 
ADRs    Zopf
81
 
Renal function MRPs Urbina
52
   Wilmer
90
 
MEs Zaal
83
    
ADEs Beckett
87
   Evans
79
 
McElnay
44 
Bates
76
 
ADRs Munoz-
Torrero
84
 
Zopf
81
 
Onder
41
 
O’Connor
88
 
Sikdar
89
 
 Tangiisuran
42
 
 
 
Expert opinion 
(ME/MRPs) 
  Falconer
49
 
Kaufmann
38
 
Roten
50
 
 
Hickson
51
  
Saedder
46
 
 
Liver function MRPs Urbina
52
    
ADEs    Beckett
87
 
Bates
76
 
ADRs Zopf
81
 Onder
41
  Munoz-Torrero
84
 
Expert opinion 
(ME/MRPs) 
  Kaufmann
38 
Hickson
51
 
 
Serum albumin ADEs Bates
76
   McElnay
44
 
ADRs Zopf
81
   Onder
41
 
Munoz-Torrero
84
 
Serum amylase ADRs Zopf
81
    
Thyroid function ADRs Zopf
81
    
Hyperlipidaemia ADRs  Tangiisuran
42
  Zopf
81
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Continued from previous page… 
Prognostic 
factor 
Outcome 
event 
Positive 
univariable 
correlation 
Positive 
multivariable 
correlation 
Selected by 
experts / 
theoretical 
modelling 
No correlation / 
considered by 
experts not 
selected 
White blood cell 
count 
ADRs  Tangiisuran
42
  Zopf
81
 
Expert opinion 
(ME/MRPs) 
  Falconer
49
  
Platelet count ADEs  Bates
76
   
ADRs  Zopf
81
   
Serum 
potassium 
ADEs  McElnay
44
   
ADRs Zopf
81
    
Expert opinion 
(ME/MRPs) 
  Falconer
49
  
Serum sodium ADRs Zopf
81
    
Expert opinion 
(ME/MRPs) 
  Falconer
49
  
Serum calcium ADRs Zopf
81
    
Prothrombin 
time / INR 
ADRs Zopf
81
    
Expert opinion 
(ME/MRPs) 
  Falconer
49
  
Blood glucose / 
HbA1c 
ADEs McElnay
44
    
ADRs Zopf
81
    
Expert opinion 
(ME/MRPs) 
  Falconer
49
  
Serum C-
reactive protein 
ADRs Zopf
81
    
Individual 
medicines / 
groups 
MRPs  Urbina
52
  Wilmer
90
 
MEs Nguyen
47
 Zaal
83
 
Ashcroft
91
 
  
ADEs Beckett
87
 
Dequito
85
 
 
Van den 
Bemt
77
 
Bates
76
 
McElnay
44
 
Johnston
80
 
Trivalle
45
 
  
ADRs  Dequito
85
 
Tangiisuran
42
 
Kiguba
43
 
 Onder
41
 
 
Expert opinion 
(ME/MRPs) 
  Cottrell
48
 
Falconer
49
 
Kaufmann
38
 
Roten
50
 
Hickson
51
 
 
‘ISMP high-alert 
medication’ / risk 
of harm 
ADEs  Beckett
87
   
Expert opinion 
(ME/MRPs) 
  Saedder
46
  
‘Narrow 
therapeutic 
index’ medicines 
MRPs    Wilmer
90
 
ADRs    Tangiisuran
42
 
Expert opinion 
(ME/MRPs) 
  Falconer
49
 
Kaufmann
38 
Hickson
51
 
 
Drug 
interactions 
ADRs  Munoz-
Torrero
84
 
  
Expert opinion 
(ME/MRPs) 
  Saedder
46
  
Route of 
administration of 
medication 
MEs  Zaal
83
 
Ashcroft
91
 
  
ADEs Beckett
87
 Evans
79
   
Dosing 
frequency of 
medication 
MEs  Zaal
83
   
ADEs Beckett
87
   McElnay
44
 
Drug dose (high 
versus low) 
ADEs  Evans
79
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MRP = medication related problem, ME = medication error, ADE = adverse drug event, ADR = 
adverse drug reaction, DRG = Diagnosis-related group, INR = International Normalised Ratio, 
HbA1c = Haemoglobin A1c / glycated haemoglobin test, ISMP = Institute for Safe Medication 
Practices 
3.3.4.2 Prediction tool development studies  
Prediction tools were developed in 12 of the 31 studies, five using a consensus method 
46 48-51 and seven using statistical analysis41-45 47 52. Details for each study are given in 
Table 5. This shows the method of development (consensus or statistical), type of tool 
developed (electronic scoring algorithm, or risk model / score); prognostic / risk factors 
included in the prediction tool, scoring system, and results of testing / validation.  
None of the 12 studies report having carried out research related to implementation or 
impact. 
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Table 5 – Summary of the prediction tool development studies 
Source Model / score Testing / validation 
Roten et 
al. 
(2010)
50
  
 
Consensus derived electronic scoring algorithm 
based on integrated electronic systems. Six 
factors used to identify patients at risk of MRPs: 
high-risk medicines (e.g. enzyme inducers, 
anticoagulants); renal impairment; digoxin & low 
serum potassium; >3 days intravenous 
antibiotics; >3 days intravenous paracetamol; 
elderly patients with polypharmacy. 
Prospective validation study of 
501 patients, risk scoring 
compared to manual check by 
pharmacist (sensitivity 85.1%, 
specificity 60.4%). 
Cottrell et 
al. 
(2013)
48
 
 
Consensus derived electronic scoring algorithm 
based on electronic prescribing system (i.e. age 
& medicines related factors only). Factors 
included in score: age; medicine count; 
medicines by group (e.g. opiates, epilepsy 
treatment); medicines not verified; restricted 
supply / high-risk / non-formulary medicines; 
duration review needed; allergy status. 
Scoring varies with factor. 
Patients scored by algorithm as 
‘high-risk’ compared to those 
identified by ‘traditional ward 
round’ – match reported. 
Falconer 
et al. 
(2014)
49
 
 
Consensus derived electronic scoring algorithm 
based on integrated electronic systems. Thirty 
eight factors included in score: patient profile 
(e.g. age, ethnicity); patient encounter (e.g. 
number of previous admissions, recent 
readmission); clinical profile (i.e. patients with 
chronic disease); high-risk medication (e.g. >8 
regular medicines, anticoagulants); laboratory 
values (e.g. renal function, serum potassium). 
Scoring varies with factor. 
None reported. 
Saedder 
et al. 
(2016)
46
 
 
Consensus derived risk score based on 4 
factors: renal function; number of medicines; 
number of high-risk medicines (subdivided into 3 
risk categories); number of interactions 
(subdivided into 3 risk categories). 
Scoring varies with factor. 
Sensitivity 64%, specificity 75%, 
area under ROC curve 0.76, 
(95% CI 0.62-0.89). 
Hickson 
et al. 
(2016)
51
 
Consensus derived acuity pharmaceutical 
assessment screening tool to assign a patient 
acuity (level 1, 2 or 3). Acuity assessment based 
on patient factors: number of decompensated 
organs, need for input from intensive care team, 
specific comorbidities (e.g. cystic fibrosis, organ 
transplant), use of high-risk medicine; plus a 
range of triggers needing pharmacist input (e.g. 
use of high-cost medicines, home intravenous 
therapy); or the need for senior pharmacist 
input. 
Acuity level allocation based on patient meeting 
criteria specified for each level. 
Quasi-experimental service 
evaluation to quantify agreement 
among pharmacist-documented 
and per-guidance patient acuity 
level (PAL), no other testing or 
evaluation reported. 
Onder et 
al. 
(2010)
41
 
 
Statistical risk score based on 7 factors: 
≥4 comorbid conditions; heart disease; liver 
disease; number of medicines; previous ADR; 
renal failure. 
Scoring varies with factor. 
Internal validation: sensitivity 
68%, specificity 65%); 
area under ROC curve 0.71 
(95% CI 0.68-0.73) 
Prospective validation study of 
483 patients, area under ROC 
curve 0.70 (95% CI 0.63-0.78). 
Calibration not reported. 
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Continued from previous page… 
Source Model / score Testing / validation 
Tangiisu-
ran et al. 
(2014)
42
  
Statistical risk score based on 5 factors: 
hyperlipidaemia; anti-diabetic agent; raised white 
blood cell count; total number of medicines; length of 
stay. 
Scoring system based on equal weighting of 1 for 
each factor. 
Internal validation: 
sensitivity 80%, specificity 
55%; area under ROC 
curve 0.74 (95% CI 0.68-
0.79). 
Prospective validation study 
of 483 patients, sensitivity 
84%, specificity 43%; area 
under ROC curve 0.73 
(95% CI 0.66-0.80). 
Calibration reported for 
developmental data only. 
Kiguba et 
al. 
(2017)
43
 
Two regression models developed (for probable 
ADRs, and possible ADRs). Final models included: 
age; gender; number of conventional medicines; 
Charlson's comorbidity index; preadmission herbal 
medicines use; HIV-positive serostatus; 
hospitalisation in previous 3 months; gynaecology 
ward. 
Risk score calculated from regression equation. 
Not performed. 
McElnay 
et al. 
(1997)
44
 
 
Statistical risk score based on 7 factors: 
antidepressants; digoxin, abnormal serum potassium; 
‘thinks medicines were responsible for 
hospitalisation’; angina; congestive obstructive 
pulmonary disease. 
Scoring system not stated. 
Prospective validation study 
of 204 patients: sensitivity 
40.5%, specificity 69%, 
overall accuracy 63%. 
Area under ROC curve and 
calibration not reported. 
Trivalle et 
al. 
(2011)
45
 
Statistical risk score based on 3 factors: number of 
medicines, antipsychotics, & recent anticoagulation.  
Scoring varies with factor.  
Score validated by 
resampling technique 
(bootstrap): area under 
ROC curve 0.70 (95% CI 
0.65-0.74). 
Calibration not reported. 
Nguyen 
et al. 
(2017)
47
 
Regression model developed. Final model included: 
age; number of prescribed medicines; treatment 
initiated before admission; best possible medication 
history available’; psycholeptics; blood substitutes 
and perfusion solutions; type of hospital admission 
(medical versus surgical); hospital admission within 
previous 30 days; admission from emergency room; 
admission time (day versus night); admission from an 
outside institution. 
Risk score calculated from regression equation. 
Internal validation: 
calibration reported as 
'good' but slight over-
estimation of high 
probabilities; area under 
ROC curve 0.718 (95% CI: 
0.689-0.748).  
Bootstrap validation: area 
under ROC curve 0.707 
(95% CI not given). 
Urbina et 
al. 
(2014)
52
 
 
Statistical risk score based on 14 factors: 
age; Charlson index; number of medicines; 6 MDC 
groups; 5 ATC groups. 
Scoring varies with factor. 
Internal validation:  
area under ROC curve 
0.778 (95% CI 0.768-
0.789). 
Prospective validation study 
of 4058 admissions: area 
under ROC curve 0.776 
(95% CI 0.759-0.792). 
Calibration not reported. 
MRP = medication related problem, ADR = adverse drug reaction, ROC = receiver operator 
characteristic, CI = confidence interval, HIV = human immunodeficiency virus, ATC = 
Anatomical Therapeutic Chemical, MDC = major diagnostic category 
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3.4 Discussion  
Key findings 
In summary, this review suggests that the existing evidence is not sufficient to 
definitively select prognostic factors for development of the MOAT. It also suggests that 
the currently available prediction tools are not suitably robust for routine clinical use, in 
terms of validated predictive accuracy, and/or generalisability. 
Prognostic factor identification 
Overall, the existing evidence is not sufficient to identify which prognostic factors 
should be included in a prognostic model to predict the risk of MRPs for adult patients 
admitted to hospital medical wards, as shown by the variation in results among studies 
(see Table 3). This may be due to the range in the types of studies selected for the 
review, including both consensus and statistical methods, and the outcome measures 
(MRPs, ADEs, ADRs and MEs), although as shown in Table 4, there are significant 
differences in results among studies assessing the same outcome event using the 
same research method. 
This could be explained by additional differences in study design, including: 
 prospective versus retrospective; 
 the differences in the definitions used for each outcome type across different 
studies, plus further subcategorisation (e.g. Saedder et al46, Zaal et al
83, Ashcroft et 
al91, Ben-Yehuda et al86 and Nguyen et al47 all studied medication errors, but Zaal 
et al and Ben-Yehuda et al included only prescribing and transcribing errors, and 
Ashcroft restricted his study to prescribing errors); 
 the range of patient groups / specialties included in the different studies (e.g. 
studies combining patients from different inpatient settings, such as maternity, 
surgery and medicine), who may have different risk factors for adverse medication-
related outcomes; 
 differences in the criteria used to select the outcome measures for statistical 
analysis, for example  seven of the 25 statistical studies selected the outcome 
events based on severity rating, and two used a preventability rating; 
 methodological limitations, as highlighted by the risk of bias assessments. 
Despite the variation among studies, the results of this review are comparable with the 
systematic review published by Suggett et al64, which reported the ten most frequently 
reported risk factors associated with the need for pharmaceutical interventions in a 
hospital setting. All ten risk factors identified by Suggett et al were also identified by my 
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review: high-risk medicines; polypharmacy; age; gender; renal function; multiple 
comorbidities; length of hospital stay; drug allergy; compliance-issues, and liver 
function. My review also identified four additional, frequently reported, predictors: 
diagnosis / reason for admission; readmission to hospital; weight / height related 
factors, and serum potassium level. Another difference between the reviews was the 
total number of risk factors identified, with Suggett et al reporting 20, whereas I 
identified 59. Differences may be due to the study inclusion criteria, as Suggett et al 
included literature reviews and excluded consensus studies. Suggett et al also 
excluded risk factors that could not be accessed from patient medical notes. In addition 
there were differences in the way risk factors were grouped, for example Suggett 
grouped alcohol abuse and swallowing difficulties with compliance issues, whereas I 
reported these separately, and I grouped ‘type of hospital department / specialities’ 
while Suggett reported these separately. 
Prediction tool development studies 
The studies that developed a prediction tool are subject to the same considerations 
and variations as above. This can be seen by the selection of different prognostic 
factors for models predicting the same outcome event. For example Onder et al41  and 
Tangiisuran et al42 developed prognostic models to predict ADRs in older adults, and 
both used logistic regression analysis, but despite there being overlap in the prognostic 
factors investigated, for example previous ADR, number of medicines, comorbidities, 
and renal function, Tangiisuran’s final model only included number of medicines, 
whereas Onder’s model included all of these. 
Clinical usefulness of prediction tools is dependent on clinical credibility, accuracy, 
generalisability, and ideally, clinically effectiveness55. Each will next be discussed in 
turn, considering the quality, applicability and limitations of tools included in this review. 
Clinical credibility covers a range of issues: the prediction outcome needs to be seen 
as clinically important, the tool should contain all potentially relevant predictors, and it 
should be straightforward to use98. Given that assessment of clinical credibility requires 
subjective judgement rather than statistical assessment, I will confine this discussion to 
issues related to the selection of relevant predictors and ease of use.  
To enhance clinical credibility predictors should ideally be chosen based on theoretical 
and clinical knowledge63, but Cottrell et al48 were unable to do this as they were limited 
to data available in an electronic prescribing system, therefore could not include  
medical or laboratory-related factors. In some cases a conscious decision was taken to 
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exclude factors, for example Onder41 excluded high-risk medicines, and Nguyen et al47 
excluded laboratory results, diagnostic categories or comorbidities. While there may be 
legitimate reasons, it may make users question whether the model adequately 
assesses all sources of risk. 
Regarding ease of use, automated electronic scoring systems permit the use of 
complex and unambiguous scoring systems, but potential issues with the manual 
scores include:  
 unclear definitions used for predictors in all studies; 
 overlap in the categories for ‘number of medicines’ (‘≤5’ and ‘5-7’) in the score 
developed by Onder et al41; 
 no recommendation provided regarding required course of action, i.e. no risk 
groups created (Kiguba et al43, Trivalle et al45, Nguyen et al47, Urbina et al52); 
 the need for users to: 
o categorise the risks of harm and interaction for each medicine (Saedder46); 
o calculate the Charlson index (Urbina et al52 and Kiguba et al43); 
o categorise medicines and diagnostic category using Anatomical Therapeutic 
Chemical (ATC) and major diagnostic category (MDC) classifications 
respectively (Urbina et al52); 
o calculate the risk score using the regression equation, i.e. no simplified 
scoring system developed (Kiguba et al43 and Nguyen et al47). 
An additional issue with Tangiisuran’s tool42 was the inclusion of ‘length of stay’ as a 
predictor, despite this not being known prior to discharge. 
Predictive accuracy is a product of robust methodology at all stages of prediction tool 
development60. It was not possible to fully assess the predictive performance of all 
studies as four did not report performance measures43 48 49 51, but the results of the 
others suggest modest overall performance. Eight studies reported performance in 
terms of the sensitivity, specificity and/or area under the receiver operating 
characteristic (ROC) curve41 42 44-47 50 52. Excluding McElnay et al44, who concluded that 
their model had insufficient sensitivity, the remaining prediction tools had adequate 
discrimination capacity102 (area under the ROC curve 0.70-0.78), reasonable sensitivity 
(64-85%), but  poor-moderate ability to correctly identify those without the outcome 
event (specificity 43-75%). This means the risk-scores may fail to identify high-risk 
patients, while incorrectly categorising others as high-risk, so reducing the ability of the 
risk-score to manage workload efficiently.  Model calibration (a measure of agreement 
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between predictions and observed outcomes94), was only reported for two studies42 47. 
While calibration is likely to be good for model development studies (as the model is 
optimised for the developmental data), the reporting of calibration is considered 
‘fundamental’ for validation studies94. Despite this, neither of the studies that carried out 
external validation41 42 reported model calibration in the validation dataset, despite one 
reporting it for model development42.  
Validation studies for five of the prediction tools have subsequently been published, 
with all finding that the tools performed less well than in the original studies88 103-106. 
Three studies have validated Onder’s score88 103 104. O’Connor et al88 concluded that 
Onder’s score incorrectly classified 38% of patients as low-risk (area under ROC curve 
0.62, 95% CI 0.57-0.68), and Petrovic et al103 found that the score had ‘fair’ accuracy 
(area under ROC curve 0.64, 95% CI 0.55-0.74), good sensitivity, but very poor 
specificity across a range of subpopulations. Stevenson104 compared the performance 
of Onder’s41 model with Tangiisuran’s42 and Trivalle’s models45, and concluded that 
there was poor agreement among scores, with only four patients (of 270) being 
categorised as high-risk by all three risk-scores. Of the consensus studies, Falconer et 
al published the results of a validation study of her original risk-score105. This found no 
significant differences in prescribing errors among the risk groups. Bonnerup et al106 
have also published a study validating Saedder’s score46. Although the sensitivity and 
specificity are not stated in the paper, it is possible to calculate them from the results 
(sensitivity 57%, specificity 85%), suggesting better specificity but lower sensitivity than 
the development study. The tool failed to correctly identify 22 (42%) of 52 patients who 
experienced a ME, so one could argue that the sensitivity may be too low to instil 
clinical confidence in users. One option could be to lower the detection limit, as this 
may improve the sensitivity, but this would also reduce the specificity, so increasing the 
number of patients who would require a medication review. Using the original detection 
limit, 37% of patients in Bonnerup’s study required medication review, which they 
suggest is in accordance with other prediction tools, so given the high outcome 
prevalence in their study (50.5%), it may not be practical to aim for 100% sensitivity, as 
this could result in the majority of patients requiring review. An alternative prediction 
outcome, based on severity or clinical significance, may be more pragmatic and 
relevant to practice. Although this is not a conclusion the authors reach, it is supported 
by the finding that only 29 (60%) of 48 recommendations made by pharmacists for the 
high-risk category patients were implemented by the hospital physician, which could 
suggest the remaining ME were not considered to be clinically significant. 
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Generalisability includes whether the tool is likely to be applicable to other settings. 
This depends on: the source of data used for the study (that is, whether the sample 
adequately represents the true population); whether the patient characteristics of the 
study sample reflect patients at different sites; whether the tool is up-to-date / reflects 
practice at the new site; and whether the outcome event and predictors are relevant to 
new sites, and measured in similar ways60.  
Potential issues with existing prediction tools include: 
 the need for integrated electronic information systems48-50 52;  
 potentially differences in patient characteristics due to country where study 
conducted: 
o Kiguba’s study took place in Uganda, where the HIV-positive serostatus and 
use of herbal medicines (two predictors in the tool) are potentially higher 
than in European countries; 
o high-risk medicines were included in ten tools42 44-52, but usage patterns may 
differ among countries; 
 age of participants (Onder et al41, Tangiisuran et al42, McElnay et al44 and Trivalle et 
al45) developed tools for older adults, which may not be transferable to younger 
patients; 
 four studies excluded patients who were unable to provide written consent41-44, 
which may mean acutely unwell / confused patients may be inadequately 
represented; 
 Urbina et al52 used an integrated electronic warning system unique to their study 
site to identify outcome events, and therefore results may not be reproducible.  
Clinical effectiveness in improving decision making and patient outcomes has not been 
adequately assessed in any of the studies. Nguyen et al47 compared strategies for 
pharmaceutical intervention, comparing the model predictions with patient age to 
identify patients in need of intervention, and found that pharmacists were more likely to 
identify MEs using the model than age alone, although in practice age would not be 
used alone to prioritise patients. 
In summary, none of the prediction tools included in this review have evidence for 
sufficient predictive accuracy and/or generalisability to recommend them for routine use 
outside of the site where they were developed. I am aware that Hickson’s tool51 is 
routinely used across hospitals in Manchester, England, but due to acknowledged 
limitations, the team who developed it are in the process of developing a more 
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comprehensive prioritisation-tool as part of an National Institute for Health Research 
(NIHR) funded study107.  
Strengths and limitations 
Strengths of this review include the use of reporting guidelines for systematic reviews66 
and prognostic modelling studies60, and the use of recognised tools to assess the risk 
of bias for prognostic studies60 69. I also formulated a clear review question, used a 
range of databases for the initial search, and followed this with weekly alerts to identify 
subsequent publications. 
There are a number of limitations, the key one being the lack of independent review 
during study selection, data extraction, and critical appraisal68. Ideally I would also have 
included grey literature, and studies published in languages other than English, but 
these were excluded for pragmatic reasons. The Cochrane Library could also have 
been used as an additional information source. It was also not possible to assess the 
likelihood of publication bias as there is currently no requirement to register prognostic 
studies. 
Implications for future research 
The findings of this literature review led me to the following recommendations for 
development of the MOAT: 
 robust methodology, guided by the PROGRESS recommendations53 55 58 59, should 
be used at all stages of development to improve predictive accuracy and credibility; 
 the selection of prognostic factors should be guided by expert opinion in addition to 
the findings of the literature search (to build on existing research, and enhance 
clinical credibility); 
 the prognostic factors should be clearly defined, measureable, and routinely used 
in clinical practice (to prevent the need for additional measurements, calculations or 
complex categorisation prior to use of the MOAT); 
 a clinically relevant outcome event, based on severity / clinical significance should 
be used (to ensure workload efficiency); 
 outcome identification should be reliably assessed, involving inter-rater reliability 
assessment among data collectors, and a consensus method to validate and 
classify the outcome event; 
 high-risk medicines should be grouped rather than modelled individually to increase 
generalisability; 
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 model performance should be reported as the calibration and discrimination, and 
shrinkage should be applied to account for model overfitting;  
 use of the MOAT should not be predicated on electronic capability such as 
integrated electronic systems, as this would limit generalisability; 
 to enhance ease of use; the MOAT should be presented as a simplified scoring 
system to avoid the need for complex calculations; 
 the MOAT should provide users with recommendations regarding required course 
of action (i.e. risk groups); 
 validation, and impact and implementation studies, should be undertaken following 
MOAT development. 
3.5 Conclusion 
The literature review has permitted the identification of 59 possible prognostic factors / 
groups that are associated with adverse medication-related outcomes in hospitalised 
adult patients. It has also permitted a review of the quality, applicability and limitations 
of existing prediction tools for this outcome, and highlighted the need to follow sound 
methodological principles in order to minimise the risk of bias, and optimise predictive 
accuracy. 
In chapter 2 of the thesis I described a gap in the evidence base, the need for a 
methodologically sound prognostic model to target hospital patients most in need of 
pharmacists’ input, based on their risk of MRPs. This literature review has clarified how 
this gap should be addressed, and steps that should be taken to ensure the MOAT is 
usable in clinical practice. This led to development of aim and objectives, which will be 
presented in the next chapter. 
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Chapter 4: Aim and objectives 
The aim of this study was to use prognostic modelling to develop a prediction tool, the 
Medicines Optimisation Assessment Tool (MOATTM), to identify adult patients at 
highest risk of moderate or severe preventable medication related problems (MRPs) 
during admission to a medical ward in the United Kingdom, irrespective of age. It is 
proposed that the MOAT could be used to increase the efficiency of hospital pharmacy 
services, reduce risks and improve patient outcomes. 
MRPs were chosen as the prediction outcome to permit the MOAT to identify patients 
in need of medicines optimisation, not simply those at risk of medication-related harm. 
Moderate or severe MRPs were chosen to ensure the MOAT targets patients most in 
need of pharmacists’ input. This is to ensure the MOAT is clinically relevant and 
feasible to implement in terms of workload for pharmacists. Similarly, preventable 
MRPs were chosen to ensure the MOAT identifies patients with MRPs that are 
amenable to pharmacist intervention. No other methodologically sound prognostic 
model to target hospital patients based on their risk of moderate or severe preventable 
MRPs currently exists.  
The objectives were to: 
 identify potential prognostic factors based on evidence from previous research, 
expert opinion, and suitability in terms of methodological requirements for 
prognostic models; 
 use prognostic modelling to develop a decision aid (the MOAT) for use in clinical 
practice to allocate patients to risk groups;  
 assess predictive performance of the MOAT using calibration, discrimination, 
sensitivity, and specificity; 
 review the MOAT’s content validity, feasibility of use, potential efficiency savings, 
and the potential clinical risk associated with false negative predictions.  
 
The first stage in developing the MOAT was to select the potential prognostic factors, 
also known as candidate predictors. This will be discussed in more detail in the next 
chapter.  
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Chapter 5: Selection of candidate predictors 
5.1 Introduction 
Potential prognostic factors, also known as candidate predictors, are the variables that 
predict the outcome event of a prognostic model. These can include patient 
demographics, clinical history, physical examination, disease characteristics, test 
results, and treatments used93.  
When developing a prognostic model it is necessary to limit the number of candidate 
predictors. Selecting too many can result in ‘overfitting’/‘optimism’ (type I errors) 
leading to an overestimation of the predictive performance of the model, and the 
selection of spurious predictors94. It can also cause ‘underfitting’ (type II errors), which 
increases the risk that important predictors are not included in the model94. Both can 
lead to poor performance when the model is used in a new set of subjects94. One 
method to reduce the number of candidate predictors is to base the selection on the 
univariable association between each predictor and the outcome event. This is not 
recommended as it results in overfitting due to selection bias62, and can lead to 
predictors being wrongly excluded from the model due to the fact that the association 
may only become significant after adjustment for the other predictors63. It is therefore 
recommended that the candidate predictors are selected a priori58 95.  
The choice of potential candidate predictors is ultimately guided by the intended use of 
the model, but various recommendations have been made: 
 predictors already reported as prognostic should be included62 63; 
 the selection should be informed by clinical understanding (i.e. expert opinion) to 
ensure the list is comprehensive and clinically relevant56 63; 
 where predictors are highly correlated (e.g. weight and body mass index), only one 
should be selected63; 
 use of predictors that occur infrequently can lead to inaccurate results63 95; 
 candidate predictors should be: 
o available at the time when the model is intended to be used93; 
o clearly defined, standardised, and reproducible (to enhance generalisability 
and applicability of study results to practice)93; 
o have minimal measurement error (as this may dilute their prognostic 
value)60. 
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An additional consideration for this study was the selection of predictors that form part 
of standard clinical datasets. This was to increase the reliability of the data and 
minimise the potential for missing data, and to enable the Medicines Optimisation 
Assessment Tool (MOATTM) to be readily incorporated into clinical practice without the 
need for additional tests / measurements.  
These recommendations therefore provide three key elements to consider when 
selecting candidate predictors: (1) evidence from previous research; (2) the consensus 
of clinical experts; and (3) suitability in terms of methodological requirements. 
The aim of the work presented in this chapter was to pre-select the candidate 
predictors for development of the MOAT. The objectives were to: 
 review the potential predictors identified by the literature review to identify those 
reported as prognostic; 
 carry out an expert survey of  healthcare professionals and patient / public 
representatives to obtain clinical understanding and lay views on potential 
predictors; 
 review each potential predictor, based on the above recommendations (theoretical 
knowledge, clinical understanding, and methodological considerations) to pre-
select candidate predictors for the MOAT. 
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5.2 Methods 
The selection of candidate predictors was split into three stages: the selection of 
predictors for the expert survey, expert survey, and final candidate predictor selection. 
Each of these is described in turn. 
A summary of the methods used to operationalise the candidate predictor selection 
recommendations (listed in the introduction, section 5.1) is given in Table 6.  
Table 6 – Assessment of predictors against selection recommendations 
Methodological 
recommendation 
Method of operationalision 
Predictors reported as 
prognostic should be included62 
63 
Literature review performed and simple count used 
to identify predictors. 
Strength of evidence categorised as ‘low’ if 
association found in 33% or fewer studies (that 
investigated the predictor), ‘moderate’ if higher than 
33% but fewer than 66%, and ‘high’ if higher than 
66%. 
Selection of predictors should 
be informed by clinical 
understanding56 63 
Expert survey of healthcare professionals and 
patient / public representatives to obtain clinical 
understanding and lay views on potential predictors. 
If predictors are highly 
correlated only one should be 
selected63 
Where high interdependency anticipated, one 
predictor excluded based on level of evidence / 
other methodological recommendations.  
Predictors that occur 
infrequently can lead to 
inaccurate results63 95 
Predictor excluded if estimated occurrence <10% 
patients*. 
Predictors should be available 
at the time model intended to be 
used93 
Predictor excluded if data not available on day 
patient admitted to hospital. 
Predictors should be clearly 
defined, standardised, and 
reproducible93 
Predictor excluded if definition subjective and/or 
subjective measurement scale used. 
Predictors should have minimal 
measurement error60 
Predictor excluded if low reliability anticipated with 
test-retest, intra-rater and/or inter-rater 
measurements. 
Predictors should form part of 
standard clinical datasets 
Predictor excluded if not included in standard 
medical records and/or estimated data availability 
<50% patients
†. 
*  5% used in previous prognostic model studies
42 44 45
, but 10% selected to allow for 
estimation error (as review based on personal clinical experience / knowledge) 
† Based on Steyerberg’s
70
 recommendation that predictors with more than 50% missing 
data generally mistrusted 
  
Chapter 5: Selection of candidate predictors 
 
73 
 
 
5.2.1 Selection of predictors for the expert survey 
The selection of predictors for the expert survey involved two stages: (1) identification 
of predictors previously reported as prognostic; and (2) an assessment of suitablilty in 
terms of methodological requirements. 
To establish which predictors have previously been reported as prognostic I reviewed 
31 published studies (see literature review, chapter 3). I then made an initial 
assessment of each predictor against the remaining methodological recommendations 
for candidate predictors using personal clinical experience / knowledge, 
operationalising each recommendation as summarised in Table 6. Predictors were 
excluded if they did not meet all of the methodological requirements. All remaining 
predictors were included in the expert survey. 
5.2.2 Expert survey 
I developed an electronic survey, comprising both open and closed questions, to obtain 
expert opinion on: (1) the perceived importance / clinical relevance of the proposed 
predictors; and (2) other potential predictors. During development I circulated the 
survey to members of the MOAT project steering group (comprising PhD supervisors; 
clinical supervisors; patient / public representatives) to obtain comments on readability, 
layout, and content, and amended the survey accordingly. See Appendix A5.1 for the 
final version of the survey. The survey was administered during April-June 2016, with 
target subjects comprising both healthcare professionals and patient / public 
representatives. Invitations to participate were shared through the following fora / 
networks: 
 Royal Pharmaceutical Society of Great Britain Research and Evaluation Network; 
 Eastern Academic Health Science Network; 
 CHAIN (Contact, Help, Advice and Information) Network; 
 Medication Safety Officers Network for England; 
 East of England Chief Pharmacists’ Group. 
It was also emailed directly to: 
 Medication Safety Team, NHS England; 
 other researchers in the field (identified during the literature review); 
 pharmacists, consultants and senior nurses at the study sites; 
 members of the MOAT project steering group. 
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All respondents were also requested to share the survey further within their networks / 
organisations. 
Respondents were asked to rate each potential predictor using five Likert options (very 
important, important, 50:50, less important, not important). The median and 
interquartile range was calculated for each predictor to establish central tendency and 
variability, treating responses as ordinal data.  
Respondents were also asked whether the MOAT should include or exclude an 
assessment of topical medicines. This was to establish if the MOAT should be limited 
to assessing risk associated with medicines taken internally, specifically by mouth, 
injection, inhalation, rectally or vaginally, excluding topical medicines such as creams 
and eye drops. Respondents were also asked to suggest other predictors that should 
be included. 
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5.2.3 Final candidate predictor selection 
I made the final selection of candidate predictors following an assessment of the 
potential predictors included in the expert survey, and those suggested by survey 
respondents. I assessed each predictor against the recommendations for candidate 
predictors: the evidence from previous research (where available), clinical 
understanding and lay views (in terms of survey scores for perceived importance / 
clinical relevance, or number of times additional predictors suggested by respondents), 
and the remaining methodological recommendations for candidate predictors as 
summarised in Table 6 (see below for alteration to method used to assess if predictors 
were part of standard clinical datasetsii). I also considered each of the predictors 
suggested by survey respondents in terms of appropriateness for identifying patients at 
risk of MRPs during admission rather than post-discharge. This was based on personal 
clinical understanding. 
 
To review the evidence from previous research I performed a simple count of the 
studies that identified a predictor as prognostic (a recognised method to identify key 
predictors70). As there is no evidence base / precedent to categorise strength of 
evidence for predictors, I used a pragmatic approach, namely to categorise the 
evidence as ‘low’, ‘moderate’ or ‘high’, which is consistent with the categorisation used 
in the Quality in Prognostic Studies tool69 to assess methodological bias within 
prognostic studies. Evidence was categorised as low if an association was found in 
33% or fewer (of the studies that investigated the predictor), ‘moderate’ if higher than 
33% but fewer than 66%, and ‘high’ if higher than 66%.  
 
In summary, predictors were selected for use in development of the MOAT if they had: 
 
 moderate or high strength of evidence, and/or were categorised as important or 
very important by survey respondents; 
 met all of the methodological requirements; 
 were related to the risk of MRPs during admission, rather than post-discharge.  
 
 
   
                                                          
ii
 To identify if predictor data were routinely collected as part of standard clinical datasets I 
reviewed the standard admission proformas used at each study site. Where data were included 
on the proformas I then reviewed the medical records of 84 patients (50 from Hospital A and 34 
from Hospital B) to establish the actual, rather than perceived frequency of data availability. 
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5.3 Results 
The results will be presented in three sections: selection of predictors for the expert 
survey; expert survey, and final candidate predictor selection. Each of these is 
described in turn. 
5.3.1 Selection of predictors for the expert survey  
The literature review identified 59 possible predictors (Table 3, chapter 3). Following a 
review of the methodological requirements, 26 predictors were selected for inclusion in 
the expert survey. The predictors that were not selected are summarised in Table 7, 
with reason(s).  
Social deprivation was initially excluded from the expert survey, but members of the 
MOAT project steering group suggested it may be a potentially significant predictor. I 
therefore decided to include it on the basis that while it is not routinely recorded, it can 
be calculated from postcode data. 
The 27 predictors included in the expert survey are listed in section 5.3.2. 
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Table 7 – Potential predictors excluded from the expert survey with reason(s) 
Predictor 
Reason(s) for non-selection 
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Other (see details) 
 
 
 
 
 
 
Non-native speaker        
Marital status       
Unlikely to be 
associated with MRPs 
during hospital stay 
Weight / height 
related factors 
      
 
Non-compliance 
with medication 
      
 
Disability        
Ability to sign 
consent form 
      
 
Smoking status / 
nicotine use 
      
 
Social deprivation        
Alcohol related        
Falls risk        
Impaired manual 
skills 
      
 
Visual impairment        
Cessation of 
medicines used 
before admission 
      
 
Prescription of new 
medicines during / 
before admission 
      
 
Length of stay        
Time of day 
prescribed 
      
Not patient specific 
Month of stay       Not patient specific  
Stage of patient 
stay (admission / 
during stay / 
discharge) 
      
MOAT not intended to 
target stage of 
pharmacist input 
Comorbidity index       
Plan to use ‘number of 
comorbidities 
DRG weight       
Plan to use diagnostic 
categories 
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Continued from previous page… 
Predictor 
Reason(s) for non-selection 
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Other (see details) 
 
 
 
 
 
 
Anaemia / 
haemoglobin 
 
      
Temperature        
Heart rate / blood 
pressure 
      
 
Serum amylase        
Thyroid function        
Serum calcium        
Prothrombin time / 
INR 
      
 
Blood glucose / 
HbA1c 
      
 
Serum C-reactive 
protein 
      
 
‘ISMP high-alert 
medication’ / risk of 
harm 
      
Plan to use alternative 
method to categorise 
high-risk medicine use. 
‘Narrow therapeutic 
index’ medicines 
      
Plan to use alternative 
method to categorise 
high-risk medicine use. 
Drug interactions        
Drug dose (high 
versus low) 
      
 
* Estimated occurrence <10% 
† Not included in in standard medical records and/or estimated that data available for 
<50% patients 
DRG = Diagnosis-related group, INR = International Normalised Ratio,  HbA1c = Haemoglobin 
A1c / glycated haemoglobin test, ISMP = Institute for Safe Medication Practices 
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5.3.2 Expert survey 
A total of 247 responses were received. Table 8 summarises the professional role of 
the 237 respondents who answered this question.  
Table 8 – Current role of survey respondents 
Current role Number Percentage  
Pharmacist / member of the pharmacy team 178 75.2 
Doctor 31 13.1 
Nurse 10 4.2 
Academic (no other professional role stated) 10 4.2 
Patient or public representative 6 2.5 
Other healthcare professional 2 0.8 
 
Due to the ‘infinite’ target population it is not possible to determine a response rate. 
Perceived importance / clinical relevance of predictors 
The survey found that the majority of predictors (23/27) were considered ‘important’ or 
‘very important’. Details are given in Table 9.  
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Table 9 – Categorisation of the perceived importance of the proposed predictors 
as determined by median response 
Predictor 
Survey results 
Median 
response* 
Interquartile 
range 
Renal function 1 0 
Liver function 1 1 
Age 1 1 
Comorbidities 1 1 
Allergies 1 1 
Swallowing problems 1 1 
Number of medicines prescribed 1 1 
Number of potentially inappropriate medicines 
prescribed 
1 1 
Type of medicine prescribed 1.5 1 
Serum sodium level 2 1 
Serum potassium level 2 1 
Platelet count 2 1 
Serum albumin level 2 1 
White blood cell count 2 2 
Diagnosis / reason for admission 2 1 
Type of hospital department / speciality 2 1 
Readmission to hospital within 30 days 2 1 
Number of hospital admissions within 6 months 2 1 
Elective versus unplanned admission 2 1 
Route of administration of medication 2 1 
Dosing frequency of medication 2 1 
Social deprivation 2 1 
Dependent living situation 2 1 
Ethnicity 3 2 
Hyperlipidaemia 3 2 
Number of outpatient appointments within 6 months 3 1 
Gender 4 1 
*  Likert responses allocated ordinal numbers, 1= very important, 2=important, 3=50:50, 
4=less important, 5=not important  
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Inclusion of topical medicines 
A total of 247 responses were received to the question related to the inclusion / 
exclusion of topical medicines in the development of the MOAT: 82 (33%) answered 
‘yes’ (it is acceptable to exclude topical medicines), 129 (52%) answered no, and 36 
(15%) were ‘unsure’. Below are all comments received related to the exclusion of 
topical medicines. 
 
 “Deciding to leave out eye drops is not a good idea - should not exclude patients 
with glaucoma.” 
 “Not necessarily a risk factor but by not including topical medicines how will you 
identify use of patches especially opiate for pain.” 
 “Opioid patches are applied topically to the skin and are an example of a medicine 
that should be included, so there needs to be greater consideration about 
exclusions / inclusions.”  
 “Unclear whether patches would be included, but I believe they should be.” 
 “Patches, like fentanyl patches are associated with considerable patient safety 
issues, thus it is not appropriate to exclude them from the study.”  
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Additional predictors suggested 
One hundred and fifty respondents suggested additional predictors they felt should be 
considered for inclusion in the MOAT. These were categorised into 59 predictors / 
groups as listed in Table 10. 
Table 10 – Additional predictors suggested by survey respondents 
Predictor 
Number of 
suggestions 
Medicine related  
Over the counter / herbal medicine use 5 
Length of time on medicine / newly prescribed 5 
Medication Regimen Complexity Index / "complex" medication 
regimen 
2 
Irregular dose and administration / unusual dosage regimens 2 
Anticholinergic burden 2 
Medicine use ‘off label’ 1 
Homecare provided medicines 1 
Length and appropriateness of antibiotic treatment 1 
Use of an antidote e.g. naloxone, vitamin K 1 
Constituents in formulations that may be pharmacologically active 1 
Medicines or combination of medicines that predispose falls 1 
Patient related 
Dementia / cognitive function / mental capacity / mental health 
status / confusion / delirium 
34 
Adherence / compliance 17 
Physical / sensory impairment 14 
Patient health beliefs / behaviours 11 
Compliance aid  11 
Frailty score 10 
Language barrier 9 
Self-care for medicines / whether patient / family / carer is 
responsible for medicines 
9 
Carer status 7 
Intellectual disability / learning difficulty 6 
Weight (obese and anorexia) 6 
Poor health literacy 5 
Patient education level / literacy 5 
Recreational drugs / substance misuse 4 
End of life care 3 
Patient / carer level of knowledge / patient baseline understanding 
of disease state / medication 
3 
Alcohol use / misuse 3 
Nil by mouth / enteral tube 3 
Social / cultural issues 3 
Chapter 5: Selection of candidate predictors 
 
83 
 
 
Continued from previous page… 
Predictor 
Number of 
suggestions 
Overdose risk / previous overdose / misuse of medication 2 
Falls risk 2 
Housing status (e.g. homeless) 2 
Activities of Daily Living score / functional level 2 
Medicines related admission 2 
Social-related admission 1 
Capacity as defined by Mental Capacity Act 1 
Member of travelling community 1 
Elderly living alone 1 
Decanting of medicines occurring 1 
Significant weight changes 1 
Bariatric patient 1 
Nutritional status 1 
Smoking status 1 
Transgender  1 
Housebound 1 
Disability 1 
Pain score 1 
Venous access patient / type of cannula  1 
Having received antibiotics in last 3 months 1 
Frequency of GP contact 1 
Identifying if patient is on a risk register with general 
practitioner 
1 
Pregnancy / breastfeeding 1 
Requirement to manipulate the medicine before 
administration 
1 
Critical care admission 1 
System / process related 
Staffing levels on ward / hospital 5 
Communication problems across interfaces 4 
The days admitted / time of year 3 
Number of patient transfers across wards  1 
 
Additional suggestions were received regarding how ‘diagnosis’ and ‘type of medicine 
prescribed’ should be categorised for the analysis. Suggestions for diagnoses included 
diabetes, Parkinson’s disease, immunodeficiency, and sepsis. Suggestions for analysis 
of medicines included ‘drugs with narrow therapeutic index’, ‘intravenous antibiotics’, 
‘anticoagulants’, ‘insulin’, and ‘antiepileptics’. 
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5.3.3 Final candidate predictor selection 
Predictors included in the expert survey 
The review of predictors included in the expert survey is summarised in Table 11, 
together with those pre-selected as candidate predictors. 
Table 11 – Review of candidate predictors included in expert survey  
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Renal function High 1 0        
Liver function Mod 1 1        
Age Mod 1 1        
Comorbidities High 1 1        
Allergies High 1 1        
Swallowing 
problems 
Mod 1 1    X X X X 
Number of 
medicines 
prescribed 
High 1 1        
Number of 
potentially 
inappropriate 
medicines 
prescribed 
High 1 1      X X 
Type of medicine 
prescribed 
High 1.5 1        
Serum sodium level High 2 1        
Serum potassium 
level 
High 2 1        
Platelet count High 2 1        
Serum albumin 
level 
Mod 2 1        
White blood cell 
count 
High 2 2        
Diagnosis / reason 
for admission 
Mod 2 1        
Type of hospital 
department / spec-
iality 
High 2 1 X      X 
Continued from previous page… 
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Readmission to 
hospital within 30 
days 
Mod 2 1 X     X X 
Number of hospital 
admissions within 6 
months 
Low 2 1        
Elective versus 
unplanned 
admission 
Mod 2 1  X     X 
Route of 
administration of 
medication 
High 2 1        
Dosing frequency 
of medication 
High 2 1 X      X 
Social deprivation Low 2 1      X § 
Dependent living 
situation 
Low 2 1    X X X X 
Ethnicity Low 3 2       X 
Hyperlipidaemia Mod 3 2      X X 
Number of 
outpatient 
appointments within 
6 months 
Low 3 1 X      X 
Gender Low 4 1       X 
*  Strength of evidence categorised as ‘Low’ association found in ≤33% published studies, 
‘Mod’ (moderate) >33% and <66%, ‘High’ ≥66% (see Table 3, chapter 3 for a detailed 
breakdown) 
†  Likert responses allocated ordinal numbers, 1= very important, 2=important, 3=50:50, 
4=less important, 5=not important 
‡ Included in standard admission proforma at study sites and/or data available for ≥50% 
patients (based on a review of the patient records of 84 patients, 50 from Hospital A and 
34 from Hospital B) 
§ Not routinely recorded in medical records, but can be calculated from postcode   
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Additional predictors suggested by survey respondents 
The review of additional predictors suggested by survey respondents is summarised in 
Table 12. Two of the 59 predictors, dementia and weight, were selected as candidate 
predictors. Dementia was included as dementia / cognitive function received a high 
number of suggestions (34), and dementia meets the remaining methodological 
requirements. I had previously excluded weight based on estimated data availability, 
but the further assessment found that it would be possible to calculate the body mass 
index for 62 of the 84 patients reviewed (74%) therefore this was also selected as a 
candidate predictor. 
Table 12 – Review of candidate predictors suggested by survey respondents  
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H
ig
h
 c
o
rr
e
la
ti
o
n
 w
it
h
 o
th
e
r 
p
re
d
ic
to
r(
s
) 
O
c
c
u
rs
 i
n
fr
e
q
u
e
n
tl
y
* 
N
o
t 
a
v
a
il
a
b
le
 w
h
e
n
 m
o
d
e
l 
in
te
n
d
e
d
 t
o
 b
e
 u
s
e
d
 
N
o
t 
c
le
a
rl
y
 d
e
fi
n
e
d
 /
 
s
u
b
je
c
ti
v
e
 d
e
fi
n
it
io
n
 /
 n
o
t 
re
p
ro
d
u
c
ib
le
 
P
o
te
n
ti
a
l 
m
e
a
s
u
re
m
e
n
t 
e
rr
o
r 
N
o
t 
p
a
rt
 o
f 
s
ta
n
d
a
rd
 d
a
ta
s
e
ts
 
&
/o
r 
n
o
t 
re
li
a
b
ly
 r
e
c
o
rd
e
d
†
 
R
e
la
te
d
 t
o
 p
ro
b
le
m
s
 
e
n
c
o
u
n
te
re
d
 b
y
 p
a
ti
e
n
ts
 i
n
 
p
ri
m
a
ry
 c
a
re
 
 
 
 
 
Other / comments 
 
 
 
 
 
Over the counter / herbal 
medicine use 
       
 
Length of time on medicine / 
newly prescribed 
       
 
Medication Regimen 
Complexity Index  
       
 
Irregular dose and 
administration 
       
 
Anticholinergic burden         
Medicine use ‘off label’         
Homecare provided 
medicines 
       
 
Length and appropriateness 
of antibiotic treatment 
       
Antibiotics to be 
analysed as high-
risk medicines 
Use of an antidote e.g. 
naloxone, vitamin K 
       
Sign of MRP rather 
than predictor 
Constituents in formulations 
that may be 
pharmacologically active 
       
 
Medicines or combination of 
medicines that predispose 
falls 
  
    
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Other / 
comments 
Dementia        INCLUDE  
Cognitive function / mental 
capacity / mental health 
status / confusion / delirium 
       
 
Adherence / compliance         
Physical / sensory 
impairment 
       
 
Patient health beliefs / 
behaviours 
       
 
Compliance aid         
Frailty score         
Language barrier         
Self-care for medicines / 
whether patient / family / 
carer is responsible for 
medicines 
       
 
Carer status         
Intellectual disability / 
learning difficulty 
       
 
Poor health literacy         
Weight (obese and anorexia)        INCLUDE 
Patient education level / 
literacy 
       
 
Recreational drugs / 
substance misuse 
       
 
End of life care         
Patient / carer level of 
knowledge / patient baseline 
understanding of disease 
state / medication 
       
 
Alcohol use / misuse         
Nil by mouth / enteral tube         
Social / cultural issues         
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Other / 
comments 
Overdose risk / previous 
overdose / misuse of 
medication 

      
 
Falls risk         
Housing status (e.g. 
homeless) 
       
 
Activities of Daily Living 
score / functional level 
       
 
Medicines related admission         
Social-related admission         
Capacity as defined by 
Mental Capacity Act 
       
 
Member of travelling 
community 
       
 
Elderly living alone         
Decanting of medicines 
occurring 
       
 
Significant weight changes         
Bariatric patient         
Nutritional status         
Smoking status        
Low strength of 
evidence 
Transgender          
Housebound         
Disability         
Pain score         
Venous access patient / type 
of cannula  
       
Cannulas 
routinely used for 
all study patients 
Having received antibiotics in 
last 3 months 
       
 
Frequency of GP contact         
Identifying if patient is on a 
risk register with general 
practitioner 
       
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Continued from previous page… 
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Other / 
comments 
Pregnancy / breastfeeding         
Requirement to manipulate 
the medicine before 
administration 
        
Critical care admission         
Staffing levels on ward / 
hospital 
       
Related to 
‘process’ of 
prescribing rather 
than patient 
specific 
Communication problems 
across interfaces 
       
 
The days admitted / time of 
year 
       
Related to 
‘process’ of 
prescribing rather 
than patient 
specific 
Number of patient transfers 
across wards  
      
  
* Estimated occurrence <10% patients 
† Not included in standard admission proforma at study sites and/or data available for 
<50% patients (based on a review of the patient records of 84 patients, 50 from Hospital 
A and 34 from Hospital B) 
MRP = medication related problem  
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5.4 Discussion  
Key findings 
This research has involved joint consideration of evidence from previous research, 
expert opinion, and the methodological considerations for prognostic modelling to 
provide an evidence-based approach for selecting the candidate predictors for use in 
development of the MOAT. One hundred and eighteen potential predictors were 
considered, 59 from previous research and 59 suggested by survey respondents. The 
total number pre-selected for use in development of the MOAT was 18. 
Comparison with previous literature  
Of the 59 potential predictors identified by the literature review, 32 were not selected 
for the expert survey because they did not meet the methodological requirements for 
prognostic modelling. The most common reasons were not being clearly defined, 
standardised and reproducible, or not forming part of standard clinical datasets. These 
issues could be overcome by developing clear, objective definitions, then collecting the 
data specifically for study purposes, but this would impact on the usability of the MOAT 
in clinical practice, as it would require additional measurements to be made / recorded. 
There is the also the potential for alternative definitions to be used, leading to 
measurement error and reduced prognostic accuracy. 
Of the 27 predictors included in the expert survey, a further 11 were excluded, three 
because they had low strength of evidence plus low rating for clinical relevance by 
survey respondents. Four were excluded as they were not clearly defined, 
standardised and reproducible, and/or not part of standard datasets. The remainder 
were excluded as they were correlated with other predictors, or occurred infrequently. 
Eight of the 59 predictors suggested by expert survey respondents, such as ‘disability’ 
and ‘adherence with medicine taking’, had already been identified by the literature 
review, but the majority had not. Examples include ‘activities of daily living’, ‘patient 
health beliefs’, ‘nil by mouth / enteral tube use’, and ‘pain score’. There are three 
possible reasons for this. 
1. The literature review included predictors for ‘adverse medication-related outcomes’, 
including adverse drug reactions (ADRs), adverse drug events (ADEs), medication 
related problems (MRPs), and medication errors (MEs). As the definition for MRPs 
is broader than the other outcome events it is likely that the predictors for MRPs are 
more varied.  
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2. Many of the suggested predictors did not meet the methodological requirements for 
predictors, often lacking a clear definition or standardisation. This may have 
resulted in them being excluded in previous studies.  
3. Some predictors suggested by the survey respondents relate to the identification of 
patients who may require pharmacist input to prevent MRPs post-discharge, for 
example the ‘Medication Regimen Complexity Index’ which was designed to 
identify patients who would benefit from additional pharmaceutical input such as 
domiciliary reviews and special pharmacotherapy consultations108. This outcome 
was outside the scope of the literature review.  
Interpretation and implications  
This research highlights the value of using an expert survey to identify potential 
predictors as it permitted broader identification of potential predictors than literature 
review alone. It also provided expert advice on the need to include topical medicines in 
the analysis, which may otherwise have been omitted, and provided suggestions 
regarding how to categorise diagnoses and high-risk medicines. 
It is of note that 32 of the 59 potential predictors identified by the literature review, and 
57 of the 59 predictors suggested by the expert survey respondents were excluded 
from the final selection, either due to methodological limitations, and/or because they 
relate to the risk of MRPs post discharge, which is outside the scope of the present 
study. This raises two issues: (1) recognition that it is not possible to model the impact 
of all potential predictors; and (2) pharmacists may need to combine the MOAT with 
alternative methods of patient prioritisation to identify patients at risk of alternative 
outcome events. 
Steyerberg advises that it is appropriate to omit predictors if their effect cannot be 
reliably estimated70, similarly Sullivan et al100 acknowledge the need to restrict 
predictors to those that are ‘readily available in clinical practice and precisely 
measured’. Steyerberg recommends that if potentially highly significant predictors are 
excluded the model should be presented with an appropriate warning70. This will be an 
important consideration when introducing the MOAT into clinical practice.  
A potential area for future research may be to investigate the impact of combining the 
MOAT with other triggers for pharmacist review that we are unable to model, such as 
patients with swallowing difficulties, or those receiving end of life care. Another 
potential area may be to investigate the benefits of combining the MOAT with tools 
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aimed at identifying patients at risk of MRPs post discharge, such as the PREVENT 
tool109, to provide a more holistic approach to prioritisation. 
Strengths and limitations 
Strengths of the research presented in this chapter include the evidence-based 
approach, and high number of survey responses.  
A potential limitation was the use of a simple count to identify predictors previously 
reported as prognostic. While this is a recognised method to identify predictors70, it 
does not take into account differences in study design, study quality, or magnitude of 
effect. In addition, the categorisation of strength of evidence, based on the proportion 
of studies that found an association, does not reflect the number of studies 
investigating each predictor. For example, both gender and social deprivation are 
categorised as having low strength of evidence, but gender was included in 19 studies, 
and social deprivation in only one; this could further reduce the reliability of the 
assessment. I accounted for these potential weaknesses by not relying solely on the 
strength of evidence to select candidate predictors. Limitations for the expert survey 
include the use of convenience sampling, the ‘infinite’ target population which 
precludes calculation of a response rate, and the potential impact of volunteer bias.  
5.5 Conclusion 
This research resulted in the pre-selection of 18 candidate predictors for use in 
development of the MOAT. The method used theoretical knowledge, clinical 
understanding, and methodological considerations, with the aim of increasing the 
predictive performance94, and clinical credibility56 of the MOAT. In addition the research 
presented in this chapter highlighted that not all potential risk factors can be included in 
prognostic modelling, which will need to be considered when introducing the MOAT 
into clinical practice.  
The next chapter will explore the data collection for model development in more detail, 
including the need to develop clear definitions for the selected candidate predictors.  
 
  
Chapter 6: Data collection for model development 
 
93 
 
 
Chapter 6: Data collection for model development 
6.1 Introduction 
As discussed in chapter 2, many published prognostic model studies have been 
criticised in terms of methodological shortcomings55 56 and poor reporting54 57, limiting 
their usefulness. In response, the PROGnosis RESearch Strategy (PROGRESS) group 
published recommendations to improve the quality and impact of prognosis research53. 
In relation to data collection, they recommended ‘greater efforts to understand and 
improve the quality of clinically collected data’, and a need for better reporting to 
‘improve transparency’ and ‘identify good-quality from low-quality research’53. The 
PROGRESS recommendations were followed by publication of the ‘CHecklist for 
critical Appraisal and data extraction for systematic Reviews of prediction Modelling 
Studies’ (CHARMS)60, and the ‘Transparent Reporting of a multivariable prediction 
model for Individual Prognosis Or Diagnosis’ (TRIPOD) statement57. While neither 
prescribe how to develop a prognostic model, CHARMS highlights potential sources of 
bias, and TRIPOD summarises the qualities of good studies, and highlights 
inappropriate approaches that should be avoided. Both also provide guidance on the 
level of reporting required to permit quality to be adequately assessed.  
The aim of the work presented in this chapter was therefore to describe the 
methodology, methods, and results of data collection, using approaches informed by 
the PROGRESS53 55, TRIPOD94, and CHARMS60 recommendations. The objectives 
were to: 
 enhance the potential clinical credibility and usability of the Medicines Optimisation 
Assessment Tool (MOATTM) by selecting appropriate definitions for the outcome 
measure and candidate predictors; 
 select methods that minimise the risk of bias (selection and information biases); 
 explain and justify participant inclusion and data collection methods; 
 provide descriptive analysis of the sample population to permit potential users of 
the MOAT to assess applicability and generalisability; 
 demonstrate the rigour and consistency employed throughout all stages of data 
collection. 
This chapter includes both the methods and results for this part of the research. 
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6.2 Methodological considerations 
When designing this study it was necessary to make a number of fundamental 
methodological decisions related to data collection. These included the choice of: 
 outcome measure (the adverse medication-related outcome to be predicted by the 
MOAT); 
 data collection method for the outcome measure; 
 classification system to categorise the outcome data; 
 definitions and/or categories for the candidate predictors selected in chapter 5 
(including data collection methods where methodological decisions required). 
Each of these is described below. 
6.2.1 Selection of outcome measure  
As discussed in chapter 3, various outcome measures have been used in studies to 
predict adverse medication-related outcomes including adverse drug reactions (ADRs), 
adverse drug events (ADEs), medication related problems (MRPs), and medication 
errors (MEs). Moons et al94 advise that the choice of outcome event is a critical factor 
in determining the clinical relevance of a prognostic model, making this a key early 
consideration. The potential advantages of ADEs or ADRs over MRPs or MEs are as 
follows: 
 ADRs and ADEs are objective measures of harm, whereas MRPs and MEs include 
potential harm, therefore are subjective; 
 while ADRs and ADEs represent harmful events, only a small proportion of MRPs 
or MEs result in actual adverse medication-related outcomes78 83. It could therefore 
be argued that patient safety initiatives that target patients at risk of actual rather 
than potential harm may be more efficient; 
 unlike ADRs and ADEs, MRPs and MEs are proxy measures for patient-oriented 
outcomes, which limits the ability to directly relate a reduction in MRPs or MEs to 
patient outcomes. 
While these are valid arguments, the proposed purpose of the MOAT is to target 
patients most in need of pharmacists’ input, and as pharmacists routinely identify and 
resolve potential in addition to actual adverse medication-related outcomes, a 
prediction tool that more closely reflects clinical practice is likely to have greater clinical 
credibility. Another consideration was the ability to collect valid outcome data given that 
regular patient review by ward-based clinical pharmacists is standard practice at the 
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proposed study sites, as it is in many United Kingdom (UK) hospitals. Pharmacist 
intervention therefore had the potential to prevent harmful events from occurring, so 
reducing ADE occurrence (i.e. outcome data would only include events that were not 
intercepted, or could not be prevented by pharmacist intervention). Although it would 
be possible to eliminate this source of bias by removing the clinical pharmacy service 
during the study, withholding standard care would raise significant ethical issues. It was 
therefore decided to look at MRPs or MEs. 
Regarding the choice between MRPs and MEs, MRPs encompass a wider range of 
events, including any untoward medication related outcome irrespective of whether an 
error occurred. The use of MRPs as the outcome measure also permits targeting of 
patients with unrealised benefits (as discussed in chapter 2). I therefore selected MRPs 
as the outcome measure as I believe it will align the MOAT more closely with 
pharmaceutical care practice110, so enhancing clinical credibility.  
Severity and preventability of outcome measure 
Previous research suggests that a significant proportion of hospitalised patients 
experience MRPs (for example Blix et al reported a prevalence of 81%78), many of 
which are of limited clinical significance. A model developed to predict MRPs would 
therefore lead to a high proportion of patients being labelled as high-risk, potentially 
leading to inefficient workload management. An option suggested in chapter 3 was to 
select a clinically significant outcome measure, based on severity. I therefore chose to 
severity rate all MRPs, and only use moderate or severe MRPs for model development 
(as described in chapter 8). Similarly, the aim of the MOAT is to target patients with 
MRPs amenable to pharmacist intervention (i.e. those with preventable MRPs). 
Unpreventable MRPs, such as ADRs that could not have been anticipated, were 
therefore excluded from MOAT development. As no established grading system for 
MRP preventability is available, I considered two possible methods: the criteria 
provided by Schumock and Thornton111, and the ‘P Method’112. I concluded that both 
methods were developed for ADRs, most of which are unpreventable, whereas the 
majority of MRPs are inherently preventable. Neither method was therefore appropriate 
for the present study. Pharmacists were therefore asked to review each MRP at the 
point of identification to assess whether it was preventable, expressed as a 
dichotomous variable of yes or no.  
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6.2.2 MRP data collection 
Previous research into the detection of prescribing errors, a subset of MRPs, has 
shown that the observed prevalence is extremely dependent on the method of 
detection113. I chose to use prospective identification by pharmacy staff for this study 
because: (1) the purpose of the study was to develop a prognostic model for MRPs that 
can be identified during routine clinical practice; (2) it would permit the identification / 
inclusion of MRPs that are not routinely recorded in medical notes, such as potential 
prescribing or administration errors that are intercepted; and (3) it would permit the 
MRPs to be identified by staff personally involved in the care of the study patients, 
increasing clinical and practical relevance.  
6.2.3 MRP classification  
A number of classification systems for MRPs have been developed, which vary in the 
definition used, and method to classify causes and outcomes. As there is no universally 
accepted classification system, and perceived deficiencies with many published 
classification systems, I used the aggregated classification system recently developed 
by Basger et al114 (Table 13). This is based on the most commonly used systems 
(Pharmaceutical Care Network Europe20, Cipolle et al115, Westerlund116, 
DOCUMENT117, Norwegian118, and the individualised Medication Assessment and 
Planning / iMAP tool119), and provides a comprehensive classification system based on 
the causes of MRPs, thereby preventing any potential confusion between MRP causes 
and outcomes. 
Table 13 – Basger’s medication related problem classification system 
1. Drug selection 
1.1 Inappropriate drug  
1.2 No indication for drug / duplication 
1.3 Interaction (drug-drug, or drugs and food / alcohol) 
1.4 Indication not treated / missing therapy 
1.5 More cost effective drug available 
1.6 Synergistic / preventive drug required and not given 
2. Drug form 
2.1 Inappropriate or suboptimal drug form 
3. Dose selection 
3.1 Drug dose too low  
3.2 Drug dose too high  
3.3 Dosage regimen not frequent enough 
3.4 Dosage regimen too frequent 
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3.5 Dose needs adjustment to organ function or change in disease state 
3.6 Dosage instructions unclear, incomplete or not understood by patient / carer 
4. Treatment duration / withdrawal 
4.1 Duration of treatment too short 
4.2 Duration of treatment too long 
5. Drug use process 
5.1 Inappropriate timing of administration / dosing by prescriber; administration error by nurse 
5.2 Drug underused / under-administered 
5.3 Drug overused / over-administered 
5.4 Drug not taken / administered at all 
5.5 Wrong drug taken by patient 
5.6 Drug abused 
5.7 Patient or nurse uses drug incorrectly through lack of knowledge or barriers (e.g. swallowing, 
dexterity)  
5.8 Adequate information not provided or not understood or misunderstood or not followed 
5.9 Drugs stored inappropriately / expired drug administered / preparation error 
6. Logistics 
6.1 Prescribed drug not available 
6.2 Drug order incorrect, incomplete, poorly legible / illegible / illegal / incorrect / allergy status 
incomplete  
6.3 Error in drug selection 
7. Monitoring 
7.1 Monitoring too frequent 
7.2 No or too infrequent monitoring 
7.3 Inappropriate test ordered 
7.4 Patient unable to attend / pay for monitoring 
8. Unexpected reaction / adverse drug reaction (ADR) / no obvious cause 
8.1 An ADR occurred 
8.2 No obvious cause of treatment failure 
Three of Basger’s MRP subcategories were not used for the present study as they 
relate to primary care: 
 3.6 ‘dosage instructions unclear, incomplete or not understood by patient / carer’;  
 5.8 ‘adequate information not provided or not understood or misunderstood or not 
followed’; 
 7.4 ‘patient unable to attend / pay for monitoring’. 
I also added a category for ‘inappropriate abrupt withdrawal of a medicine’, as I did not 
feel that this was adequately captured by Basger’s classification system.  
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6.2.4 Selection of candidate predictor definitions / categories 
Once the candidate predictors had been selected (as described in chapter 5), it was 
necessary to choose appropriate definitions for each of these. Unambiguous definitions 
are needed to improve the accuracy and replicability of predictions60 98, but clinical 
credibility can be reduced if definitions are not clinically relevant, or too difficult to apply 
in practice102. My aim was, therefore, to: (1) select definitions commonly used in clinical 
practice; (2) use data that are readily available (to avoid the need for additional 
measurements, which could be perceived as inconvenient and/or costly102); and (3) 
avoid the need for complex calculations or categorisation (to ensure ease of use in 
clinical practice102).  
It was also necessary to pre-select categories for the categorical predictors with more 
than two categories (primary diagnosis and high-risk medicines), to reduce the risks of 
model overfitting (associated with using too many variables60), and selection bias 
(caused by data-driven analysis62). 
The selection of predictor definitions and categories is described below. 
6.2.4.1 Laboratory results  
Laboratory results vary throughout a patient’s admission to hospital, it was therefore 
necessary to select a time point for data collection to ensure consistency and 
reproducibility.  
Prognostic modelling investigates the relationship between future outcomes 
(endpoints) among people with a given baseline health status (startpoint)120. For the 
MOAT study the ‘startpoint’ was admission to a hospital medical ward, I therefore used 
the first documented laboratory results following admission. In six cases (all from 
Hospital A), no results were available during the hospital stay (i.e. serum sodium, 
potassium, creatinine, albumin, white cell count and liver function tests), but results 
were available from the preceding week. I consulted the MOAT project steering group 
(comprising PhD supervisors, clinical supervisors, patient / public representatives) to 
discuss whether to use these results for the study. It was agreed that this was 
appropriate, on the basis that the results were the only ones available to the healthcare 
team during admission. This represented 0.4% of patients (i.e. six from a total of 
1,503). 
Details of how laboratory results were used to estimate renal and liver function are 
given next. 
Chapter 6: Data collection for model development 
 
99 
 
 
Renal function  
The two prediction formulas commonly used to estimate renal function are the 
Cockcroft-Gault, and modified Modification of Diet in Renal Disease (MDRD) 
equations121. There is relatively good correlation between the two for patients of 
average weight122, but results are not interchangeable, particularly at extremes of body 
weight121. A key deciding factor in selecting which equation to use for this study was 
the availability of data. Both equations require serum creatinine, age and gender, but 
Cockcroft-Gault adjusts for body weight, whereas the modified MDRD adjusts for race. 
My original intention was to use Cockcroft-Gault, as this is more frequently used by 
pharmacists in clinical practice (to adjust medicine dosages in renal impariment122). 
However, in reviewing the study data I found that weight was unavailable for 186 
(12.4%) of 1,503 patients. Race was more reliably recorded, with data unavailable for 
only 96 (6.4%) of patients. 
A further consideration was the increasing use of the modified MDRD equation by 
laboratories throughout the UK to routinely report renal function whenever a 
measurement of serum creatinine is requested123, as is the case at Hospital B. 
I therefore chose to use the modified MDRD equation to estimate renal function for this 
study, calculated using the following formula: 
Estimated GFR (ml/min/1.73m2) = 186 x (creatinine / 88.4)-1.154 x (age)-0.203 x (0.742 if 
female) x (1.210 if black) 
as recommended by National Institute for Health and Care Excellence124, Renal 
Association (UK)125, and used by Renal Drug Database122.  
I discussed how to handle the missing ethnicity data with Dr Li Wei (academic 
supervisor), and we decided that where ethnicity was not recorded, patients would be 
categorised as non-black for the purposes of estimating renal function. This decision 
was taken due to the relatively small number of admissions with missing ethnicity data, 
and the low number of ‘black’ patients within the remaining 1,407 admissions (45 
patients, i.e. 3.2%). Although this proportion may not be representative of the patients 
with missing ethnicity data (as individual ethnic groups may be more or less likely to 
withhold ethnicity information), if one assumes that 3.2% of the admissions with 
missing ethnicity data were black, this would equate to three additional black patients 
(i.e. 3.2% of 96 admissions). Given the potentially small number, it was agreed that 
classifying all missing ethnicity data as ‘non-black’ would not significantly affect the 
overall predictor-outcome relationship.   
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Liver disease definition  
Liver disease is not straightforward to quantify due to the variation in liver function tests 
(LFTs) dependent on the type and stage of disease126. I therefore chose to treat liver 
disease as a binary variable (yes/no). To establish a suitable definition, I reviewed the 
definitions used by studies included in the literature review (chapter 3), and pharmacy 
triage tools currently in use within hospitals in the UK: NHS Greater Glasgow and 
Clyde, Royal Cornwall Hospitals NHS Trust, and Leeds Teaching Hospitals NHS Trust. 
I became aware of these consensus derived tools during a meeting at NHS England 
(July 2016), held to discuss pharmacy prioritisation methods used in UK hospitals (as 
part of their work on developing seven day clinical pharmacy services in acute 
hosptials36). 
Liver disease was included as a risk factor in the following triage tool / studies, but was 
not defined: 
 Leeds Teaching Hospitals NHS Trust (triage tool); 
 Hickson et al51; 
 Kaufmann et al38; 
 Onder et al41; 
 Evans et al79. 
The definitions used for liver disease by the remaining triage tools / studies are 
summarised in Table 14.  
Table 14 – Definitions used for liver disease 
Source Liver disease definition 
NHS Greater Glasgow and 
Clyde triage tool 
Severe hepatic impairment defined as liver function tests 
(LFTs) ≥ 3 times upper limit of normal 
Moderate liver impairment defined as LFTs elevated from 
normal but < 3 times upper limit of normal 
Royal Cornwall Hospitals NHS 
Trust triage tool 
High priority (level 3) patients: 
LFTs: alkaline phosphatase (ALP), alanine aminotransferase 
(ALT), bilirubin ≥ 3 times upper limit of normal 
Blix et al. (2004)
78
 LFTs – aspartate aminotransferase (AST) or ALT 3 times 
above normal value  
Wilmer et al. (2015)
90
 Child-Pugh score  
O’Connor et al. (2012)
88
 Liver disease defined as synthetic liver dysfunction, or liver 
injury with raised transaminases greater than twice the 
normal range, or documented liver disease 
Beckett et al. (2012)
87
 Liver impairment taken as ALT or AST > 40mg/dL (standard 
reference range not given) 
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As shown in Table 14, a range of tests and/or cut-points have been used to define liver 
disease. Wilmer et al90 used the Child-Pugh score, whereas the reminder used LFTs. I 
chose to use LFTs rather than the Child-Pugh score as this is consistent with clinical 
practice, as shown by the use in two of the pharmacy triage tools already in use in the 
UK (NHS Greater Glasgow and Clyde, and the Royal Cornwall Hospitals NHS Trust). 
In addition, the Child-Pugh score is a measure of prognosis of chronic liver disease, 
therefore not routinely assessed.  
LFTs is a term used for a range of tests of liver function, including aspartate 
aminotransferase (AST), alkaline phosphatase (ALP), alanine aminotransferase (ALT), 
gamma-glutamyl transpeptidase (GGT), bilirubin, and serum albumin126. As shown in 
Table 14, the LFTs commonly used to establish a diagnosis of liver disease were AST, 
ALT, ALP and bilirubin. Blix et al78 and Beckett et al87 used AST, but this was not an 
option for the present study as it was not routinely measured at either of the study 
sites. I therefore chose to use ALP, ALT, and bilirubin, as this is consistent with clinical 
practice at both study sites, and the Royal Cornwall Hospitals NHS Trust. I chose to 
use a cut-point of greater than or equal to three times normal ranges. This is consistent 
with the triage tools used by NHS Greater Glasgow and Clyde, and the Royal Cornwall 
Hospitals NHS Trust. It was also the cut-point used by Blix et al78.  
Where no LFT results were available (i.e. where tests not performed) I assigned the 
outcome as ‘normal LFTs’ on the assumption that the medical team had not considered 
the tests necessary. This occurred for 26 (1.7%) of 1,503 patients. Where not all results 
were available (due to the laboratory being unable to analyse the sample for specific 
tests, for example where sample haemolysed) I also assigned the result as ‘normal 
LFTs’ if the remaining result(s) were within normal range. This occurred for 71 (4.7%) 
of the 1,503 patients. 
Given the variation in liver function tests dependent on the type and stage of 
disease126, and the lack of laboratory data for some patients (as detailed above), I also 
chose to include ‘documented liver disease’ as an alternative marker of liver 
impairment, as used by O’Connor et al88 (see Table 14). For this, I reviewed the 
International Classification of Diseases (ICD) data for all study patients (diagnoses and 
comorbidities). Patients with one or more of the following ICD codes were assigned the 
outcome ‘documented liver disease’: 
 acute and subacute hepatic failure; 
 acute viral hepatitis; 
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 alcoholic cirrhosis of liver; 
 alcoholic fatty liver; 
 alcoholic fibrosis and sclerosis of liver; 
 alcoholic hepatic failure; 
 alcoholic liver disease, unspecified; 
 autoimmune hepatitis; 
 chronic passive congestion of liver; 
 chronic viral hepatitis B; 
 chronic viral hepatitis C; 
 fatty change of liver; 
 hepatic failure; 
 hepatomegaly; 
 hepatorenal syndrome; 
 liver disease, unspecified; 
 other and unspecified cirrhosis of liver; 
 other specified diseases of liver; 
 other specified inflammatory liver diseases; 
 portal hypertension; 
 malignant neoplasm: liver cell carcinoma; 
 secondary malignant neoplasm of liver and intrahepatic bile duct; 
 malignant neoplasm, liver cell carcinoma; 
 abnormal results of liver function studies. 
Study patients were therefore recorded as having liver disease if they had an abnormal 
LFT result, and/or documented liver disease. 
6.2.4.2 Comorbidity  
Comorbidity is a complex entity, with little consensus on the best approach to measure 
it127. Various methods have been developed including: 
 organ-based approaches, such as the Modified Cumulative Illness Rating Scale 
(CIRS)128; 
 weighted indices, such as the Charlson Index129; 
 prevalence of individual conditions, such as the Elixhauser system130; 
 simple counts of individual conditions127. 
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After reviewing the above options I chose to use a simple comorbidity count. The 
reasons for this were:  
 the Charlson Index and Elixhauser system were developed to predict the risk of 
mortality, and recent studies suggest they are poor predictors of nonfatal 
outcomes47. They are also based on a limited range of conditions, rather than being 
comprehensive measures of disease burden. For example, the Charlson Index 
excludes arrhythmias and thyroid diseases, and Elixhauser excludes 
cerebrovascular disease and previous myocardial infarction (Appendix A6.1 shows 
a detailed breakdown of the comorbidities included in CIRS, Charlson, and 
Elixhauser); 
 the Charlson Index and CIRS require knowledge of disease severity. As 
comorbidity data for the MOAT study were obtained from ICD coding, it was not 
possible to perform this level of assessment. In addition, neither score is routinely 
used in clinical practice, potentially reducing ease of use of the MOAT; 
 the Elixhauser system uses 30 dichotomous variables, while this would provide 
study-specific regression coefficients for each comorbidity, it could jeopardise 
regression modelling due to overfitting70. In addition, Elixhauser uses ICD coding 
from administrative systems. This is not available until after hospital discharge, so 
would not be available to pharmacists when the MOAT is intended to be used 
(unless patients had previous hospital admissions); 
 a simple comorbidity count uses data that are routinely collected in clinical practice, 
are available at the point of hospital admission, and do not require complex 
manipulation. In addition, Steyerberg advises they ‘may be rather robust and 
generalise well to new patients’70. 
Having decided to use a simple comorbidity count, I then reviewed the available ICD 
comorbidity data to assess usability, and identified the following issues: 
 some ICD codes are not specific to conditions (e.g. ‘abnormal finding of blood 
chemistry’, ‘malaise and fatigue’); 
 some are not directly related to illness (e.g. ‘inadequate housing’, ‘allergy to 
penicillin’); 
 duplication can occur (e.g. ‘atrial fibrillation and atrial flutter, unspecified’ and ‘atrial 
fibrillation and atrial flutter’ used for the same patient); 
 comorbidities related to the same underlying condition can be coded separately for 
the same patient (e.g. ‘chronic obstruct pulmonary disease’, and ‘emphysema’); 
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 temporary conditions are included as comorbidities (e.g. ‘pregnant state’, 
‘pneumonia’), or relatively minor conditions (e.g. ‘conjunctivitis’, ‘otitis externa’). 
This is likely to relate to ICD codes being used for a wide variety of signs, symptoms, 
abnormal findings, complaints and social circumstances131. It was therefore necessary 
to modify the ICD data to reduce the risk of double counting, and inclusion of conditions 
that may not be considered to be true comorbidities in clinical practice. I therefore 
reviewed the medical records of 96 randomly selected patients from Hospital A, 
(approximately 10% of study patients from that site), to compare ICD coding with the 
comorbidities listed on each patient’s discharge prescription (taking the latter as a 
source consistent with clinical practice). I found that the two sources of data were not 
directly comparable. As expected, the number of comorbidities was higher based on 
the ICD data (mean 8.2 comorbidities per patient compared to 4.3 for data from 
discharge prescriptions), for the reasons discussed above. As a result I chose to 
exclude the following ICD codes from the study comorbidity count:  
 temporary conditions (e.g. infections); 
 non-specific symptoms (e.g. cough); 
 abnormal laboratory or other clinical findings (e.g. abnormal glucose tolerance test); 
 procedures performed (e.g. cardiac catheterisation); 
 trauma (e.g. unspecified injury of forearm); 
 lifestyle factors (e.g. smoking, alcohol or illicit drug use); 
 findings unrelated to illness burden (e.g. allergy status). 
I also restricted the comorbidity count to conditions present prior to the current 
admission, that is, I excluded the primary diagnosis, as this may not be established at 
the point of admission to hospital. This is consistent with the definition used by 
Elixhauser130. I also grouped similar comorbidities to prevent double counting. I used 
the 14 CIRS organ-based categories as a framework, as this provided a 
comprehensive list of conditions associated with chronic illness burden128, then sub-
divided each category to permit more than one condition within an organ-based group 
to be counted individually. I created an additional category for tumours / malignancies; 
CIRS includes these within each organ-based system, but I grouped them to simplify 
the count, and prevent double counting of primary and secondary malignancies. This 
created 76 separate categories (shown in Appendix A6.2). These categories were used 
to recode the comorbidity related ICD data for all study patients, then duplicates 
removed to give a final comorbidity count for each patient.  
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6.2.4.3 Dementia 
In addition to the inclusion of dementia in the comorbidity count, it was also selected as 
a separate candidate predictor. ICD coding was used to establish a documented 
diagnosis of dementia. All study patients with one or more of the following ICD codes 
were classed as having a history of dementia, expressed as a dichotomous variable of 
yes or no: 
 dementia in Alzheimer disease;  
 vascular dementia;  
 unspecified dementia;  
 delirium superimposed on dementia;  
 Alzheimer disease with early onset;  
 Alzheimer disease, unspecified;  
 circumscribed brain atrophy;  
 dementia in Alzheimer disease with early onset;  
 dementia in Alzheimer disease, atypical or mixed type;  
 dementia in Alzheimer disease, unspecified;  
 dementia in other specified diseases classified elsewhere;  
 dementia in Parkinson disease;  
 dementia in Pick disease;  
 other Alzheimer disease.  
I excluded 'delirium', 'mild cognitive disorder', and 'signs involving cognitive function', 
due to their non-specific, and potentially temporary nature. I also excluded ‘senility’, 
due to its potentially subjective definition (covering both physical and mental age-
related decline)132. 
6.2.4.4 Use of medicines 
Three medicine related predictors were selected for development of the MOAT; the 
number of medicines, route of administration, and type of medicine prescribed (shown 
in Table 11, chapter 5). Before selecting definitions for these, it was necessary to 
define ‘medicine’.  
During hospitalisation, medicines can be prescribed to be given in three ways, ‘STAT’ 
(abbreviated from the Latin word ‘statum’, meaning to be given immediately132), ‘PRN’ 
(from the Latin phrase ‘pro re nata’, meaning as required132), or as a regular, on-going 
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prescription. I chose to restrict the study to medicines prescribed to be given on a 
regular basis for the following reasons: 
 STAT medicines may pose different risks to regular medication due to the range 
prescribed, e.g. vaccines and medicines used for diagnostic purposes;  
 PRN medicines may be prescribed, but administered infrequently or not at all, 
which could falsely inflate the medicine count. For example, medicines such as 
analgesics and antiemetics are often prescribed to be given only if symptoms 
occur.  
I also excluded the following: 
 dietary products and emollients, on the basis these are non-medicated; 
 wound dressings, as although sometimes medicated, they are not used as a means 
of medicines administration; 
 oxygen therapy, and blood products, as these are not recorded as part of the 
medication records at all hospitals; 
 ‘water’ or ‘saline flushes’.  
All other medicines prescribed to be administered on a regular on-going basis, 
including analgesics and antiemetics, were included, irrespective of the route of 
administration.  
Conventions were used to ensure consistency in data recording (summarised in 
Appendix A6.3). 
Number of medicines  
As with laboratory results, the number of medicines prescribed will vary throughout a 
patient’s admission to hospital, it was therefore necessary to select a time point to 
perform the medicine count. I chose to use the first full day of admission to hospital, as 
this provided ‘startpoint’ data, and included all medication prescribed to be given over a 
24 hour period.  
In some cases medicines were changed to a clinical equivalent on the first full day of 
admission, for example from intravenous to oral, or to a direct clinical alternative. 
Where this was clearly the case (i.e. where the same medicine was prescribed, but the 
route changed, or where it would not be clinically appropriate to use both medicines 
concurrently), this was counted as ‘one’ medicine.  
Other conventions that were used were: 
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 combination medicines (e.g. solifenacin 6mg with tamsulosin 0.4mg modified 
release tablets) were counted as ‘one’ medicine; 
 where more than one formulation of the same medicine was prescribed by same 
route (e.g. standard and modified release oral preparations, or suppository and 
enema), this was counted as ‘one’ medicine. If the same medicine was prescribed 
via different routes (e.g. mesalazine orally and rectally), both were counted 
separately; 
 at Hospital A, medicines administered using a 24-hour subcutaneous syringe driver 
were prescribed as ‘syringe driver’ on the electronic prescribing record, irrespective 
of the number of medicines within the syringe. Syringe drivers were therefore 
counted as ‘one’ medicine at both sites; 
 the count included all medicines prescribed to be given, even if withheld on the day 
the count was performed (e.g. once weekly medication not due to be administered 
on the day of the count, or medicines withheld for clinical reasons such as 
dehydration, or while awaiting results of other investigations). 
Route of administration 
Previous research suggests that the route of medicine administration is associated with 
adverse medication-related outcomes, with the strongest associations found with 
parenteral use79 87 91. This is supported by the National Patient Safety Agency alert, 
‘promoting safer use of injectable medicines’133. I therefore chose to assess the impact 
of parenteral medicine use, that is, administration via the intravenous, intramuscular, or 
subcutaneous route. 
The following were excluded from this assessment: 
 medicines prescribed as ‘parenteral or oral’, as it was not possible to establish 
whether the parenteral route had been used; 
 prophylactic low molecular weight heparins, as they are routinely used in the 
majority of patients admitted to hospital medical wards134; 
 parenteral fluid replacement therapy.  
For simplicity, parenteral medicine use was expressed as a dichotomous variable of 
yes or no. 
Type of medicine 
The risk associated with different medicines has been assessed in various ways in 
previous studies, including grouping by Anatomical Therapeutic Chemical (ATC) 
Chapter 6: Data collection for model development 
 
108 
 
 
codes52 85, Institute for Safe Medication Practices (ISMP) high-alert medication87, those 
with a ‘narrow therapeutic index’38 90, and by assessing individual medicines and/or 
classes76 80. 
Grouping medicines, rather than assessing individually, has the advantage of 
increasing the generalisability of results (as discussed in section 3.4), but the use of 
broad categories, for example ATC codes (where medicines are divided into different 
groups according to the organ or system on which they act135), can result in medicines 
with different pharmacological and chemical properties being grouped together. I 
therefore chose to focus on high-risk medicines / groups (discussed further in section 
6.2.4.6). 
6.2.4.5 Allergies 
Data on all medicine-related allergies were collected for study patients. I considered 
using either a count of allergies, or treating it as a binary variable (yes/no), and chose 
the latter because: (1) a count may be dependent on breadth of medicine exposure, 
therefore correlated with comorbidity and/or age; and (2) this is consistent with 
previous research38 41 42 44. All non-drug allergies (e.g. food, latex) were excluded. 
6.2.4.6 Categorisation of primary diagnosis and high-risk medicines 
Primary diagnosis 
My original intention was to categorise primary diagnosis using the ICD categorisation 
system, as used by other researchers41 42, but after further consideration I chose to use 
an organ-based approach. ICD coding for primary diagnosis classifies diseases into 22 
mutually exclusive chapters131 based on ‘the main condition treated or investigated 
during the relevant episode of healthcare’136. As ICD codes are allocated following the 
episode of care, codes for hospital inpatients are informed by investigations performed 
during admission. For example, up to 30% of patients with symptoms indicative of an 
acute ischaemic stroke may in fact have a ‘stroke mimic’, a non-vascular condition that 
also presents with acute neurological deficit, including seizures, brain tumours and 
infections137. As a result, further investigations, such as brain imaging, are required 
before the primary diagnosis can be confirmed. In this example, a confirmed stroke 
would be coded under the ICD chapter ‘circulatory system’, seizures under ‘nervous 
system’, brain tumours under ‘neoplasms’, with infections coded as either ‘systemic 
infections’ (under the chapter covering ‘certain infectious diseases’) or as a disease of 
the nervous system, depending on the site and type of infection. While ICD based 
categorisation may be useful for a retrospective analysis, the purpose of the MOAT is 
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to predict outcome events based on startpoint data (data available at the point of 
admission120). Use of an organ-based approach therefore permits categorisation ahead 
of definitive investigations, as all potential diagnoses are grouped together. For 
example, in the scenario above stroke and stroke mimics would be grouped as 
disorders of the nervous system. This has the potential to simplify use of the MOAT, 
and reduce the risk of misclassification. 
I chose to use the CIRS organ-based classification system128 as a framework to 
categorise primary diagnosis, as this is a recognised and comprehensive system, and 
is consistent with the approach used for the comorbidity count.  
CIRS has 14 categories (shown in Table 15), but I chose to combine some categories 
(for example upper and lower gastrointestinal and liver diseases) to both simplify use of 
the MOAT in clinical practice, and reduce the risk of model overfitting (associated with 
using too many variables60). Remaining diagnoses were combined into an ‘other’ 
category on the basis they did not fall into the selected organ-based categories, or 
were symptoms or findings that are not specific to a diagnosis. This created eight 
categories, as shown in Table 15. Details of the specific diagnoses included in each 
category (based on the MOAT patients) are given in Appendix A6.4. 
As discussed in section 5.3.2, the expert survey respondents suggested four diagnoses 
as potential risk factors for MRPs (diabetes, Parkinson’s disease, immunodeficiency, 
and sepsis).  Although it was not possible to include each of these individually, all fall 
within the primary diagnosis categories selected for the study. 
Table 15 – Grouping used for primary diagnosis  
Medicines Optimisation 
Assessment Tool category 
Modified Cumulative Illness Rating Scale 
categories128 
1. Cardiovascular system 
Cardiac  
Hypertension  
Vascular-haematopoietic  
2. Respiratory system Respiratory 
3. Gastrointestinal system 
Upper gastrointestinal  
Lower gastrointestinal 
Hepatic 
4. Genitourinary system 
Renal  
Other genitourinary  
5. Musculoskeletal-
intergumentary systems 
Musculoskeletal-intergumentary 
6. Endocrine-metabolic 
diseases 
Endocrine-metabolic  
7. Nervous system and mental 
disorders 
Neurological  
Psychiatric / behavioural  
8. Other Includes CIRS category ‘eyes, ear, nose & throat’ 
and symptoms or findings not specific to a diagnosis 
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High-risk medicines 
The categorisation of high-risk medicines served two purposes; reducing the risk of 
model overfitting, and increasing the potential generalisability of the MOAT (as 
discussed in section 3.4). 
I used the following sources to select the high-risk medicines categories for the MOAT 
study: 
 two systematic reviews (a review by Suggett et al64 that was specific for risk factors 
associated with the need for pharmaceutical intervention due to ADEs, ADRs and 
MRPs in adult hospitalised patients, and a review by Saedder et al138 that identified 
high-risk medicines associated with MEs in adults, but was not specific to 
hospitalised patients); 
 a meta-analysis by Boeker et al139 of four studies of preventable ADEs in adult 
inpatients; 
 a consensus study by Thomas et al140 to identify prescribing indicators associated 
with potential harm in hospital settings; 
 the consensus studies included in the literature review38 46 48-51 (discussed in 
chapter 3); 
 ISMP high-alert medication list141; 
 personal correspondence with staff at UK hospitals currently using pharmacy triage 
tools (NHS Greater Glasgow and Clyde, Royal Cornwall Hospitals NHS Trust, and 
Leeds Teaching Hospitals NHS Trust); 
 suggestions received from the expert survey respondents (listed in Table 10, 
section 5.3.2). 
Direct comparison between sources was difficult due to differences in the outcome 
measures, setting (hospital and primary care), the way medicines were grouped, and 
county specific issues (e.g. the ISMP high-alert medication list contains a number of 
medicines not routinely used in the UK). I therefore chose to include medicines as high-
risk if there was evidence from more than one of the above sources, including a UK 
source. Five groups of medicines met these criteria, but were excluded for the following 
reasons: 
 benzodiazepines / sedatives – excluded as often prescribed on an ‘as required’ 
basis during hospitalisation (whereas only medicines prescribed to be given on a 
‘regular’ basis were included in the present study); 
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 non-steroidal anti-inflammatory drugs (NSAIDs) – also often prescribed ‘as 
required’ during hospitalisation;  
 diuretics – not selected as high-risk in any of the consensus prediction tool studies, 
or pharmacy triage tools; 
 anti-thrombotics – not selected as high-risk in any of the consensus studies, or 
pharmacy triage tools; 
 corticosteroids – not identified as high-risk in any of the pharmacy triage tools, plus 
dosage and duration varies dependent on indication, which is likely to impact on the 
level of risk. 
Clozapine, anti-retrovirals, and medicines for Parkinson’s disease were identified as 
high-risk, but I chose to group these, as I anticipated usage would be too infrequent to 
model each individually. 
This resulted in 15 categories, as summarised in Table 16, section 6.3.4. Each was 
treated as a binary variable of yes or no. My original intention, as detailed in the 
published MOAT protocol142, was to include ‘antibiotics’ as one of the 15 categories. I 
subsequently decided to change this to ‘antimicrobials’, as this permitted the inclusion 
of agents that act against all microbial organisms (i.e. antibiotics, antivirals antifungals, 
and antiprotozoal agents).  
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6.3 Methods 
The methods are presented according to the TRIPOD reporting guidelines57.  
This section includes the source of data, selection of study participants, method of data 
collection for the outcome measure and candidate predictors, analysis of missing data, 
data entry checks for candidate predictors, statistical analysis, and ethical 
considerations. Each of these is described in turn below; the results are described in 
section 6.4. 
6.3.1 Source of data  
This prospective cohort study included patients admitted to two UK hospitals in South 
East England. The two study sites, Hospitals A and B, were chosen to increase 
generalisability of the MOAT as they have markedly different patient demographics.  
Eligible patients were consecutively included at Hospital A from 28 April 2016 to 31 
May 2016, and Hospital B from 19 October 2016 to 1 November 2016. All patients 
were followed up until discharge from hospital, or the date the study closed (two weeks 
after inclusion of the final study patient) whichever occurred sooner. A study close date 
was used to facilitate practicality in terms of data collection, while permitting data to be 
collected from admission to discharge for the majority of study patients (as the mean 
length of stay at the study sites was estimated at approximately six days). 
6.3.2 Participants 
The choice of participants was guided by the intended use of the MOAT, which is to 
identify adult patients at highest risk of MRPs during admission to a UK medical ward, 
irrespective of age. I therefore included all adults (aged 17 years and over). They were 
selected by means of being consecutive admissions to the medical wards (general, 
acute, and elderly medicine) at the study sites. At Hospital A there were 11 study wards 
(six general, one acute, and four elderly medicine). Hospital B had 19 study wards (six 
general, four acute, and nine elderly medicine). Patients admitted to other specialities 
such as surgery, maternity and paediatrics were excluded due to potential differences 
in the prevalence / type of MRPs in these patient groups. Patients admitted more than 
once during the data collection period were eligible to re-enter the study. 
Patients were excluded if: 
 their admission was for investigation only (as changes to medication would be 
minimal); 
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 they were not prescribed any medication during the admission; 
 their entire admission was outside of core pharmacy working hours (i.e. 9am-5pm 
Monday-Friday) as these patients would be unlikely to receive review by a clinical 
pharmacist;  
 their prescribing records were not reviewed by a clinical pharmacist during the 
admission (e.g. a patient who was present on a study ward during core pharmacy 
working hours but discharged before a clinical pharmacist was able to review their 
medication). 
Patients admitted for investigation only, and those not prescribed medication during the 
admission, were excluded on the basis that they did not represent the target population 
for the MOAT. Those with admissions outside core pharmacy working hours, and 
whose prescribing records were not reviewed by a clinical pharmacist during their 
admission, were excluded on the basis that it was not possible to ascertain whether 
they experienced an MRP (using the chosen data collection method); inclusion of these 
patients may therefore have distorted the predictor-outcome relationship. 
Patients were also excluded if their prescribing records and/or medical notes were 
unavailable. This was to ensure complete data were available for the medicine-related 
candidate predictors. The potential impact of excluding these patients is discussed in 
section 6.4.3 as part of the analysis of missing data. 
The sample size target was 1,500 study admissions (1,000 from Hospital A and 500 
from Hospital B). Section 9.2.3 in chapter 9 describes how this sample size was 
derived (as part of the methods used for model development). An additional 10% were 
included at each site to allow for potential losses due to exclusions. 
The characteristics of the sample population are reported in section 6.4.2 to provide 
information on the context, case mix, and setting of the study94. This includes 
demographic data and the distribution of candidate predictors. Results are presented 
as percentage, mean or medians dependent on the type and distribution of data. 
Standard deviations or interquartile ranges (IQRs) are reported to establish variability, 
and ranges given for all continuous variables to inform values that will be compatible 
with the MOAT94. Due to the observational nature of the study, and retrospective 
collection of candidate predictor data, it was not possible to review measurement 
reliability, but reliability was assumed on the basis that data were collected for routine 
clinical purposes by healthcare professionals.    
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6.3.3 Outcome measure  
As discussed in section 6.2.1, the outcome measure of interest for this study was 
MRPs. The definition used was ‘all circumstances involving a patient’s drug treatment 
that actually, or potentially, interfere with the achievement of an optimal outcome’12 16 19 
20. Data were collected on all MRPs that occurred during the hospital stay, and then 
each was accessed for preventability and severity to identify the outcome event 
selected for MOAT development, namely moderate or severe preventable MRPs (MSP 
MRPs). 
All pharmacists involved in the study were provided with training prior to 
commencement of the study (32 pharmacists at Hospital A and 44 at Hospital B). As 
MRP data were collected during daily ward visits and by staff in the centralised 
pharmacy dispensaries, the training was provided for all pharmacists who may have 
been required to clinically screen study patients’ medication charts (i.e. ward-based 
pharmacists working routinely on the study wards, and all pharmacists who were 
involved in dispensary duties during the study period). The training comprised a 45-
minute face-to-face session (delivered by myself) covering the purpose and design of 
the study, method of MRP data collection, discussion about the types of adverse 
medication-related outcomes covered by the MRP definition12 16 19 20, and instructions 
on how to use Basger’s MRP classification system114.  
Following this training, MRP data were identified and recorded by pharmacy staff at the 
study sites as part of their routine daily clinical assessment of patients, using a data 
collection form designed for this purpose (Appendix A6.5). Data were collected during 
daily ward visits (Monday to Friday 9am-5pm), and by staff in the centralised pharmacy 
dispensaries (Monday to Friday 9am-6.30pm and Saturday and Sunday 10am-4pm). 
The majority of clinical screening of medication orders occurred at ward level at both 
study sites, but data were collected in the centralised dispensaries to permit recording 
of MRPs identified outside routine ward pharmacy visits, for example medication 
requests made when the ward pharmacy team were unavailable. Pharmacy staff 
recorded data on all MRPs identified personally or through discussion with other 
healthcare professionals. The hospital incident reporting systems were also reviewed 
to check for any additional significant MRPs that were not identified by pharmacy staff.  
In prognostic research it is recommended that the outcome event is assessed while 
blinded to the candidate predictors to prevent bias60 93 94. In the present study it was not 
possible to blind pharmacy staff collecting the outcome data to the patient’s clinical 
Chapter 6: Data collection for model development 
 
115 
 
 
information (such as age, diagnosis and laboratory results) as this information formed 
part of their clinical assessment of patients. Despite this, pharmacy staff did not know 
which factors would be used as predictors, minimising the potential for this to influence 
their outcome assessment.  
At the point of identification, pharmacy staff classified each MRP using Basger’s 
classification system114, and recorded whether they considered the MRP was 
preventable, expressed as a dichotomous variable of yes or no. I then performed a 
second check to increase consistency. To prevent judgement drift ‘case law 
documents’143 were developed and referred to at each stage.  
Additional data were collected on the following: 
 date MRP occurred and date resolved (to enable identification of duplicate reports); 
 whether MRP was identified during ward visit or in the pharmacy department (to 
provide data on working practices at the study sites); 
 whether MRP was resolved by pharmacy staff or other healthcare professionals (to 
differentiate between MRPs resolved by pharmacy staff and those identified and 
resolved by other healthcare professionals then reported to pharmacy staff 
retrospectively); 
 stage in ‘patient stay’ when MRP identified, classified as during/before first ward 
review by pharmacist, during the remainder of the inpatient stay, or during clinical 
screening at discharge (to provide additional data on MRP occurrence to inform 
MOAT implementation); 
 whether MRP was a medicines reconciliation discrepancy (as evidence suggests 
that patients are at increased risk of medication-related harm during transitions of 
care3 7). Medicines reconciliation discrepancies were defined as errors identified 
after creating the most accurate list possible of all medications a patient takes, 
including drug name, dosage, frequency, and route, and comparing that list against 
the physician’s admission, transfer, and/or discharge orders, with the goal of 
providing correct medications to the patient at all transition points within the 
hospital144.  
A potential limitation was the possibility of incomplete data due to pharmacy staff being 
required to complete this work in addition to other routine duties. To minimise this, I 
worked closely with the study sites to ensure that data collection occurred at an optimal 
time in terms of staffing levels and workload. Staff involved in MRP data collection were 
also provided with initial training (as described above) to improve the consistency and 
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reliability of data collection. I reviewed all data collection forms daily and sought 
clarification where needed, and provided the pharmacy staff with on-going fidelity 
training. 
I also recognised that identification of MRPs may vary depending on the knowledge, 
experience and skills of the pharmacists collecting data. To quantify this potential 
variability, a simulated ‘MRP identification assessment exercise’ was developed and 
used in a training scenario, discussed further in chapter 7.  
Following anonymisation to maintain patient confidentiality and blinding, each potential 
MRP was independently assessed by an expert panel (consisting of a hospital 
pharmacist, senior nurse, consultant physician plus myself). The panel reached 
agreement by consensus on whether it was a true MRP (expressed as a dichotomous 
variable of yes or no). Where there was not full agreement, a final decision was made 
following discussion between panel members. To prevent ‘judgement drift’ a ‘case law 
document’143 was used as above.  
6.3.4 Candidate predictors 
The work undertaken in chapter 5 identified 18 candidate predictors for use in 
development of the MOAT. 
All data on candidate predictors were collected retrospectively. Data were obtained 
from the information department at the study hospitals where possible, including 
demographic, diagnostic and comorbidity data. Laboratory data were extracted 
manually from the electronic reporting system used at both hospitals, Sunquest 
Integrated Clinical Environment (ICE)145. The remaining data were extracted manually 
from patient medical records. Hospital A has electronic medical and prescribing 
records; Hospital B has paper-based systems. Manual extraction of laboratory data 
were performed by a single data analyst at each study site, independently of the 
research team. Data from the patient medical records were collected by the 
independent data analyst at Hospital A, but due to the use of paper-based systems at 
Hospital B, and the need to read hand-written prescribing records, I extracted these 
data at Hospital B. All manually extracted data were entered directly into an electronic 
database. All data were recorded as reported, with no categorisation of continuous 
data.  
As discussed in section 6.2.4.1, where no laboratory results were available during the 
hospital stay, results from the preceding week were used (if available). Similarly, if no 
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height or weight data were available (for the study admission) data were extracted for 
previous or subsequent admissions. If available, data on height were used irrespective 
of the date recorded (on the basis that height is relatively stable). Weight data were 
only used if results were available within one month of the study admission. These 
decisions were made following discussion with the MOAT project steering group. 
Table 16 shows the candidate predictors that were pre-selected for development of the 
MOAT, with definition / measurement methods used (pre-selected to minimise 
heterogeneity and bias94, as described in section 6.2.4).  
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Table 16 – Pre-selected candidate predictors  
Variable Details / categories 
Age Age at admission to hospital (in years) 
Socioeconomic status Based on the English indices of deprivation 2015 (Index of Multiple 
Deprivation Rank) 
Previous allergy / adverse 
drug reaction 
Binary (YES/NO) 
Body mass index First documented result following admission 
Number of hospital 
admissions  
Number of admissions to the study hospital in the previous 6 months  
Primary diagnosis From hospital clinical coding data (ICD-10 codes). Grouped into: 
1. Cardiovascular system  
2. Respiratory system 
3. Gastrointestinal system 
4. Genitourinary system  
5. Musculoskeletal-intergumentary systems  
6. Endocrine-metabolic diseases  
7. Nervous system and mental disorders  
8. Other (all other diagnoses combined) 
Number of comorbidities  From hospital clinical coding data (ICD-10 codes) 
History of dementia  Binary (YES/NO) 
From hospital clinical coding data (ICD-10 codes) 
Number of medicines 
prescribed  
Number of ‘regular’ medicines prescribed to be given on the first full 
day of admission to hospital. i.e. excluding ‘when required’ and ‘once 
only’ medicines, dietary products, non-medicated topical products (e.g. 
emollients), wound dressings  
Parenteral administration 
route  
Binary (YES/NO) 
Administration of one or more regular medicines via the parenteral 
route (intravenous, intramuscular, subcutaneous) during the hospital 
stay (excluding prophylactic low molecular weight heparins, fluid 
replacement therapy) 
Use of ‘high-risk 
medicines’ 
Binary (YES/NO) 
Prescribed to be given as a ‘regular’ medicine during the hospital stay: 
1. Anticoagulants / direct oral anticoagulants  
2. Therapeutic heparin 
3. Anti-diabetic medication 
4. Opiates (excluding codeine, tramadol, meptazinol & 
dihydrocodeine) 
5. Systemic aminoglycosides & glycopeptides 
6. Systemic antimicrobials (excluding aminoglycosides & 
glycopeptides) 
7. Theophylline & aminophylline 
8. Epilepsy medicines 
9. Antipsychotics (excluding clozapine) 
10. Immunosuppressants (excluding corticosteroids) 
11. Cytotoxics 
12. Lithium 
13. Antiarrhythmics 
14. Antidepressants 
15. Other (clozapine, anti-retrovirals, medicines for Parkinson’s 
disease) 
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Continued from previous page… 
Variable Details / categories 
Renal function Glomerular filtration rate calculated using the modified Modification of 
Diet in Renal Disease equation (using first documented results 
following admission) 
Liver disease Binary (YES/NO) 
Liver disease defined as ALT / ALP and/or bilirubin ≥ 3 times normal 
range and/or documented liver disease 
Laboratory results were the first documented results following 
admission 
Documented liver disease was established from hospital clinical coding 
data (ICD-10 codes) 
Serum albumin First documented result following admission 
Serum potassium First documented result following admission 
Serum sodium First documented result following admission 
White cell count First documented result following admission 
Platelet count First documented result following admission 
ICD = International Statistical Classification of Disease, ALT = alanine aminotransferase, ALP = 
alkaline phosphatase 
6.3.5 Analysis of missing data 
To assess the potential impact of missing data I calculated the number of admissions 
with missing data, number of values missing, and number of missing values for each 
variable (i.e. each set of data collected). I then compared characteristics for admissions 
with missing values and those with completely observed data to inform possible 
reasons for the missingness94.  
6.3.6 Candidate predictor data entry checks  
In prognostic research it is recommended that data on candidate predictors is collected 
blind in terms of knowledge of the outcome event and other predictors60 94. This is 
particularly important when subjective judgement is required as it prevents the 
assessment being influenced, which could artificially increase the associations between 
the predictors and outcome events. Full blinding was not possible for this study as both 
myself and the independent data analysts were not blinded to all other predictor data, 
and I was not blinded to the MRP status. It was anticipated that this would have 
minimal impact on the accuracy of data collection as all candidate predictors selected 
for this study were objective measurements that are independent of observer 
interpretation; subjective judgement was therefore not required. In addition all 
candidate predictors were recorded contemporaneously during the admission as part of 
routine care / documentation, therefore without knowledge of the MRP status. To 
identify any possible bias, and to assure the accuracy of data collection, I performed a 
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double check of data entry. This involved an on-going check of a randomly selected 
10% sample of study patients (selected using a random number generator). Sixteen 
data items were checked for each patient. This included four from prescribing records, 
nine from laboratory reports, and three from patient medical records: 
 prescribing records – medicines reconciliation completed (yes/no), list of allergies, 
list of medicines prescribed to be given on first full day of admission, and additional 
medicines prescribed during admission; 
 laboratory reports – serum sodium, potassium, creatinine, albumin, bilirubin, ALT, 
ALP, white cell count, and platelet count; 
 patient medical records - weight, height, and body mass index. 
As the data entry checks were performed at regular intervals throughout data collection 
it was possible to refine data entry where necessary. Accuracy was calculated as the 
percentage of data items recorded correctly.  
6.3.7 Statistical analysis of data 
Statistical analyses were performed to test for differences between study sites in the 
characteristics of study admissions, MRP identification processes (such as whether 
identified during ward duties or in the pharmacy department), the proportion of each 
MRP subcategory, and the prevalence of MRPs; this was to inform the potential 
generalisability of the MOAT. The characteristics of admissions with and without 
missing data were also compared to identify the possible missingness mechanism, so 
informing how missing data should be handled during MOAT development. 
The Mann-Whitney U test and two-sample t-test were used for numeric data, selected 
based on whether data distribution was compatible with normality. Chi-square or 
Fisher’s exact tests were used to compare proportions, with the choice based on the 
expected distribution of results in the absence of association, with Fisher’s exact test 
used when an expected cell frequency was less than five. Where appropriate, the 
Bonferroni correction was applied to the probability (p) values to account for the risk of 
type I (false positive) errors associated with multiple analyses146; Bonferroni corrected p 
values were calculated based on the number of comparisons (to maintain the critical p 
level over all tests at 0.05). 
6.3.8 Ethical considerations 
This study was approved by the Proportionate Review Service Sub-Committee of the 
NHS Research Ethics Committee Wales REC 7 (16/WA/0016), and Health Research 
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Authority (HRA) (project ID 197298). Informed written consent was not required as I 
held a contract of employment with both study sites. 
All relevant policies and guidance related to confidentiality were followed to ensure the 
confidentiality of all patient-identifiable or confidential information. This included the use 
of study codes to allow data to be pseudonymised, recording the minimum information 
necessary, only sharing patient identifiable data with healthcare staff directly involved 
in the care of the patient, storing data securely, and ensuring that patient identifiable 
data was not disclosed in publications / presentations.  
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6.4 Results  
The results are presented according to the TRIPOD reporting guidelines for prognostic 
model studies57, and STROBE guidelines for the reporting of observational studies147. 
Recommendations for reporting the analysis of missing data have also been 
followed148. 
This section includes the flow of patients through the study, key characteristics of study 
admissions, analysis of missing data, results of data entry checks, and descriptive 
analysis of MRP data. The results of the preventability and severity assessment of 
MRPs are discussed in chapter 8, and the univariable relationship between the 
candidate predictors and outcome events (patients with at least one MSP MRP) is 
discussed in chapter 9. 
6.4.1 Flow of patients through the study 
One thousand six hundred and fifty two patient admissions were included in the study, 
1,100 from Hospital A and 552 from Hospital B, as summarised in Figure 3. Of these 
admissions, 149 (9%) were excluded (114 did not meet the eligibility criteria, and 
prescribing records and/or medical records were unavailable for 35).  
Of the remaining 1,503 study admissions, 1,378 were followed up until discharge from 
hospital; 933 (93%) of 1,006 at Hospital A, and 445 (90%) of 497 at Hospital B. The 
remaining admissions were followed until the study end date (two weeks after inclusion 
of the final patient at each site).  Eight hundred and ninety four (59.5%) experienced at 
least one MRP, with 610 (40.6%) experiencing the outcome event, namely at least one 
MSP MRP. 
Fifty seven patients entered the study twice, 46 at Hospital A and 11 at Hospital B. One 
further patient at Hospital B entered the study three times. The total number of patients 
included in the study was therefore 1,444 (960 at Hospital A and 484 at Hospital B). 
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MRP = medication related problem 
Figure 3 – Participant flow diagram 
6.4.2 Characteristics of participants 
The key characteristics of the 1,503 admissions included in the regression analyses 
are summarised in Table 17. This includes demographic variables and all candidate 
predictors.    
Eligible patient admissions 
(n = 1,652) 
Admissions included in regression analyses (n = 1,503) 
Hospital A = 1,006, Hospital B = 497 
  
Hospital A 
(n = 1,100) 
Excluded admissions (n = 94) 
Admission outside working hours: 1 
No medicines prescribed: 11 
No review by pharmacist: 52 
Not medical patient: 18 
Admitted prior to start of study: 7 
Prescribing records unavailable: 1 
Elective admissions: 4 
 
MRP present 
 (n = 894) 
 
Hospital B 
(n = 552) 
Excluded admissions (n = 55) 
No medicines prescribed: 1 
No review by pharmacist: 2 
Not medical patient: 13 
Admitted prior to start of study: 4 
Prescribing records unavailable: 17 
Elective admission: 1 
Study admission not in medical 
notes / notes unavailable: 17 
  
Moderate or severe 
preventable MRP 
present  
(n = 610) 
Moderate or severe 
preventable MRP 
absent  
(n = 284) 
MRP absent 
 (n = 609) 
  
Chapter 6: Data collection for model development 
 
124 
 
 
The median age of participants was 75 years (range 17 to 103), with female patients 
comprising 693 (46.1%) of 1,503 admissions. The statistical analysis suggests 
significant differences between study sites in terms of socioeconomic status, with 
Hospital A having a lower median socioeconomic status (p < 0.001). Hospital A also 
had a lower proportion of patients with an ethnic origin described as ‘white’, suggesting 
greater ethnic diversity (p < 0.001). A difference was also observed in the proportion of 
admissions with allergies (p = 0.002), and in antimicrobial use (p = 0.0073), although 
these differences were not statistically significant given the Bonferroni corrected p 
value of 0.0012.  
The laboratory results at the two sites were broadly comparable, although the median 
platelet count was lower at Hospital B compared to Hospital A (p < 0.001). This may be 
explained by the of lower standard reference range at Hospital B (Hospital A: 150-450 
109/L, Hospital B: 120-400 109/L). In addition one needs to consider the clinical 
significance of the difference, as the median results for both sites are within the 
standard reference ranges; this means that while the difference may be statistically 
significant, it may not be considered to be of clinical significance. This issue was 
discussed with Dr Li Wei (academic supervisor), and it was agreed that it would be 
appropriate to combine the data for the regression analyses irrespective of the 
difference, as this has the potential to increase the generalisability of the MOAT (as 
reference ranges often differ between hospitals). This also avoided the need to 
categorise the data, which as discussed in chapter 3, is associated with reduced model 
reliability60.  
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Table 17 – Characteristics of study admissions  
Characteristic 
Hospital A 
(admissions 
= 1,006) 
n (% of 
admissions) 
Hospital B 
(admissions 
= 497) 
n (% of 
admissions) 
All patients  
(admissions 
= 1,503) 
n (% of 
admissions) 
p value 
(test for 
difference 
between 
study sites) 
Demographic 
Age (years) 
Median: 75 
IQR: 58-85 
Range: 19-103 
Median: 76  
IQR: 57.5-86 
Range: 17-100 
Median: 75  
IQR: 58-85 
0.358
 
(Mann-Whitney) 
Gender (female) 446 (44.3) 247 (49.7) 693 (46.1) 0.050
 
(Chi-square) 
Socioeconomic status*, ranked using 
English Indices of Deprivation 2015 – 
Index of Multiple Deprivation
149†  
Median: 40  
IQR: 22-67 
Range: 3-100 
Median: 72 
IQR: 49-91 
Range: 10-100 
Median: 50 
IQR: 30-79 
<0.001 
(Mann-Whitney) 
Ethnic origin (white)* 
777 
(82.3) 
431 
(93.1) 
1208 
(85.9) 
<0.001
 
(Chi-square)
 
Patient related 
Previous allergy* 
362  
(36.0) 
220  
(44.3) 
582  
(38.8) 
0.0020 
(Chi-square) 
Body mass index* (kg/m
2
)  
Median: 24.7 
IQR: 21.4-29.5 
Range: 10.6-
65.5 
Median: 25.2 
IQR: 21.5-28.7 
Range: 14.9-
55.6 
Median: 24.9 
IQR: 21.4-29.1 
0.852 
(Mann-Whitney) 
Number of hospital admissions in 
previous 6 months 
Median: 0  
IQR: 0-1 
Range: 0-10 
Median: 0  
IQR: 0-1 
Range: 0-7 
Median: 0  
IQR: 0-1 
0.956 
(Mann-Whitney) 
Primary diagnosis:     
Endocrine and metabolic 52 (5.2) 30 (6.0) 82 (5.5) 0.486
 
(Chi-square) 
Nervous system and mental 
disorders 
92 (9.1) 57 (11.5) 149 (9.9) 0.156 
(Chi-square) 
Cardiovascular system 225 (22.4) 90 (18.1) 315 (21.0) 0.056 
(Chi-square) 
Respiratory system 219 (21.8) 113 (22.7) 332 (22.1) 0.671 
(Chi-square) 
Gastrointestinal system 89 (8.9) 55 (11.1) 144 (9.6) 0.169 
(Chi-square) 
Genitourinary system 100 (9.9) 44 (8.9) 144 (9.6) 0.501 
(Chi-square) 
Musculoskeletal-intergumentary 
systems 
68 (6.8) 25 (5.0) 93 (6.2) 0.191 
(Chi-square) 
All other categories 161 (16.0) 83 (16.7) 244 (16.2) 0.731 
(Chi-square) 
Number of comorbidities 
Median: 3 
IQR: 2-5 
Range: 0-13 
Median: 4 
IQR: 2-5 
Range: 0-11 
Median: 4 
IQR: 2-5 
0.845 
(Mann-Whitney) 
History of dementia  103 (10.2) 58 (11.7) 161 (10.7) 0.399
 
(Chi-square) 
Length of hospital stay (days) 
Median: 5 
IQR: 2-13 
Range: 0-148 
Median: 5 
IQR: 2-11 
Range: 0-179 
Median: 5 
IQR: 2-12 
0.110 
(Mann-Whitney) 
Medicines related 
Medicines reconciliation completed 810 (80.5) 482 (97.0) 1292 (86.0) <0.001
 
(Chi-square) 
Number of medicines  
Median: 7 
IQR: 5-10 
Range: 0-27 
Median: 8 
IQR: 5-11 
Range: 0-21 
Median: 8 
IQR: 5-10 
0.095
 
(Mann-Whitney) 
Parenteral administration  674 (67.0) 334 (67.2) 1008 (67.1) 0.937
 
(Chi-square) 
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Continued from previous page… 
Characteristic 
Hospital A 
(admissions 
= 1,006) 
n (% of 
admissions) 
Hospital B 
(admissions 
= 497) 
n (% of 
admissions) 
All patients  
(admissions 
= 1,503) 
n (% of 
admissions) 
p value 
(test for 
difference 
between 
study sites) 
Use of high-risk medicines: 
Anticoagulants 194 (19.3) 118 (23.7) 312 (20.8) 0.045 
(Chi-square) 
Therapeutic heparin 152 (15.1) 70 (14.1) 222 (14.8) 0.598
 
(Chi-square) 
Anti-diabetic medication 210 (20.9) 89 (17.9) 299 (19.9) 0.175
 
(Chi-square) 
Opiates 100 (9.9) 45 (9.1) 145 (9.6) 0.584
 
(Chi-square)
 
Aminoglycosides and glycopeptides 58 (5.8) 47 (9.5) 105 (7.0) 0.083
 
(Chi-square) 
Other antimicrobials 657 (65.3) 280 (56.3) 937 (62.3) 0.0073
 
(Chi-square) 
Theophylline and aminophylline 28 (2.8) 10 (2.0) 38 (2.5) 0.370
 
(Chi-square) 
Epilepsy medicines 161 (16.0) 66 (13.3) 227 (15.1) 0.165
 
(Chi-square) 
Antipsychotics (excluding clozapine) 56 (5.6) 36 (7.2) 92 (6.1) 0.202
 
(Chi-square) 
Immunosuppressants 12 (1.2) 9 (1.8) 21 (1.4) 0.337
 
(Chi-square) 
Cytotoxics 11 (1.1) 3 (0.6) 14 (0.9) 0.355 
(Fisher’s exact) 
Lithium 4 (0.4) 2 (0.4) 6 (0.4) 1.000
 
(Fisher’s exact) 
Antiarrhythmics 110 (10.9) 40 (8.0) 150 (10.0) 0.079
 
(Chi-square) 
Antidepressants 239 (23.8) 112 (22.5) 351 (23.4) 0.598
 
(Chi-square) 
Other (clozapine, anti-retrovirals, 
medicines for Parkinson’s disease) 
27 (2.7) 13 (2.6) 40 (2.7) 0.938
 
(Chi-square) 
Laboratory results 
Renal function - estimated glomerular 
filtration rate*
‡
 (ml/min/1.73m
2
) 
Median: 73 
IQR: 53-95 
Range: 5-294 
Median: 73 
IQR: 51-97 
Range: 3-309 
Median: 73 
IQR: 53-99 
0.871
 
(Mann-Whitney) 
Liver disease 107 (10.6) 57 (11.5) 164 (10.9) 0.626
 
(Chi-square) 
Serum albumin* (g/L) 
Mean: 33.0  
SD: 5.8 
Range: 10-51 
Mean: 32.9  
SD: 6.4 
Range: 7-55 
Mean: 33.0  
SD: 6.0 
0.791 
(Two-sample t-
test) 
Serum potassium* (mmol/L) 
Mean: 4.5  
SD: 0.63 
Range: 2.3-7.8 
Mean: 4.4  
SD: 0.59 
Range: 2.7-6.9 
Mean: 4.4 
SD: 0.62 
0.017 
(Two-sample t-
test) 
Serum sodium* (mmol/L) 
Mean: 137.1 
SD: 5.1 
Range: 111-170 
Mean: 137.4 
SD: 5.5 
Range: 113-165 
Mean: 137.2 
SD: 5.2 
0.238 
(Two-sample t-
test) 
White cell count* (10
9
/L) 
Median: 9.8 
IQR: 7.5-13.0 
Range: 0.3-93.0 
Median: 9.8 
IQR: 7.7-12.6 
Range: 2.5-32.9 
Median: 9.8 
IQR: 7.5-12.8 
0.707
 
(Mann-Whitney) 
Median platelet count* (10
9
/L) 
Median: 249 
IQR: 196-320 
Range: 5-977 
Median: 230 
IQR: 185-293 
Range: 14-738 
Median: 244 
IQR: 192-312  
<0.001
 
(Mann-Whitney) 
* For patients without missing data (further details provided in Appendix A6.6) 
† Deprivation rank based on patients’ postcode, shown as the ranked position as a 
percentage of all neighbourhoods in England (where 1 is the most deprived) 
‡ Glomerular filtration rate estimated using modified Modification of Diet in Renal Disease 
equation
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IQR = interquartile range, SD = standard deviation 
Bonferroni adjusted p value used to judge statistical significance 0.0012 (based on 43 statistical 
tests) 
6.4.3 Analysis of missing data 
Thirty five (2.1%) of the 1,652 patient admissions were excluded from the study as 
prescribing and/or medical records were unavailable (Figure 3). These were excluded 
to ensure complete data on medicine-related candidate predictors were available for 
the regression analyses. Thirty four of these admissions occurred at Hospital B, where 
paper-based medical and prescribing records were used. Of these, the medical records 
could not be located for seven admissions, and the study admission and/or prescribing 
records were missing for the remaining 27. This issue was raised with the Medical 
Records department, who advised that the records were likely to be misfiled. 
Prescribing records were unavailable for one patient at Hospital A. This appeared to be 
due to the patient’s unique identification number being changed during the admission.  
Of the 1,503 admissions included in the regression analyses, 449 (29.9%) had one or 
more missing data point. Table 18 gives the number of admissions with missing values, 
and number of values missing. There was no evidence for a difference in the proportion 
of admissions with missing data between study sites (p = 0.830). 
Table 18 – Number of missing values per admission 
Number of missing 
values 
Number of admissions 
(admissions = 1,503) 
n (% of all admissions) 
0 1054 (70.1) 
1 390 (26.0) 
2 52 (3.5) 
3 4 (0.3) 
6 1 (0.07) 
7 2 (0.1) 
 
Appendix A6.6 gives a breakdown of the number of missing data points for each study 
variable. This shows that no data were missing for age, gender, primary diagnoses, 
comorbidities, number of previous hospital admissions, length of hospital stay, liver 
disease, and medicine usage.  
Socioeconomic status was unavailable for six admissions. This was because the 
English Indices of Deprivation 2015149 is based on patients’ postcodes, and the six 
patients with missing socioeconomic data were either not resident in England (four 
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admissions), or had no fixed abode (two admissions). Allergy status was not available 
for one admission, although this patient was prescribed nine medicines during their 
admission, including antimicrobials, which may suggest they had no allergies (as 
nursing staff at the study sites are required to check a patient’s allergy status before 
administering any medication). Body mass index (BMI) was the variable with the 
highest number of missing values, with data missing for 341 (22.7% of admissions). Of 
these, 98 admissions had a weight measurement only, 96 had height only, and 147 
had neither. Although it is not possible to ascertain the reason(s) why these data were 
missing, there are numerous possibilities including patients being acutely unwell 
(therefore unable to stand / sit for measurement to take place), short length of hospital 
stay (i.e. patient discharged before measurement could be taken), or a refusal to be 
weighed / measured. It was not possible to estimate the renal function for nine 
admissions (0.6%) as serum creatinine measurements were unavailable. In six cases 
this appears to be due to high bilirubin levels interfering with the creatinine assay150. 
Similarly, of the 30 missing serum potassium values, 27 were missing due to the 
laboratory being unable to analyse the sample (rather than the test not being 
requested), which may be due to haemolysis of the blood sample151. Of the remaining 
43 missing laboratory results (albumin, sodium, white cell count and platelet count), 38 
were not tested, and five were tested but the sample could not be analysed (two for 
white cell count and three for platelet count). 
Ethnic origin data were collected for descriptive purposes rather than for use in the 
regression modelling, but were unavailable for 96 admissions. Reasons for the missing 
data could include patients being too unwell to provide the information, having a 
complex racial heritage (although the study sites used categories for mixed heritage 
and ‘other’ ethnicity), or a reluctance to disclose this information. It was necessary to 
establish ethnic origin to estimate renal function, but only to the extent of whether 
patients were ‘black’ or ‘non-black’ (discussed in section 6.2.4.1).  
To inform the possible missingness mechanism I compared the characteristics of 
admissions with missing values and those with completely observed data (Appendix 
A6.7). Statistically significant differences were observed, with results suggesting that 
fewer patients with missing values experienced the outcome event (p < 0.0001). 
Patients with missing values were also statistically: younger (p < 0.001), had fewer 
admissions in the previous six months (p < 0.001), fewer comorbidities (p < 0.001), 
fewer medicines (p < 0.001), and a shorter length of hospital stay (p < 0.001). In 
addition, a lower proportion of patients with missing data received parenteral medicines 
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(p < 0.001), and a higher proportion were male (p = 0.0015). There was also weak 
evidence (given the Bonferroni adjusted p value of 0.0028) that a higher proportion of 
patients with missing values had results within the standard reference range for serum 
albumin (p = 0.0069), normal renal function (p = 0.0334), and a higher BMI (p = 0.029). 
These findings may suggest that patients with missing data had fewer indicators of 
long-standing illness burden, and/or severity of the current admission compared to 
those with completely observed data. It is of note that some markers of current illness 
(deranged serum potassium, sodium, white cell count, and platelets) were comparable 
between the two groups. The slightly higher BMI in the group with missing data may 
suggest that patients with higher BMIs were less likely to have their weight and/or 
height recorded.  
Missingness mechanisms fall into three categories, missing completely at random 
(MCAR), missing at random (MAR) and missing not at random (MNAR)148, which have 
been described as follows147: 
 data are MCAR if the probability that a particular observation is missing does not 
depend on the value of any observed variable(s); 
 data are MAR if, given the observed data, the probability that observations are 
missing is independent of the actual value of the missing data; 
 data are MNAR if the probability of missing still depends on the missing value even 
after taking the available data into account. 
It is known that differences in the extent and type of missing data, and the methods 
used to handle this missing data, may greatly influence model development and 
predictive performance of prognostic models60. It was therefore necessary to consider 
the possible missingness mechanism to decide how to deal with the missing data. 
Where data are MCAR, it is considered reasonable to use complete-case analysis, as 
participants with missing data are likely to be a truly random subset of the study 
sample60. Where missing data are related to other observed participant data (i.e. MAR), 
a complete-case analysis would lead to a non-random subset, and biased results60 147. 
Multiple imputation is generally considered to be the preferred method to handle data 
that are MAR60 147, but is not appropriate where data are MNAR, as MNAR data are 
related to unobserved data, and therefore cannot be plausibly estimated from the 
observed study variables.  
Of the MOAT study data, the patients excluded due to the unavailability of prescribing 
and/or medical records were likely to be MCAR, as the misfiling was likely to be 
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completely random, and unrelated to any patient related factors. Exclusion of these 
patients is therefore unlikely to bias the study results.  
Of the variables included in MOAT development, the comparison of admissions with 
and without missing data suggests the missingness mechanism was MAR rather than 
MCAR, as admissions with missing data were clearly not a random subset of the study 
sample. On this basis it is appropriate to use multiple imputation, but as it is not 
possible to distinguish between MAR and MNAR using observed data, sensitivity 
analyses will be required to investigate possible departure from the MAR assumption94 
147. The imputation of missing data and sensitivity analyses will be discussed further in 
chapter 9.  
6.4.4 Data entry checks for candidate predictors  
Data entry checks were performed for 152 admissions (99 from Hospital A and 53 from 
Hospital B), giving a total of 2,432 data item checks. Accuracy was calculated as the 
percentage of data items recorded correctly. Results are summarised in Table 19.  
Table 19 – Accuracy of data entry for candidate predictors 
Hospital 
Prescribing records Laboratory reports 
Patient medical 
records 
Total 
items 
checked 
Accuracy  
n (% of 
items 
checked) 
Total 
items 
checked 
Accuracy  
n (% of 
items 
checked) 
Total 
items 
checked 
Accuracy  
n (% of 
items 
checked) 
Hospital A  
(99 admissions) 
396 396 (100) 891 891 (100) 297 297 (100) 
Hospital B  
(53 admissions) 
212 212 (100) 477 
474 
(99.4)* 
159 159 (100) 
*  Accuracy prior to remedial action 
 
As shown in Table 19, the accuracy of data entry for the randomly selected admissions 
at Hospital A was 100%, as were the prescribing, and patient medical record checks at 
Hospital B.  
Data entry checks of laboratory reports for the first eight randomly selected admissions 
at Hospital B (a total of 72 data items) identified one numerical transcription error. I 
therefore checked all laboratory data items collected to that point (91 admissions, 819 
data items), and found one further error. This was discussed with the data analyst and 
the data extraction method refined. No further numerical transcription errors were 
identified in the remaining 45 randomly selected admissions (405 data items), but two 
further errors were identified where results were recorded as ‘not tested’, despite being 
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available. I therefore checked all results recorded as ‘not tested’. This gave an overall 
error rate for the randomly selected sample of three (0.6%) of 477 data items (95% 
confidence interval -0.1 to 1.3%), which I considered to be acceptable, particularly 
given the remedial action and further checks undertaken. 
6.4.5 MRP descriptive data 
The MRP descriptive data results are presented in three sections: MRP identification, 
categorisation (using Basger’s classification system114), and the prevalence of MRPs in 
the study sample.  
This chapter includes data for all MRPs irrespective of severity or preventability. 
Results for MSP MRPs are presented in chapter 8. 
6.4.5.1 MRP identification 
A total of 2,747 MRPs were reported for the 1,503 study admissions. Eight MRPs (all 
from Hospital A) were identified via the hospital incident reporting system; these 
occurred and were resolved outside of pharmacy working hours. The remainder were 
reported by pharmacy staff after being identified personally or through discussion with 
other healthcare professionals. 
As shown in Table 20, 11 MRPs were excluded from the analysis as they were 
duplicate entries (i.e. the same MRP reported twice on the same day). The remaining 
2,736 were reviewed by the expert panel, and 122 (4.4%) were not considered to be 
true MRPs. There was no evidence for a statistically significant difference in the 
proportion of MRPs excluded due to non-validation by expert panel members between 
the study sites (p = 0.129). 
Table 20 – Medication related problem identification  
 Medication related problems (MRPs) 
Hospital A 
n (% of MRPs) 
Hospital B 
n (% of MRPs) 
  All patients  
n (% of MRPs) 
Number of MRPs reported  1,778 (100) 969 (100) 2,747 (100) 
Number of MRPs excluded as 
duplicate reports  
10 (0.6) 1 (0.1) 11 (0.4) 
Number of MRPs excluded as 
not considered to be true MRPs 
by expert panel  
71 (4.0) 51 (7.3) 122 (4.4) 
Total MRPs remaining  1,697 (95.4) 917 (94.6) 2,614 (95.2) 
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Table 21 gives the reasons for non-validation of the 122 excluded MRPs (i.e. why they 
were not considered to be true MRPs). This shows that ‘unnecessary pharmacy 
contribution’ formed the largest category, accounting for 50 (41%).  
Table 21 – Reasons for non-validation of medication related problems 
Reason for non-validation 
Non-validated medication related 
problems (MRPs) 
Hospital A 
(non-validated 
MRPs = 71) 
n (% of non-
validated 
MRPs) 
Hospital B 
(non-validated 
MRPs = 51) 
n (% of non-
validated 
MRPs) 
All patients 
(non-validated 
MRPs = 122) 
n (% of non-
validated 
MRPs) 
Lack of documentation (rather than true MRP)  
e.g. indication / duration for medicine not stated 
(rather than inappropriate use) 
9 (12.7) 3 (5.9) 12 (9.8) 
Unnecessary pharmacy contribution  
e.g. pharmacist advised use of once daily (modified 
release) oral nitrate rather than twice daily ‘to get 
better serum concentrations’ (when both were 
considered by panel members to be clinically 
acceptable) 
36 (50.7) 14 (27.5) 50 (41.0) 
Local policy issue only  
e.g. formulary issues 
19 (26.8) 4 (7.8) 23 (18.9) 
Non-clinically significant drug interaction 
e.g. concomitant use of omeprazole and clopidogrel 
(although there is a theoretical drug interaction, 
panel members felt it was not clinically significant) 
7 (9.9) 22 (43.1) 29 (23.8) 
Insufficient information to permit validation (but 
from data available appears to be ‘an 
unnecessary pharmacy contribution’ and/or 
minor severity)* 
e.g. anxiolytic not prescribed on discharge, which 
would have been appropriate if treatment intended 
during hospitalisation only (but no further information 
given) 
0 8 (15.7) 8 (6.6) 
* Due to a delay between MRP data collection and expert panel consensus discussions 
(approximately one year due to temporary unavailability of one panel member) it was 
not possible to seek further information/clarification from reporting pharmacists 
A review of the eight MRPs with ‘insufficient information to permit validation’ found they 
related to seven study admissions. Of these admissions, two patients experienced 
another MRP that met the requirements for a MSP MRP. The remaining five patients 
were recorded as not having experienced an MRP/MSP MRP. 
Additional MRP descriptive data are summarised in Table 22. This shows that the 
majority of MRPs (93.2%) were identified during routine ward visits, and resolved by 
pharmacy staff (97.9%). MRPs were also more frequently identified during (or before) 
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the first review of the patient (74.6%); this may be related to the high proportion of 
medicines reconciliation related MRPs (55.9%), as medicines reconciliation is often 
undertaking during the first ward review5.  
Table 22 – Descriptive data for medication related problems  
 
Hospital A 
(MRPs = 
1,697) 
n (% of MRPs) 
Hospital B 
(MRPs = 
917) 
n (% of 
MRPs) 
All patients 
(MRPs = 
2,614) 
n (% of MRPs) 
p value  
(test for 
difference 
between 
study sites) 
When MRP identified: 
During ward visit  
In the pharmacy department 
Other (pharmacist referral / reported via 
hospital incident reporting system) 
 
1,584 (93.3) 
105 (6.2) 
8 (0.5) 
 
 
853 (93.0) 
56 (6.1) 
8 (0.9) 
 
2,437 (93.2) 
161 (6.2) 
16 (0.6) 
0.455 
(Chi-square) 
Who resolved MRP: 
Pharmacy staff  
Other healthcare professionals 
 
1,650 (97.2) 
47 (2.8) 
 
908 (99.0) 
9 (1.0) 
 
2,558 (97.9) 
56 (2.1) 
 
0.0026
 
(Chi-square) 
 
Stage in patient stay MRP identified: 
During first ward review (or before) 
Remainder of inpatient stay 
Clinical screening at discharge  
Missing data  
 
1246 (73.4) 
307 (18.1) 
144 (8.5) 
0 
 
704 (76.8) 
119 (13.0) 
88 (9.6) 
6 (0.7) 
 
1,950 (74.6) 
426 (16.3) 
232 (8.9) 
6 (0.2) 
0.0036 
(Chi-square)
 
Medicines reconciliation discrepancy  935 (55.1) 526 (57.4) 1,461 (55.9) 0.260 
(Chi-square) 
MRP = medication related problem 
Bonferroni adjusted p value used to judge statistical significance 0.0125 (based on 4 statistical 
tests) 
There was evidence for a statistically significant difference between study sites for the 
stage in patient stay when MRP identified. The results suggest that a greater proportion 
of MRPs were identified during the first ward review at Hospital B compared to Hospital 
A (76.8% compared to 73.4%), with fewer identified during the remainder of the 
admission (13.0% compared to 18.1%). This may be explained by the higher number of 
patients receiving medicines reconciliation at Hospital B (Table 17, 97% compared to 
80.5%, p <0.0001), as this may have led to a greater proportion of pharmacists’ time 
being spent reviewing new rather than existing patients. It is not possible to investigate 
this hypothesis further as no data were collected on the frequency or duration of 
pharmacy reviews.  
There is also evidence that the proportion of MRPs resolved by pharmacy staff (as 
opposed to other healthcare professionals) was lower at Hospital A compared to 
Hospital B (97.2% and 99.0% respectively, p  = 0.0026). While this is of limited 
practical significance (given the relatively small percentage difference), it may be 
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explained in part by the eight MRPs identified via the hospital incident reporting system 
at Hospital A, as these were resolved without pharmacist intervention, and the number 
of MRPs related to non-availability of medicines that were resolved by nursing staff (21 
at Hospital A, compared to three at Hospital B).  
MRPs identified when clinically screening discharge prescriptions were subdivided (to 
provide additional information on workflow, and to potentially inform implementation of 
the MOAT into clinical practice) as follows: 
 those occurring prior to the discharge prescription being written (i.e. MRPs that had 
already occurred but not identified / resolved, such as medicines reconciliation 
omissions);    
 those occurring when the discharge prescription was written (e.g. transcription 
errors, technical errors, MRPs related to newly prescribed medication, or alterations 
made at the point of hospital discharge). 
The results are summarised in Table 23, and show that the majority of discharge 
related MRPs occurred when the discharge prescription was written (70.4%). There 
was no statistically significant difference between study sites (p = 0.126). 
Table 23 – Breakdown of identification of medication related problems identified 
when discharge prescription screened 
When medication related problem (MRP) 
occurred 
Hospital A 
(MRPs at 
discharge 
= 145) 
n (% of 
MRPs at 
discharge) 
Hospital B 
(MRPs at 
discharge 
= 88) 
n (% of 
MRPs at 
discharge) 
All 
patients 
(MRPs at 
discharge 
= 233) 
n (% of 
MRPs at 
discharge) 
p value 
(test for 
difference 
between 
study 
sites) 
Prior to writing discharge prescription 48 (33.1) 21 (23.9) 69 (29.6) 0.126
 
(Chi-
square) When discharge prescription written 97 (66.9) 67 (76.1) 164 (70.4) 
6.4.5.2 MRP classification  
The classification of the 2,614 MRPs is summarised in Table 24. This shows that the 
most frequently identified subcategory was ‘indication not treated / missing therapy’, 
accounting for 1,116 (42.7%). MRPs related to dose selection were the next most 
frequently reported with ‘dose too low’ and ‘dose too high’ each accounting for 9.6% of 
the total MRPs (252 and 250 respectively).    
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Table 24 – Classification of medication related problems 
Medication related problem (MRP) 
subcategory 
Hospital 
A 
(MRPs = 
1,697) 
n (% of 
MRPs) 
Hospital 
B 
(MRPs = 
917) 
n (% of 
MRPs) 
All patients 
(MRPs = 
2,614) 
n (% of MRPs) 
p value 
(test for 
difference 
between 
study sites) 
1. Drug selection 
1.1 Inappropriate drug  85 (5.0) 36 (3.9) 121 (4.6) 0.210 
(Chi-square) 
1.2 No indication for drug / duplication 73 (4.3) 42 (4.6) 115 (4.4) 0.740 
(Chi-square) 
1.3 Interaction (drug-drug, or drugs and 
food / alcohol) 
19 (1.1) 16 (1.8) 35 (1.3) 0.184
 
(Chi-square) 
1.4 Indication not treated / missing therapy 677 (39.9) 439 (47.9) 1,116 (42.7) 0.000083
 
(Chi-square) 
1.5 More cost effective drug available 8 (0.5) 0 8 (0.3) 0.057
 
(Fisher’s exact) 
1.6 Synergistic / preventive drug required 
and not given 
25 (1.5) 2 (0.2) 27 (1.0) 0.0025
 
(Chi-square) 
2. Drug form 
2.1 Inappropriate or suboptimal drug form 59 (3.5) 22 (2.4) 81 (3.1) 0.130
 
(Chi-square) 
3. Dose selection 
3.1 Drug dose too low  166 (9.8) 86 (9.4) 252 (9.6) 0.739
 
(Chi-square) 
3.2 Drug dose too high  159 (9.4) 91 (9.9) 250 (9.6) 0.646
 
(Chi-square) 
3.3 Dosage regimen not frequent enough 5 (0.3) 4 (0.4) 9 (0.3) 0.728
 
(Fisher’s exact) 
3.4 Dosage regimen too frequent 9 (0.5) 2 (0.2) 11 (0.4) 0.348
 
(Fisher’s exact) 
3.5 Dose needs adjustment to organ 
function or change in disease state 
22 (1.3) 8 (0.9) 30 (1.2) 0.331
 
(Chi-square) 
3.6 Dosage instructions unclear, incomplete 
or not understood by patient / carer* 
N/A* N/A* N/A* N/A* 
4. Treatment duration / withdrawal 
4.1 Duration of treatment too short 4 (0.2) 1 (0.1) 5 (0.2) 0.663
 
(Fisher’s exact) 
4.2 Duration of treatment too long 39 (2.3) 15 (1.6) 54 (2.1) 0.256
 
(Chi-square) 
4.3 Inappropriate abrupt withdrawal
†
 2 (0.1) 0 2 (0.08) 
0.544
 
(Fisher’s exact) 
5. Drug use process 
5.1 Inappropriate timing of administration / 
dosing by prescriber; administration error 
by nurse 
58 (3.4) 20 (2.2) 78 (3.0) 0.076
 
(Chi-square) 
5.2 Drug underused / under-administered 11 (0.7) 11 (1.2) 22 (0.8) 0.141
 
(Chi-square) 
5.3 Drug overused / over-administered 0 1 (0.1) 1 (0.04) 0.351
 
(Fisher’s exact) 
5.4 Drug not taken / administered at all 7 (0.4) 11 (1.2) 18 (0.7) 0.020
 
(Chi-square) 
5.5 Wrong drug taken by patient 0 0 0 N/A 
5.6 Drug abused 0 0 0 N/A 
5.7 Patient or nurse uses drug incorrectly 
through lack of knowledge or barriers (e.g. 
swallowing, dexterity)  
1 (0.1) 2 (0.2) 3 (0.1) 0.283 
(Fisher’s exact) 
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Continued from previous page… 
Medication related problem (MRP) 
subcategory 
Hospital 
A 
(MRPs = 
1,697) 
n (% of 
MRPs) 
Hospital 
B 
(MRPs = 
917) 
n (% of 
MRPs) 
All patients 
(MRPs = 
2,614) 
n (% of MRPs) 
p value 
(test for 
difference 
between 
study sites) 
5.8 Adequate information not provided or 
not understood or misunderstood or not 
followed* 
N/A* N/A* N/A* N/A* 
5.9 Drugs stored inappropriately / expired 
drug administered / preparation error 
0 3 (0.3) 3 (0.1) 0.043
 
(Fisher’s exact) 
6. Logistics 
6.1 Prescribed drug not available 38 (2.2) 13 (1.4) 51 (2.0) 0.148
 
(Chi-square) 
6.2 Drug order incorrect, incomplete, poorly 
legible / illegible / illegal / incorrect / allergy 
status incomplete  
126 (7.4) 75 (8.2) 201 (7.7) 0.490
 
(Chi-square) 
6.3 Error in drug selection 91(5.4) 15 (1.6) 106 (4.1) 0.00004
 
(Chi-square) 
7. Monitoring 
7.1 Monitoring too frequent 1 (0.1) 0 1 (0.04) 1.000
 
(Fisher’s exact) 
7.2 No or too infrequent monitoring 6 (0.4) 1 (0.1) 7 (0.3) 0.433
 
(Fisher’s exact) 
7.3 Inappropriate test ordered 1 (0.1) 0 1 (0.04) 1.000
 
(Fisher’s exact) 
7.4 Patient unable to attend / pay for 
monitoring* 
N/A* N/A* N/A* N/A* 
8. Unexpected reaction / adverse drug reaction (ADR) / no obvious cause 
8.1 An ADR occurred 5 (0.3) 1 (0.1) 6 (0.2) 0.672
 
(Fisher’s exact) 
8.2 No obvious cause of treatment failure 0 0 0 N/A 
*  Category not used for MOAT study as relates to primary care (discussed in section 
6.2.3) 
†
  
Category not included in Basger’s original classification system
114
 (discussed in section 
6.2.3) 
N/A = not applicable  
Bonferroni adjusted p value used to judge statistical significance 0.0018 (based on 28 statistical 
tests) 
Statistically significant differences between study sites were found for the following 
MRP subcategories (using Bonferroni corrected p value of 0.0018): 
 ‘indication not treated / missing therapy’ (p = 0.000083); 
 ‘error in drug selection’ (p = 0.00004). 
Of the MRPs categorised as ‘indication not treated / missing therapy’ 91.2% were 
medicines reconciliation related discrepancies, 624 (92.2%) of the 677 MRPs at 
Hospital A, and 394 (89.8%) of 439 MRPs at Hospital B. Although there was no 
evidence for a difference in the proportion of medicines reconciliation discrepancies 
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between sites (shown in Table 22), there does appear to be a difference in the type of 
errors identified during medicines reconciliation, with ‘indication not treated / missing 
therapy’ accounting for significantly more of the medicines reconciliation related 
discrepancies at Hospital B compared to Hospital A, that is, 394 (74.9%) of the 526 
medicines reconciliation related discrepancies at Hospital B, and 624 (66.7%) of the 
935 discrepancies at Hospital A (p = 0.0012). 
The difference between study sites in the proportion of MRPs classified as ‘error in 
drug selection’ may be explained by the different medication prescribing systems used, 
with Hospital A using electronic prescribing, and Hospital B using a paper-based 
system. Previous research suggests that electronic prescribing systems can reduce the 
overall occurrence of prescribing errors but can also contribute to new types of errors, 
including selection errors related to the use of ‘drop-down’ lists152 153. Possible 
examples of selection errors that may be related to the electronic prescribing system at 
Hospital A include ten MRPs where soluble, effervescent, or orodispersbile 
formulations of medicines were prescribed where a standard formulation appeared to 
be intended, and 16 where an incorrect inhaler device was selected. Some selection 
errors were potentially more clinically significant, including a patient prescribed 
Levonelle (an emergency hormonal contraceptive) when levetiracetam (a medicine for 
epilepsy) was intended. 
There was weak evidence for a difference between sites for the category ‘synergistic / 
preventive drug required and not given’ (p = 0.0025), which may be explained by the 
routine use of probiotic supplements at Hospital A only (for older patients prescribed 
broad spectrum antibiotics). This accounted for 16 of the 25 MRPs at Hospital A, which 
if excluded from the analysis, results in no evidence for a statistically significant 
difference (Fisher’s exact test, p = 0.348). 
6.4.5.3 Prevalence of MRPs 
As shown in Table 25, 894 (59.5%) of 1,503 study admissions experienced at least one 
MRP. Of the admissions that experienced an MRP, the number of MRPs per admission 
ranged from one to 17, with a median of two.  
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Table 25 – Prevalence of medication related problems 
Medication related problem (MRP) 
characteristics 
Hospital A 
(admissions 
= 1,006) 
n (% of 
admissions) 
Hospital B 
(admissions 
= 497) 
n (% of 
admissions) 
All patients  
(admissions 
= 1,503) 
n (% of 
admissions) 
p value 
(test for 
difference 
between 
study sites) 
Admissions with at least one MRP* 576 (57.3) 318 (64.0) 894 (59.5) 
0.012
 
(Chi-square) 
Number of MRPs per admission (of 
the admissions with an MRP) 
Median: 2  
IQR: 1-4 
Range: 1-16 
Median: 2 
IQR: 1-4 
Range: 1-17 
Median: 2 
IQR: 1-4 
0.390
 
(Mann-Whitney) 
*
  
MRPs considered by expert panel to be true MRPs  
Bonferroni adjusted p value used to judge statistical significance 0.025 (based on 2 statistical 
tests) 
There was evidence for a difference in the proportion of admissions who experienced 
at least one MRP between study sites (p = 0.012). This may be explained by the higher 
proportion of patients receiving medicines reconciliation at Hospital B (97% versus 
80.5% at Hospital A, as shown in Table 17) given the high number of unintentional 
discrepancies known to occur at transitions of care3 7.  
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6.5 Discussion  
Key findings 
Of the 1,652 patient admissions included in the study, 1,503 met the study’s eligibility 
criteria and were included in the analyses. Over 2,700 MRPs were reported for the 
eligible admissions, of which 2,614 were considered to be true MRPs by an expert 
panel. This equates to an average of 1.7 MRPs per admission. The most frequently 
identified MRP subcategories were ‘indication not treated / missing therapy’, ‘dose too 
low’ and ‘dose too high’, accounting for almost 62% of MRPs. Eight hundred and ninety 
four (59.5%) of the eligible admissions experienced at least one MRP. As anticipated, 
there were significant differences in socioeconomic status and ethnicity between the 
two study sites. 
Comparison with previous literature  
The MRP prevalence found in the present study is consistent with findings from other 
research. Blix et al78 (Norway, 2004) reported that 81% of hospitalised patients (from 
internal medicine and rheumatology wards) experienced an MRP, with an average of 
2.1 clinically relevant MRPs recorded per patient. In comparison, the present study 
found that 59.5% of admissions experienced at least one MRP, with an average of 1.7 
MRPs per admission. The data collection method and sample population were similar 
for both studies, but the prevalence reported by Blix et al may have been higher due to: 
 higher prevalence of ADRs, occurring in 7.8% of the 827 patients (number not 
reported), whereas only 6 ADRs were reported for the 1,503 MOAT patients; 
 higher proportion of patients reported by Blix et al to have ‘medical chart errors’ 
(16.3%). This category accounted for only 7.7% of MOAT MRPs; 
 inclusion of the MRP subcategory ‘information / therapy discussions’, which was 
reported for 17.3% of patients by Blix et al. This category does not form part of 
Basger’s classification system114 (as used for the MOAT study). 
Two, more recent studies (both using similar data collection methods and target 
populations to the MOAT study), reported MRP prevalence closer to that found by the 
MOAT study. Wilmer et al (Netherlands, 2015)90, reported that 70 (53%) of 131 patients 
experienced one or more MRP, with an average of 1.0 MRPs per patient. Ayalew et al 
(Ethiopia, 2015)72, reported MRPs in 117 (52%) of 225 study subjects, and an average 
of 0.68 MRPs per patient.  
Urbina et al (Spain, 2014)52 conducted a larger study, comprising 8,713 admissions; of 
these, 2,425 (27.8%) experiencing at least one MRP, with an average of 0.3 MRPs per 
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admission. This prevalence is significantly lower than the studies discussed above, but 
Urbina’s results are not directly comparable as surgical and maternity patients were 
included (in additional to general medicine), and a computerised warning system used 
to identify MRPs (rather than identification by pharmacy staff).  
Due to the use of different MRP classification systems it is not possible to directly 
compare the distribution of MRP subcategories between these studies, but it appears 
that the use of different data collection methods may have led to some variation. For 
example, Ayalew et al used a ‘drug interaction checker’ as part of their MRP 
identification process, which may have resulted in the high proportion of drug 
interactions (48%). Similarly, Urbina et al used a computerised system to identify 
MRPs, and found that ‘incorrect use of the computerised physician order entry system’ 
accounted for 23.9% of MRPs. 
Despite the potential differences in MRP sub-categorisation, there do appear to be 
some similarities between the findings of the MOAT study and previous research. The 
MOAT study identified ‘indication not treated / missing therapy’ as the highest MRP 
subcategory, accounting for 39.9%, which is comparable with Wilmer et al, where 
‘under-treatment’ accounted for 35.5%. Wilmer et al also reported that incorrect dosing 
(overdose or under-dose) accounted for 25.0%, which is similar to the 19.1% found in 
the MOAT study.  
Ayalew et al and Urbina et al both reported a higher proportion of ‘drug interactions’ 
than the MOAT study (46.0%, 11.2%, and 1.3% respectively), which may be due to the 
methods of identification used (a drug interaction checker by Ayalew et al, 
computerised system by Urbina et al, and pharmacists’ clinical judgement for the 
MOAT study). Although not specified, it is possible that Ayalew and Urbina et al 
included all potential drug interactions irrespective of clinical relevance, as opposed to 
the MOAT study, where only drug interactions considered to be clinically significant 
were counted as true MRPs. 
Strengths and limitations 
A strength of the approach taken for MOAT data collection was adherence with 
PROGRESS53 55, TRIPOD94, and CHARMS60 recommendations. This has the potential 
to enhance the quality of data collection, reduce bias, and facilitate full and detailed 
reporting of results to permit the quality and relevance of the study to be adequately 
assessed. Other strengths include the detailed description of data collection methods 
(to ensure reproducibility of results), and the choice of candidate predictor definitions 
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that are clinically relevant and straight forward to use, so enhancing the potential 
clinical credibility and usability of the MOAT in clinical practice.  
A limitation is the possible underestimation of the prevalence of MRPs due to: 
 not all participants receiving medicines reconciliation - this may have resulted in 
non-identification of MRPs, therefore measurement bias154; 
 potential differences in MRP identification depending on the knowledge, experience 
and skills of pharmacists collecting data. A simulated ‘MRP identification 
assessment exercise’ was therefore used to permit this to be quantified (described 
in chapter 7); 
 the observational nature of the study, which meant data collection was not carried 
out under strict trial conditions, with pharmacy staff required to complete data 
collection in addition to other routine duties, and ward staff required to inform 
pharmacists about MRPs that occurred outside pharmacy working hours and/or 
report incidents via the hospital incident reporting systems. In addition, pharmacists 
may not have identified all MRPs during routine reviews as it is not standard 
practice for pharmacists to review the laboratory results for all patients daily, or 
routinely ask patients about possible side-effects (which may have occurred if data 
were collected under trial conditions). 
Other potential limitations include: 
 use of a combined outcome event (MRP is an umbrella term for ADRs, ADEs and 
MEs), which raises two issues: 
o there is a risk that candidate predictors may have opposite predictive effects 
in components of a combined outcome event, causing  their effect to cancel 
out, leading to important predictors being excluded from the final model60; 
o differences in the proportion of the outcome components may impact on the 
predictive accuracy in new datasets60. 
While use of a combined outcome event is a potential limitation, the predictors were 
selected based on combined evidence for all outcome components (i.e. MRP 
subcategories), therefore consistent predictive effects are likely. Potential 
differences in the proportion of MRP subcategories of the outcome event (MSP 
MRPs) at the two study sites is reviewed in chapter 8, but this will need to be 
considered further during MOAT validation studies;   
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 no data were collected on the frequency or duration of pharmacist reviews of study 
participants, it is therefore not possible to investigate whether this impacted on 
MRP data collection; 
 retrospective collection of candidate predictor data was used to permit consecutive 
inclusion of patients from all study wards concurrently (given constraints of time and 
resources), but this led to a proportion of admissions being excluded due to 
unavailability of medical records. Despite the consequent reduction in sample size 
(35 admissions), exclusion is unlikely to bias the analysis as data appears to be 
MCAR; 
 routine clinical records were used as the data source for predictors, resulting in 
some missing values (where routine assessments not performed / documented);  
 there was ‘insufficient information’ to fully validate eight (0.3%) of the 2,736 MRPs. 
While this may have biased identification of MSP MRPs (due to measurement 
error154), it is unlikely to have a significant impact on MOAT development given the 
low number of study admissions affected (five of 1,503, i.e. 0.3%), and likelihood 
they these were not true MRPs; 
 it was necessary to categorise high-risk medicines to permit modelling, but 
medicines within the same category may not have equivalent risks (e.g. insulin and 
oral diabetes medication, which are both categorised as ‘anti-diabetic medication’). 
In addition, some medicines are used for more than one indication (e.g. gabapentin 
can be used for epilepsy and neuropathic pain); the impact of an MRP may 
therefore be dependent on the indication (e.g. missing doses of gabapentin 
prescribed for epilepsy may confer higher risk than if used for pain). Similarly, 
parenteral medicine use was treated as a binary variable, which does not take into 
account the number or type of parenteral medicine(s) prescribed, or the duration of 
use. In summary, categorisation is potentially simplistic, albeit necessary to prevent 
model overfitting; 
 when selecting categories for primary diagnosis it was not possible to group 
‘infections’ as a separate category. While this was a logical category from a clinical 
perspective, as discussed in section 6.2.4.6, it could lead to incorrect categorisation 
when using the MOAT in clinical practice. 
The limitations associated with the use of the Bonferroni correction also need to be 
considered in terms of the risk of false negative (type II) errors, causing real differences 
to be overlooked146. The Bonferroni correction was used as the primary objective was 
to test universal null hypotheses, and false positive errors were a greater issue than 
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false negative errors as the purpose was to establish an answer to these hypotheses, 
rather than generate hypotheses for further investigation. 
Implications  
Given the above limitations, it is possible that the present study may underestimate the 
prevalence of MRPs, although the prevalence was consistent with previous studies72 78 
90. Subsequent research may be able to improve on the present study by ensuring that 
all participants receive consistent levels of pharmacist review (for example the duration 
and frequency of reviews, and consistent use of medicines reconciliation). Use of 
alternative methods of MRP data collection (for example, use of a dedicated research 
team) may also improve the consistency of MRP identification, although as discussed 
in section 6.2.2, prospective identification by pharmacy staff was chosen as it aligns 
with the proposed purpose of the MOAT, which is to identify patients at risk of MRPs 
that can be identified during routine clinical practice. Other possible improvements for 
subsequent research include: 
 the use of prospective collection of predictor data, as this may increase the 
completeness of data, overcoming the need to impute missing values; 
 carrying out validation of MRPs as soon as possible after MRP data collection (to 
permit clarification where needed, overcoming the issue of there being insufficient 
data to validate all MRPs); 
 use of a larger sample to increase the number of outcome events, so permitting the 
inclusion of more variables in the regression modelling (given the rule of thumb of 
at least ten ‘events per variable’92), as this would allow the use of less simplistic 
categorisation of candidate predictors. 
The results presented in this chapter provide support for the potential generalisability of 
the MOAT. As expected, the comparison of study participants between the two study 
sites identified statistically significant differences in socioeconomic status and ethnicity, 
but despite these differences, other participant characteristics were broadly similar, 
(including age, gender, number of comorbidities, primary diagnoses, number of 
medicines, and length of hospital stay). This suggests that the MOAT target population 
may share similar characteristics irrespective of their socioeconomic status and 
ethnicity. The prevalence of MRPs was also broadly similar between study sites, as 
were working practices (related to the identification of MRPs during ward duties), 
suggesting similar medicines optimisation needs, and clinical pharmacy provision 
between hospitals.  
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The results also indicated that a number of high-risk medicine categories contained 
only a small proportion of admissions. For example ‘theophylline and aminophylline’, 
and ‘lithium’, contained only 2.5% and 0.4% respectively. As discussed in section 6.2.4, 
predictor categories were pre-selected to reduce the risk of selection bias associated 
with data-driven analysis62, but on the understanding that it may be necessary to 
collapse groups if there were insufficient participants to adequately represent the target 
population (taken by other researchers to be less than 5% of the study sample42 44 45). A 
review of the high-risk medicine categories was therefore required prior to MOAT 
development.  
In addition, the review of missing data (for admissions included in MOAT development) 
led to the conclusion that the data were likely to be MAR, suggesting that use of 
multiple imputation is appropriate  
6.6 Conclusion 
The work presented in this chapter suggests that the observed prevalence of MRPs 
was consistent with other published research, occurring in 894 (59.5%) of study 
participants, with ‘indication not treated / missing therapy’, ‘dose too low’ and ‘dose too 
high’, being the most frequently observed MRP subcategories. There were statistically 
significant differences in socioeconomic status and ethnicity between study sites, but 
other participant characteristics were comparable. Where predictor data were missing, 
it appears to be MAR, permitting the use of multiple imputation to estimate the missing 
values.  
The next chapter will quantify potential variability in MRP identification by pharmacists 
at the study sites through the development and use of a simulated MRP identification 
assessment exercise. 
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Chapter 7: Pharmacists’ identification of medication related 
problems: a validation exercise 
7.1 Introduction 
Medication related problem (MRP) data for this study were collected by pharmacy staff 
at the study sites as part of their routine daily clinical assessment of patients. A 
potential limitation, identified in chapter 6, is the possible impact of knowledge, 
experience and skills of pharmacists on their ability to identify potential MRPs. The aim 
of the work presented in this chapter was therefore to quantify potential variability in 
MRP identification by pharmacists at the study sites. The objectives were to: 
 identify the extent of variation among pharmacists in identification of MRPs; 
 establish the proportion of potential MRPs identified by pharmacists; 
 assess whether identification varies dependant on the type of MRP or potential 
severity; 
 identify implications of variability in MRP identification for the interpretation of 
overall study findings. 
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7.2 Methods 
This assessment involved the development and then use of a simulated MRP 
identification assessment exercise, followed by analysis of the results. Each of these 
stages is described below. The results are described in section 7.3. 
7.2.1 Development of the MRP identification assessment exercise 
In designing the assessment exercise I considered the need for it to: 
 be clinically relevant in terms of current prescribing; 
 reflect the breadth and complexity of MRPs commonly experienced by potential 
study patients; 
 be at a level suitable for all study pharmacists irrespective of clinical / service 
speciality and experience (i.e. aimed at newly qualified, non-specialist 
pharmacists); 
 be simple to complete, both in terms of time taken, and facilities required. 
To ensure the assessment met the above requirements I enlisted the assistance of two 
junior pharmacists working on study wards at Hospital A to advise on design and 
content. In collaboration, we created four fictitious medication charts (Appendix A7.1), 
each containing three or four simulated MRPs. The number of medication charts was 
selected to provide a representative range of patients and MRPs, while being realistic 
in terms of time taken to review (estimated five to ten minutes to complete the review of 
all four medication charts). We chose to use paper medication charts to remove the 
need for access to a computer, and to permit the same assessment process to be used 
at both study sites. The chart originated from Hospital A, where it was used prior to the 
introduction of an electronic prescribing system. 
7.2.2 Pharmacist completion of MRP identification assessment exercise 
All pharmacy staff involved in the study were provided with training prior to 
commencement of the study (described in section 6.3.3). Following this training, all 
pharmacists (who may have been required to clinically screen study patients’ 
medication charts) were asked to complete the MRP identification assessment 
exercise. Prior to undertaking the assessment its purpose was explained, as was the 
proposed use of the results (i.e. for research purposes to quantify potential variability in 
MRP identification). The assessment was completed anonymously, as its purpose was 
not to assess the ability of individual pharmacists. Pharmacists were asked to complete 
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the assessment exercise individually at a time convenient to them, without discussing 
the scenarios with other pharmacists. They were advised that the exercise should take 
between five and ten minutes to complete, but no time limit was set, and pharmacists 
were not required to record the time taken. Pharmacists were instructed to review each 
medication chart and list the potential MRPs identified using a form designed for this 
purpose. They were not told the number of potential MRPs on each medication chart, 
or the overall number across all four charts. Pharmacists were permitted to refer to 
references sources if required (to reflect standard clinical practice), but were advised 
that no other patient information was available (such as medical notes or laboratory 
results). Once the assessment was completed each pharmacist confirmed return of 
their form by signing a completion register. The two pharmacists involved in developing 
the assessment did not take part. 
7.2.3 Analysis of results 
Each simulated MRP was treated as having a binary outcome in terms of whether or 
not it was identified by each pharmacist. To identify the extent of variation among 
pharmacists the median number of simulated MRPs identified per pharmacist and 
interquartile range (IQR) were calculated (to establish central tendency and variability). 
The Mann-Whitney U test was also performed to test whether there was a difference 
between sites (based on a null hypothesis of no difference).  
The characteristics of pharmacists (who returned assessment forms) at the two 
hospitals were compared in terms of their grades and roles. The completion registers 
were used to obtain pharmacist’s names, from which it was possible to establish grade 
/ roles. Grading was based on the Agenda for Change pay scale, which is the National 
Health Service pay system for employees155. Band 6 is the pay point for newly qualified 
pharmacists, increasing to band 8c for senior / specialist posts156. Role was divided into 
categories based on whether the pharmacists’ main role was clinical (i.e. patient 
facing), or non-clinical, for example service based roles such as technical services or 
dispensary. Clinical roles were further divided into those based predominantly on study 
wards, and those predominantly based in other clinical areas (such as surgery and 
paediatrics). A similar comparison was also made between pharmacists who did, or did 
not, return an assessment form. Fisher’s exact tests were performed to test for 
differences between groups (chosen due to size of the sub-groups and expected 
distribution of results in the absence of association). 
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The number / proportion of pharmacists who identified each MRP was calculated to 
give the percentage agreement for each MRP, and the results reported separately for 
each MRP by study site, in addition to combined results for both sites. To test if there 
was evidence for a difference in the proportion of simulated MRPs identified by 
pharmacists at the two study sites a chi-square test was performed. Sub-group 
analysis was performed to identify potential differences in percentage agreement for 
individual MRPs between sites (using Fisher’s exact tests). 
Randolph’s kappa was used to assess chance-adjusted agreement between 
pharmacists (calculated using Randolph’s online kappa calculator157). Randolph’s 
kappa was chosen as it is a multiple rater kappa test. Other multi-rater tests are 
available, including Light’s, Hubert’s, and Fleiss’ kappa158, but these are ‘fixed-
marginal’ versions, unlike Randolph’s kappa, which is ‘free-marginal’159.  Fixed-
marginal tests are recommended where the marginals (i.e. the proportion that should 
be distributed into each category) is known to raters prior to the assessment, whereas 
free-marginal versions are recommended when raters are not restricted in the number 
of cases assigned to each category159, as was the case for the MRP assessment 
exercise. When fixed-marginal varieties of kappa are used in free-marginal 
assessments the value of kappa can vary significantly dependent on the marginal 
distributions, a finding attributed to the prevalence  (proportion of cases), and bias 
(defined as the bias of one rater relative to another)160. Kappa values were interpreted 
as poor if lower than 0.00, slight if 0.00 to 0.20, fair if 0.21 to 0.40, moderate if 0.41 to 
0.60, substantial if 0.61 to 0.80, and almost perfect if between 0.81 and 1.00161 162.  
Exploratory analysis was performed to assess whether identification was influenced by 
either the type (MRP subcategory) or potential severity of the simulated MRPs. 
Basger’s aggregated classification system114 was used to classify the MRPs, and 
severity was assessed using a validated visual analogue scale for medication errors163 
(as used for the MRP study data, described in chapters 6 and 8 respectively). For the 
severity rating I categorised MRPs as either potentially ‘minor’, or ‘moderate or severe’. 
Where possible this assessment was based on ratings assigned to similar MRPs in the 
study dataset. The percentage agreement for each classification and severity category 
were calculated, and chi-square tests performed to assess evidence for statistically 
significant differences. 
Where appropriate, the Bonferroni correction was applied to the probability (p) values 
to account for the risk of type I (false positive) errors associated with multiple 
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analyses146; Bonferroni corrected p values were calculated based on the number of 
comparisons (to maintain the critical p level over all tests at 0.05). 
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7.3 Results 
The MRP identification assessment comprised four medication charts, with a total of 13 
simulated MRPs. Fifty nine pharmacists completed the assessment for all four 
medication charts and were included in the analysis (30 from Hospital A and 29 from 
Hospital B). This represented all pharmacists involved in the study at Hospital A 
(excluding the two pharmacists involved in developing the assessment), and 66% of 
the 44 pharmacists at Hospital B. One further pharmacist at Hospital B returned an 
assessment form, but it was not possible to include their results in the analysis as only 
three of the four medication charts had been assessed (the number of raters needs to 
be consistent for all assessments when calculating the kappa statistic). Due to 
anonymisation of the forms it was not possible to identify the pharmacist concerned to 
find out why their assessment was incomplete. 
The grade and main role of pharmacists who completed the assessment is 
summarised in Table 26. This shows that the highest proportion of pharmacists at 
Hospital A were graded 8a (46.7%), whereas the highest proportion at Hospital B were 
graded at band 7 (43.3%), although there was no evidence for a statistically significant 
difference in pharmacists’ grades between the two sites (p = 0.381). A difference was 
also observed between the main roles of pharmacists at the two sites, with a higher 
proportion of pharmacists at Hospital B working predominantly on study wards (73.3% 
compared to 43.3% at Hospital A). Given the Bonferroni corrected p value of 0.025 the 
difference was not statistically significant (p = 0.051), although the lack of evidence 
against the null hypothesis may be explained by the small sample size. The apparent 
differences between sites in terms of the band and role of pharmacists may be 
explained by the greater number of study wards at Hospital B compared to Hospital A 
(19 and 11 respectively, described in section 6.3.2), leading to Hospital B requiring 
proportionally more junior pharmacists (bands 6 or 7) to provide routine pharmacy 
services to study wards.  
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Table 26 – Grade and role of pharmacists who returned the assessment  
Grade / main role 
Assessment form returned  
Hospital A  
(n = 30) 
n (%) 
Hospital B 
(n = 30
†
) 
n (%) 
Grade* 
Band 6 7 (23.3) 5 (16.7) 
Band 7 6 (10.0) 13 (43.3) 
Band 8a 14 (46.7) 9 (30.0) 
Band 8b 2 (6.7) 2 (6.7) 
Band 8c 1 (3.3) 1 (3.3) 
Main role 
Clinical role (predominantly working on study wards) 13 (43.3) 22 (73.3) 
Clinical role (predominantly working on non-study wards e.g. 
surgery, paediatrics) 
7 (23.3) 2 (6.7) 
Non-clinical role (e.g. technical services, dispensary)  10 (33.3) 6 (20.0) 
*  Grade based on Agenda for Change pay scale  
†  All returned assessment forms, therefore includes the incomplete form 
Bonferroni adjusted p value used to judge statistical significance 0.025 (based on 2 statistical 
tests) 
Table 27 summarises the response rates at Hospital B by the grade and role of 
pharmacists, permitting the potential impact of the completion rate of 66% to be 
examined. Interpretation is limited by the small sample size, but results suggest that 
response rates were relatively consistent for all grades of pharmacists (64.3% to 71.4% 
for bands 6 to 8b), with no evidence for a statistically significant difference (p = 0.97). 
There appears to be a difference in response rate related to pharmacists’ role, with 
forms returned by 75.9% of pharmacists working on study wards compared to 40.0% 
and 60.0% for the other categories. This difference was not statistically significant (p = 
0.193), but may have contributed to the increased variability observed in roles at 
Hospital B compared to Hospital A (Table 26).   
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Table 27 – Response rates for pharmacists at Hospital B  
Grade / main role 
Number of 
pharmacists  
(n = 44
†
) 
Assessment 
returned 
(n = 30
†
) 
n (% response 
rate) 
Grade* 
Band 6 7  5 (71.4) 
Band 7 19  13 (68.4) 
Band 8a 14  9 (64.3) 
Band 8b 3  2 (66.7) 
Band 8c 1  1 (100.0) 
Main role 
Clinical role (predominantly working on study wards) 29  22 (75.9) 
Clinical role (predominantly working on non-study wards 
e.g. surgery, paediatrics) 
5  2 (40.0) 
Non-clinical role (e.g. technical services, dispensary)  10  6 (60.0) 
*   Grade based on Agenda for Change pay scale  
†  All returned assessment forms, therefore includes the incomplete form 
Bonferroni adjusted p value used to judge statistical significance 0.025 (based on 2 statistical 
tests) 
7.3.1 Variation among pharmacists in identification of medication related 
problems 
As summarised in Table 28, each pharmacist identified between five and 13 simulated 
MRPs, with a median of 12 identified per pharmacist across both study sites (IQR ten 
to 12). 
Pharmacists at Hospital A identified a median of 12 simulated MRPs, compared to 11 
at Hospital B, with a greater proportion of pharmacists identifying all 13 MRPs at 
Hospital A (30.0% compared to 13.3% at Hospital B). Greater variability was observed 
at Hospital A, shown by the range in the number of MRPs identified (from five to 13 at 
Hospital A, and 7 to 13 at Hospital B), and IQR (ten to 13 at Hospital A, compared to 
ten to 12 at Hospital B). Despite these differences there was no evidence for a 
statistically significant difference between study sites (p = 0.357), but this may be due 
to the small sample size.  
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Table 28 – Number of simulated medication related problems identified per 
pharmacist 
Number of simulated 
medication related problems 
identified per pharmacist 
Frequency 
Hospital A  
(pharmacists = 30) 
n (% of 
pharmacists) 
Frequency 
Hospital B 
(pharmacists = 29) 
n (% of 
pharmacists) 
 Combined 
frequency 
(pharmacists = 59) 
n (% of 
pharmacists) 
5 1 (3.3) 0 1 (1.7) 
7 1 (3.3) 1 (3.3) 2 (3.4) 
8 2 (6.7) 0 2 (3.4) 
9 2 (6.7) 5 (16.7) 7 (11.9) 
10 4 (13.3) 6 (20.0) 10 (16.9) 
11 3 (10.0) 4 (13.3) 7 (11.9) 
12 8 (26.7) 9 (30.0) 17 (28.8) 
13 9 (30.0) 4 (13.3) 13 (22.0) 
Median 12 11 12 
Interquartile range 10-13 10-12 10-12 
7.3.2 Proportion of potential medication related problems identified 
A brief description of each simulated MRP and the number / percentage of pharmacists 
who identified each MRP (percentage agreement) is given in Table 29 (results shown 
separately for each study site and also as a combined result for both sites). The overall 
percentage agreement at Hospitals A and B was 85% and 84% respectively, with no 
evidence for a difference between sites (p = 0.617). Sub-group analysis also found no 
evidence for differences in percentage agreement for individual MRPs between sites 
(using Bonferroni corrected p value of 0.0036), therefore the remaining analyses were 
performed using the combined results. 
The combined percentage agreement for each simulated MRP ranged from 70% to 
98%, with an overall agreement for all MRPs of 84.5%. Randolph’s kappa was 
calculated to assess the chance-adjusted agreement for each MRP, with results 
ranging from 0.14 to 0.93, suggesting agreement varied from ‘slight’ to ‘almost 
perfect’161 162. Randolph’s kappa for the combined results (both study sites and all 
MRPs) was 0.50, suggesting moderate agreement161 162 164.  
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Table 29 – Medication related problem identification and chance-adjusted 
agreement  
M
e
d
ic
a
ti
o
n
 
c
h
a
rt
 Description of simulated 
medication related problem 
(MRP) 
MRP 
identified 
Hospital A 
(pharmacists 
= 30) 
n (% of 
pharmacists) 
MRP 
identified 
Hospital B 
(pharmacists 
= 29) 
n (% of 
pharmacists) 
Combined 
results 
(pharmacists = 
59) 
n (% of 
pharmacists) 
Kappa 
(combined 
results) 
p 
value 
1 
Methotrexate and 
trimethoprim prescribed 
concurrently  
21 (70.0) 22 (75.9) 43 (72.9) 0.20 
0.771 
(Fisher’s 
exact) 
Paracetamol prescribed 
regularly (maximum dose) 
plus when required 
29 (96.7) 29 (100.0) 58 (98.3) 0.93 
1.000 
(Fisher’s 
exact) 
Methotrexate prescribed 
daily (not weekly) 
30 (100.0) 27 (93.1) 57 (96.6) 0.87 
0.237 
(Fisher’s 
exact) 
2 
Furosemide prescribed at 
6pm (no indication that 
patient was catheterised) 
25 (83.3) 21 (72.4) 46 (78.0) 0.30 
0.360 
(Fisher’s 
exact) 
Two loop diuretics 
(furosemide and bumetanide) 
co-prescribed 
29 (96.7) 27 (93.1) 56 (95.0) 0.80 
0.612 
(Fisher’s 
exact) 
Nicorandil prescribed once 
daily (usually twice daily) 
24 (80.0) 25 (86.2) 49 (83.1) 0.43 
0.731 
(Fisher’s 
exact) 
3 
Simvastatin prescribed in the 
morning (usually taken in 
evening) 
20 (66.6) 21 (72.4) 41 (69.5) 0.14 
0.779 
(Fisher’s 
exact) 
Digoxin dose prescribed as 
milligrams (rather than 
micrograms) 
26 (86.7) 20 (69.0) 46 (78.0) 0.30 
0.125 
(Fisher’s 
exact) 
Apixaban prescribed once 
daily (usually twice daily) 
24 (80.0) 28 (96.6) 52 (88.1) 0.58 
0.103 
(Fisher’s 
exact) 
Simvastatin 40mg daily co-
prescribed with amlodipine 
(maximum dose of 
simvastatin is 20mg when 
co-prescribed) 
25 (83.3) 21 (72.4) 46 (78.0) 0.30 
0.360 
(Fisher’s 
exact) 
4 
Patient prescribed a penicillin 
containing antibiotic (when 
allergic to penicillin) 
24 (80.0) 27 (93.1) 51 (86.4) 0.52 
0.254 
(Fisher’s 
exact) 
Patient not received 
phenytoin for 3 days as nil-
by-mouth (no alternative 
formulation prescribed) 
28 (93.3) 20 (69.0) 48 (81.4) 0.38 
0.021 
(Fisher’s 
exact) 
Prophylactic enoxaparin co-
prescribed with therapeutic 
tinzaparin (therapeutic 
duplication) 
27 (90.0) 28 (96.6) 55 (93.2) 0.74 
0.612 
(Fisher’s 
exact) 
Overall results (all MRPs) 
332  
(85.1) 
316  
(83.8) 
648  
(84.5) 
0.50 
0.617
 
(Chi-
square) 
Bonferroni adjusted p value used to judge statistical significance 0.0036 (based on 14 statistical 
tests) 
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7.3.3 Analysis by MRP subcategory 
Categorisation of the 13 simulated MRPs (using Basger’s aggregated classification 
system) resulted in seven subcategorises (Table 30). Percentage agreement for the 
seven subcategories ranged from 73% to 94%, with strong evidence for a difference 
among subcategories (p < 0.0001). 
Table 30 – Medication related problem (MRP) identification analysed by MRP 
subcategory  
Medication 
related problem 
(MRP) 
subcategory* 
Description of simulated MRP 
Percentage 
agreement 
Percentage 
agreement 
(grouped by 
MRP 
subcategory) 
1.1 Inappropriate 
drug 
Patient prescribed a penicillin containing 
antibiotic (when allergic to penicillin) 
86% 86% 
1.2 No indication 
for drug / 
duplication 
Two loop diuretics (furosemide and 
bumetanide) co-prescribed 
95% 
94% Prophylactic enoxaparin co-prescribed 
with therapeutic tinzaparin (therapeutic 
duplication) 
93% 
1.3 Interaction Methotrexate and trimethoprim 
prescribed concurrently  
73% 
75% 
Simvastatin 40mg daily co-prescribed 
with amlodipine (maximum dose of 
simvastatin is 20mg when co-
prescribed) 
78% 
3.1 Drug dose too 
low 
Nicorandil prescribed once daily (usually 
twice daily) 
83% 
86% 
Apixaban prescribed once daily (usually 
twice daily) 
88% 
3.2 Drug dose too 
high 
Paracetamol prescribed regularly 
(maximum dose) plus when required 
98% 
94% 
Methotrexate prescribed daily (not 
weekly) 
97% 
Digoxin dose prescribed as milligrams 
(rather than micrograms) 
78% 
5.1 Inappropriate 
timing of 
administration / 
dosing by 
prescriber 
Furosemide prescribed at 6pm (no 
indication that patient was catheterised) 
78% 
73% 
Simvastatin prescribed in the morning 
(usually taken in evening) 
70% 
5.4 Drug not taken 
/ administered at all 
Patient not received phenytoin for 3 
days as nil-by-mouth (no alternative 
formulation prescribed) 
81% 81% 
* Classified using Basger’s aggregated classification system
114
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7.3.4 Analysis by severity 
Table 31 summarises the percentage agreement for MRPs based on their potential 
severity. Although agreement was higher for the MRPs rated as ‘moderate or severe’ 
compared to those rated as ‘minor’ (86% and 81% respectively), there was no 
evidence for a statistically significant difference (p = 0.122). 
Table 31 – Medication related problem identification analysed by potential 
severity 
Potential 
severity of 
medication 
related 
problem 
(MRP)* 
Description of simulated MRP 
Percentage 
agreement 
Percentage 
agreement 
(grouped by 
severity) 
Moderate or 
severe 
outcome  
Methotrexate and trimethoprim prescribed 
concurrently 
73% 
86% 
Paracetamol prescribed regularly (maximum 
dose) plus when required 
98% 
Methotrexate prescribed daily (not weekly) 97% 
Nicorandil prescribed once daily (usually twice 
daily) 
83% 
Digoxin dose prescribed as milligrams (rather than 
micrograms) 
78% 
Apixaban prescribed once daily (usually twice 
daily) 
88% 
Simvastatin 40mg daily co-prescribed with 
amlodipine (maximum dose of simvastatin is 
20mg when co-prescribed) 
78% 
Patient prescribed a penicillin containing antibiotic 
(when allergic to penicillin) 
86% 
Patient not received phenytoin for 3 days as nil-
by-mouth (no alternative formulation prescribed) 
81% 
Prophylactic enoxaparin co-prescribed with 
therapeutic tinzaparin (therapeutic duplication) 
93% 
Minor 
outcome  
Furosemide prescribed at 6pm (no indication that 
patient was catheterised) 
78% 
81% 
Two loop diuretics (furosemide and bumetanide) 
co-prescribed 
95% 
Simvastatin prescribed in the morning (usually 
taken in evening) 
70% 
* Classified using a validated visual analogue scale for medication errors
163
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7.4 Discussion  
Key findings 
The assessment found there were no statistically significant differences between 
results from the two study sites. Each study pharmacist identified between five and 13 
of the simulated MRPs (out of a total of 13), with a median of 12 and IQR of ten to 12. 
The overall percentage agreement (proportion of MRPs identified) was 84.5%, with a 
kappa coefficient of 0.50. No statistically significant differences were found between the 
percentage agreement for MRPs graded as potentially ‘minor’ compared to ‘moderate 
or severe’, but a difference was found among different types of MRPs (MRP 
subcategories).   
Interpretation  
While no statistically significant differences were seen in the characteristics of 
pharmacists between study sites, or between pharmacists who completed the 
assessment compared to those who did not, this may be due to the limited sample 
size. Despite not reaching statistical significance, one could hypothesise that the 
differences observed between sites (in grading and role) may explain other variability in 
the results of the assessment. For example it is possible that the slightly lower 
variability in the number of MRPs identified per pharmacist at Hospital B compared to 
Hospital A may be explained by the higher proportion of pharmacists at Hospital B who 
routinely worked on study wards, as they would be more familiar with the scenarios 
used for the MRP identification exercise. Similarly, the higher proportion of senior 
pharmacists (band 8a) at Hospital A may explain the higher median number of MRPs 
identified, due to increased experience and knowledge. A larger study, or more detailed 
analysis (incorporating the grade and role of individual pharmacists), would be required 
to investigate these hypotheses further.  
Regarding variation in the proportion of MRPs identified, there is no 
standardised interpretation for percentage agreement or kappa statistic, with the 
decision on what level is acceptable being determined by the purpose of the 
assessment161. In health research 80% is often recommended as the minimum 
acceptable percentage agreement164, with a kappa of 0.41 to 0.60 interpreted as 
demonstrating ‘moderate agreement’161 162.    
While the overall percentage agreement exceeded 80%, agreement for individual 
MRPs ranged from 69.5% to 98.3%, with six of the 13 MRPs achieving a percentage 
agreement lower than 80% (at one or both study sites), causing the corresponding 
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reduction in the overall kappa statistic. These MRPs, together with possible 
explanations for the variability, are listed below. 
1. Medication chart 1, methotrexate and trimethoprim prescribed concurrently 
(percentage agreement 72.9%, kappa 0.20) 
This is potentially serious interaction165, therefore the result cannot be explained by 
differing professional judgement. Although it is possible that pharmacists were less 
vigilant when completing the assessment (compared to routine practice) other 
MRPs had percentage agreement close to 100%, suggesting this variability reflects 
differences in pharmacists’ awareness of the interaction. 
2. Medication chart 2, furosemide prescribed at 6pm with no indication of 
catheterisation (percentage agreement 78.0%, kappa 0.30) 
Furosemide is a loop diuretic, therefore should ideally be administered no later than 
early afternoon to prevent nocturia (excessive urination at night)165. As identification 
of MRPs is influenced by professional judgement, some pharmacists may not have 
considered this MRP to be clinically relevant, particularly as the patient was 
hospitalised therefore able to request assistance with toileting overnight. 
3. Medication chart 3, simvastatin prescribed in the morning rather than evening 
(percentage agreement 69.5%, kappa 0.14)  
This may be another example of differing professional judgement regarding clinical 
relevance. While there is evidence that simvastatin is best taken in the evening, this 
is not true for all statins166, there is also recognition that adherence may be 
compromised by multiple dosing167. Both factors may have influenced pharmacists’ 
decisions regarding whether this was a potential MRP. 
4. Medication chart 3, digoxin prescribed as milligrams rather than micrograms 
(percentage agreement 78.0%, kappa 0.30)  
Although this is a potentially serious overdose, the likelihood of the error reaching 
the patient is minimal as it would involve administering 1,000 times the standard 
dose. This may cause pharmacists to be less alert to this type of error. 
5. Medication chart 3, interaction between simvastatin and amlodipine  
(percentage agreement 78.0%, kappa 0.30) 
Identification of this MRP may have been influenced by differences in medicines 
usage between the study sites. Amlodipine was commonly used at Hospital A, 
whereas felodipine was the more commonly used calcium channel blocker at 
Hospital B. This may have resulted in lower awareness of the interaction at Hospital 
B, leading to reduced identification (72.4% compared to 83.3% at Hospital A). 
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6. Medication chart 4, phenytoin not administered for 3 days (percentage 
agreement 81.4%, kappa 0.38)  
The difference in percentage agreement between sites (90% at Hospital A and 69% 
at Hospital B) may be due to pharmacists at Hospital B being unfamiliar with the 
medication charts used for the assessment (the chart used for the assessment 
originated at Hospital A, where different ‘codes’ were used to record non-
administration). While the difference in percentage agreement between the two 
sites did not reach statistical significance (once Bonferroni correction applied), 
there was some evidence for a difference (p = 0.021). 
The analysis of MRPs by MRP subcategories found a statistically significance 
difference between categories, with the results suggesting that ‘interactions’ and 
‘inappropriate timing of administration’ may be less likely to be identified by 
pharmacists than the other types of MRPs. This is consistent with the findings 
(discussed above) regarding the impact of professional judgement (in relation to 
inappropriate timing of administration), and pharmacist’s awareness of the two 
interactions included in the assessment. Caution is required when interpreting these 
results though, due to: 
 the relatively small number of MRPs (and MRP subcategories) included in the 
assessment; 
 the variation in percentage agreement among MRPs within subcategories (for 
example percentage agreement for the MRPs classified as ‘dose too high’ ranged 
from 78% to 98%); 
 two subcategories consisting of only one MRP, which may not have been 
representative of other MRPs within the category (in terms of percentage 
agreement).  
The analysis of MRP identification by severity found no evidence for a difference 
between MRPs categorised as ‘minor’ compared to ‘moderate or severe’, but as above, 
caution is required due to the small number of MRPs (with only three categorised as 
potentially minor). 
In summary, the results of this assessment suggest acceptable agreement among 
pharmacists in relation to MRP identification. It is possible that some of the observed 
variability in MRP identification was related to limitations in the assessment method, 
but additional factors linked to the knowledge, experience and skills of study 
pharmacists (such as awareness of interactions, differences in professional judgement, 
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and perceived likelihood of the error reaching the patient) also appear to have an 
impact. MRP identification also appears to be associated with MRP classification 
subcategory, but not with MRP severity, although these findings need to be interpreted 
with caution. 
Strengths and limitations 
A strength of the research presented in this chapter was its reproducibility, between 
individual pharmacists and study sites, which would have been difficult to achieve using 
non-standardised assessment methods, such as observation. Other strengths include 
the input of practising pharmacists (working with study patients) to inform development 
of the assessment exercise, and the time-efficient nature of the assessment, from both 
the assessor and assessee perspectives. 
Potential limitations include: 
 the choice of medication chart used for the assessment (given that Hospital A had 
recently introduced an electronic prescribing system, and Hospital B used a slightly 
different paper chart). This represented a compromise between developing an 
assessment that was true to practice, and one that could be used across both study 
sites, and was time efficient and simple to complete; 
 the inability to assess all types of MRPs using this method, for example, it was not 
possible to assess pharmacists’ ability to identify medicines reconciliation 
discrepancies, the need for dosage adjustments due to organ dysfunction, and 
administration or monitoring errors; 
 the response rate at Hospital B (66%), as this is a potential source of selection 
bias, and prevented a direct comparison between study pharmacists at the sites; 
 the use of anonymisation, meaning it was not possible to trace the pharmacist who 
submitted the incomplete form, or carry out more detailed analyses based on 
grade, role, and/or experience; 
 the size of the study, limiting the statistical inferences that could be made; 
 the length of the assessment (number of medication charts / simulated MRPs), as 
although the length of the assessment was chosen to limit the amount of time 
needed (to enhance completion) a longer assessment would have permitted: 
o inclusion of a greater number and/or a broader range of MRPs (to permit a 
more robust comparison between MRP classification and severity 
categories); 
o inclusion of medication charts with no MRPs (to more accurately reflect 
practice). 
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As in chapter 6, the limitations associated with the use of the Bonferroni correction also 
need to be considered146. The Bonferroni correction was used as the primary objective 
was to test universal null hypotheses (that identification was unrelated to study site, 
MRP classification and severity). In addition, false positive errors were a greater issue 
than false negative errors as the purpose was to establish an answer to this 
hypothesis, rather than generate hypotheses for further investigation. 
Implications  
Based on this assessment, the best estimate is that pharmacists are likely to identify 
approximately 85% of study MRPs (although this assumes similar percentage 
agreements for MRP subcategories not included in the assessment). While a 
percentage agreement of 80% may be considered acceptable in health research164, 
identification of less than 100% of outcome events may be subject to criticism. This 
potential variability therefore needs to be recognised as a limitation of the MRP data 
collection method, although as discussed in section 6.2.2, prospective identification by 
pharmacy staff was chosen as it aligns with the proposed purpose of the Medicines 
Optimisation Assessment Tool (MOATTM), which is to identify patients at risk of MRPs 
that can be identified during routine clinical practice. The potential variability in 
identification also needs to be taken into account when interpreting study data, for 
example the observed prevalence of MRPs is likely to be underestimated. As the 
variability appears to be unrelated to MRP severity it may also impact on identification 
of patients with the outcome event (i.e. at least one moderate or severe preventable 
MRP). This has the potential to reduce the accuracy and replicability of MOAT 
predictions, which highlights the need for robust external validation of the MOAT 
(following initial development), including the possible need for updating or 
recalibratation94. 
7.5 Conclusion 
The work presented in this chapter suggests that pharmacists at the study sites are 
likely to identify approximately 85% of study MRPs. Identification appears to be 
unaffected by MRP severity, but may be associated with the type of MRP (classification 
subcategory). This variability in MRP identification needs to be recognised as a 
limitation, and the implications will need to be considered when interpreting overall 
study findings. 
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The next chapter will describe the severity assessment of MRPs identified by 
pharmacists at the study sites. This was undertaken to identify patients with the 
outcome event, namely at least one moderate or severe preventable MRP. 
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Chapter 8: Analysis of outcome events 
8.1 Introduction 
As discussed in chapter 6, previous research suggests that a significant proportion of 
hospitalised patients experience medication related problems (MRPs), with estimates 
as high as 81%78. A prognostic model developed to predict MRPs would therefore lead 
to a high proportion of patients being labelled as high-risk, potentially leading to 
inefficient workload management. I therefore chose to select ‘clinically significant’ 
MRPs as the outcome event for the Medicines Optimisation Assessment Tool 
(MOATTM), based on potential severity. Similarly, I chose to use ‘preventable’ MRPs, to 
enable the MOAT to identify patients with MRPs that are amenable to pharmacist 
intervention. The outcome event selected for development of the MOAT was therefore 
moderate or severe preventable MRPs (MSP MRPs). MRP preventability was 
assessed at the point of identification (see section 6.3.3), but it was necessary to select 
a suitable method to rate the potential severity of MRPs, which is described in the 
present chapter. 
The aim of the MOAT is to permit targeting of hospital patients most in need of 
pharmacists’ input. This will require accurate prediction of those at risk, but may also 
require understanding of ‘when’ patients are most at risk, as it is possible that risk will 
vary throughout an admission to hospital. An awareness of the stage of patient stay 
when patients are most likely to experience MSP MRPs may therefore be useful in 
informing implementation of the MOAT. Similarly, an understanding of working 
practices at the study sites, for example the proportion of MSP MRPs identified by 
pharmacists working at ward level compared to those identified in the pharmacy 
department, may permit future MOAT users to assess the applicability of the MOAT to 
their own setting. 
In addition, a potential limitation of the present study, as discussed in chapter 6, was 
use of a combined outcome measure; MRP is an umbrella term for a number of 
‘outcome components’ (i.e. MRP subcategories), therefore significant differences in the 
proportion of these components in new datasets could impact on the MOAT’s 
predictive accuracy60. To permit comparison with future validation datasets it was 
therefore necessary to determine the proportion of each ‘outcome component’ in the 
developmental dataset, that is to say, to establish the proportion of each MRP 
subcategory for the MOAT’s outcome event (MSP MRPs). As two hospitals were used 
for MOAT development, it was also possible to compare the proportion of each MRP 
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subcategory between sites, so providing an indication of potential generalisability of the 
MOAT. That is to say, consistency in the composition of MSP MRPs between hospital 
sites may suggest greater generalisability.  
The aim of the work presented in this chapter was therefore to describe the MRP 
severity assessment, and descriptive analyses of the outcome event, namely MSP 
MRPs. The objectives were to: 
 identify MSP MRPs (the outcome event for development of the MOAT); 
 describe descriptive information on the MSP MRPs (to inform future implementation 
of the MOAT); 
 determine the composition of the ‘outcome components’ (i.e. MRP subcategories) 
of the MSP MRPs to permit comparison with future validation datasets, and provide 
some indication of potential generalisability of the MOAT. 
8.2 Methods 
The methods are presented in three sections: the severity rating of MRPs, descriptive 
analysis of MSP MRPs, and the prevalence of MSP MRPs in the study sample. Each is 
described below, with the results described in section 8.3. 
8.2.1 Severity rating of MRPs 
As no established grading for MRPs is available, severity was classified using a 
validated visual analogue scale developed originally for medication errors163, used 
previously to severity rate MRPs by Rashed et al168. This method requires four 
experienced healthcare professionals (pharmacists, medical, or nursing staff) to 
independently score each event in terms of potential patient outcomes on a scale of 
zero to ten. Zero represents a case with no potential adverse effect on the patient, and 
ten a case that would result in death. The mean score for each event is then used as 
an index of severity, with a score of less than three being considered as a minor 
outcome (very unlikely to have an adverse effect), a score of three to seven considered 
as moderate (likely to cause some adverse effects or interfere with therapeutic goals, 
but very unlikely to result in death or lasting impairment), and a score of greater than 
seven considered to be a severe outcome (likely to cause death or lasting impairment). 
Dean et al163 suggest that at least one judge be selected from each of the three 
professions to facilitate ownership of the results163; I therefore chose a hospital 
pharmacist, senior nurse, and consultant physician (plus myself) to form the MOAT 
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expert panel. All had medication / patient safety experience, and had worked in clinical 
practice for between 12 and 30 years. 
These expert panel members validated each MRP, that is to say they decided whether 
it was a ‘true MRP’ (described in chapter 6, section 6.3.3). Validated MRPs that were 
considered to be preventable (preventability assessment also described in section 
6.3.3), were then assessed for severity by the expert panel as described above. To 
facilitate the assessment process, and aid consistency, expert panel members met 
twice prior to carrying out the MRP assessment. During the first meeting we discussed 
the proposed assessment method and general administrative issues, then during the 
second meeting we discussed 35 randomly selected MRPs in terms of their validation 
and potential severity (assessed / graded individually by panel members in advance of 
the meeting). The outcome of this ‘sample grading’ was shared with panel members 
(for reference purposes), and the following conventions were agreed: 
 MRPs were graded on the basis of the potential severity if not identified during the 
hospital stay; 
 severity ratings were based on perceived risk (rather than local policy / guidance). 
Similarly, national guidance was taken into account if applicable; 
 MRPs were graded based on the potential severity to the patient involved, rather 
than wider implications. For example, when reviewing MRPs related to 
unnecessary antibiotic use, panel members were asked to consider the direct risk 
to the patient, such as toxicity, rather than wider societal concerns, such as 
antimicrobial resistance. 
8.2.2 Descriptive analysis of MSP MRPs  
MSP MRP data were analysed to establish: 
 whether the MSP MRPs were identified during ward visits or in the pharmacy 
department; 
 whether MSP MRPs were resolved by pharmacy staff or other healthcare 
professionals; 
 the stage in ‘patient stay’ when MSP MRPs identified, classified as during / before 
first ward review by pharmacist, during the remainder of the inpatient stay, or during 
clinical screening at discharge; 
 whether MSP MRPs were medicines reconciliation discrepancies. 
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This was to permit comparison between study sites in terms of working practices, 
inform MOAT implementation, and permit a comparison with equivalent data collected 
for ‘all MRPs’ (i.e. all validated MRPs irrespective of severity and preventability, as 
reported in chapter 6). 
MSP MRPs were also categorised using Basger’s MRP classification system114. This 
was to permit comparison of the subcategories: 
 between study sites (to provide some indication of potential generalisability of the 
MOAT); 
 with ‘all MRPs’ (to identify potential differences);  
 with future validation datasets (as significant differences in the proportion of MRP 
subcategories in new datasets could impact on the MOAT’s predictive accuracy60). 
Statistical analysis was performed to test for differences between study sites. Chi-
square or Fisher’s exact tests were used, with the choice based on the expected 
distribution of results in the absence of association, with Fisher’s exact test used when 
an expected cell frequency was less than five. The Bonferroni correction was applied to 
the probability (p) values to account for the risk of type I (false positive) errors 
associated with multiple analyses146; Bonferroni corrected p values were calculated 
based on the number of comparisons (to maintain the critical p level over all tests at 
0.05). 
8.2.3 Prevalence of outcome event 
The prevalence of the outcome event (i.e. the proportion of study admissions that 
experienced at least one MSP MRP), and median number MSP MRPs per admission 
(of admissions with an outcome event) were calculated, and statistical analysis 
performed to test for differences between study sites.  
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8.3 Results 
The results are presented in three sections: severity rating of MRPs, descriptive 
analysis of MSP MRPs, and the prevalence of MSP MRPs in the study sample. Each 
will be described in turn. 
8.3.1 Severity rating of MRPs  
As discussed in section 6.4.5.1, a total of 2,614 MRPs were judged by the expert panel 
to be true MRPs. As shown in Table 32, five were non-preventable (all adverse drug 
reactions), and 1,456 were rated as ‘minor severity’. The remaining 1,153 MRPs were 
therefore MSP MRPs (i.e. the outcome event selected for development of the MOAT). 
There was no evidence for a statistically significant difference in the proportion of 
MRPs rated as ‘minor severity’ compared to ‘moderate or severe’ between study sites 
(p = 0.445). 
Table 32 – Identification of moderate or severe preventable medication related 
problems  
 
 
Medication related problems (MRPs) 
Hospital A 
n (% of MRPs) 
Hospital B 
n (% of MRPs) 
All patients  
n (% of MRPs) 
Number of validated MRPs (as 
reported in chapter 6) 
1,697 (100) 917 (100) 2,614 (100) 
Number of non-preventable 
MRPs (therefore excluded as 
outcome events) 
5 (0.3) 0 (0) 5 (0.2) 
Number of preventable MRPs 
rated as ‘minor severity’ 
(therefore excluded as outcome 
events) 
935 (55.1) 521 (56.8) 1,456 (55.7) 
Total MRPs remaining  
(i.e. moderate or severe 
preventable MRPs)  
757 (44.6) 396 (43.2) 1,153 (44.1) 
Of the 1,153 MSP MSPs, only one (from Hospital A) was rated as potentially ‘severe’. 
This involved a patient prescribed prophylactic heparin (for thromboprophylaxis) 
despite having a raised International Normalised Ratio (of 7.9), increasing the risk of 
bleeding165. The remaining MSP MRPs were all graded as ‘moderately severe’. The 
median scores and interquartile ranges (IQR) for ‘moderately severe’ MRPs were the 
same for both study sites (median 3.25, IQR 3.0 to 3.75); the median was calculated 
(rather than the mean) due to the non-parametric distribution of data. 
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8.3.2 Descriptive analysis of MSP MRPs 
The descriptive analysis results are summarised in Table 33. This shows that the 
majority of MSP MRPs (93.6%) were identified during routine ward visits, resolved by 
pharmacy staff (98.2%), and identified during (or before) the first review of the patient 
(73.9%). Given the Bonferroni corrected p value of 0.0125, there were no statistically 
significant differences between study sites, although there was weak evidence for a 
difference in the proportion of medicines reconciliation discrepancies, accounting for 
55% at Hospital A, and 47.5% Hospital B (p = 0.016).  
Table 33 – Descriptive data for moderate or severe preventable medication 
related problems  
 
Hospital A 
(MSP MRPs 
= 757) 
n (% of MSP 
MRPs) 
Hospital B 
(MSP MRPs 
= 396) 
n (% of MSP 
MRPs) 
All patients 
(MSP MRPs 
= 1,153) 
n (% of MSP 
MRPs) 
p value 
(test for 
difference 
between 
study sites) 
When MSP MRP identified: 
During ward visit  
In the pharmacy department 
Other (pharmacist referral / reported via 
hospital incident reporting system) 
 
709 (93.7) 
43 (5.7) 
5 (0.7) 
 
370 (93.4) 
22 (5.6) 
4 (1.0) 
 
1,079 (93.6) 
65 (5.6) 
9 (0.8) 
 
0.812
 
(Chi-square) 
Who resolved MSP MRP: 
Pharmacy staff  
Other healthcare professionals 
 
740 (97.8) 
17 (2.2) 
 
392 (99.0) 
4 (1.0) 
 
1,132 (98.2) 
21 (1.8) 
0.136
 
(Chi-square) 
Stage in patient stay MSP MRP 
identified: 
During first ward review (or before) 
Remainder of inpatient stay 
Clinical screening at discharge  
Missing data  
 
 
559 (73.8) 
118 (15.6) 
80 (10.6) 
0 
 
 
293 (74.0) 
58 (14.6) 
42 (10.6) 
3 (0.8) 
 
 
852 (73.9) 
176 (15.3) 
122 (10.6) 
3 (0.3) 
0.934 
(Chi-square) 
Medicines reconciliation discrepancy  416 (55.0) 188 (47.5) 604 (52.4) 
0.016
 
(Chi-square) 
MSP MRP = moderate or severe preventable medication related problem 
Bonferroni adjusted p value used to judge statistical significance 0.0125 (based on 4 statistical 
tests) 
The overall results (combining MSP MRPs from both study sites) are comparable with 
the descriptive analysis of ‘all MRPs’ (Table 22, chapter 6), where 93.2% of MRPs 
were identified during routine ward visits, 97.9% resolved by pharmacy staff, 74.6% 
identified during (or before) the first review of the patient, and 55.9% were medicines 
reconciliation discrepancies. While no statistically significant differences were found 
between study sites in the descriptive analysis of MSP MRPs, the analysis of ‘all 
MRPs’ found evidence for a difference between the two study sites in the stage of the 
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patient stay when MRPs were identified. As discussed in chapter 6, this may have 
been due to a greater proportion of pharmacists’ time being spent reviewing new rather 
than existing patients at Hospital B (linked to undertaking medicines reconciliation). 
The lack of evidence for a difference between sites for MSP MRPs may therefore 
suggest that the occurrence of MSP MRPs is less sensitive to differences in hospital 
processes (such as the proportion of patients receiving medicines reconciliation) 
compared to ‘all MRPs’.  
Table 34 gives the breakdown of MSP MRPs identified during clinical screening at 
discharge, in terms of whether they occurred prior to the discharge prescription being 
written (i.e. those that had occurred, but not identified / resolved, such as medicines 
reconciliation omissions), or when the discharge prescription was written (e.g. 
transcription errors). This shows that the majority of MSP MRPs occurred when 
discharge prescriptions were written (66.4%), with no statistically significant difference 
between study sites (p = 0.394).  
Table 34 – Breakdown of identification of moderate severe preventable 
medication related problems when discharge prescription screened 
When MSP MRP occurred 
Hospital A 
(MSP MRPs 
at 
discharge = 
80) 
n (% of MSP 
MRPs at 
discharge) 
Hospital B 
(MSP MRPs 
at 
discharge = 
42) 
n (% of MSP 
MRPs at 
discharge) 
All 
patients 
(MSP MRPs 
at 
discharge = 
122) 
n (% of MSP 
MRPs at 
discharge) 
p value 
(test for 
difference 
between 
study sites) 
Prior to writing discharge prescription 29 (36.2) 12 (28.6) 41 (33.6) 
0.394
 
(Chi-square) 
When discharge prescription written 51 (63.8) 30 (71.4) 81 (66.4) 
MSP MRP = moderate or severe preventable medication related problem 
 
This is comparable with the results for ‘all MRPs’ (Table 23, chapter 6) where 70.4% of 
MRPs occurred when discharge prescriptions were written, with no statistically 
significant difference between study sites. 
The classification of the 1,153 MSP MRPs is summarised in Table 35. This shows that 
the most frequently identified subcategory was ‘indication not treated / missing 
therapy’, accounting for 529 (45.9%). Dose selection issues were the next most 
frequently reported, with ‘dose too low’ and ‘dose too high’ accounting for 13.2% and 
10.8% respectively. The proportion of MSP MRPs in each subcategory was tested for 
evidence of statistically significant differences between study sites (to inform potential 
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generalisability of the MOAT); no statistically significant differences were found (given 
the Bonferroni corrected p value of 0.0022).  
Table 35 – Classification of moderate or severe preventable medication related 
problems  
 
Medication related problem (MRP) 
subcategory 
Hospital A 
(MSP 
MRPs = 
757) 
n (% of MSP 
MRPs) 
Hospital B 
(MSP 
MRPs = 
396) 
n (% of MSP 
MRPs) 
All 
patients 
(MSP 
MRPs = 
1,153) 
n (% of MSP 
MRPs) 
p value 
(test for 
difference 
between 
study sites) 
1. Drug selection 
1.1 Inappropriate drug  41 (5.4) 22 (5.6) 63 (5.5) 0.921
 
(Chi-square) 
1.2 No indication for drug / duplication 16 (2.1) 16 (4.0) 32 (2.8) 0.059
 
(Chi-square) 
1.3 Interaction (drug-drug, or drugs and 
food / alcohol) 
16 (2.1) 9 (2.3) 25 (2.2) 0.860
 
(Chi-square) 
1.4 Indication not treated / missing therapy 351 (46.4) 178 (45.0) 529 (45.9) 0.646
 
(Chi-square) 
1.5 More cost effective drug available 0  0  0 N/A 
1.6 Synergistic / preventive drug required 
and not given 
3 (0.4) 1 (0.3) 4 (0.4) 
1.0
 
(Fisher’s 
exact) 
2. Drug form 
2.1 Inappropriate or suboptimal drug form 12 (1.6) 5 (1.3) 17 (1.5) 0.666
 
(Chi-square) 
3. Dose selection 
3.1 Drug dose too low  99 (13.1) 53 (13.4) 152 (13.2) 0.884
 
(Chi-square) 
3.2 Drug dose too high  79 (10.4) 45 (11.4) 124 (10.8) 0.629
 
(Chi-square) 
3.3 Dosage regimen not frequent enough 1 (0.1) 1 (0.3) 2 (0.2) 
1.0
 
(Fisher’s 
exact) 
3.4 Dosage regimen too frequent 4 (0.5) 2 (0.5) 6 (0.5) 
1.0
 
(Fisher’s 
exact) 
3.5 Dose needs adjustment to organ 
function or change in disease state 
20 (2.6) 5 (1.3) 25 (2.2) 0.127
 
(Chi-square) 
3.6 Dosage instructions unclear, incomplete 
or not understood by patient / carer* 
N/A* N/A* N/A* N/A* 
4. Treatment duration / withdrawal 
4.1 Duration of treatment too short 2 (0.3) 0 2 (0.2) 
0.549
 
(Fisher’s 
exact) 
4.2 Duration of treatment too long 10 (1.3) 7 (1.8) 17 (1.5) 0.550
 
(Chi-square) 
4.3 Inappropriate abrupt withdrawal
†
 2 (0.3) 0 2 (0.2) 
0.549
 
(Fisher’s 
exact) 
5. Drug use process 
5.1 Inappropriate timing of administration / 
dosing by prescriber; administration error 
by nurse 
8 (1.1) 3 (0.8) 11 (1.0) 0.620
 
(Chi-square) 
5.2 Drug underused / under-administered 8 (1.1) 5 (1.3) 13 (1.1) 0.753
 
(Chi-square) 
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Continued from previous page… 
Medication related problem (MRP) 
subcategory 
Hospital A 
(MSP 
MRPs = 
757) 
n (% of MSP 
MRPs) 
Hospital B 
(MSP 
MRPs = 
396) 
n (% of MSP 
MRPs) 
All 
patients 
(MSP 
MRPs = 
1,153) 
n (% of MSP 
MRPs) 
p value 
(test for 
difference 
between 
study sites) 
5.3 Drug overused / over-administered 0 0 0 N/A 
5.4 Drug not taken / administered at all 5 (0.7) 6 (1.5) 11 (1.0) 0.156
 
(Chi-square) 
5.5 Wrong drug taken by patient 0 0 0 N/A 
5.6 Drug abused 0 0 0 N/A 
5.7 Patient or nurse uses drug incorrectly 
through lack of knowledge or barriers (e.g. 
swallowing, dexterity)  
0 0 0 N/A 
5.8 Adequate information not provided or 
not understood or misunderstood or not 
followed* 
N/A* N/A* N/A* N/A* 
5.9 Drugs stored inappropriately / expired 
drug administered / preparation error 
0 3 (0.8) 3 (0.3) 0.040
 
(Chi-square) 
6. Logistics 
6.1 Prescribed drug not available 11 (1.5) 5 (1.3) 16 (1.4) 0.792
 
(Chi-square) 
6.2 Drug order incorrect, incomplete, poorly 
legible / illegible / illegal / incorrect / allergy 
status incomplete  
51 (6.7) 27 (6.8) 78 (6.8) 0.959
 
(Chi-square) 
6.3 Error in drug selection 15 (2.0) 2 (0.5) 17 (1.5) 0.048
 
(Chi-square) 
7. Monitoring 
7.1 Monitoring too frequent 0 0 0 N/A 
7.2 No or too infrequent monitoring 3 (0.4) 0 3 (0.3) 
0.555
 
(Fisher’s 
exact) 
7.3 Inappropriate test ordered 0 0 0 N/A 
7.4 Patient unable to attend / pay for 
monitoring* 
N/A* N/A* N/A* N/A* 
8. Unexpected reaction / adverse drug reaction (ADR) / no obvious cause 
8.1 An ADR occurred 0 1 (0.3) 1 (0.1) 
0.343
 
(Fisher’s 
exact) 
8.2 No obvious cause of treatment failure 0 0 0 N/A 
*  Subcategory not used for MOAT study as relates to primary care (discussed in section 
6.2.3) 
†
  
Subcategory not included in Basger’s original classification system
114
 (discussed in 
section 6.2.3) 
MSP MRP = moderate or severe preventable medication related problem, N/A = not applicable 
Bonferroni adjusted p value used to judge statistical significance 0.0022 (based on 23 statistical 
tests) 
The overall results (combining MSP MRPs from both study sites) are comparable with 
the descriptive analysis of ‘all MRPs’ (Table 24, chapter 6), with ‘indication not treated / 
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missing therapy’ and issues related to dose selection being the most frequently 
identified for both sets of data. Slight differences may be explained by some MRPs 
being inherently less likely to result in adverse patient outcomes. For example, MRPs 
categorised as ‘more cost effective drug available’ are more likely to be associated with 
economic rather than patient safety benefits, therefore are unlikely to be rated as 
‘moderate or severe’ in terms of potential adverse patient outcomes.  
While no statistically significant differences were found between study sites in the 
classification of MSP MRPs, the analysis of ‘all MRPs’ found evidence for statistically 
significant differences for two subcategories (‘indication not treated / missing therapy’ 
and ‘error in drug selection’), which appeared to relate to differences in the proportion 
of patients undergoing medicines reconciliation, and the use of different medication 
prescribing systems at the two sites. As above, this may suggest that the occurrence of 
MSP MRPs is less sensitive to differences in these hospital processes compared to ‘all 
MRPs’. 
8.3.3 Prevalence of outcome events 
As shown in Table 36, 610 (40.6%) of 1,503 study admissions experienced the 
outcome event, namely at least one MSP MRP. Of the admissions that experienced an 
outcome event, the number of MSP MRPs per admission ranged from one to ten, with 
a median of one. 
Table 36 – Prevalence of outcome event 
Moderate or severe preventable 
medication related problem (MSP 
MRP) characteristics 
Hospital A 
(admissions 
= 1,006) 
n (% of 
admissions) 
Hospital B 
(admissions 
= 497) 
n (% of 
admissions) 
All patients  
(admissions 
= 1,503) 
n (% of 
admissions) 
p value 
(test for 
difference 
between 
study sites) 
Admissions with outcome event (at 
least one MSP MRP)  
391 (38.9) 219 (44.1) 610 (40.6) 0.054 
(Chi-square) 
Number of MSP MRPs per patient (of 
the admissions with outcome event) 
Median: 1  
IQR: 1-2 
Range: 1-10 
Median: 1 
IQR: 1-2 
Range: 1-7 
Median: 1  
IQR: 1-2 
0.287
 
(Mann-Whitney 
Bonferroni adjusted p value used to judge statistical significance 0.025 (based on 2 statistical 
tests) 
While there was evidence for a difference in the proportion of admissions who 
experienced at least one MRP between the two study sites (discussed in section 
6.4.5.3), there was no statistically significant difference in the proportion of patients 
who experienced the outcome event (at least one MSP MRP) between study sites (p = 
0.054), particularly given the Bonferroni adjusted p value of 0.025).  
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8.4 Discussion  
Key findings 
Of the 2,736 MRPs reviewed by the expert panel, 1,153 met the requirements for the 
outcome event, namely MSP MRPs. The majority of MSP MRPs were identified during 
(or before) the first review of the patient (73.9%). This compares to 15.3% that were 
identified during the remainder of the inpatient admission, and 10.6% identified during 
clinical screening of discharge prescriptions. The most frequently identified 
subcategories were ‘indication not treated / missing therapy’, ‘dose too low’ and ‘dose 
too high’, accounting for almost 70%, with no statistically significant differences in the 
proportion of MRP subcategories between study sites. Six hundred and ten (40.6%) of 
the 1,503 study admissions experienced an outcome event, namely at least one MSP 
MRP. 
Comparison with previous literature   
No estimation of the prevalence of the MSP MRPs in the United Kingdom exists, but 
Blix et al78 (Norway, 2004) assessed the ‘clinical significance’ of MRPs for a subset of 
patients included in a study to describe the frequency and types of MRPs in 
hospitalised patients. Blix et al reviewed the MRPs for every sixth patient in their 
dataset, and found that 5.9% of MRPs were ‘extremely important’ (with the potential to 
cause death, severe or irreversible detrimental effects), 43.7% were ‘major’ (requiring 
intervention to prevent major or reversible detrimental effects, or lack of therapy), 40% 
were ‘moderate’ (where intervention resulted in moderate benefit), and 10.4% were of 
‘minor’ clinical significance. Although this grading system is not directly comparable 
with the present study, if we assume a moderate or severe MRP (graded using the 
visual analogue scale163 used for the MOAT study), equates to an ‘extremely important’ 
or ‘major’ MRP (using Blix’s definitions), the proportions are broadly comparable; Blix et 
al reported that 49.6% of MRPs were either extremely important or major, compared to 
44.2% of MOAT MRPs being found to be moderate or severe (i.e. 1,153 of the 2,609 
preventable MRPs).  
Strengths and limitations 
Strengths of the MRP severity rating include use of a validated method (used 
previously for this purpose), and the selection of clinically experienced expert panel 
members from a range of professions, increasing the credibility of the assessment and 
facilitating ownership of the results by the professions involved.   
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A potential limitation was the inclusion of myself on the expert panel, as I could not be 
fully blinded to the candidate predictors, and had a potentially vested interest in the 
grading of MSP MRPs. This was necessary due to financial constraints, but had the 
potential to bias results in two ways. First, access to candidate predictor data meant 
imperfect blinding, despite the use of anonymisation. Second, there was potential for 
confirmation bias due to a subconscious desire to influence the number of MSP 
MRPs154. This was addressed in the following ways: 
 separation of MRP data entry / severity rating and candidate predictor data 
collection by as much time as possible (to reduce the likelihood that I may 
recognise study codes, or recall related data). In addition I avoided accessing 
candidate predictor data during MRP severity rating; 
 use of a review / discussion of 35 MRPs by panel members (prior to carrying out 
the MRP assessment). This permitted identification of potential discrepancies in 
panel member’s approaches to grading, and led to the development of simple 
conventions to standardise severity assessments between myself and other panel 
members. The ‘sample grading’ provided an initial benchmark, then to minimise 
‘judgement drift’ I referred to it throughout the assessment period, and kept an on-
going ‘case law document’143. 
Another potential limitation was the occurrence of a small amount of missing data, with 
the ‘stage of patient stay’ missing for three (0.3%) of 1,153 MSP MRPs. As this data 
was collected for descriptive purposes only, it did not impact on development of the 
MOAT. 
As in previous chapters, the limitations associated with the use of the Bonferroni 
correction also need to be considered146. The Bonferroni correction was used as the 
primary objective was to test universal null hypotheses, and as previously, false 
positive errors were a greater issue than false negative errors (as the purpose was to 
establish an answer to these hypotheses, rather than generate hypotheses for further 
investigation). 
Implications  
Given the above limitations, it is possible that subsequent studies may be able to 
improve on the research presented in this chapter by excluding members of the 
research team from the expert panel, and collecting MRP data under strict trial 
conditions (to avoid ambiguities or missing data). 
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The findings of this chapter provide additional support for the potential generalisability 
of the MOAT, in that no statistically significant differences were observed in the 
prevalence of the outcome event (i.e. the proportion of study admissions that 
experienced at least one MSP MRP), or ‘outcome components’ (i.e. the MSP MRP 
subcategories) between study sites60. While this only represents two hospitals, both in 
the South East of England, it does provide some evidence for consistency. Indeed, the 
comparison between analyses for ‘MSP MRPs’ and ‘all MRPs’ found that differences 
between study sites were less pronounced for ‘MSP MRPs’, suggesting that 
differences in hospital processes, that appear to impact on the prevalence of ‘all 
MRPs’, have less influence on the occurrence of ‘MSP MRPs’.  
Analysis of the stage in admission when MSP MRPs were identified suggests that the 
MOAT should be used to target patients at the point of admission to hospital. Results 
found that the majority of MSP MRPs (73.9%) were identified during (or before) the first 
review of the patient, with 52.4% related to medicines reconciliation discrepancies 
(often undertaken during the first review). Future research may be warranted to 
investigate whether this is influenced by working practices at the study sites (for 
example, it may reflect a focus on new admissions), but based on the information 
currently available, these results suggest that patients are at highest risk of 
experiencing MSP MRPs in the early stages of their hospital stay. Regarding 
subsequent stages in hospital stay, 15.3% of MSP MRPs occurred during the 
‘remainder of inpatient stay’ and 10.6% during clinical screening of discharge 
prescriptions, suggesting that risk may diminish, but that patients continue to require 
pharmacist review. Risk is unlikely to be static throughout admission, in practice risk 
may reduce because MRPs have already been identified and resolved, fewer 
prescribing alterations occur, or due to changes in modifiable predictors, for example 
the discontinuation of high-risk or parenteral medicines, or improvements in laboratory 
results. Similarly, risk may increase as a patient’s treatment changes or their condition 
deteriorates. A potential limitation of the MOAT is that it has been designed to identify 
patients at risk of experiencing an outcome event at any stage in the hospital stay, that 
is, the predictions are based on ‘startpoint data’ (i.e. on admission to a hospital medical 
ward), meaning it is not possible to predict if or when a patient’s risk status will change. 
A future development could be to investigate whether predictors vary depending on the 
stage of patient stay, potentially leading to the development of separate risk prediction 
tools that are specific to the different stages. This would require a larger sample than 
the present study as sufficient MSP MRPs for each stage of patient stay would be 
needed to permit robust statistical modelling. Repeated measurement for modifiable 
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candidate predictors would also be needed (to provide startpoint data for each stage of 
patient stay). 
The results may also be of use to future MOAT users when assessing the applicability 
of the MOAT, as they provides an indication of working practices at the study sites; for 
example, the high proportion of MSP MRPs identified during routine ward visits (93.6%) 
and resolved by pharmacy staff (98.2%).  
8.5 Conclusion 
A validated method was used to grade the severity of study MRPs163, and identified 
1,153 that met the definition for the outcome event (MSP MRPs). This equates to 
44.2% of the total MRPs, which is consistent with previous literature78. In terms of the 
prevalence of MSP MRPs, 610 (40.6%) of 1,503 study admissions experienced at least 
one MSP MRP, but this may underestimate the true prevalence (given that study 
pharmacists identified approximately 85% of simulated MRPs as part of an 
identification assessment exercise). Further analysis found there were no statistically 
significant differences in the proportion of each subcategory of MSP MRPs between 
study sites. MSP MRPs were most frequency identified during or before the first review 
by pharmacists, suggesting the MOAT should be used to target high-risk patients as 
early as possible following admission to hospital. 
The next chapter will describe the development of the MOAT. This will involve the use 
of multivariable logistic regression to determine the relationship between candidate 
predictors and patients with an outcome event.  
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Chapter 9: Modelling 
9.1 Introduction 
As discussed in chapters 2 and 6, recommendations to improve the quality and impact 
of prognosis research were published by the PROGnosis RESearch Strategy 
(PROGRESS) group in 201353. In relation to the quality of studies, they recommended 
the need for ‘integrated standards of design, analysis and reporting’, with specific 
advice on the need to address deficiencies in statistical modelling, including: ‘multiple 
sources of significance chasing bias, lack of appreciation of type II errors associated 
with small sample sizes, and the arbitrary dichotomisation or categorisation of 
continuous variables’. The ‘CHecklist for critical Appraisal and data extraction for 
systematic Reviews of prediction Modelling Studies’ (CHARMS)60, and ‘Transparent 
Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis’ 
(TRIPOD) statement57 followed; providing further guidance on the qualities of good 
studies (and inappropriate approaches that should be avoided), potential sources of 
bias, and the level of reporting required to permit quality to be adequately assessed. 
The aim of the work presented in this chapter was therefore to develop the Medicines 
Optimisation Assessment Tool (MOATTM) using approaches informed by the 
PROGRESS53 55, TRIPOD94, and CHARMS60 recommendations. The objectives were 
to: 
 select statistical methods that minimise the risk of bias; 
 develop a regression model that predicts the outcome event well with the minimum 
number of variables; 
 develop a decision aid (the MOAT) to permit pharmacists to target patients at 
highest risk of experiencing the outcome event; 
 report all stages of the statistical analysis clearly and fully (to permit assessment of 
the quality of the study to be assessed). 
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9.2 Methods 
The methods are presented according to the TRIPOD reporting guidelines57. This 
section includes: 
 handling of continuous predictors; 
 pooling of data; 
 sample size calculation; 
 exploratory data analysis; 
 imputation of missing data; 
 model development;  
 assessment of model performance; 
 internal validation / adjustment for model ‘optimism’; 
 development of the MOAT (decision aid based on the regression model).  
Each of these will be described in turn; results are described in section 9.3. 
9.2.1 Handling of continuous predictors 
All continuous predictors were analysed on their continuous scale, that is 
dichotomisation or categorisation were not used (as this can lead to optimistic model 
performance58 60 62 94). As scaling of continuous variables is important for interpretability 
and comparability of effects70, predictors with a wide range in units (age, 
socioeconomic status, estimated glomerular filtration rate, and platelet count) were 
analysed as deciles (i.e. after dividing the actual value by ten). This approach is 
recommended by Steyerberg, on the basis that changes in predictive effect per one 
unit increase would otherwise be small, making comparison with other predictors more 
difficult70. 
9.2.2 Pooling of data  
Given that no statistically significant differences were found in the prevalence of 
outcome events between study sites (reported in chapter 8), data from the two study 
sites were combined for the exploratory data analysis and model development.  
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9.2.3 Sample size calculation  
Sample size is often calculated based on power calculations, but this is not 
straightforward for prognostic modelling studies as there is often not a clear ‘measure 
of effect’ to power the research. An alternative method is to calculate the sample size 
based on the desired precision of a sample estimate94. An alternative approach that is 
commonly used is the ‘rule of thumb’ of at least ‘ten events per variable’ (EPV)92. This 
method requires the sample size to be based on the prevalence of the outcome event 
and the number of candidate predictors that will be used in model development60 92-94. 
Although there is debate over the optimal number of EPV, with recognition that ‘the rule 
of ten or more EPV is not a well-defined bright line’95, there is agreement that models 
developed with less than ten EPV need to be interpreted with caution94 95. The reason 
for the potential problem with using less than ten EPV relates to the reliability of the 
model when used in a new group of patients. If a model is too closely adapted to the 
developmental data it can reflect associations between the candidate predictors and 
outcome event that are due to chance rather than true associations, known as 
‘overfitting’ or ‘optimism’60 62 94. 
For the present study the sample size was dictated by practical considerations 
(funding, time available, and accessibility of data at the study sites), resulting in the 
capacity to include 1,500 admissions. I therefore used both the precision and EPV 
methods to consider the adequacy of this sample size, based on an estimation of the 
outcome event prevalence in the study population. 
The outcome event of interest for this study was the occurrence of at least one 
moderate or severe preventable medication related problem (MSP MRP) in 
hospitalised UK patients. As discussed in chapter 8, no estimate for the prevalence of 
this outcome event currently exists, but Blix et al78 (Norway 2004) reported that 81% of 
827 hospitalised patients experienced an MRP, with approximately half of all MRPs 
classified as ‘extremely important’ or ‘major’ in terms of clinical significance 
(preventability not reported). To establish the prevalence of the outcome event in the 
study population I carried out pilot work involving 200 patients, and found that 39% 
(95% confidence interval 32-45%) experienced at least one MSP MRP (assessed using 
the same methods used for the main study). Although this was consistent with Blix’s 
work, the estimate was based on a small sample of 200 patients. In addition the MRPs 
were severity-rated by three members of the expert panel, rather than the four used for 
the main study. I therefore chose to use the lower confidence interval limit as an 
estimate of event prevalence, i.e. 32%. Given an anticipated event prevalence of 32%, 
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and a sample size of 1,500, it was anticipated there would be 480 admissions with at 
least one MSP MRP. 
To consider the adequacy of the sample size using the precision method I first 
established acceptable target sensitivity for the MOAT by including a question in the 
survey of healthcare professionals and patient / public representatives (discussed in 
chapter 5). A target sensitivity of 90% was proposed, and survey respondents asked if 
this was acceptable. This sensitivity was selected based on previous research to 
develop a ‘clinical decision rule’ to identify emergency department patients at risk of 
adverse drug events169. Hohl et al used a target sensitivity of 90% as this was deemed 
acceptable by emergency physicians, and considered feasible for implementation in 
terms of workload for pharmacists169. A total of 237 responses were received for this 
question: 189 (80%) answered that 90% was an acceptable target; 21 (9%) answered 
no, and 27 (11%) were ‘unsure’. This was discussed with my academic supervisors, 
and it was concluded that 90% was an acceptable target for sensitivity. Given the 
anticipated number of outcome events and a target sensitivity of 90%, this would permit 
the precision of the sensitivity to be estimated with 95% confidence intervals of +2.7%, 
which we considered to be an acceptable level of precision in terms of clinical 
usefulness of the MOAT.  
For the EPV method the aim would be to have at least ten events for every variable 
used in model development. Given the estimate of 480 outcome events, this would 
permit the inclusion of 48 ‘variables’ in model development. The number of variables 
includes all proposed candidate predictors, interactions examined (that is where a 
candidate predictor has a different association with the response variable depending on 
the value of a third variable), transformations for continuous predictors (which permits 
modelling of non-linear predictors), and indicator variables for categorical predictors.  
As discussed in chapters 5 and 6, the candidate predictors were pre-selected to reduce 
the risk of selection bias62. Table 37 shows the total number of variables that were 
proposed for each pre-selected candidate predictor (including the indicator variables, 
i.e. the artificial variables used to represent distinct groups within a categorical 
variable), giving a total of 37 variables. This resulted in 13 EPV assuming no 
interactions or transformations were required (it was not possible to predict if 
transformations would be required before examining the linearity of continuous 
predictors, and no interactions were hypothesised a priori). 
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Table 37 – Number of variables for development of the Medicines Optimisation 
Assessment Tool based on pre-selected candidate predictors  
Variable Type of 
measurement 
Number of 
variables* 
Age Continuous numeric 1 
Socioeconomic status Continuous numeric 1 
Previous allergy / adverse drug reaction Binary (YES/NO) 1 
Body mass index Continuous numeric 1 
Number of hospital admissions in previous 6 months Continuous numeric 1 
Primary diagnosis 
Nominal categorical  
(7 categories) 
6 
Number of comorbidities  Continuous numeric 1 
History of dementia  Binary (YES/NO) 1 
Number of medicines prescribed  Continuous numeric 1 
Parenteral administration route  Binary (YES/NO) 1 
Use of ‘high-risk medicines’ 
Binary (YES/NO)  
for each of 15 groups 
15 
Renal function (glomerular filtration rate calculated using 
the modified Modification of Diet in Renal Disease 
equation) 
Continuous numeric 1 
Liver disease Binary (YES/NO) 1 
Serum albumin Continuous numeric 1 
Serum potassium Continuous numeric 1 
Serum sodium Continuous numeric 1 
White cell count Continuous numeric 1 
Platelet count Continuous numeric 1 
Total number of variables*  37 
*  Number of variables in relation to calculating the ‘events per variable’  
Review of adequacy of sample size following data collection  
Following data collection it was possible to review the adequacy of the sample size 
based on the actual prevalence of the outcome event in the study sample (40.6%, i.e. 
610 of 1,503 admissions experienced at least one MSP MRP).  
Using the precision method, the higher number of events (compared to the provisional 
estimate) equates to an increased precision in the estimation of the MOAT’s sensitivity 
(95% confidence intervals +2.4%).  
Two changes impact on the EPV calculation: 
 increased number of admissions experiencing the outcome event compared to 
provisional estimate (610 versus 480); 
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 reduced number of variables from 37 to 33 (due to the need to collapse four of the 
proposed high-risk medicine categories, discussed further in section 9.3.1.1). 
As non-linear transformations were not required (discussed in section 9.3.1.3), and no 
interactions examined, this resulted in an increase in the EPV to 18. While the original 
estimate was adequate (i.e. above ten EPV), it is acknowledged that more events and 
higher EPV are almost always prefereable95 due to the reduced risk of model 
overfitting60 62 94. 
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9.2.4 Exploratory data analysis 
Descriptive statistics for the candidate predictors were presented in chapter 6, including 
percentages for categorical predictors, and measures of central tendency, variability, 
and ranges for continuous predictors. Further exploratory data analyses were carried 
our prior to undertaking model development to maximise insight into the dataset, 
specifically to: 
 identify categorical predictors with narrow distributions (resulting in the need to 
collapse groups); 
 identify values of continuous predictors outside their typical ranges (i.e. outliers); 
 assess linearity between continuous predictors and the outcome event (to identify 
the need to include non-linear transformations during multiple imputation and 
model building); 
 test for multicollinearity between candidate predictors;  
 establish univariable associations between predictors and the outcome event. 
Each of these will be described in turn. 
Stata version 14.2 was used for all statistical analyses using the observed (i.e. non-
imputed) data. 
9.2.4.1 Review of distribution of categorical predictors  
It was necessary to review the categorical candidate predictors prior to data analysis to 
identify and eliminate sparse categories94. This prevents low predictor prevalence 
biasing results, or causing non-convergence of regression models63 95. Although there 
is no clear definition of ‘sparse’, 5% has been used as the minimum predictor 
prevalence by other researchers developing prognostic models for adverse medication-
related outcomes42 44 45.  
Ideally the decision to collapse categories should be made while blinded to the 
relationship between predictor and outcome events in the sample population, as this 
limits overfitting70 94; the prevalence of all categorical predictors was therefore reviewed 
prior to univariable or multivariable regression modelling. Predictor categories 
containing less than 5% of the study population were identified, then consideration 
given to alternative categorisation, collapsing categories only where clinically sensible.    
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9.2.4.2 Identification and review of outliers (continuous predictors)  
Outliers, defined by Tukey as values more than (or equal to) one and a half 
interquartile ranges (IQRs) above the third quartile or below the first quartile170, have 
the potential to substantially distort statistical estimates and inflate error rates171. Box-
plots were therefore used to identify outliers, and where identified, values were 
reviewed to establish plausibility. Implausible values were considered as errors and 
hence set to missing70.  
As advised by Steyerberg70, ‘truncation’ was used to reduce the influence of outliers on 
the regression coefficients (known as leverage). This involved assessing the impact of 
shifting very high and very low values to truncation points, defined by examining the 
distribution of data, and predictor-outcome relationship. More specifically: 
 truncation points were set at one and a half times the IQRs above or below the third 
or first quartile respectively, with truncation points for laboratory results checked 
against standard reference ranges (to ensure clinical sensibility); 
 outliers were identified using visual inspection of box-plots, and Stata’s ‘extremes’ 
module172 (which provides distance of outliers from the nearer quartile); 
 univariable logistic regression models were specified for each predictor using non-
truncated and truncated data. Where predictors had outlying values that were both 
above the upper truncation point, and below the lower truncation points, the impact 
of each group of outlying values were considered separately; 
 ‘regression coefficients’ (i.e. the relationship between independent and dependent 
variable, more specifically the change in predicted log oddsiii of the regression 
outcome that would be predicted by a one unit increase in the candidate predictor) 
were then compared to identify ‘substantial differences’ between the non-truncated 
and truncated models. As there is no accepted definition of what constitutes a 
‘substantial difference’, I chose to interpret a change in regression coefficients of 
10% or more as being substantial. This was to permit a consistent approach, and 
reduced the risk of significance chasing bias53 (i.e. selection based on which 
version of the data produced the most statistically significant model). Where there 
was no substantial difference in the regression coefficients between the model 
fitted with non-truncated and truncated data, non-truncated data were used for 
subsequent analyses and MOAT development (on the basis that the outlying cases 
                                                          
iii
 Logistic regression uses a combination of odds ratios and natural log transformations, 
therefore the probability of the outcome event is modelled on a log-odd scale. This permits 
predictions to be unbounded (i.e. from plus infinity to minus infinity), preventing invalid values 
(such as probabilities above one or below zero).  
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were representative of the population of interest173). Where a substantial difference 
was observed, truncated data were used.  
The model chi-square for non-truncated and truncated models was also compared to 
indicate the impact of truncation on model fit. The model chi-square is twice the 
difference in the log likelihood of a model with and without the predictor(s)70, and is an 
omnibus test of statistical significance of the model174. It has no meaning in itself, but 
provides a comparison of nested models175. As the truncated and non-truncated 
models were fitted using slightly different data, it is not possible to directly compare 
their log likelihoods using standard statistical tests such as the likelihood ratio test 
(which compares the log likelihoods of two models under the null hypothesis of no 
association70); model chi-square results were therefore recorded to provide an 
indication of the change in the predictive information provided by the predictor before 
and after truncation, with a decrease indicating a loss of predictive information70. 
Truncation was used rather than data transformation (for example using logarithms or 
quadratics), due to the potential impact of transformations on the interpretability of the 
MOAT (as regression coefficients would no longer relate to meaningful measurement 
scales)171.  
9.2.4.3 Linearity  
Standard logistic regression models assume linearity between continuous predictors 
(modelled on their continuous scales) and the log-odds of the outcome variable, that is 
to say the effect is the same at each part of the predictor range70. Where this is not the 
case, it is necessary to account for the non-linearity during model building. While 
checks for non-linearity are often performed during model development, it was 
necessary to identify potential non-linearity prior to imputing missing data, to permit the 
inclusion of non-linear transformations in the multiple imputation model; failure to do so 
can cause misspecification of the imputation model, leading to biased results176 177.  
Non-linearity can be checked using various methods, such as applying simple 
transformations (for example, logarithms or square roots), the inclusion of quadratic or 
cubic polynomials as an extension to a model (for example 𝓍, 𝓍 + 𝓍2, 𝓍 + 𝓍2 + 𝓍3), or 
the use of fractional polynomials (which extends ordinary polynomials by including non-
positive and fractional powers)70. Improvements in model fit are then investigated (i.e. 
the extent to which fitted values of the outcome variable compare with observed 
values178) following inclusion of non-linear transformations in the model.  
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Traditionally quadratic or cubic polynomials have been used to check for non-linear 
relationships, but they are limited in the shapes they can take. Fractional polynomials 
(FPs) allow for smoother and more flexible transformations, therefore are now widely 
recommended70 94. It is also possible to use FPs to assess the linearity of all continuous 
predictors simultaneously, using ‘multivariable fractional polynomial (MFP) modelling’179 
180. Given these advantages, I decided to use MFP modelling to check for non-linearity 
between the candidate predictors and outcome.  
In MFP modelling, null models (that exclude each predictor in turn), are compared to 
models including the predictor as a linear variable, and models containing the predictor 
with one or two FPs (selected by searching all power combinations from the set -2, -1, -
0.5, 0, 0.5, 1, 2, 3, where inverse is 𝓍−1, square root is 𝓍0.5, log is 𝓍0, linear is 𝓍1, 
squared is 𝓍2, and so on). Where there is evidence for non-linearity of the continuous 
predictor (from comparisons of model fit), either one or two FP transformations are 
automatically selected in the final MFP model, depending on which fits the data better. 
The Stata code used to run the MFP model was: 
 
where: 
 ‘xi:’ expands terms containing nominal categorical variables (i.e. primary diagnosis); 
 ‘mfp’ is the command to perform MFP modelling; 
 ‘alpha’ sets the significance levels for testing between different fractional 
polynomials models (0.05 is the default nominal p value); 
 ‘select’ sets the nominal significance level for variable selection by backward 
elimination. This was set at 1 to force all variables to remain in the model (i.e. to 
produce a full model); 
 ‘logit’ is the command to run a logistic regression; 
 the logit command is followed by the outcome variable, then a list of all candidate 
predictors (e.g. ‘age_dec_F’ was the variable name used for ‘age in deciles’).  
I also ran a MFP model using the backward elimination option to determine if linearity 
was altered following removal of ‘non-significant’ variables. This involved changing the 
‘select’ option to 0.157 (i.e. the nominal significance level used for development of the 
MOAT, discussed further in section 9.2.6.2).  
> icoags heparin diabetes opiates gent_vanc antimicrob epilepsy antipsychot antiarryth antidepres other_high_risk liver_dx
> _F egfr_trun_F albumin_trun_F potassium_trun_F sodium_F wcc_trun_F platelets_trun_F allergy i.prim_diag dementia iv_use ant
. xi: mfp, alpha(.05) select(1): logit study_outcome age_dec_F ses_dec_F bmi_trun_F num_hosp_adm_trun_F num_comorb_F num_meds
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9.2.4.4 Multicollinearity  
Multicollinearity occurs when two or more candidate predictors are highly correlated181. 
This can cause problems when fitting and interpreting regression models, as very 
strong correlations can prevent accurate estimation of the regression coefficients of 
affected predictors70. As a result, Steyerberg advises that where predictors are strongly 
correlated, it may be appropriate to combine them into a single combined variable70. To 
establish whether this would be necessary for the present study I assessed 
multicollinearity by calculating variance inflation factors (VIFs), which measure ‘the 
degree to which collinearity among the predictors degrades the precision of estimate 
coefficients’70. 
Where predictors are completely uncorrelated with each other, the VIF is equal to one, 
whereas if predictors are very closely related to other variable(s) the VIF gets very 
large174. A rule of thumb is that a VIF greater than ten indicates multicollinearity70. 
The Stata programme ‘collin’ was used to calculate the VIF for each predictor, using 
the following code: 
 
where: 
 ‘xi:’ expands terms containing nominal categorical variables (i.e. primary diagnosis); 
 ‘collin’ is the command to perform the multicollinearity diagnostics; 
 the collin command is followed by a list of all candidate predictors (e.g. 
‘age_dec_F’, the variable name used for ‘age in deciles’).  
9.2.4.5 Univariable analyses  
Univariable analyses were performed to provide data on the unadjusted association 
between candidate predictors and the outcome event. Cross-tabulation was used to 
compare admissions with and without the outcome event. Proportions were recorded 
for categorical predictors, and means recorded as a measure of central tendency for 
continuous predictors (as examination of the truncated data suggested compatibility 
with normal distributions). Odds ratios were also obtained using univariable logistic 
regression.  
  
> c antimicrob epilepsy antipsychot antiarryth other_high_risk liver_dx
> trun_F sodium_F wcc_trun_F platelets_trun_F allergy i.prim_diag dementia iv_use anticoags heparin diabetes opiates gent_van
. xi: collin age_dec_F ses_dec_F bmi_trun_F num_hosp_adm_trun_F num_comorb_F num_meds_F egfr_trun_F albumin_trun_F potassium_
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9.2.5 Missing data 
The comparison of study admissions with and without missing values (chapter 6) 
suggested data were missing at random (MAR). Due to the risk of selection bias 
associated with the use of complete-case analysis when data are MAR94 148, in addition 
to a loss of statistical power / precision associated with a reduced sample size62, it was 
decided to deal with missing data using multiple imputation. The purpose of multiple 
imputation is to permit valid statistical inference, rather than to recreate individual 
missing values176. This is achieved by creating multiple datasets, with missing 
observations substituted with plausible values based on other observed participant 
data60. Analysis is then performed on each completed dataset and the results 
combined, so allowing for the uncertainty around the true values148. This differs from 
single imputation, where missing values are treated as known in subsequent analyses; 
single imputation therefore underestimates the variance of the estimates (by not taking 
sampling variability into account), and overestimates precision, resulting in confidence 
intervals and significance tests that are too optimistic176. 
In a review of the use of multiple imputation in epidemiology and clinical research, 
Sterne et al148 advised that multiple imputation ‘needs to applied carefully to avoid 
misleading conclusions’. Sterne proposes reporting guidelines for missing data (which 
extend the STROBE guidelines for observational studies147, and TRIPOD statement for 
prognostic model studies57). These guidelines are summarised below: 
1. report number of missing values, with reasons for missing values in terms of other 
variables; 
2. clarify whether there are important differences between individuals with and without 
missing data (e.g. comparison table of key variables); 
3. describe the type of analysis used to account for missing data, the missingness 
assumption used, and for multiple imputation, whether the MAR assumption is 
plausible; 
4. for analyses based on multiple imputation provide: 
 software used and key settings for imputation modelling; 
 number of imputed datasets created (with at least 20 preferable); 
 which variables were included in imputation procedure; 
 how non-normally distributed and categorical variables were dealt with; 
 whether interactions were included in final analyses and imputation models; 
5. comparison of observed and imputed values (where large fraction of data imputed);  
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6. sensitivity analysis comparing results from complete-case analysis with those from 
multiple imputation, with investigation of ‘the robustness of key inferences to 
departure from the MAR assumption’. 
Items one and two are reported in chapter 6. Regarding item 3, the analysis of the 
likely missingness mechanism, and plausibility of the MAR assumption are also 
reported to chapter 6. As a result of these assessments, multiple imputation was 
chosen to deal with missing data, but prior to undertaking the imputation modelling I 
explored the data to identify any missing data that could be predicted using less formal 
methods182 (results presented in section 9.3.2.1). Items four to six are addressed 
below, together with the ‘imputation diagnostics’, which were performed to assess how 
well the imputation performed. 
9.2.5.1 Software and imputation method 
Imputation modelling was conducted using Stata version 14.2. ‘Multiple imputation by 
chained equations’ (MICE) was used to create 30 imputed datasets. A random seed 
(53421) was used to permit results to be reproduced.  
9.2.5.2 Selection of variables for imputation modelling 
Sterne et al148 advise that the MAR assumption is only valid if variables predictive of 
the missing values are included in the imputation model, and that bias is only avoided if 
sufficient variables (that are predictive of the missing values) are included. Sterne 
recommends inclusion of all candidate predictors, plus ‘auxiliary variables’, which are 
variables predictive of the missing values, and those influencing the process causing 
the missing values.  The following variables were therefore included in the imputation 
model as auxiliary variables: 
 weight and height (as predictive of BMI for those patients with only one or other 
measurement available); 
 gender (as being male appears to be positively associated with missing data, and 
gender is likely to be associated with BMI); 
 length of hospital stay (as shorter hospital stay was associated with missing data). 
Pairwise correlation supported use of these variables, with positive correlations 
between weight and height (r = 0.46), weight and gender (r = 0.27), weight and BMI     
(r = 0.87), height and gender (r = 0.65), and length of hospital stay and serum albumin 
(r = 0.30).  
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As recommended by Sterne et al148, the outcome event was also used to impute the 
missing predictor values.  This is advised as the outcome event carries information 
about the missing predictor values, and failure to include it may falsely weaken 
associations between predictors and outcomes.  
Truncated candidate predictor data were used for the imputation model where selected 
for the MOAT development model (as discussed in section 9.2.4.2). This was to 
preserve data characteristics that would later be explored at the analysis stage176.  
9.2.5.3 Analysis of data distribution 
Sterne et al148 advise that the inclusion of non-normally distributed variables can lead to 
bias and/or implausible results, therefore the distributions of continuous variables were 
established by plotting the data and reviewing the skewness statistic, which is a 
measure of the degree and direction of asymmetry, with symmetric (normal) distribution 
having a skewness of zero. A skewness statistic of between minus one and plus one 
was interpreted as representing normal distribution183. Normality tests (such as the 
Shapiro-Wilk test) were not used as they can be overly conservative for large samples 
(i.e. greater than 300)184. Transformations were then applied as appropriate, with the 
choice dependent on the direction and extent of skew181.  
9.2.5.4 Inclusion of variable transformations 
It is recommended that variable transformations intended for use in the final analyses, 
such as logs, FPs and interaction terms, are included in the imputation model to 
prevent misspecification of the model176 177. 
No interaction terms were included in the imputation model as none were hypothesised 
a priori for the final analyses. Regarding non-linear transformations, the exploratory 
data analysis found no evidence for non-linearity between the continuous predictors 
and outcome variable (section 9.3.1.3); it was therefore not necessary to include non-
linear transformations in the imputation model or final analyses. 
9.2.5.5 Comparison of observed and imputed values 
The MICE imputation model was specified using linear regression as the conditional 
distribution for variables with missing values (as all variables with missing data were 
continuous)176 177: 
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where: 
 ‘mi impute chained’ is the Stata command to run a MICE imputation; 
 ‘regress’ specifies that MICE distribution for imputation of the missing variables (i.e. 
linear regression); 
 variables on the left of the equal sign have missing information, those on the right 
have no missing values (e.g. ‘ses_dec_F’ was the variable name used for 
‘socioeconomic status in deciles’).; 
 ‘add’ specifies the number of imputations to be performed (i.e. 30 imputations); 
 ‘rseed’ is the random seed used to permit reproducibility of the results; 
 ‘savetrace(trace1,replace)’ specifies to Stata to save a file of the predicted values 
from each iteration of the imputation for the purposes of imputation diagnostics 
(section 9.2.5.6). 
All imputed values were then reviewed to identify implausible results (e.g. negative or 
clinically implausible values). Where the imputed values were implausible, truncated 
distributions were specified (i.e. upper and/or lower limits) using Stata’s ‘truncreg’ 
imputation method176. 
9.2.5.6 Imputation diagnostics 
It is possible to assess how well an imputation has performed by fitting a standard 
logistic regression model using the imputed data176 177, then checking the: 
 Relative Increase in Variance (RVI) – the proportional increase in total sampling 
variance that is due to missing information;  
 Fraction of Missing Information (FMI) – the proportion of the total sampling variance 
that is due to missing data. 
The RVI is interpreted by how close it is to zero (signifying minimal effect of missing 
data on the variance of the estimate). FMI is used to assess whether sufficient 
imputations have been used, with a commonly used rule of thumb that the number of 
imputations should be at least equal to the highest FMI percentage. 
> tudy_outcome ln_length_stay male , add (30) rseed (53421) savetrace(trace1,replace)
> iv_use anticoags heparin diabetes opiates gent_vanc antimicrob epilepsy antipsychot antiarryth antidepres other_high_risk s
> ets_trun_dec_F weight height = age_dec_F num_hosp_adm_trun_F num_comorb_F num_meds_F i.prim_diag allergy dementia liver_dx 
. mi impute chained (regress) ses_dec_F bmi_trun_F egfr_trun_dec_F albumin_trun_F potassium_trun_F sodium_F wcc_trun_F platel
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I also checked convergence of the MICE algorithm by visually examining ‘trace’ plots 
for BMI and serum potassium, chosen as these variables had the highest proportion of 
missing values (22.7% and 2.0% respectively)177. The option ‘savetrace’ was used 
when imputing the missing values (as shown in section 9.2.5.5). This specifies Stata to 
save the means and standard deviations of imputed values from each iteration to a 
Stata dataset177. The predicted mean and standard deviation for BMI and serum 
potassium were then plotted, with the ten imputation chains (the default number used 
by MICE) graphed simultaneously to establish whether anything unexpected occurred 
in a single chain; absence of any sort of trend in the summaries of the imputed values 
indicates good convergence177. 
9.2.5.7 Multiple imputation sensitivity analysis 
As discussed in chapter 6, multiple imputation is not appropriate where data are 
missing not at random (MNAR), as MNAR data are related to unobserved data, and 
therefore cannot be plausibly estimated from the observed study variables. Sensitivity 
analysis was therefore carried out to compare complete-case and multiple imputation 
analyses.  
Multivariable logistic regression models (including all candidate predictors) were 
specified for the complete-case and imputed datasets; regression coefficients, standard 
errors, and p values were then compared. Given the large number of admissions with 
missing BMI data, I also re-ran the analyses, omitting BMI; this increased the number 
of observations for the complete-case analysis. 
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9.2.6 Model development 
Model development is presented in three sections: the choice of model type, selection 
of predictors during modelling, and model diagnostics. Each of these is described in 
turn. 
9.2.6.1 Type of model  
Multivariable binary logistic regression was selected for model development. This was 
chosen as the outcome event is binary, and all participants were followed up to the end 
of the study period.  A random effects model was used to account for possible 
correlation between observations, that is, between patients admitted more than once 
during the study period. Failure to take account of this lack of independence may have 
resulted in standard errors and p values being too small, hence confidence intervals 
too narrow, resulting in a belief that evidence was stronger than it actually is185.    
The full model was specified using the Stata code: 
 
where: 
 ‘mi estimate’ runs the model estimation command on the multiply imputed data, 
adjusting coefficients and standard errors for the variability between imputations 
according to the combination rules by Rubin176; 
 ‘xtlogit’ is the command to run a ‘random effects’, ‘fixed-effect’, or ‘population-
averaged’ logistic regression; 
 the xtlogit command is followed by the outcome variable, then a list of all candidate 
predictors (e.g. ‘age_dec_F’ was the variable name used for ‘age in deciles’); 
 ‘re’ is the option used to specify a ‘random effects’ model; 
 ‘i(id)’ indicates the data structure (i.e. identifies the duplicate admissions). 
9.2.6.2 Predictor selection during modelling 
The aim was to produce a parsimonious model to increase clinical applicability while 
retaining reasonable predictive performance; it was therefore necessary to reduce the 
number of candidate predictors included in the final prediction model. Univariable 
associations between predictors and the outcome event were not used to preselect 
> base
> eparin diabetes opiates gent_vanc antimicrob epilepsy antipsychot antiarryth antidepres other_high_risk liver_dx, re i(id) 
> _F albumin_trun_F potassium_trun_F sodium_F wcc_trun_F platelets_trun_dec_F allergy i.prim_diag dementia iv_use anticoags h
. mi estimate: xtlogit study_outcome age_dec_F ses_dec_F bmi_trun_F num_hosp_adm_trun_F num_comorb_F num_meds_F egfr_trun_dec
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variables; this is not recommended on the basis that important predictors may be 
excluded due to their predictive effect being masked by other predictors94. 
Backwards elimination was used to reduce the set of candidate predictors during 
modelling, with the aim of including only the most significant in the model. Backward 
elimination starts with a full model (i.e. one that contains all predictors), the ‘least 
significant’ predictor (based on a predetermined ‘stopping rule’), is then removed, and 
the model re-fitted. This is continued until all predictors in the model are ‘significant’70. I 
used a significance level of p greater than 0.157 to exclude predictors, chosen as it is 
comparable with the more complex Akaike Information Criterion (AIC)70, which 
compares models based on their fit to the data while penalising for the complexity of 
the model. Use of the AIC, or even higher p values (for example a p value of greater 
than 0.5), is considered to be a suitable for relatively small dataset (hence relatively 
larger p-values for the predictors) as this is less likely to result in underfitting than 
alternative methods70. Automated variable selection was not used because: (1) manual 
selection permitted clinical judgement to be incorporated, for example to decide which 
predictor to exclude in cases where two predictors had similar significance levels; and 
(2) automated techniques are generally considered to have a high probability of 
generating spurious findings63. 
As ‘primary diagnosis’ was a nominal categorical variable it was necessary to select a 
‘base category’. This does not fundamentally alter the estimation, but provides a base 
level, with the reported coefficients for the remaining categories measured as the 
difference from this base category186. I chose to use the category ‘other’ (which 
consisted mainly of symptoms or findings not specific to a diagnosis) as this would be 
difficult to use as a predictive category in clinical practice. It also contained a 
reasonable number of admissions, that is 244 (16.2%) of 1,503 admissions, so 
increasing the reliability of parameter estimates181. The remaining primary diagnosis 
categories were then considered individually during the backwards elimination, and 
removed as appropriate. 
Once all predictors in the model were significant (i.e. p smaller than or equal to 0.157), 
I reviewed the selected predictors to consider the sensibility of including each of them 
in the MOAT. This involved consideration of whether the predictor’s contribution to the 
predictive ability of the model justified the workload / inconvenience of obtaining the 
data in clinical practice. The concordance index (c-index) was used to estimate 
predictive ability (discussed further in section 9.2.7). 
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Results are presented for the full regression model (i.e. containing all candidate 
predictors), and the model produced following backward elimination; the latter will be 
referred to as the ‘backward selection model’ (BS model) to distinguish it from the ‘final 
model’ (i.e. the model produced following adjustment of the BS model to account for 
optimism, as discussed in section 9.2.8). The regression coefficients and p values for 
the candidate predictors are given. The ‘constant’ for the model (i.e. the expected value 
of the log-odds of the outcome event when all predictor variables equal zero) is also 
reported; this permits calculation of the predicted risk for an individual patient using the 
standard logistic regression equation: 
Log-odds of the outcome event = 𝛽0 +  𝛽1𝓍1  +  𝛽2𝓍2 + ⋯ + 𝛽𝑝𝓍𝑝   
where 𝛽0 is the constant. The quantity on the right-hand side of the equal sign is the 
linear predictor of the log-odds of the outcome given the particular value of the 𝑝 
exposure variables 𝓍1 to 𝓍𝑝 (where 𝓍 takes the numerical value of continuous 
variables, and is coded zero or one for categorical variables). The 𝛽’s are the 
regression coefficients associated with the 𝑝 exposure variables181.  
The predicted probability can then be calculated by exponentiating the log-odds (to 
give the odds of the outcome event), followed by use of the formula: 
Predicted probability = 
𝑜𝑑𝑑𝑠
(1 + 𝑜𝑑𝑑𝑠)
 
Alternatively, predicted probability = 
1
(1 + exp (−(𝑙𝑜𝑔 𝑜𝑑𝑑𝑠))
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9.2.6.3 Model diagnostics 
The following model diagnostic checks were performed for the BS model: 
 evidence for clustering caused by the duplicate admissions (to assess the suitability 
of random effects modelling); 
 accuracy of the ‘quadrature approximation’ used to estimate the random effects 
model (to assess model reliability); 
 evidence for ‘specification error’ (to assess whether the model included all relevant 
predictors); 
 the impact of outlying observations (to identify the need to make adjustments to the 
model by removing or modifying influential observations).  
Each is described below. 
Evidence of clustering 
After specifying a random effects model, Stata automatically reports the intra-cluster 
correlation (rho), which is a measure of the correlation within clusters. Where 
individuals within a cluster are no more similar than individuals in different clusters, rho 
is equal to zero. Where rho is one, everyone within a cluster acts the same. Stata also 
performs a likelihood ratio test, with the null hypothesis that there is no clustering (i.e. 
rho equal to zero).  
Stata reports rho for models fitted with both non-imputed and multiply imputed data, but 
only reports the likelihood ratio test for non-imputed data. This is because the analysis 
of multiply imputed data involves an initial analysis being performed on each imputed 
dataset, with results then pooled using Rubin’s combination rules. As a consequence, 
some postestimation procedures (such as the likelihood ratio test) are not directly 
applicable to multiply imputed data176. Rho was therefore reviewed after fitting the BS 
model in both the non-imputed and multiply imputed datasets, and the likelihood ratio 
test result reviewed after fitting the model using the non-imputed data. 
Accuracy of the quadrature approximation 
Random effects models are calculated using quadrature, which is an approximation 
whose accuracy depends partially on the number of integration points used187. After 
fitting a random effects model it is recommended that the accuracy of the quadrature 
approximation is checked185 187. With Stata, this can be performed using the ‘quadchk’ 
command188. This compares the parameter estimates obtained using different numbers 
of integration points, and calculates the relative difference in the regression 
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coefficients; if the coefficients do not change by more than a relative difference of 
0.01%, this indicates that the choice of quadrature points does not significantly affect 
the outcome, and the results may be confidently interpreted188. 
The ‘quadchk’ command is not compatible with multiply imputed datasets; I therefore 
used the non-imputed data to check the accuracy of the quadrature approximation. 
This permitted inclusion of 1,494 (99.4%) of the 1,503 admissions, therefore providing 
a close approximation to the equivalent multiply imputed model in terms of the number 
of observations.   
Testing for specification error 
When building a logistic regression model, it is assumed that the log-odds of the 
outcome is a linear combination of the independent variables, and that all relevant 
independent variables have been included in the model. If this is not the case, the 
model is said to be ‘miss-specified’ (i.e. there is a specification error)174.  
After fitting a logistic regression it is possible to detect a specification error by refitting a 
model using the ‘predicted value’, and ‘predicted value squared’. If the model is 
correctly specified, the ‘predicted value’ should be a statistically significant predictor (as 
it is the predicted value from the model). Conversely, the ‘prediction squared’ should 
have little predictive power except by chance. If the ‘prediction squared’ is significant, 
this suggests that relevant variables were excluded from the model, or that possible 
interactions have been overlooked174. 
The Stata command ‘linktest’ can be used to perform the above procedure in non-
imputed data. As multiply imputed data were used to create the BS model, the 
specification error check was performed manually as follows: 
1. The BS model was specified using the standard Stata commands, saving the 
estimation results in a file named ‘miest’;  
   
2. ‘Predicted value’ (_hat) was generated using the saved estimation results; 
 
3. ‘Prediction squared’ (_hatsq) was generated, (i.e. ‘_hat’ multiplied by ‘_hat’); 
 
>  6 7).prim_diag  gent_vanc antimicrob epilepsy , re i(id)
. mi estimate, saving(miest,replace): xtlogit study_outcome num_comorb_F num_meds_F egfr_trun_dec_F wcc_trun_F allergy io(1 3
. mi predict _hat using miest, xb
. mi passive: gen _hatsq = _hat*_hat
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4. A logistic regression model was specified using the ‘predicted value’, and ‘predicted 
value squared’. 
 
It was then possible to review the statistical significance of ‘_hat’ and ‘_hatsq’, thereby 
testing for evidence of a specification error. 
Detection and review of outlying observations 
Outlying observations (cases) have the potential to yield biased regression coefficients 
as they may have significant leverage on the regression line. Following specification of 
the BS model I therefore checked for outliers and influential cases using the following 
residual and influence measures174 189: 
 standardised Pearson residuals (a measure of the relative deviation between 
observed and fitted values); 
 deviance residuals (a measure of disagreement between the observed and fitted 
log likelihoods functions); 
 Pregibon leverage (a measure of the influence of observations). 
The following diagnostic statistics were also used to identify cases with a substantial 
impact on the regression model in terms of: 
 chi-square fit statistic (dx2);  
 deviance statistic (dd); 
 regression coefficients (Pregibon’s dbeta). 
The results were examined graphically by plotting each of the above measures against 
the model’s predicted values.  
The following standard rule of thumb cut-off values were used to identify outliers174 189: 
 standardised Pearson or deviance residuals outside the range of plus or minus two; 
 Pregibon leverage greater than three times the average leverage for the model; 
 chi-square fit statistic or deviance statistic greater than 3.84 (i.e. the upper ninety-
firth percentile of chi-square distribution with one degree of freedom). 
A cut-off value of 0.04 was used for Pregibon’s dbeta, selected after visually examining 
the plotted values.  
. mi estimate: logit study_outcome _hat _hatsq
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The residuals, influence measure, and diagnostic statistics for each of the outliers were 
then tabulated. The impact of these outlying cases was assessed by fitting regression 
models with and without the outliers, and comparing the regression coefficients and p 
values for each predictor, and the overall model chi-square values. 
The commands used by Stata to generate the residuals, influence measures, and 
diagnostic statistics are not compatible with random effects modelling, or multiply 
imputed datasets190-192. I therefore tested for influential cases after fitting a standard 
logistic regression model using non-imputed data. This excluded nine (0.6%) of the 
1,503 admissions (due to missing data). 
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9.2.7 Assessing model performance 
The two key measures of the performance of prognostic models are discrimination and 
calibration94. 
Discrimination refers to be ability of a prediction model to differentiate between those 
who do or do not experience the outcome event94. The c-index is the most commonly 
used performance measure to indicate the discriminatory ability of prognostic models, 
with the c-index being identical to the area under the Receiver Operating Characteristic 
(ROC) curve for models with binary oucomes193. The area under the ROC curve can be 
interpreted as the probability that a patient with the outcome is given a higher 
probability of the outcome by the model than a randomly chosen patient without the 
outcome; an uninformative model has an area of 0.5, and a perfect model has an area 
of one70. 
Calibration refers to the agreement between observed outcomes and predictions from 
the model, and can be assessed graphically by plotting predictions on the x-axis and 
the observed outcome frequency on the y-axis194. As the observed outcome is binary, 
smoothing techniques can be used to visualise the association, so displaying the 
direction and magnitude of model miscalibration across the probability range94. Perfect 
predictions should be on the 45 degree line, with an intercept of zero, and slope of one; 
deviation from this suggests imperfect calibration194.  Alternatively, the observed 
proportion of outcome events for groups of patients with similar probabilities can be 
plotted, so comparing the mean predicted probability and mean observed outcome 
(although this is less precise193); for example, observed outcome by decile of 
prediction193 194.  
To assess the calibration of the BS model I therefore: 
 reported the estimates for the calibration slope and intercept; 
 plotted the predicted probability of an outcome event against the observed outcome 
frequency, using a ‘locally weighted scatterplot smoothing’ (lowess) line to visualise 
the association and permit identification of the direction and magnitude of any 
model miscalibration. 
Discrimination was reported as the c-index. 
Clinical usefulness, as assessed using decision curve analysis, is discussed in section 
9.2.9.3. 
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9.2.8 Internal validation / adjustment for optimism 
The predictive performance of prognostic models is overestimated when assessed 
using the same data used in development (known as the apparent performance), 
simply because the model has been optimised for that data. This results in 
overconfident predictions in independent data, where higher predictions are too high, 
and low predictions too low195. It is therefore recommended that all model development 
studies include some form of internal validation; for example split-sample validation 
(where the development data is divided into two datasets, one for model development 
and one for validation), or bootstrapping (which mimics the process of sampling from 
the underlying population by drawing random samples from the developmental 
dataset)70 94. Bootstrap validation is generally regarded as the preferred method as it 
permits all data to be used for model development, so is more statistically efficient60. In 
addition, bootstrap validation permits optimism to be quantified, and provides an 
estimate of any adjustments required70 94.  
Bootstrap validation involves the following steps70 94 196: 
1. take a random bootstrap sample from the original dataset, identical in size, and 
drawn with replacement (therefore a patient may be included a number of times or 
not at all); 
2. construct a model in the bootstrap sample, using similar steps to those used to 
develop the original regression model, then record the apparent performance of this 
bootstrap model (for example, c-index and calibration slope); 
3. apply the bootstrap model to the original datasetiv and record the performance 
(known as the test performance); 
4. calculate the optimism as the difference between bootstrap and test performance; 
5. repeat steps 1 to 4 until stable estimates for the optimism are obtained (at least 100 
times); 
6. calculate the optimism for the c-index and calibration slope by averaging the results 
for each, as obtained in step 4. 
Steyerberg advises that 100-200 bootstraps may be sufficient70; I chose to use 200 to 
increase the stability of the estimates. 
                                                          
iv
 The bootstrap model is applied to the original dataset using the regression equation for the 
model, as described in section 9.2.6.2. The regression equation is also known as the ‘linear 
predictor’ or ‘prognostic index’. 
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The optimism calculated for the c-index was then used to correct the c-index of the BS 
model (by subtracting the value obtained in step 6). The c-index for the BS model prior 
to removal of ‘non-sensible’ predictors (as discussed in section 9.2.6.2) was used in 
this calculation. This was to permit direct comparison, that is to say, between models 
produced by backward elimination that contained all significant predictors (according to 
the predetermined ‘stopping rule’). 
The optimism in the calibration slope was used to estimate the shrinkage factor 
required to adjust the model’s regression coefficients to account for overconfident 
predictions. By definition, the average calibration slope of models developed at step 2 
will be one, with an average intercept of zero; this is because calibration plots tend to 
show good calibration in the dataset from which they were developed94. When a model 
is used in new datasets (as in step 3) the intercept indicates the extent that predictions 
are systematically too high (intercept lower than zero) or too low (intercept higher than 
zero)197. In addition, a calibration slope of smaller than one suggests the regression 
coefficients in the original model were too large, resulting in predictions that are too 
extreme197. The average optimism for the calibration slope (calculated at step 6) can 
therefore be used as a ‘linear shrinkage factor’. The initially estimated regression 
coefficients for the BS model were therefore adjusted for optimism by multiplying each 
by this shrinkage factor to create the ‘final model’ (i.e. the model used to create the 
MOAT). 
Ideally the bootstrap models should be developed using the same modelling and 
predictor selection methods as used for the original model, but it is acknowledged that 
it is often difficult to replicate all steps in the bootstrap procedure70. I therefore chose to 
develop the bootstrap models using backward elimination, with the same significance 
level to exclude predictors as used for the original model (p greater than 0.157). 
Manual predictor selection was used for the original model, but for pragmatic reasons 
(related to time required to perform manual backward elimination in each of the 200 
bootstrap samples) I chose to use an automated selection technique for the bootstrap 
models. As it is not possible to use Stata’s automated selection techniques with either 
multiply imputed data, or random effects models198, I chose to perform the bootstrap 
validation using standard logistic regression, and non-imputed data. I anticipated this 
would have minimal impact, as the purpose of bootstrap validation is to quantify 
possible optimism rather than to provide accurate estimates of the regression 
coefficients. To minimise the impact of missing data, I excluded BMI from the full model 
used to develop the bootstrap models (due to the large number of missing data for this 
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variable). I anticipated this would have minimal impact on the bootstrap models as both 
univariable and multivariable analyses suggested no evidence that BMI was associated 
with the outcome event. This permitted inclusion of 1,447 (96.3%) of the 1,503 
admissions in the bootstrap validation.  
  
Chapter 9: Modelling 
 
204 
 
 
9.2.9 Development of a decision aid (the MOAT) 
Development of the MOAT (a decision aid to permit targeting of patients at high risk of 
experiencing MSP MRPs) involved three stages: 
 selection of a ‘presentation format’ (for example a simplified paper score chart, or 
electronic scoring system); 
 creation of risk groups; 
 assessment of the potential clinical usefulness of the MOAT (based on the risk 
groups chosen). 
Each of these is described below. 
9.2.9.1 Presentation format 
Prognostic modelling studies often aim to develop a simplified scoring system to permit 
use of the model in clinical practice without the use if complex calculations (for example 
by simplifying regression equations to create an easy-to-sum score)94. Although this 
was my original intention, as stated in the MOAT study protocol142, I subsequently 
decided to use an ‘electronic’ format for the MOAT (permitting use of the final model’s 
full regression equation for risk predictions). The reasons for this were: 
 even with a simplified score chart, pharmacy staff would be required to assign 
‘points’ to each predictor, then sum the final score. Use of an electronic tool simply 
requires pharmacy staff to input the raw predictor data, then calculations are 
performed automatically, so reducing the time needed to apply the MOAT, and the 
possibility of calculation errors;  
 simplification of prognostic models generally leads to loss of predictive accuracy 
(due to rounding of regression coefficients)94. This would be avoided by use of an 
electronic format; 
 there is an aim for all English hospitals to be paperless by 2020199, which has 
resulted in the increased use of laptop computers by pharmacy staff at ward level, 
increasing routine access to electronic resources;   
 usage instructions for the MOAT can be incorporated into an electronic tool using 
‘help’ links, so increasing accessibility to guidance. I anticipated this may increase 
consistency in use of the MOAT, and reduce barriers to use (related to lack of 
familiarity, or confusion over which data are required).  
The regression equation for the final model was therefore used to create an electronic 
scoring system. Microsoft Excel was used due to its wide availability. Programming 
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was carried out by Aneesh Khurana (IT Systems Manager for Pharmacy at the Luton 
and Dunstable University Hospital). 
9.2.9.2 Creation of risk groups 
While prognostic models provide estimates of the probability that an individual patient 
will experience an outcome event, this does not provide guidance to users of the model 
on an appropriate course of action. ‘Risk groups’ are therefore often created, which 
indicate a specific course of action, so creating a ‘decision aid’ or ‘clinical decision 
rule’70. No consensus exists on how risk groups should be created94, but it is 
recommended that subject matter input is used rather than reliance on statistical 
estimation70. I therefore sought advice from a group of practising pharmacy staff (as 
part of the assessment of the MOAT, discussed in chapter 10) to inform the choice of 
cut-offs for the predicted risk probabilities (also known as decision thresholds or 
classification cut-offs)70 194. Concern exists over the arbitrary nature of categorisation, 
with all patients within a group being assumed to have the same risk94. I therefore 
chose to create risk groups, but to report both the risk group and individual predicted 
risk probability for each patient assessed using the MOAT. This was to guide general 
prioritisation decisions (by categorising patients as high, medium or low-risk), but also 
to permit some degree of prioritisation within each category (if required due to workload 
pressures).   
The predictive performance of the MOAT is reported using the classification measures: 
sensitivity and specificity, which are reported for the decision thresholds chosen for the 
medium and high-risk groups. The predicted risk probability range for each of the risk 
groups is also reported. 
9.2.9.3 Assessment of clinical usefulness 
Once decision thresholds were selected, it was possible to assess clinical usefulness, 
in terms of whether the MOAT is likely to be beneficial in clinical practice for guiding 
decision making70. This goes beyond calculation of the c-index (which is primarily 
interested in predictive accuracy) to incorporate information on consequences, for 
example considering the relative impact of false negative and false positive 
predictions200. 
Decision curve analysis has been suggested as a method to assess clinical 
usefulness70 193. This permits performance of a model to be assessed over a range of 
decision thresholds, using the theoretical relationship between threshold probabilities 
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and the relative value of false positive and false negative results200, calculated as the 
net benefit: 
𝑁𝑒𝑡 𝑏𝑒𝑛𝑒𝑓𝑖𝑡 =  
𝑡𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑜𝑢𝑛𝑡
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠
 −  
𝑓𝑎𝑙𝑠𝑒 𝑝𝑜𝑠𝑡𝑖𝑣𝑒 𝑐𝑜𝑢𝑛𝑡
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠
 ×  (
𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦
1 − 𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦
)  
Net benefit is interpreted in units of the true positives, and is a measure of how many 
more patients are correctly ‘treated’ (true positives) at the same rate of ‘not treating’ 
those who do not need treatment (false positives)70.  
By varying the threshold probability it is possible to produce a ‘decision curve’, with 
threshold probability plotted on the x-axis, and net benefit plotted on the y-axis. The net 
benefit of default policies of ‘treat none’ and ‘treat all’ are also plotted to permit 
comparisons to be made. The net benefit of ‘treating none’ is zero (as the true and 
false positive counts are both zero), therefore if the net benefit of the prediction model 
is positive, it is better to use the model than ‘treat none’. The true and false positive 
counts for the ‘treat all’ strategy are the number of patients with and without the 
outcome respectively; the net benefit of ‘treat all’ is therefore equal to the outcome 
prevalence at a threshold probability of zero, and equal to zero at the prevalence of the 
outcome200. 
The decision curve informs the range of threshold probabilities for which the prediction 
model would be of value in clinical practice201.To interpret a decision curve one 
identifies a range of plausible threshold probabilities, and then determines whether the 
model has benefits (i.e. a net benefit greater than ‘treating all’ and ‘treating none’) at all 
values within this range70. I therefore plotted the decision curve for the MOAT to 
establish whether it has the potential to be clinically useful at the decision thresholds 
selected in section 9.2.9.2. 
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9.3 Results 
The results are presented according to the TRIPOD reporting guidelines57. This section 
includes: 
 exploratory data analysis; 
 imputation of missing data; 
 model development;  
 assessment of model performance; 
 internal validation / adjustment for model ‘optimism’; 
 development of the MOAT (decision aid based on the regression model).  
Each of these will be described in turn. 
9.3.1 Exploratory data analysis 
9.3.1.1 Review of distribution of categorical predictors  
A review of the distributions of categorical candidate predictors pre-selected for MOAT 
development identified five categories containing fewer than 5% of the study population 
(Table 17, chapter 6). All were categories of ‘high-risk medicines’: 
 theophylline and aminophylline (2.5% of study population) 
 immunosuppressants (1.4%) 
 cytotoxics (0.9%) 
 lithium (0.4%) 
 ‘other high-risk medicines’, which included clozapine, anti-retrovirals, and 
medicines for Parkinson’s disease (2.7%) 
Given the low prevalence of each of the above categories I decided to combine them, 
so creating a larger ‘other high-risk medicines’ category. I felt this was clinically 
sensible, as it prevented any of the high-risk medicines being excluded from the 
analyses. In addition, the ‘other’ category already contained medicines with diverse 
pharmacological uses; as discussed in chapter 6, the overall categorisation of high-risk 
medicines was recognised as simplistic, albeit necessary to prevent model overfitting. I 
also moved clozapine from ‘other high-risk medicines’ to ‘antipsychotics’. This was on 
the basis that clozapine was used very infrequently (in only one of the 1,503 study 
admissions), in addition to clozapine being more closely related to the remaining 
antipsychotics in terms of pharmacological use. This resulted in the ‘other high-risk 
category’ increasing from 2.7% of the sample population to 7.8%, so permitting robust 
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modelling. The prevalence of ‘antipsychotics’ increased marginally (from 6.1% to 
6.2%). 
The high-risk medicine categories included in model development (following the above 
review) are listed below: 
 anticoagulants / direct oral anticoagulants; 
 therapeutic heparin; 
 anti-diabetic medication; 
 opiates (excluding codeine, tramadol, meptazinol and dihydrocodeine); 
 systemic aminoglycosides and glycopeptides; 
 systemic antimicrobials (excluding aminoglycosides and glycopeptides); 
 epilepsy medicines; 
 antipsychotics; 
 antiarrhythmics; 
 antidepressants; 
 other high-risk medicines (including anti-retrovirals, cytotoxics, 
immunosuppressants, lithium, medicines for Parkinson’s disease). 
Details of the specific medicines included in each category (based on the MOAT 
sample population) are given in Appendix A9.1. 
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     226.   2.667         13  
                              
     516.   2.333         12  
    1047.   2.000         11  
     867.   2.000         11  
     818.   2.000         11  
     291.   2.000         11  
                              
    1216.   1.667         10  
     997.   1.667         10  
     949.   1.667         10  
     861.   1.667         10  
     826.   1.667         10  
                              
     653.   1.667         10  
     332.   1.667         10  
     253.   1.667         10  
     231.   1.667         10  
      45.   1.667         10  
                              
     obs:    iqr:   num_co~b  
                              
9.3.1.2 Identification and review of outliers (continuous predictors)  
The 12 continuous candidate predictors pre-selected for MOAT development were 
assessed for the presence of outlying values using box-plots and tables of extreme 
values. Figure 4 and Figure 5 provide examples of the respective Stata outputs. 
 
Central box represents 
interquartile range, with median 
shown as central line.  
Whiskers show the ‘adjacent line’ 
(one and a half times the 
interquartile range above or below 
the third or first quartile 
respectively).  
Outlying values shown as points 
above or below the adjacent line. 
 
 
Figure 4 – Box-plot of variable ‘number of comorbidities’ 
 
 
obs = observation number (i.e. unique identifier) 
iqr = number of interquartile ranges above or below 
third or first quartile respectively 
num_comb = variable name for ‘number of 
comorbidities’  
 
 
 
 
Figure 5 – Stata output for ‘extremes’ module   
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Table 38 gives the number (and percentage) of outliers for each predictor, with the 
range of values. The number of outliers per variable ranged from one data point 
(0.07%) for ‘age’, to 132 (8.8%) for ‘number of hospital admissions in previous six 
months’.  
Table 38 – Number and ranges for outliers 
Predictor 
Outlier(s)* 
(admissions = 1,503) 
n (% of admissions
†
) 
Value / range of 
outlier(s) 
Below 
lower 
truncation 
point 
Above 
upper 
truncation 
point 
Below 
lower 
truncation 
point 
Above 
upper 
truncation 
point 
Age (years) 1 (0.07) 0 17 N/A 
Socioeconomic status, ranked using English 
Indices of Deprivation 2015 – Index of Multiple 
Deprivation
149
 
0 0 N/A N/A 
Body mass index (kg/m
2
) 0 30 (2.6) N/A 40.8-65.5 
Number of hospital admissions in previous 6 
months 
0 132 (8.8) N/A 3-10 
Number of comorbidities 0 16 (1.1) N/A 10-13 
Number of medicines prescribed 0 26 (1.7) N/A 18-27 
Renal function - estimated glomerular filtration 
rate
‡
 (ml/min/1.73m
2
) 
0 38 (2.5) N/A 162-309 
Serum albumin (g/L)  34 (2.3) 5 (0.3) 7-19 48-55 
Serum potassium (mmol/L) 9 (0.6) 18 (1.2) 2.3-2.8 6-7.8 
Serum sodium (mmol/L) 68 (4.5) 20 (1.3) 111-127 148-170 
White cell count (10
9
/L) 0 64 (4.3) N/A 20.8-93.0 
Platelet count (10
9
/L) 3 (0.2) 51 (3.4) 5-7 492-977 
N/A = not applicable  
*   Limit set at one and a half times the interquartile range above or below the third or first 
quartile respectively 
† Calculated as the number of outliers / number of available values for each variable (i.e. 
excludes admissions with missing data) 
‡ Glomerular filtration rate estimated using modified Modification of Diet in Renal Disease 
(MDRD) equation
121
 
 
Plausibility of the outlying values was assessed by reviewing the distribution of each 
predictor across the full range of observed values. This found that all outlying results 
were clinically plausible, and consistent with the overall data distributions, that is, no 
data points were significantly remote, with outliers representing extreme values within 
skewed or wide distributions (illustrated by Figure 6 and Figure 7 respectively). No 
obvious data entry errors were identified; therefore no data were set to missing. 
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    Body mass index (kg/m2) 
Figure 6 – Histogram showing distribution of body mass index 
    
 
 
 
 
 
 
 
 
 
Serum sodium (mmol/L) 
Figure 7 – Histogram showing distribution of serum sodium 
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The results of univariable logistic regressions using non-truncated and truncated data 
are given in Table 39. The impact of truncation, in terms of the difference in the 
regression coefficients for individual predictors, ranged from zero to 170%, with a 
‘substantial difference’ (i.e. a change of 10% or more) observed for seven of the 12 
predictors (suggesting that the affected predictors had outlying data points that were 
not representative of the remaining sample population). For example, truncation of 64 
outlying results for ‘white cell count’, representing 4.3% of admissions, caused an 
increase in the regression coefficient of 125%; inclusion of these outlying data points in 
the analysis therefore had the potential to significantly alter the predictor-outcome 
relationship.  
Table 39 also shows that truncation resulted in an increased model chi-square for most 
predictors, suggesting that outlying values generally caused underestimation of 
predictive effect. This was not the case for ‘number of comorbidities’, ‘serum albumin’ 
(upper truncation), ‘serum potassium’ (upper truncation), and ‘serum sodium’ (lower 
truncation), where outlying values appear to overestimate the predictive effect. While 
this is only indicative of the potential impact of truncation on the statistical significance 
of the univariable models, it provides some justification for the method chosen to 
decide whether or not to truncate outlying data. That is, basing the decision on the 
percentage change in regression coefficients is an objective approach, driven by a 
desire to obtain accurate parameter estimates, rather than simply maximise model fit, 
which could lead to overoptimistic predictions171.  
Regarding the clinical sensibility of the truncation points, the upper truncation point for 
albumin was lower than the standard reference range (i.e. 50 g/L). All other truncation 
points were outside standard ranges. As shown in Table 39, it was not necessary to 
truncate the high albumin values, therefore no further action was needed to address 
this anomaly. 
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Table 39 – Univariable regression of truncated and non-truncated data 
Predictor  
and  
truncation point 
Regression coefficient* 
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Age/10 (years) 
Lower truncation point = 18 years 
0.167 0.167 0 No 33.87 33.86 
Body mass index (kg/m
2
) 
Upper truncation point = 40.6 kg/m
2
 
0.0042 0.0052 23.8 Yes 0.20 0.27 
Number of hospital admissions in 
previous 6 months 
Upper truncation point = 2 
0.0643 0.1735 169.8 Yes 2.48 6.96 
Number of comorbidities 
Upper truncation point = 9 
0.2131 0.2164 1.6 No 82.34 81.91 
Number of medicines prescribed 
Upper truncation point = 17 
0.0952 0.0992 4.2 No 53.00 53.64 
Estimated glomerular filtration 
rate
§
/10 (ml/min/1.73m
2
) 
Upper truncation point = 161 ml/min/1.73m2 
-0.079 -0.088 11.4 Yes 28.82 30.77 
Serum albumin (g/L)  
Upper truncation point = 47 g/L 
-0.0279 
-0.0278 0.4 No 
9.86 
9.70 
Serum albumin (g/L)  
Lower truncation = 20 g/L 
-0.0312 11.8 Yes 11.46 
Serum potassium (mmol/L) 
Upper truncation point = 5.9 mmol/L 
0.0964 
0.0821 14.8 Yes 
1.28 
0.85 
Serum potassium (mmol/L) 
Lower truncation = 2.9 mmol/L 
0.1017 5.5 No 1.40 
Serum sodium (mmol/L) 
Upper truncation point = 147 mmol/L 
-0.0114 
-0.0123 7.9 No 
1.29 
1.34 
Serum sodium (mmol/L) 
Lower truncation point = 128 mmol/L 
-0.0109 4.4 No 0.93 
White cell count (10
9
/L) 
Upper truncation point = 20.7 10
9
/L  
0.0126 0.0283 124.6 Yes 2.28 5.30 
Platelet count (10
9
/L) 
Upper truncation point = 490 10
9
/L  
0.0020 
0.0023 15 Yes 
0.16 
0.17 
Platelet count/10 (10
9
/L) 
Lower truncation point =14 10
9
/L  
0.0020 0 No 0.16 
* Relationship between the independent and dependent variable (amount of increase in 
predicted log odds of the outcome event that would be predicted by a one unit increase 
in the independent variable) 
† Based on the likelihood ration chi-square test (difference in the log likelihood of a model 
with and without the independent variable) 
‡ Truncation points set at one and a half times the interquartile range above or below the 
third or first quartile respectively 
§ Glomerular filtration rate estimated using modified Modification of Diet in Renal disease 
(MDRD) equation
121  
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9.3.1.3 Linearity  
Figure 8 shows the Stata output for the full MFP model (i.e. including all predictors). As 
MFP is performed in cycles, the output gives the results for the ‘initial’ and ‘final’ cycles, 
with the ‘final’ cycle showing the powers selected for the MFP model. The output shows 
that MFP modelling selected a power of ‘1’ for all predictors (i.e. no transformation 
required).  
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df = degrees of freedom, which is twice the degree of the fractional polynomial (FP). The df for 
the ‘initial’ model represents the FPs considered in the first cycle of multivariable fractional 
polynomial (MFP) modelling, and the df for the ‘final’ model represents the FP selected for the 
final model 
Select = nominal significance level for variable selection by backward elimination (set at ‘1’ to 
force all variables to remain in the model (i.e. full model produced) 
Alpha = significance levels for testing between different FP models (0.05 is the default nominal 
p value) 
Status = whether variable selected during backward elimination (all variables ‘in’ as backwards 
elimination not used) 
Power = FP power selected from the default set (−2, −1, −0.5, 0, 0.5, 1, 2, 3), where inverse 
is 𝓍−1, square root is 𝓍0.5, log is 𝓍0, linear is 𝓍1, squared is 𝓍2, and so on  
Figure 8 – Stata output for full multivariable fractional polynomial model  
                                                                    
    liver_dx      1     1.0000   0.0500     in      1     1
other_hig...      1     1.0000   0.0500     in      1     1
  antidepres      1     1.0000   0.0500     in      1     1
  antiarryth      1     1.0000   0.0500     in      1     1
 antipsychot      1     1.0000   0.0500     in      1     1
    epilepsy      1     1.0000   0.0500     in      1     1
  antimicrob      1     1.0000   0.0500     in      1     1
   gent_vanc      1     1.0000   0.0500     in      1     1
     opiates      1     1.0000   0.0500     in      1     1
    diabetes      1     1.0000   0.0500     in      1     1
     heparin      1     1.0000   0.0500     in      1     1
   anticoags      1     1.0000   0.0500     in      1     1
      iv_use      1     1.0000   0.0500     in      1     1
    dementia      1     1.0000   0.0500     in      1     1
_Iprim_di...      1     1.0000   0.0500     in      1     1
_Iprim_di...      1     1.0000   0.0500     in      1     1
_Iprim_di...      1     1.0000   0.0500     in      1     1
_Iprim_di...      1     1.0000   0.0500     in      1     1
_Iprim_di...      1     1.0000   0.0500     in      1     1
_Iprim_di...      1     1.0000   0.0500     in      1     1
_Iprim_di...      1     1.0000   0.0500     in      1     1
     allergy      1     1.0000   0.0500     in      1     1
platelets...      4     1.0000   0.0500     in      1     1
  wcc_trun_F      4     1.0000   0.0500     in      1     1
    sodium_F      4     1.0000   0.0500     in      1     1
potassium...      4     1.0000   0.0500     in      1     1
albumin_t...      4     1.0000   0.0500     in      1     1
 egfr_trun_F      4     1.0000   0.0500     in      1     1
  num_meds_F      4     1.0000   0.0500     in      1     1
num_comor...      4     1.0000   0.0500     in      1     1
num_hosp_...      1     1.0000   0.0500     in      1     1
  bmi_trun_F      4     1.0000   0.0500     in      1     1
   ses_dec_F      4     1.0000   0.0500     in      1     1
   age_dec_F      4     1.0000   0.0500     in      1     1
                                                                    
                 df     Select   Alpha    Status    df    Powers
    Variable           Initial                    Final     
                                                                    
Final multivariable fractional polynomial model for study_outcome
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Figure 9 shows the Stata output for the MFP model produced using backward 
elimination. This shows that linearity was not altered following removal of non-
significant variables. It should be noted that this backward elimination was performed 
using complete-case analysis (i.e. prior to multiple imputation). Results may therefore 
differ following multiple imputation (as discussed in section 9.2.5). 
 
See Figure 8 for explanation of abbreviations 
Figure 9 – Stata output for multivariable fractional polynomial model selected 
using backward elimination 
Both models therefore failed to reject linear relationships for the continuous predictors 
(given the default ‘alpha’ of 0.05). It was therefore not necessary to include non-linear 
transformations in the imputation model, or during model building. 
  
                                                                    
    liver_dx      1     0.1570   0.0500     out     0     
other_hig...      1     0.1570   0.0500     out     0     
  antidepres      1     0.1570   0.0500     in      1     1
  antiarryth      1     0.1570   0.0500     out     0     
 antipsychot      1     0.1570   0.0500     out     0     
    epilepsy      1     0.1570   0.0500     in      1     1
  antimicrob      1     0.1570   0.0500     in      1     1
   gent_vanc      1     0.1570   0.0500     in      1     1
     opiates      1     0.1570   0.0500     out     0     
    diabetes      1     0.1570   0.0500     out     0     
     heparin      1     0.1570   0.0500     in      1     1
   anticoags      1     0.1570   0.0500     out     0     
      iv_use      1     0.1570   0.0500     out     0     
    dementia      1     0.1570   0.0500     out     0     
_Iprim_di...      1     0.1570   0.0500     out     0     
_Iprim_di...      1     0.1570   0.0500     out     0     
_Iprim_di...      1     0.1570   0.0500     out     0     
_Iprim_di...      1     0.1570   0.0500     in      1     1
_Iprim_di...      1     0.1570   0.0500     in      1     1
_Iprim_di...      1     0.1570   0.0500     out     0     
_Iprim_di...      1     0.1570   0.0500     in      1     1
     allergy      1     0.1570   0.0500     in      1     1
platelets...      4     0.1570   0.0500     out     0     
  wcc_trun_F      4     0.1570   0.0500     in      1     1
    sodium_F      4     0.1570   0.0500     out     0     
potassium...      4     0.1570   0.0500     out     0     
albumin_t...      4     0.1570   0.0500     out     0     
 egfr_trun_F      4     0.1570   0.0500     out     0     
  num_meds_F      4     0.1570   0.0500     out     0     
num_comor...      4     0.1570   0.0500     in      1     1
num_hosp_...      1     0.1570   0.0500     out     0     
  bmi_trun_F      4     0.1570   0.0500     out     0     
   ses_dec_F      4     0.1570   0.0500     out     0     
   age_dec_F      4     0.1570   0.0500     out     0     
                                                                    
                 df     Select   Alpha    Status    df    Powers
    Variable           Initial                    Final     
                                                                    
Final multivariable fractional polynomial model for study_outcome
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9.3.1.4 Multicollinearity  
The VIF for the candidate predictors is shown in Table 40. The VIFs ranged from 1.11 
(for ‘socioeconomic status’, and ‘other high-risk medicines’) to 4.67 (for the primary 
diagnosis ‘respiratory’). As all VIFs were below 10, this suggests no excessive 
correlation between predictors. As a result, it was not necessary to take further action 
regarding multicollinearity. 
Table 40 – Variance inflation factors for the candidate predictors 
Predictor Variance inflation factor 
Age  1.94    
Socioeconomic status  1.11     
Previous allergy / adverse drug reaction 1.13     
Body mass index  1.24     
Number of hospital admissions in previous 6 months 1.20     
Number of comorbidities 1.82     
History of dementia 1.20     
Number of medicines prescribed 1.64     
Parenteral administration route 1.48     
Estimated glomerular filtration rate 1.50     
Liver disease 1.16     
Serum albumin  1.38     
Serum potassium  1.19    
Serum sodium  1.17     
White cell count  1.36     
Platelet count  1.32     
High-risk medicines:  
Anticoagulants 1.33     
Therapeutic heparin 1.36     
Anti-diabetic medication 1.25     
Opiates 1.13     
Aminoglycosides and glycopeptides 1.14     
Other antimicrobials 1.61     
Epilepsy medicines 1.18     
Antipsychotics 1.08     
Antiarrhythmics 1.27    
Antidepressants 1.13     
Other high-risk medicines       1.11     
Primary diagnosis:   
Nervous system and mental disorders 2.90 
Cardiovascular system 4.62 
Respiratory system 4.67 
Gastrointestinal system 2.67 
Genitourinary system 2.94 
Musculoskeletal-intergumentary systems 2.32 
All other categories of primary diagnosis 3.66 
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9.3.1.5 Univariable analyses  
The results of the univariable analyses are shown in Table 41. There was strong 
evidence for statistically significant associations between the outcome event and the 
following predictors (p <0.05):  
 age; 
 socioeconomic status; 
 previous allergy; 
 number of hospital admissions in previous six months; 
 primary diagnosis (as a combined effect); 
 number of comorbidities; 
 estimated glomerular filtration rate; 
 serum albumin; 
 white cell count; 
 number of medicines prescribed; 
 use of anticoagulants, anti-diabetic medication, aminoglycosides and 
glycopeptides, other antimicrobials, epilepsy medicines, and antidepressants; 
 parenteral medicine administration. 
There was also weak evidence for an association between the outcome and the use of 
therapeutic heparin (p = 0.057), opiates (p = 0.073), and antiarrhythmics (p = 0.053). 
There was no evidence for an association between the remaining candidate predictors 
and the outcome event. 
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Table 41 – Univariable association between predictors and outcome events 
Predictor 
Occurrence of outcome 
event Odds ratio
‡
 
(95% CI) 
Univariable 
p value
§
 
No (%) Yes (%) 
Demographic     
Age/10 (years) Mean: 6.78  
(i.e. 67.8 years) 
Mean: 7.35 
(i.e. 73.5 years) 
1.18  
(1.12 to 1.25) 
<0.001 
Socioeconomic status/10*, ranked 
using English Indices of Deprivation 
2015 – Index of Multiple 
Deprivation
149†
 
Mean: 5.2 Mean: 5.5 
1.04 
(1.00 to 1.08) 
0.044 
Patient related     
Previous allergy*  302 (33.8) 280 (46.0) 
1.67 
(1.35 to 2.06) 
<0.001 
Body mass index* (kg/m
2
) Mean: 25.6 Mean: 25.7 
1.01 
(0.99 to 1.03) 
0.610 
Number of hospital admissions in 
previous 6 months  
Mean: 0.56 Mean: 0.67 
1.19 
(1.05 to 1.35) 
0.008 
Primary diagnosis:    
Combined 
effect 0.0078 
Endocrine and metabolic 46 (5.2)     36 (5.9) 
1.16 
(0.74 to 1.81) 
0.530 
Nervous system and mental 
disorders 
82 (9.2) 67 (11.0) 
1.22 
(0.87 to 1.72) 
0.252 
Cardiovascular system 186 (20.8) 129 (21.2) 
1.02 
(0.79 to 1.31) 
0.882 
Respiratory system 197 (22.1) 135 (22.1) 
1.00 
(0.78 to 1.29) 
0.974 
Gastrointestinal system 105 (11.8) 39 (6.4) 
0.51 
(0.35 to 0.75) 
<0.001 
Genitourinary system 76 (8.5) 68 (11.2) 
1.35 
(0.96 to 1.90) 
0.090 
Musculoskeletal-intergumentary 
systems 
47 (5.3) 46 (7.5) 
1.47 
(0.96 to 2.23) 
0.074 
All other categories 154 (17.3) 90 (14.8) 
0.83 
(0.63 to 1.10) 
0.197 
Number of comorbidities  Mean: 3.3 Mean: 4.4 
1.24 
(1.18 to 1.30) 
<0.001 
History of dementia  94 (10.5) 67 (11.0) 
1.05 
(0.75 to 1.46) 
0.779 
Laboratory results 
Estimated glomerular filtration 
rate/10* (ml/min/1.73m
2
) 
Mean: 8.03 
(i.e. 80.3 
ml/min/1.73m
2
) 
Mean: 7.04 
(i.e. 70.4 
ml/min/1.73m
2
) 
0.92 
(0.89 to 0.95) 
<0.001 
Liver disease  101 (11.3) 63 (10.3) 
0.90 
(0.65 to 1.26) 
0.548 
Serum albumin*  (g/L) Mean: 33.5 Mean: 32.4 
0.97 
(0.95 to 0.99) 
<0.001 
Serum potassium* (mmol/L) Mean: 4.4 Mean: 4.4 
1.09 
(0.91 to 1.29) 
0.358 
Serum sodium* (mmol/L) Mean: 137.3 Mean: 137.0 
0.99 
(0.97 to 1.01) 
0.257 
White cell count* (10
9
/L) Mean: 10.4 Mean: 10.9 
1.03 
(1.00 to 1.05) 
0.021 
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Continued from previous page… 
Predictor 
Occurrence of outcome 
event Odds ratio
‡
 
(95% CI) 
Univariable 
p value
§
 
No (%) Yes (%) 
Platelet count/10* (10
9
/L) 
Mean: 25.59 
(i.e. 255.9 10
9
/L) 
Mean: 25.80 
(i.e. 258.0 10
9
/L) 
1.00 
(0.99 to 1.01) 
0.682 
Medicines related     
Number of medicines  Mean: 7.2 Mean: 8.7 
1.10 
(1.07 to 1.13) 
<0.001 
Use of high-risk medicines:     
Anticoagulants 161 (18.0) 151 (24.8) 
1.50 
(1.16 to 1.92) 
0.002 
Therapeutic heparin 119 (13.3) 103 (16.9) 
1.32 
(0.99 to 1.76) 
0.057 
Anti-diabetic medication 146 (16.4) 153 (25.1) 
1.71 
(1.33 to 2.21) 
<0.001 
Opiates 76 (8.5) 69 (11.3) 
1.37 
(0.97 to 1.93) 
0.073 
Aminoglycosides and glycopeptides 49 (5.5) 56 (9.2) 
1.74 
(1.17 to 2.59) 
0.006 
Other antimicrobials 512 (57.3) 525 (69.7) 
1.71 
(1.38 to 2.13) 
<0.001 
Epilepsy medicines 104 (11.7) 123 (20.2) 
1.92 
(1.44 to 2.55) 
<0.001 
Antipsychotics 50 (5.6) 43 (7.1) 
1.28 
(0.84 to 1.95) 
0.255 
Antiarrhythmics 78 (8.7) 72 (11.8) 
1.40 
(1.00 to 1.96) 
0.053 
Antidepressants 182 (20.4) 169 (27.7) 
1.50 
(1.18 to 1.90) 
0.001 
Other high-risk medicines 62 (6.9) 55 (9.0) 
1.33 
(0.91 to 1.94) 
0.143 
Parenteral administration  569 (63.7) 439 (72.0) 
1.46 
(1.17 to 1.83) 
<0.001 
* For patients without missing data (further details provided in Appendix A6.6) 
† Deprivation rank based on patients’ postcode, shown as the ranked position as a 
percentage of all neighbourhoods in England (where 1 is the most deprived) 
‡ Measure of association between exposure and outcome event (the odds that an 
outcome will occur given a particular exposure, compared to the odds of the outcome 
occurring in the absence of exposure)  
§ Test for difference between admissions with and without occurrence of outcome event. 
Obtained from univariable regression modelling (based on the likelihood ratio chi-
square test) 
Age, socioeconomic status, estimated glomerular filtration rate, and platelet count analysed as 
deciles to aid interpretability (i.e. after dividing the actual value by ten) 
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9.3.2 Missing data 
Chapter 6 identified the proportion of study admissions with missing data, with possible 
reasons for the missingness. Of the 1,503 admissions included in the regression 
analyses, 449 (29.9%) had one or more missing data point (Table 18). Excluding 
ethnicity, (as it is not a candidate predictor) the total number of admissions with one or 
more missing data point was 387 (25.7%). The number of missing data points for each 
candidate predictor is shown in Table 42. This shows that 430 data points (i.e. 1.6% of 
the total candidate predictor data) were missing.  
Table 42 – Details of missing data for candidate predictors 
Candidate predictor 
Admissions with missing data 
(admissions = 1,503) 
n (% of admissions) 
Age  0 
Socioeconomic status  6 (0.4) 
Previous allergy  1 (0.07) 
Body mass index  341 (22.7) 
Number of hospital admissions in previous 6 months  0 
Primary diagnosis  0 
Number of comorbidities  0 
History of dementia  0 
Number of medicines  0 
High-risk medicines use 0 
Parenteral administration route 0 
Renal function  9 (0.6) 
Liver disease  0 
Serum albumin  26 (1.7) 
Serum potassium  30 (2.0) 
Serum sodium  3 (0.2) 
White cell count  6 (0.4) 
Platelet count 8 (0.5) 
Total missing data points  
n (% for all predictors i.e. 27,054*) 
430 (1.6) 
* Total number of data points for all predictors calculated as the total number of 
predictors multiplied by the total number of study admissions 
The remaining results for the missing data analysis are presented in five sections: use 
of common sense approaches to predict missing data, analysis of data distribution prior 
to imputation, comparison of observed and imputed values, imputation diagnostics, and 
the sensitivity analysis. Each is described below. 
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9.3.2.1 Use of common sense approaches to predict missing data values 
Exploration of the missing data identified nine missing values that could be predicted 
using common sense solutions182: 
 allergy status was undetermined for one admission. As this was a binary variable 
(yes/no), and the patient was prescribed nine medicines during their admission 
(including antimicrobials), I decided to count this admission as ‘no allergies’ for the 
purposes of the study (as this was the most likely result given that nursing staff at 
the study sites are required to check a patient’s allergy status before administering 
any medication); 
 three admissions (from Hospital B) had missing serum creatinine values, but 
estimated glomerular filtration rates (eGFR) were reported, calculated using the 
enzymatic method (potentially due to their high serum bilirubin levels, as this 
interferences with the standard creatinine assay202). Of the three admissions, one 
had an actual eGFR value reported, but two had the result reported as ‘>90 
ml/min/1.73m2’ (a cut-point used to represent ‘normal’ renal function125). As it was 
not possible to obtain an actual eGFR value for these two patients, I chose to use 
126 ml/min/1.73m2, as this is mid-way between 91 ml/min/1.73m2, representing the 
minimum possible value, and the eGFR upper truncation point of 161 
ml/min/1.73m2, which represented the highest value eGFR used for the present 
study; 
 two admissions (Hospital A) with missing BMI data were found to be duplicate 
admissions (less than one month apart), therefore BMI results for the duplicate 
admission were used; 
 Socioeconomic status was unavailable for six admissions because the method 
used to determine socioeconomic status was based on English postcodes, and two 
participants had no fixed abode, and four were not resident in England. Of the 
participants not resident in England, one lived in Scotland, and the remaining three 
were from Canada, Africa and Ibiza. It was possible to use the Scottish Index of 
Multiple Deprivation 2016203 to establish a deprivation rank for the Scottish 
participant; while not directly comparable with the English rankings, it did provide 
an informed estimate. For the two participants with no fixed abode, I chose to rank 
the individuals in the lowest socioeconomic group (i.e. an Index of Multiple 
Deprivation Rank of one). This was on the basis that the indices are mainly 
informed by income and employment (total 45% of weighting), with additional 
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contributions from living environment (9.3%), crime (9.3%), and barriers to housing 
services (9.3%), all of which are likely to be impacted by homelessness. 
Inclusion of this data reduced the number of admission with one or more missing data 
point to 379 (25.2%) of 1,503. It was therefore possible to include 1,124 complete 
cases in the multiple imputation sensitivity analysis (Table 43). 
9.3.2.2 Analysis of data distribution 
Review of the distributions of the continuous candidate predictors found that data were 
compatible with normal distributions (following the truncation of outlying data, as 
discussed in 9.3.1.2). Of the continuous auxiliary variables, ‘weight’ and ‘height’ 
appeared to follow normal distributions, but ‘length of hospital stay’ was positively 
skewed, as shown in Figure 10, with a skewness statistic of 4.0.   
 
    Length of hospital stay (days) 
Figure 10 – Histogram showing distribution of length of hospital stay 
Following use of a log transformation the skewness statistic reduced to 0.346, therefore 
a log transformation for ‘length of hospital stay’ was used for the imputation model. 
9.3.2.3 Comparison of observed and imputed values 
A review of the imputed values produced by the initial MICE imputation (specified using 
linear regression as the conditional distribution for the continuous variables) identified 
implausible values for: BMI, socioeconomic status, estimated glomerular filtration rate, 
and white cell count. 
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The imputation model was then specified using truncated distributions for the affected 
variables: 
  
where: 
 ‘trunreg’ permits specification of the upper and/or lower limits for the distributions of 
individual variables; 
 ‘ll’ sets the lower limit, and ‘ul’ sets the upper limit. 
The range for each missing variable was then rechecked, and all were clinically 
plausible (as shown in Appendix A9.2). 
9.3.2.4 Imputation diagnostics 
The average RVI of a logistic regression model fitted using the imputed data was 
0.0106, which is considered ‘small’, suggesting that missing data had a minimal effect 
on the variance of the estimate.  
The largest FMI was 0.25, meaning that the number of imputations (30) exceeded the 
minimum required number (using the rule of thumb that the number of imputations 
should be at least equal to the highest FMI percentage).  
The trace plots for BMI and serum potassium are shown in Figure 11 and Figure 12. 
There is no apparent trend in any of the iterations, suggesting good convergence of the 
imputation model. 
> dd (20) rseed (53421) savetrace(trace1,replace)
> iates gent_vanc antimicrob epilepsy antipsychot antiarryth antidepres other_high_risk study_outcome ln_length_stay male , a
> ec_F num_hosp_adm_trun_F num_comorb_F num_meds_F i.prim_diag allergy dementia liver_dx iv_use anticoags heparin diabetes op
> runcreg, ll(0.3)) wcc_trun_F (truncreg) albumin_trun_F potassium_trun_F sodium_F platelets_trun_dec_F weight height = age_d
. mi impute chained (truncreg, ll(10.6)) bmi_trun_F (truncreg, ll(.3)) egfr_trun_dec_F (truncreg, ll(.3) ul(10)) ses_dec_F (t
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SD = standard deviation, BMI = body mass index 
Figure 11  – Trace plot for body mass index 
 
 
SD = standard deviation 
Figure 12  – Trace plot for serum potassium 
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9.3.2.5 Multiple imputation sensitivity analysis 
The sensitivity analysis involved a comparison of the regression coefficients, standard 
errors, and p values obtained following multivariable logistic regression, using the 
complete-case and imputed datasets. Initially the analysis was performed using all 
candidate predictors, and then the models were re-run after omitting BMI (given the 
large number of missing data for this variable). The results are described below.  
Analyses including all candidate predictors 
Following the use of ‘common sense approaches’ to predict missing data (reported in 
section 9.3.2.1), the number of admissions with one or more missing data point was 
379, representing 25.2% of the 1,503 study admissions. The remaining 1,124 
admissions were therefore included in the complete-case analyses. The comparison of 
the multivariable logistic regression estimates for the complete-case and imputed 
datasets are shown in Table 43.  
The differences in the standard errors (between the complete-case and multiply 
imputed datasets) can be explained by the sample size, with larger standard errors 
observed for the complete-case analyses. Using a significance level of p smaller than 
0.157, as selected for MOAT development (discussed in section 9.3.3.1), one predictor 
that was statistically significant in the complete-case analysis (the use of parenteral 
medicines) became non-significant following multiple imputation. Conversely, two 
predictors only became significant following multiple imputation; the use of anti-diabetic 
medication, and renal function (measured using estimated glomerular filtration rate). As 
the presumed missingness mechanism was MAR, differences between the two 
datasets was anticipated. That is to say, only if data were MCAR would the complete 
cases be a random sub-set of the sample population60. While there is no definitive way 
to distinguish between MAR and MNAR, it has been suggested that observed 
differences are reviewed to consider if they make sense scientifically204, with plausible 
explanations supporting the MAR assumption. I therefore considered whether the 
change in statistical significance of the three predictors had rational explanations: 
 parenteral medicines use – the complete-case analysis suggests that parenteral 
medicine use reduces the risk of an outcome event (albeit at a nominal significance 
level), which is counterintuitive given that parenteral administration is known to 
increase the risk of adverse medication-related outcomes79 87 91. The imputed result 
(i.e. no association) is therefore more plausible; 
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 anti-diabetic medicine use, and impaired renal function, became statistically 
significant (in terms of increasing the risk of an outcome event) after multiple 
imputation. These are logical findings given the recognised risks associated with 
both165.  
I therefore concluded that it is reasonable to assume that data were MAR. 
Table 43 – Comparison of multivariable regression coefficients for complete-
case and multiply imputed datasets 
Predictor 
Complete-cases  
(observations = 1,124*) 
Multiple imputation 
(observations = 1,503) 
Regression 
coefficient
†
 
Standard 
error 
p 
value
‡
 
Regression 
coefficient
†
 
Standard 
error 
p 
value
‡
 
Demographic 
Age 0.0508  0.048    0.288 0.0397 0.042 0.349 
Socioeconomic status  0.0414 0.024 0.081 0.0452 0.021 0.029 
Patient related 
Previous allergy 0.244 0.135 0.071 0.261 0.118 0.027 
Body mass index -0.00075 0.012 0.950 -0.0030 0.012 0.808 
Number of hospital 
admissions in previous 
6 months  
0.0586 0.085 0.490 0.0234 0.076 0.757 
Primary diagnosis: 
Endocrine and 
metabolic 
Base category 
0.072 
Base category 
0.021 
Nervous system and 
mental disorders 
0.303 0.352 0.319 0.303 
Cardiovascular system -0.214 0.329 -0.225 0.282 
Respiratory system -0.460 0.328 -0.316 0.278 
Gastrointestinal 
system 
-0.632 0.369 -0.655 0.316 
Genitourinary system -0.244 0.348 -0.055 0.301 
Musculoskeletal-
intergumentary  
-0.0525 0.377 0.041 0.330 
All other categories -0.0362 0.336 -0.0070 0.286 
Number of 
comorbidities  
0.104 0.037 0.005 0.137 0.033 <0.001 
History of dementia  -0.237 0.223 0.287 -0.264 0.194 0.175 
Medicines related     
Number of medicines  0.0211 0.020 0.285 0.0235 0.018 0.189 
Use of high-risk medicines: 
Anticoagulants 0.0256 0.172 0.882 0.110 0.154 0.477 
Therapeutic heparin 0.452 0.198 0.022 0.269 0.179 0.133 
Anti-diabetic 
medication 
0.131 0.176 0.457 0.222 0.153 0.146 
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Continued from previous page… 
Predictor 
Complete-cases  
(observations = 1,124*) 
Multiple imputation 
(observations = 1,503) 
Regression 
coefficient
†
 
Standard 
error 
p 
value
‡
 
Regression 
coefficient
†
 
Standard 
error 
p 
value
‡
 
Opiates 0.0137 0.214 0.949 0.0121 0.197 0.951 
Aminoglycosides and 
glycopeptides 
0.434 0.246 0.078 0.331 0.226 0.142 
Other antimicrobials 0.454 0.168 0.007 0.362 0.147 0.014 
Epilepsy medicines 0.316 0.187 0.092 0.478 0.165 0.004 
Antipsychotics 0.195 0.268 0.467 0.164 0.237 0.488 
Antiarrhythmics -0.132 0.223 0.552 -0.0568 0.201 0.777 
Antidepressants 0.249 0.153 0.104 0.203 0.138 0.139 
Other high-risk 
medicines 
0.145 0.243 0.549 0.120 0.216 0.580 
Parenteral 
administration  
-0.248 0.171 0.147 0.0388 0.149 0.795 
Laboratory results     
Estimated glomerular 
filtration rate 
-0.0302 0.023 0.188 -0.0366 0.020 0.069 
Liver disease  -0.0768 0.218 0.725 -0.0995 0.195 0.609 
Serum albumin -0.0069 0.013 0.598 0.00059 0.012 0.959 
Serum potassium -0.0560 0.114 0.622 -0.127 0.101 0.207 
Serum sodium -0.00087 0.013 0.949 -0.0062 0.011 0.581 
White cell count 0.0389 0.017 0.023 0.0224 0.015 0.138 
Platelet count -0.0031 0.008 0.683 0.0028 0.007 0.679   
* Following inclusion of values determined using common sense solutions
182
  
† Relationship between the independent and dependent variable (amount of increase in 
predicted log odds of the outcome event that would be predicted by a one unit increase 
in the independent variable) 
‡ Values with a significance level of p<0.157 shown in bold 
Analyses excluding body mass index 
The omission of BMI from the analyses increased the number of observations in the 
complete-case analysis from 1,124 to 1,440, representing 95.8% of 1,503 admissions. 
The comparison of the multivariable logistic regression estimates for the complete-case 
and imputed datasets are shown in Appendix A9.3. Using a significance level of p 
smaller than 0.157, only one predictor (the use of anti-diabetic medication) changed 
from non-significant to significant. Parenteral administration was non-significant in both 
datasets, and renal function was significant in both (which are logical findings, as 
discussed above). As before, given the MAR assumption, some differences between 
the complete-case and imputed datasets would be expected. It is likely that fewer 
differences were observed given the higher number of admissions included in the 
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complete-case analysis. As above, there was no evidence against the MAR 
assumption. 
9.3.3 Model development 
Model development is reported in two sections: the selection of predictors during 
modelling, and model diagnostics. 
9.3.3.1 Predictor selection during modelling 
Table 44 shows the regression coefficients and p values for the candidate predictors 
following multivariable analysis (using random effects logistic modelling). Results are 
shown for the full model (containing all candidate predictors), and the BS model.  
Backward elimination resulted in the retention of 13 predictors in the model: 
 socioeconomic status; 
 number of comorbidities; 
 number of medicines; 
 estimated glomerular filtration rate; 
 white cell count; 
 previous allergy; 
 systemic aminoglycosides and glycopeptides; 
 other systemic antimicrobials; 
 epilepsy medicines; 
 antidepressants; 
 primary diagnoses: 
o nervous system and mental disorders; 
o respiratory system; 
o gastrointestinal system. 
After considering the sensibility of using the above predictors in the MOAT, I decided to 
exclude socioeconomic status. The reasons for this were: 
1. the relative complexity involved in obtaining socioeconomic status data, requiring: 
 use of the postcode search function provided by the ‘English Indices of 
Deprivation 2015’149 (which produces an Excel spread sheet containing the 
deprivation data for the relevant ‘neighbourhood’); 
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 extraction of the ‘Index of Multiple Deprivation’ data from the spread sheet (i.e. 
the rank position, which ranges from one to 32,844). This is one of 26 separate 
data fields included in the spread sheet; 
 calculation of the neighbourhood’s rank position as a percentage of all other 
English neighbourhoods; 
2. the minimal reduction (0.3%) in the model’s c-index caused by the removal of 
socioeconomic status; 
3. recognition that inclusion of socioeconomic status may reduce the generalisability 
of the MOAT (i.e. restrict its use to hospitals in England). 
Once socioeconomic status was excluded from the regression model, ‘antidepressants’ 
became non-significant, and was therefore also excluded. This left 11 predictors in the 
BS model (Table 44). I also re-ran the backwards elimination, excluding socioeconomic 
status from the outset, to assess whether this altered the final predictor selection. The 
same model was produced.  
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Table 44 – Multivariable association between predictors and outcome events 
Predictor 
Full model 
Model following backward 
elimination 
Regression 
coefficient
†
 
(95% CI) 
p 
value
‡
 
Regression 
coefficient
†
 
(95% CI) 
p 
value
‡
 
Demographic     
Age/10 (years) 0.0403 
(-0.0446 to 0.125) 
0.352 - - 
Socioeconomic status/10, ranked 
using English Indices of Deprivation 
2015 – Index of Multiple 
Deprivation
149* 
0.0458 
(0.0034 to 0.0882) 
0.034 - - 
Patient related     
Previous allergy
§
 
0.266 
(0.0193 to 0.512) 
0.035 
0.318 
(0.0691 to 0.566) 
0.012 
Body mass index (kg/m
2
) 
-0.0030 
(-0.0272 to 0.0213) 
0.810 - - 
Number of hospital admissions in 
previous 6 months  
0.0238 
(-0.127 to 0.175) 
0.757 - - 
Primary diagnosis
§
:     
Endocrine and metabolic 0.0083 
(-0.560 to 0.577) 
0.977 - - 
Nervous system and mental 
disorders 
0.331 
(-0.129 to 0.791) 
0.158 
0.414 
(0.0183 to 0.810) 
0.040 
Cardiovascular system -0.221 
(-0.621 to 0.179) 
0.279 - - 
Respiratory system -0.313 
(-0.725 to 0.0991) 
0.137 
-0.274 
(-0.577 to 0.0296) 
0.077 
Gastrointestinal system -0.656 
(-1.177 to -0.136) 
0.013 
-0.624 
(-1.065 to -0.182) 
0.006 
Genitourinary system -0.0475 
(-0.531 to 0.436) 
0.847 - - 
Musculoskeletal-intergumentary 
systems 
0.0491  
(-0.494 to 0.592) 
0.859 - - 
All other categories Base category Base category 
Number of comorbidities  0.139 
(0.0646 to 0.214) 
<0.001 
0.146 
(0.0775 to 0.215) 
<0.001 
History of dementia
§
  -0.269 
(-0.664 to 0.126) 
0.182 - - 
Laboratory results 
Estimated glomerular filtration rate/10 
(ml/min/1.73m
2
) 
-0.0372 
(-0.0781 to 0.0038) 
0.076 
-0.0360 
(-0.0734 to 0.0014) 
0.059 
Liver disease
§  -0.101 
(-0.490 to 0.287) 
0.609 - - 
Serum albumin  (g/L) 0.00063 
(-0.0225 to 0.0237) 
0.958 - - 
Serum potassium (mmol/L) -0.129 
(-0.332 to 0.0742) 
0.213 - - 
Serum sodium (mmol/L) -0.0062 
(-0.0286 to 0.0161) 
0.583 - - 
White cell count (10
9
/L) 0.0227 
(-0.0077 to 0.0531) 
0.143 
0.0274 
(-0.0008 to 0.0557) 
0.057 
Platelet count/10 (10
9
/L) 0.0028 
(-0.0105 to 0.0161) 
0.677 - - 
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Continued from previous page… 
Predictor 
Full model 
Model following backward 
elimination 
Regression 
coefficient
†
 
(95% CI) 
p 
value
‡
 
Regression 
coefficient
†
 
(95% CI) 
p 
value
‡
 
Medicines related 
Number of medicines  0.0239 
(-0.0122 to 0.0599) 
0.194 
0.0406 
(0.0074 to 0.0737) 
0.016 
Use of high-risk medicines
§
     
Anticoagulants 0.111 
(-0.197 to 0.419) 
0.479 - - 
Therapeutic heparin 0.273 
(-0.0888 to 0.635) 
0.139 - - 
Anti-diabetic medication 0.224 
(-0.0816 to 0.530) 
0.151 - - 
Opiates 
0.0122 
(-0.379 to 0.403) 
0.951 - - 
Aminoglycosides and glycopeptides 
0.335 
(-0.118 to 0.787) 
0.147 
0.387 
(-0.0535 to 0.828) 
0.085 
Other antimicrobials 0.3670 
0.0641 to 0.670) 
0.018 
0.364 
(0.0909 to 0.637) 
0.009 
Epilepsy medicines 0.486 
(0.135 to 0.837) 
0.007 
0.450 
(0.1111 to 0.789) 
0.009 
Antipsychotics 0.165 
(-0.305 to 0.635) 
0.492 - - 
Antiarrhythmics -0.0583 
(-0.459 to 0.342) 
0.775 - - 
Antidepressants 
0.207 
(-0.0737 to 0.488) 
0.148 - - 
Other high-risk medicines 
0.120 
(-0.310 to 0.550) 
0.585 - - 
Parenteral administration
§  0.0406 
(-0.258 to 0.339) 
0.790 - - 
Constant -0.668  -1.674  
* Deprivation rank based on patients’ postcode, shown as the ranked position as a 
percentage of all neighbourhoods in England (where 1 is the most deprived) 
† Relationship between the independent and dependent variable (amount of increase in 
predicted log odds of the outcome event that would be predicted by a one unit increase 
in the independent variable) 
‡ Test for difference between admissions with and without occurrence of outcome event. 
Obtained from multivariable regression modelling 
§ Categorical exposure variable. For the purposes of calculating the predicted risk for 
individual patients (as described in section 9.2.6.2), categorical variables were coded as 
‘one’ if present and ‘zero’ if absent 
Age, socioeconomic status, estimated glomerular filtration rate, and platelet count analysed as 
deciles to aid interpretability (i.e. after dividing the actual value by ten).  
To permit direct comparison between the univariable and multivariable results (shown 
in section 9.3.1.5) the odds ratio for each predictor in the full model was also calculated 
(Appendix A9.4). 
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9.3.3.2 Model diagnostics 
The results for the model diagnostics are presented in four sections: evidence for 
clustering caused by duplicate admissions, the accuracy of the ‘quadrature 
approximation’ used to estimate the random effects model, the check for specification 
error, and detection of outlying observations. Each is described below. 
Evidence of clustering 
The estimates of the correlation within clusters (rho) produced after fitting the BS model 
in both the non-imputed and multiply imputed datasets is shown in Table 45. The result 
of the likelihood ratio test (performed following the complete-case analysis of non-
imputed data) is also shown. 
Table 45 – Evidence of clustering following random effects modelling using 
predictors selected by backward elimination 
  Random effects model (predictors selected 
by backward elimination) 
Non-imputed 
dataset 
Multiply imputed 
dataset 
Number of observations (i.e. number of 
admissions included in the analysis) 
1,494 1,503 
Number of groups (i.e. number of individual 
patients included in the analysis) 
1,436 1,444 
Rho 0.000049 0.030 
Likelihood ratio test of rho = 0 p = 0.498 N/A 
Rho = correlation within clusters, N/A = not applicable  
This shows that 59 of the 1,503 observations (admissions) included in the multiply 
imputed model were patients included in the study more than once (i.e. the number of 
admission minus the number of groups). For the complete case analysis (using non-
imputed data), 1,494 observations were included, of which 58 patients were admitted 
more than once. 
Rho was close to zero following the complete-case analysis, with the likelihood ratio 
test suggesting no evidence for clustering (p = 0.498). The value of rho was larger for 
the multiply imputed model (0.03), which may be due to the slightly higher number of 
observations included in this model; this suggests some evidence of clustering, albeit 
relatively small205. 
In summary, there is some evidence that duplicate admissions caused within patient 
correlation, providing support for the use of random effects modelling. 
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Accuracy of the quadrature approximation 
Following the use of ‘quadchk’ to check the adequacy of the quadrature approximation 
of the BS model, the largest relative difference in the regression coefficients of the 
predictors was 0.0002%. This indicates that the results may be confidently 
interpreted188. 
Testing for specification error 
The Stata output for the specification error test is shown in Table 46. This shows that 
the ‘predicted value’ (_hat) was statistically significant, and the ‘prediction squared’ 
(_hatsq) was not significant. This suggests there is no evidence for a specification error 
in the BS model. 
Table 46 – Stata output for specification error check of backward selection model 
 
_hat = ‘predicted value’, _hatsq = ‘predicted value squared’; _cons = constant, Coef = 
regression coefficient, Std Err = standard error, t and P>|t| provide the Student’s t and 2-tailed p 
value 
  
                                                                               
        _cons     .0342448   .0692424     0.49   0.621    -.1014678    .1699575
       _hatsq    -.1126027   .0958771    -1.17   0.240    -.3005184     .075313
         _hat     .9010783   .1057824     8.52   0.000     .6937487    1.108408
                                                                               
study_outcome        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
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Detection and review of outlying observations 
Plots for the residual, influence measure, and diagnostic statistics are presented below, 
followed by a summary of the impact of the outlying observations (cases).  
Standardised Pearson and deviance residuals 
Plots of the standardised Pearson and deviance residuals against the predicted risk 
probabilities are shown in Figure 13 and Figure 14 respectively. Eighteen cases had a 
standardised Pearson residual of above two (ranging from 2.06 to 2.66), and one case 
had a standardised Pearson residual below minus two (-2.06). Only one case had a 
deviance residual outside the range of two to minus two (2.05). 
A lowess line was used to create smooth lines through the scatterplots. Where a model 
is correct, with no significant incorporation of potential outliers, a lowess smooth of the 
plot of the residuals against the logistic probability should result in approximately a 
horizontal line with zero intercept; significant departure from this suggests that potential 
outliers may have dramatic impact on the fit of the model189. No significant departure 
was observed for either the standardised Pearson or deviance residuals.  
 
Pr(study-outcome) = predicted probability of study outcome, lowess = locally weighted 
scatterplot smoothing 
Figure 13  – Standardised Pearson residual against estimated logistic probability 
of study outcome 
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Pr(study-outcome) = predicted probability of study outcome, lowess = locally weighted 
scatterplot smoothing 
Figure 14  – Deviance residual against estimated logistic probability of study 
outcome 
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Pregibon leverage 
The plot of Pregibon leverage against the predicted risk probabilities is shown in Figure 
15. The average value for Pregibon leverage was 0.008, therefore a cut-off of 0.024 
was used to identify outlying cases. Nine outlying cases were found (ranging from 
0.0243 to 0.031)  
  
Pr(study-outcome) = predicted probability of study outcome 
Figure 15 – Pregibon leverage against estimated logistic probability of study 
outcome 
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Change in chi-square fit statistic 
The plot of the change in chi-square fit statistic against the predicted risk probabilities is 
shown in Figure 16. Twenty four outlying cases were found (ranging from 3.847 to 
7.094) 
  
Pr(study-outcome) = predicted probability of study outcome 
Figure 16 – Change in chi-square fit statistic against estimated logistic 
probability of study outcome 
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Change in deviance statistic 
The plot of the change in deviance statistic against the predicted risk probabilities is 
shown in Figure 17. Two outlying cases were found (4.00 and 4.20)  
 
Pr(study-outcome) = predicted probability of study outcome 
Figure 17 – Change in deviance statistic against estimated logistic probability of 
study outcome 
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Pregibon’s dbeta 
The plot of the change in regression coefficients (Pregibon’s dbeta) against the 
predicted risk probabilities is shown in Figure 18. Using a cut-off of 0.04 (selected 
following visual examination of the data), 10 cases were found to be outliers (ranging 
from 0.0405 to 0.0758) 
  
Pr(study-outcome) = predicted probability of study outcome 
Figure 18 – Pregibon’s dbeta against estimated logistic probability of study 
outcome 
Summary 
The review of the residuals, influence measure, and diagnostic statistics identified 38 
outlying cases (Table 47), Outlying values are shown in bold.  
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Table 47 – Summary of residual, influence measure and diagnostic statistics for 
the backward selection model 
Study 
identifier 
Residuals 
Pregibon 
leverage 
Change in 
chi-square 
fit statistic 
Change in 
deviance 
statistic 
Pregibon’s 
dbeta 
Standardised 
Pearson 
Deviance 
4 2.06* 1.82 0.0039 4.23 3.32 0.0166 
32 -1.27 -1.37 0.0247 1.61 1.94 0.0408 
193 1.02 1.18 0.0249 1.04 1.44 0.0266 
207 1.99 1.79 0.0046 3.96 3.21 0.0185 
270 2.09 1.83 0.0076 4.36 3.37 0.0336 
312 2.20 1.88 0.0041 4.83 3.53 0.0197 
469 2.13 1.85 0.0081 4.53 3.43 0.0369 
526 2.11 1.84 0.0043 4.43 3.39 0.0192 
528 -1.73 -1.66 0.0139 2.99 2.79 0.0423 
542 -0.83 -1.02 0.0243 0.70 1.06 0.0173 
552 2.23 1.89 0.0037 4.97 3.58 0.0182 
649 1.99 1.79 0.007 3.95 3.21 0.0278 
654 1.72 1.65 0.0199 2.95 2.77 0.0598 
661 -1.59 -1.58 0.0157 2.54 2.54 0.0405 
667 1.41 1.47 0.0205 1.99 2.21 0.0415 
672 1.04 1.20 0.0245 1.08 1.47 0.0270 
693 -1.00 -1.16 0.0250 0.99 1.39 0.0255 
744 1.96 1.77 0.0043 3.85 3.16 0.0165 
835 2.28 1.91 0.0044 5.22 3.66 0.0232 
865 2.31 1.92 0.007 5.33 3.71 0.0378 
884 -1.25 -1.50 0.0311 1.55 2.31 0.0498 
900 2.09 1.83 0.0077 4.36 3.37 0.0340 
964 -1.25 -1.50 0.0311 1.55 2.31 0.0498 
1004 2.09 1.83 0.0028 4.35 3.36 0.0120 
1078 0.99 1.15 0.0297 0.97 1.37 0.0298 
1091 -0.85 -1.04 0.0247 0.73 1.10 0.0184 
1097 2.03 1.80 0.0047 4.10 3.27 0.0192 
1100 2.66 2.04 0.0072 7.09 4.20 0.0518 
1121 2.39 1.95 0.0044 5.70 3.81 0.0254 
1179 -2.05 -1.81 0.0176 4.22 3.34 0.0758 
1232 -1.76 -1.67 0.0184 3.11 2.85 0.0582 
1277 2.00 1.79 0.0029 4.00 3.22 0.0116 
1281 1.99 1.79 0.0029 3.96 3.21 0.0115 
1296 2.34 1.93 0.003 5.49 3.75 0.0163 
1323 2.39 1.95 0.003 5.72 3.82 0.0173 
1341 2.52 1.99 0.0062 6.35 4.00 0.0398 
1406 2.14 1.85 0.0033 4.59 3.45 0.015 
1410 2.29 1.91 0.0048 5.25 3.67 0.0253 
* Outlying values shown in bold 
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To assess the impact of excluding the outlying cases from the regression analysis I 
compared the regression coefficients and p values from a model fitted using all cases, 
with a model where all outlying cases were excluded (Table 48). Removal of the 38 
cases caused the regression coefficients to change by an average of 24.7% (range 
1.6% to 42.3%), but did not change the overall significance of the predictors (i.e. all 
remained ‘significant’ using a significance level of p smaller than 0.157, as selected for 
MOAT development). Removal also caused the model chi-square to increase from 
149.9 to 205.4, indicating an increase in predictive information. 
Table 48 – Comparison of parameter estimates for regression models with and 
without outlying cases 
* Relationship between the independent and dependent variable (amount of increase in 
predicted log odds of the outcome event that would be predicted by a one unit increase 
in the independent variable) 
† Test for difference between admissions with and without occurrence of outcome event. 
Obtained from multivariable regression modelling 
‡ Comparison between models fitted with and without the outlying cases 
Deleting cases with large residuals or more extreme values almost always improves 
the fit of model189, but is not appropriate if the observations are valid. To establish 
possible explanations (for the case being an outlier), I therefore reviewed the predicted 
risk probabilities of the outlying cases, and whether each of these cases experienced 
an outcome event (Table 49).   
Predictor 
Model including  
all cases 
Model excluding 
outlying cases 
Percentage 
change in 
regression 
coefficients
‡
 
Regression 
coefficient* 
p 
value
†
 
Regression 
coefficient* 
p 
value
†
 
Number of comorbidities 0.14 <0.001 0.172 <0.001 22.9 
Number of medicines 0.041 0.011 0.055 0.001 34.1 
Estimated glomerular 
filtration rate/10
 
(ml/min/1.73m
2
) 
-0.04 0.029 -0.056 0.003 40.0 
White cell count (10
9
/L) 0.027 0.053 0.038 0.008 40.7 
Previous allergy 0.297 0.010 0.344 0.004 15.8 
Nervous system and 
mental disorders 
0.395 0.040 0.562 0.005 42.3 
Respiratory system -0.284 0.056 -0.327 0.034 15.1 
Gastrointestinal system -0.577 0.006 -0.586 0.011 1.6 
Anticoagulants 0.404 0.063 0.483 0.037 19.6 
Other antimicrobials 0.345 0.008 0.425 0.002 23.2 
Epilepsy medicines 0.448 0.005 0.521 0.002 16.3 
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Table 49 – Predicted risk probabilities and occurrence of the outcome event for 
outlying cases 
Study identifier  
of outlying case 
Predicted risk 
probability 
Occurrence of 
outcome event 
4 0.19 Yes 
32 0.61 No 
193 0.50 Yes 
207 0.20 Yes 
270 0.19 Yes 
312 0.17 Yes 
469 0.18 Yes 
526 0.19 Yes 
528 0.75 No 
542 0.41 No 
552 0.17 Yes 
649 0.20 Yes 
654 0.26 Yes 
661 0.71 No 
667 0.34 Yes 
672 0.49 Yes 
693 0.49 No 
744 0.21 Yes 
835 0.16 Yes 
865 0.16 Yes 
884 0.43 No 
900 0.19 Yes 
964 0.43 No 
1004 0.19 Yes 
1078 0.51 Yes 
1091 0.42 No 
1097 0.20 Yes 
1100 0.12 Yes 
1121 0.15 Yes 
1179 0.81 No 
1232 0.75 No 
1277 0.20 Yes 
1281 0.20 Yes 
1296 0.16 Yes 
1323 0.15 Yes 
1341 0.14 Yes 
1406 0.18 Yes 
1410 0.16 Yes 
This shows that 28 of the 38 outliers experienced an outcome event, the majority of 
whom had low predicted risk probabilities. For example case ‘1100’ had no 
comorbidities, was prescribed only two medicines, had ‘normal’ renal function, a white 
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cell count within the standard reference range, and was not prescribed any of the three 
high-risk medicines included in the BS model. Despite his low predicted risk probability 
(of 0.12), this patient experienced a valid outcome event; they were prescribed a sub-
therapeutic dose of prophylactic heparin for thromboprophylaxis (based on their 
weight), resulting in an increased risk of thromboembolism. 
The remaining ten cases did not experience an outcome event despite having relatively 
high predicted risk probabilities. Given the potential under-reporting of MRPs by study 
pharmacists (as discussed in chapter 7), it was possible that these patients may have 
experienced an outcome event that was not reported. I therefore re-ran the regression 
excluding the outlying cases that were recorded as not having experienced an outcome 
event. This resulted in a small average change in the regression coefficients (of 3.8%), 
and a modest increase in the model chi-square compared to the model with all cases 
(from 149.9 to 159.7).   
After considered the evidence presented above, I chose not to exclude the outlying 
cases from the analysis for the following reasons:  
 although the outlying cases had some impact on the regression coefficients and 
model fit, this was not sufficient to impact on the statistical significance of any of the 
model predictors (i.e. all predictors would be retained in the model irrespective of 
whether outliers included); 
 the cases that experienced an outcome event despite having low predicted risk 
probabilities appear to be genuine findings; 
 exclusion of patients with high predicted risk probabilities who did not experience a 
study event resulted in only minor changes in the model’s parameters. 
An additional consideration was the fact that while exclusion of the outlying cases 
would result in increased model fit, it may cause overfitting, with overestimation of the 
predictive performance of the model when used in a new set of patients. 
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9.3.4 Assessing model performance 
The discrimination and calibration of the BS model are reported below. The optimism-
corrected discrimination is reported in section 9.3.5. 
Discrimination 
The c-index for the BS model was 0.681 (95% confidence interval 0.654 to 0.708). 
Calibration 
The calibration plot for the BS model is shown in Figure 19. This is a plot of the 
predicted probability of an outcome event against observed outcome frequency. The 
smoothed (lowess) line, and line of equality (i.e. the 45 degree line) are shown. This 
plot suggests slight overestimation of the risk of an outcome event for patients at lower 
risk (i.e. predicted risk probability under 20%), and those at higher risk (over 60%), but 
the calibration slope suggests good overall calibration (slope 0.974, intercept 0.012). 
 
Predicted probability of an outcome event 
 
 
Study outcome = observed outcome frequency 
Figure 19 – Calibration plot of predicted probability of an outcome event against 
the proportion of admissions that experienced an event 
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9.3.5 Internal validation / adjustment for optimism 
Discrimination 
Following bootstrap validation the estimated optimism for the c-index was found to be 
0.027 (range -0.021 to 0.0632, standard deviation 0.014). Subtracting this value from 
the corresponding BS model, that is to say, prior to the removal of ‘non-sensible’ 
predictors (c-index 0.684), the estimated optimism-corrected c-index for the BS model 
was 0.657. 
Calibration 
Bootstrap validation suggested slight overfitting of the BS model, with an average 
calibration slope of 0.855 (range 0.703 to 1.126, standard deviation 0.066). The 
optimism for the calibration slope was therefore used as a linear shrinkage factor to 
adjust the regression coefficients of the BS model (Table 50).  
Table 50 – Multivariable association between predictors and outcome events 
(backward elimination model) before and after correction for optimism 
Predictor 
Regression coefficient* 
(backward elimination 
model) 
Regression coefficient* 
(following correction for 
optimism
†
) 
Number of comorbidities  0.146 0.125 
Estimated glomerular filtration rate/10
 
(ml/min/1.73m
2
) 
-0.0360 -0.0308 
White cell count (10
9
/L) 0.0274 0.0234 
Number of medicines  0.0406 0.0347 
Previous allergy
§
 0.318 0.272 
Nervous system and mental disorders
§
 0.414 0.354 
Respiratory system
§
 -0.274 -0.234 
Gastrointestinal system
§
 -0.624 -0.533 
Aminoglycosides and glycopeptides
§
 0.387 0.331 
Other antimicrobials
§
 0.364 0.311 
Epilepsy medicines
§
 0.450 0.385 
Constant -1.674 
* Relationship between the independent and dependent variable (amount of increase in 
predicted log odds of the outcome event that would be predicted by a one unit increase 
in the independent variable) 
† Original regression coefficients corrected by uniform linear shrinkage factor (0.855) 
§ Categorical exposure variable. For the purposes of calculating the predicted risk for 
individual patients (as described in section 9.2.6.2), categorical variables were coded as 
‘one’ if present and ‘zero’ if absent 
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9.3.6 Development of a decision aid (the MOAT) 
The development of the MOAT is reported in three sections: the presentation format, 
creation of risk groups, and assessment of clinical usefulness. 
9.3.6.1 Presentation format 
The MOAT was developed as a Microsoft Excel data entry sheet (Figure 20) that 
calculates individual patients’ probability of an outcome event. This requires pharmacy 
staff to input data for all candidate predictors, including data required to estimate renal 
function using the modified Modification of Diet in Renal Disease (MDRD) equation121: 
 number of comorbidities; 
 number of ‘regular’ medicines prescribed to be given on the first full day of 
admission to hospital; 
 white cell count, 109/L (first documented result following admission); 
 Previous allergy (yes or no); 
 systemic aminoglycosides and glycopeptides use (yes or no); 
 use of systemic antimicrobials other than aminoglycosides and glycopeptides (yes 
or no); 
 use of epilepsy medicines (yes or no); 
 primary diagnosis of ‘nervous system and mental disorders’ (yes or no); 
 primary diagnosis of ‘respiratory system’ (yes or no); 
 primary diagnosis of ‘gastrointestinal system’ (yes or no); 
 data required to estimate renal function: 
o serum creatinine, micromoles per litre (first documented result following 
admission); 
o age in years (at admission to hospital); 
o gender (male or female); 
o ethnicity (black or non-black). 
Additional guidance is provided using ‘help links’. 
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eGFR = estimated glomerular filtration rate 
Figure 20 – Screenshot of Medicines Optimisation Assessment Tool (MOAT) data 
entry sheet (prior to data entry) 
 
The MOAT then calculates the estimated glomerular filtration rate (eGFR), and the 
predicted probability of experiencing an MSP MRP. The probability is shown as the 
percentage probability, in addition to the patient’s risk category (high, medium or low-
risk, which is colour coded as red, amber or green respectively). An example of a 
completed MOAT assessment is shown in Figure 21. 
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eGFR = estimated glomerular filtration rate 
Figure 21 – Screenshot of Medicines Optimisation Assessment Tool (MOAT) data 
entry sheet (following data entry) 
 
9.3.6.2 Creation of risk groups 
Three risk categories were created, high, medium and low.  
The decision threshold to distinguish between low and medium-risk patients was 
informed by the target sensitivity for the MOAT. As discussed in section 9.2.1, an 
acceptable target sensitivity was established by including a question in the survey of 
healthcare professionals and patient / public representatives (discussed in chapter 5); 
as a result, a target sensitivity of 90% was chosen. The decision threshold was 
therefore selected as the predicted risk probability that corresponded to a sensitivity of 
90%; this was approximately 0.25 (i.e. 25%). Patients below this cut-off were 
categorised as low-risk, and patients above this cut-off were categorised as medium-
risk (Table 51). Using this decision threshold, the sensitivity of the MOAT was 89.9% 
(95% confidence interval 87.6% to 92.4%), and specificity 30.2% (95% confidence 
interval 27.2% to 33.2%). 
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Table 51 – MOAT outcomes using the decision threshold between low and 
medium-risk categories 
 Occurrence of moderate or severe preventable 
medication related problem Total (n) 
Yes (n) No (n) 
MOAT 
outcome 
Screen 
positive (n) 
545 620 1165 
Screen 
negative (n) 
61 268 329 
Total (n) 606 888 1494* 
* Excludes nine admissions with missing data 
A decision threshold to distinguish between medium and high-risk patients was 
informed by considering workload pressures. Following discussion with a group of 
practising pharmacy staff, it was decided to choose a threshold equivalent to pharmacy 
staff needing to see 50% of patients; this corresponded to a predicted risk probability of 
approximately 0.35 (35%). As shown in Table 52, based on this decision threshold, the 
MOAT’s sensitivity was 66.2% (95% confidence interval 62.4% to 70.0%), and 
specificity 61.0% (95% confidence interval 57.8% to 64.2%). 
Table 52 – MOAT outcomes using the decision threshold between medium and 
high-risk categories 
 Occurrence of moderate or severe preventable 
medication related problem Total (n) 
Yes (n) No (n) 
MOAT 
outcome 
Screen 
positive (n) 
401 346 747 
Screen 
negative (n) 
205 542 747 
Total (n) 606 888 1494* 
* Excludes nine admissions with missing data 
The predicted probability range for the risk groups are therefore: 
 low – lower than 25.3% risk of experiencing an outcome event; 
 medium – between 25.3 and 34.9% risk of experiencing an outcome event; 
 high – greater than or equal to 35.0% risk of experiencing an outcome event.   
9.3.6.3 Assessment of clinical usefulness 
The decision curve for the MOAT is shown in Figure 22. As anticipated, the ‘treat none’ 
and ‘treat all’ lines cross at the prevalence of the outcome event (40.6%). The MOAT is 
comparable to the strategy of ‘treat all’ at low threshold probabilities, and comparable 
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to ‘treat none’ at high probabilities. This is because the probability of an outcome event 
predicted by the MOAT ranges from 0.09 (9%) to a maximum of 0.86 (86%); using the 
MOAT below or above this range therefore gives the same result as ‘treat all’ or ‘treat 
none’. Between approximately 0.70 (70%) and 0.85 (85%) the net benefit is 
approximately equal to the strategy of ‘treat none’, this is because of the relative 
increase in false positive compared to true positive results. Between approximately 
0.15 (15%) and 0.70 (70%) the MOAT is better than both the ‘treat none’ and ‘treat all’ 
strategies, suggesting it is of value for patients with predicted risk probabilities within 
this range200. 
 
 
Figure 22  – Decision curve for the Medicines Optimisation Assessment Tool 
(MOAT) 
Given that the decision thresholds selected for the MOAT (section 9.3.6.2) were 0.25 
(25%) and 0.35 (35%), both are within the range of probability where the MOAT is 
considered to be clinically useful. Should a higher decision threshold be selected (due 
to extreme work pressures), the MOAT would continue to be of value in terms of 
clinical decision making, up to a predicted risk probability of approximately 0.7 (70%), 
suggesting significant flexibility. 
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9.4 Discussion  
Key findings 
Multivariable logistic regression modelling was used to establish the relationship 
between pre-selected candidate predictors and patients with an outcome event, namely 
at least one MSP MRP. Backwards elimination was then used to produce a 
parsimonious model, aiming to increase clinical applicability while retaining reasonable 
predictive performance. The model was then adjusted for optimism (to reduce the 
potential for overconfident predictions when applied to a new group of patients), and 
the adjusted regression equation used to develop an electronic decision aid, the 
MOAT. The predictive performance of the MOAT was fair (c-index 0.66), with a 
sensitivity of 90% for a ‘medium-risk’ category (specificity 30%), and 66% for a ‘high-
risk’ category (specificity 61%). Decision curve analysis suggests that the MOAT has 
the potential to be clinically useful across a wide range of predicted risk probabilities 
(from approximately 15% to 70%). 
Comparison with previous literature  
Seven of the prediction tool studies included in the literature review (chapter 3) 
involved development of a prognostic model for adverse medication-related outcomes 
during hospitalisation. Of these, three predict adverse drug reactions (ADRs)41 42 43, two 
predict adverse drug events (ADEs)44 45, one predicts medication errors (MEs)47, and 
one predicts MRPs52. 
Predictive performance was reported for six of these studies41 42 44 45 47 52. Of these, 
McElnay et al44 concluded their model had insufficient sensitivity to be a satisfactory 
predictor of ADEs, but the remaining five studies reported adequate discriminatory 
capacity (c-index of 0.70-0.78 following bootstrap or external validation). Only two of 
these five studies reported calibration following development42 47. No studies reported 
calibration following external validation; it is therefore not possible to judge the potential 
accuracy of predictions in new datasets. Risk groups were created in two studies41 42, 
permitting sensitivity and specificity to be reported: 
 GerontoNet ADR risk score41: 
o developmental dataset – sensitivity 68% and specificity 65%; 
o validation dataset – although sensitivity and specificity not reported, it was 
possible to calculate from data provided, giving a sensitivity of 91%, and 
specificity of 27%; 
 Brighten Adverse Drug Reactions Risk (BADRI) model42:  
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o developmental dataset – sensitivity 80% and specificity 55%; 
o validation dataset – sensitivity 84% and specificity 43%. 
The prognostic models developed by Nguyen et al47 and Urbina et al52, designed to 
target patients at risk of MEs and MRPs respectively, are potentially the most similar to 
the present study in terms of outcome event (given that MEs are a subset of MRPs). 
Despite this, key differences exist in terms of the modelling strategies used, which 
make direct comparison with the present study difficult:  
 target population – Nguyen included medical and surgical patients, and Urbina 
included medical, surgical and maternity patients (the present study includes only 
medical patients); 
 choice of candidate predictors – Nguyen did not investigate laboratory results, 
diagnostic groups, or comorbidities, all of which are included in the present study; 
 method of outcome identification – Urbina used a computerised warning system, 
impacting on the type of MRPs identified. 
In summary, although the predictive performance of the MOAT is broadly comparable 
with the existing prognostic models, it is not possible to make direct comparisons due 
to differences in the type of outcome predicted, and/or methods used for development. 
It is also not possible to compare potential clinical usefulness, as the existing studies 
did not report decision curve analysis. 
Interpretation  
While the discriminative ability of a prognostic model is important, Steyerberg advises 
that ‘it is not possible to indicate a minimum value for the c-index to make a model 
clinically useful’70. This is because the c-index alone does not consider the 
consequence of false positive or false negatives predictions. For example, a model with 
a ‘good’ c-index (for example 0.8) will not be clinically useful if all predictions are above 
or below the optimal decision threshold70 201. The use of decision curve analysis was 
therefore helpful in permitting assessment of the MOAT’s potential value in clinical 
practice. While the MOAT has a modest c-index (0.66), its predictions span a wide 
range of probabilities (from 9% to 86%), with net benefit across a significant range 
(15% to 70%). This suggests the MOAT has the potential to be useful in clinical 
practice in terms of guiding decision making at both decision thresholds (25% and 
35%). Furthermore, the creation of three risk groups (low, medium and high-risk), 
permits pharmacists to take account of workload capacity when prioritising patients, as 
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does the reporting of both the predicted risk probability and risk group for individual 
patients. 
Strengths and limitations 
A strength of the approach taken for model development was adherence with 
PROGRESS53 55, TRIPOD94, and CHARMS60 recommendations. This has the potential 
to enhance the quality of the modelling strategy, reduce bias, and facilitate full and 
detailed reporting to permit the quality and relevance of the study to be adequately 
assessed. Other strengths include: 
 inclusion of two study sites, potentially increasing the generalisability of the MOAT; 
 use of shrinkage techniques, increasing the potential accuracy of predictions in new 
patients; 
 use of clinical decision curve analysis, informing potential clinical usefulness; 
 development of an electronic scoring system, which aims to simplify use. 
Limitations include the following: 
 the presence of missing data, and subsequent use of multiple imputation. While this 
is a potential source of bias, the comparison of key characteristics of patients with 
and without missing data, and sensitivity analysis, suggest data were MAR. Given 
this missingness assumption, multiple imputation was less likely to introduce 
selection bias than complete-case analysis, in addition to being statistically more 
efficient. The use of multiple imputation also impacted on a number of the model 
diagnostic checks. For example, it was necessary to use non-imputed data for the 
review of ‘outlying observations’, resulting in 9 (0.6%) of 1,503 admissions being 
excluded from the review; 
 investigations into possible ‘interactions’ between candidate predictors were not 
performed (i.e. an assessment of whether candidate predictors have a different 
association with the outcome depending on the value of a third variable). While 
interactions may have been present, none were hypothesised a priori, and it is 
recognised that a thorough assessment of possible interactions during modelling 
increases the risk of overfitting. As a result, Steyerberg recommends considering 
interactions only in studies with relatively large sample sizes70; 
 the decision threshold between low and medium-risk patients gives a sensitivity of 
90%, meaning that 10% of patients who experienced an MSP MRP would be 
incorrectly categorised as low-risk, therefore would not receive pharmacist review. 
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The potential clinical consequence of these false negative results will be assessed 
in chapter 10; 
 to achieve 90% sensitivity the corresponding specificity is approximately 30%. An 
improvement in specificity leads to a reduction in sensitivity (i.e. the decision 
threshold for high-risk patients has a specificity of 61% and sensitivity of 66%). This 
is a consequence of the ability to accurately predict MSP MRPs, but also the 
relatively high prevalence (40.6%); 
 the potential complexity of the MOAT, requiring pharmacists to input 14 pieces of 
data. While electronic scoring has the potential to simplify use, usability will be 
investigated as part of the assessment of the MOAT (chapter 10); 
 the requirement for pharmacists to correctly interpret definitions for candidate 
predictors, for example how to count comorbidities and number of ‘regular’ 
medicines. Guidance was therefore integrated into the electronic scoring system, 
and usability assessed as part of the MOAT assessment (chapter 10). 
Implications  
Given the above limitations, subsequent research may be able to improve on the 
present study by using prospective collection for predictor data; as discussed in 
chapter 6, this may overcome the need to imputing missing values.  
Further research is required to assess the potential clinical consequence of false 
negative results, and usability of the MOAT in clinical practice. These will be assessed 
in chapter 10. 
9.5 Conclusion 
An electronic decision aid, the MOAT, was developed to permit identification of patients 
at highest risk of MSP MRPs. The predictive performance of the MOAT was fair (c-
index 0.66), with a sensitivity of 90% for the ‘medium-risk’ category and 66% for the 
‘high-risk’ category. Decision curve analysis suggests the MOAT has the potential to be 
clinically useful across a wide range of predicted risk probabilities. 
The next chapter will describe assessment of the usability of the MOAT in clinical 
practice. This will involve a review of the content validity, ease of use, potential 
workload implications, and the potential clinical risk associated with false negative 
predictions.  
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Chapter 10: Assessment of the MOAT’s clinical credibility  
10.1 Introduction 
The principal aim of this research was to develop a decision aid, the Medicines 
Optimisation Assessment Tool (MOATTM), to assist in the identification of adult patients 
at highest risk of moderate or severe preventable medication related problems (MSP 
MRPs) during hospital admission. The intention is for the MOAT to have the potential to 
be adopted widely into clinical practice, which will require clinical credibility, accuracy, 
generalisability and clinical effectiveness in improving decision making and the 
associated patient outcomes206. 
As discussed in chapter 9, the MOAT has reasonable predictive performance 
(concordance index 0.66), and the potential to be useful in guiding clinical decisions 
across a wide range of predicted risk probabilities. Assessment of the MOAT’s 
generalisability and clinical effectiveness will require external validation, plus impact 
and implementation studies (discussed further in chapter 11); the aim of the work 
presented in this chapter was therefore to assess the MOAT’s clinically credibility. The 
objectives were to: 
 obtain consensus views of practising pharmacy professionals on the clinical 
credibility and usability of the MOAT; 
 quantify the workload implications related to routine use; 
 assess the potential clinical risk related to use of the MOAT; 
 identify implications of the above findings for future development and 
implementation. 
10.2 Methods 
The clinical credibility of a prediction tool is dependent on a number of factors including 
content validity, ease of use, acceptability of the time taken to use the tool, and 
acceptability of the false negative rate98 207. This assessment therefore involved three 
stages: use of a consensus method to harness the insights of pharmacy professionals 
regarding the perceived clinical credibility and usability of the MOAT, an assessment of 
the workload implications, and an assessment of the clinical implications of false 
negative predictions. Each is described in turn below; the results are described in 
section 10.3. 
Chapter 10: Assessment of the MOAT’s clinical credibility 
 
257 
 
 
Participation was voluntary. Pharmacists and clinical pharmacy technicians from 
Hospital A were given a participant information sheet (Appendix A10.1) and invited to 
volunteer for the consensus group and/or workload assessment. Written consent was 
obtained from all participants (Appendix A10.2).  
10.2.1 Consensus views on the MOAT   
The nominal group technique (NGT) was used to obtain consensus views of practising 
pharmacy staff on the clinical credibility of the MOAT98 207. The panellists were asked to 
consider the following questions: 
 does the MOAT demonstrate content validity? That is to say, would most clinicians 
consider that the choice of predictors is appropriate for the purpose of the 
prediction tool, that no obvious predictors are missing, and that individual predictors 
are appropriately grouped?; 
 is the visual presentation of the MOAT reasonable?; 
 does the MOAT have the potential to be ‘usable’ in clinical practice (related to 
simplicity of interpretation and time taken to apply the MOAT)? 
Consensus was also obtained on the choice of decision thresholds for the creation of 
risk categories (described in section 9.2.9.2). This involved consideration of the 
sensitivity versus specificity of alternative decision thresholds, and the balance 
between false negative predictions and the number of patients requiring pharmacist 
review. 
Seven participants were included in the nominal group (as this has been reported as 
the maximum recommended number101). Pharmacists and clinical pharmacy 
technicians were invited to volunteer as the MOAT has the potential to be used by both 
professional groups; to ensure adequate representation at least three participants were 
required to be from one or other group.  
A standard NGT method was used101 208, with myself acting as facilitator. This 
comprised two meetings during which panellists discussed the issues, rated the 
questions, and then rerated the questions following further discussion. Questions were 
rated using a nine-point Likert scale; each question was worded as a statement, and 
participants asked to indicate the extent to which they agreed or disagreed with each 
statement, with a score of one indicating total disagreement, and nine indicating total 
agreement. A nine-point scale was used to permit the responses to be categorised, 
with scores of one to three representing disagreement, scores of four to six 
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representing an equivocal response, and scores of seven to nine representing 
agreement208. Consensus was interpreted as all participants’ scores falling within one 
of these predefined three-point regions208.  
The format of the meetings was as follows. 
Meeting one: 
1. the MOAT was demonstrated to the group (by myself), including a description of 
the developmental process, and instructions for use; 
2. participants were asked to reflect on one of the questions (specified above), 
and write down their views; 
3. each participant, in turn, was invited to contribute one comment (either a 
statement or clarifying question), which was recorded on a flipchart; 
4. when no more comments were forthcoming, there was a group discussion to 
clarify and evaluate the question; 
5. participants were then given a rating sheet (Appendix A10.3) and asked to 
‘score’ the question. Participants were also invited to give brief reasons for their 
score. This stage was confidential, and as facilitator, I emphasised that 
participants did not have to agree; 
6. steps two to five were repeated until all questions had been scored. 
Following this meeting, the responses were collated, with agreement for each question 
summarised using the median score and interquartile range (IQR) to establish central 
tendency and variability, treating responses as ordinal data. Where two adjacent 
scores were circled by a panellist, the mid-point between scores was used. The first-
round scores were used to develop personalised score sheets for the second meeting. 
These included the same statements, together with the individual participant’s scoring, 
median score, IQR, range, and all free text comments.  
Meeting two: 
1. the collated results from meeting one were presented (by myself), and the 
personalised second-round score sheets distributed to participants. As the 
MOAT workload assessment (section 10.2.2) took place in the interval between 
consensus meetings, these results, together with feedback received on use of 
the MOAT, were also presented and discussed; 
2. participants were asked to reflect on one of the questions, taking into account 
their own score from the first meeting and the collated results (including 
summary scores and free text comments), and write down their views; 
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3. each participant, in turn, was invited to contribute one comment, which was 
recorded on a flipchart; 
4. when no more comments were forthcoming, there was a group discussion to 
clarify and evaluate the question; 
5. participants were then asked to ‘rescore’ the question. Participants were also 
invited to give brief reasons for this score. As before, this stage was 
confidential, and participants advised they did not have to agree; 
6. steps two to five were repeated until all questions had been rescored. 
Two panellists were unable to attend the second meeting due to unforeseen 
circumstances. I therefore met with each individually and shared the collated results 
from meeting one. Each panellist was then asked to reflect on each question in turn 
and given the opportunity to discuss their views. I then shared the discussion points 
raised by the group. The two panellists then rescored each statement in turn as 
described above. 
10.2.2 Workload implications  
The workload implications regarding use of the MOAT were assessed by: 
 analysing the original dataset to estimate the proportion of patients who would be 
expected to require review by a pharmacist based on the decision thresholds 
selected during the nominal group meetings (i.e. the proportion of patients who 
would ‘screen positive’); 
 calculating the median time required to apply the MOAT. This involved using the 
MOAT for a sample of patients (without acting on the findings).  
For the second part of this assessment, four volunteers reviewed five patients each 
and recorded the time taken to use the MOAT (i.e. to obtain the required data and 
calculate the risk probability for each patient). Four assessors were used to account for 
potential inter-assessor variability. Following brief training on use of the MOAT (by 
myself), the assessors timed their use of the MOAT, and recorded the results using a 
data collection form designed for this purpose (Appendix A10.4). The median, range 
and IQR were then calculated. The median was calculated (rather than the mean) due 
to the non-parametric distribution of data. 
10.2.3 Clinical implication of false negative predictions  
The sensitivity of the MOAT (for the decision threshold selected to categorise patients 
as either low or medium-risk) was 90%, meaning that 10% of patients who experienced 
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an MSP MRP were categorised as low-risk, and therefore may not be selected for 
review by a pharmacist. To assess potential clinical risk associated with these false 
negative predictions, I reviewed the MSP MRPs experienced by these patients to 
identify the type, number and severity of these ‘missed events’. The median severity 
score and IQR of MSP MRPs experienced by patients who ‘screened positive’ was 
compared with patients who ‘screened negative’, as was the median number and IQR 
of MSP MRPs experienced by both groups. Medians were compared (rather than 
means) due to the non-parametric distribution of data. The Mann-Whitney U test was 
used to test for differences.   
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10.3 Results  
10.3.1 Consensus views on the MOAT 
The consensus panel comprised four pharmacists and three clinical pharmacy 
technicians. This included two newly qualified pharmacists (Agenda for Change band 
6), one mid-grade specialist pharmacist (band 7), and one senior specialist pharmacist 
(band 8a). Two of the clinical pharmacy technicians were band 6; one was band 7. The 
two meetings were held eight days apart; the first took two hours, and the second 
lasted one and a half hours. 
The median score for each consensus statement, IQR, and range of scores are shown 
in Table 53. This shows that following meeting two, the median response and IQR were 
within the ‘agreement category’ for all five statements (i.e. within the range of seven to 
nine). Overall consensus, defined as all scores falling within one of the predefined 
three-point regions, was achieved for four of the five statements; one panellist gave the 
statement ‘the time taken to use the MOAT is reasonable’ a score of six, representing 
an equivocal response.  
Table 53 – Consensus scores of practising pharmacy staff on the clinical 
credibility of the MOAT 
Consensus statement 
Scores – meeting 1* Scores – meeting 2* 
Median IQR Range Median IQR Range 
The choice of risk factors is 
appropriate 
7 7 - 8 7 - 8 8 8 - 8 7 - 9 
The presentation of the MOAT is 
reasonable 
8 8 - 8 8 - 9 8 8 - 8 7 - 9 
The MOAT is simple to interpret 8 8 - 9 7 - 9 8 8 - 9 8 - 9 
The time taken to use the MOAT is 
reasonable 
6 5 - 6.5† 5 - 8 8 7 - 8 6 - 8 
The proposed ‘decision thresholds’ 
for the creation of risk groups are 
appropriate 
7 6.5† - 7 6 - 8 7 7 - 8 7 - 8 
* A score of one indicates total disagreement, and nine indicates total agreement. A nine-
point scale was used to permit the responses to be categorised; a score of one to three 
represents disagreement, scores of four to six represent an equivocal response, and 
scores of seven to nine represent agreement. Consensus was interpreted as all scores 
falling within one of these predefined three-point regions 
† Score taken to be 6.5 as both 6 and 7 circled by panellist  
IQR = interquartile range, MOAT = Medicines Optimisation Assessment Tool 
The written comments given by panellists are shown in Appendix A10.5. Regarding the 
choice of risk factors, opinion was divided as to whether additional risk factors should 
be included in the MOAT irrespective of their statistical significance, in particular the 
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use of anticoagulants and anti-diabetic medication. Some panellists felt these should 
be added, others felt that ‘the line needed to be drawn somewhere’, with only 
significant factors included. There were also suggestions that it may be helpful to list 
which risk factors were considered but excluded, as this may ‘makes others trust the 
score more’. Additionally, it was suggested that all potential risk factors be included in 
the MOAT score if / when it becomes fully automated. 
While the presentation and interpretability of the MOAT were generally rated as 
‘reasonable’ (median score of eight for both statements), the following comments were 
received (as verbal comments recorded on the flipchart during the nominal group 
meetings and/or written comments on rating sheets) regarding potential improvements 
that could be made: 
 the MOAT scoring screen should remain ‘visible’ while other programmes are 
opened (e.g. prescribing system and laboratory results) to facilitate data entry; 
 add the ability to increase the size of the MOAT scoring screen (if required); 
 increase size / boldness of writing on the scoring screen; 
 remove Excel background from the behind the scoring screen; 
 add an option for alternative units for serum creatinine (i.e. mg/dl) as this may be 
how it is reported at other hospitals; 
 remove ‘calculate buttons’ for renal function and risk probability (as shown in Figure 
21), as these could be calculated automatically once data submitted;   
 add a help button to describe the probability and risk categories / explain how they 
are calculated. 
The following issues were also raised as points for consideration during further 
development of the MOAT: 
 may be difficult to distinguish ‘race’ by simply observing a patient; 
 need to check the MOAT colour scheme is suitable for users with colour blindness / 
make sure the ‘green risk score’ is sufficiently visible on the green background; 
 patients categorised as ‘low-risk’ should still be reviewed by a member of the 
pharmacy team at some point during hospital stay, for example by a clinical 
pharmacy technician, even if simply to enquire if the patient needs help with their 
medicines. 
During the first meeting some panellists commented that it was difficult to rate the 
statement ‘the time it takes to use the MOAT is reasonable’ without first using the tool, 
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or having data on the time taken. As can be seen in Table 53, once these data were 
available the median score increased from six (equivocal) to eight (agree). 
Regarding the choice of decision thresholds for the MOAT, the group appreciated the 
potential benefit of providing guidance to users on an appropriate course of action, and 
were able to agree on suitable cut-offs. Although panellists agreed that risk categories 
were helpful, they suggested that the ‘percentage probability’ may be the most useful 
output as this would permit prioritisation within risk categories. While not included as a 
written comment, the panellists also discussed the possibility of using the MOAT to 
allocate workload within the team, with initial allocation based on a patient’s risk 
category (i.e. higher risk patients flagged for review by more experienced / qualified 
team members), with a referral system used to escalate care if required. It was 
suggested that this may improve the use of skill mix within the team, and provide 
greater clarity on the roles and responsibilities of team members. 
10.3.2 Workload implications  
As discussed in section 9.3.6.2, the MOAT’s sensitivity was 90% (using the decision 
threshold to categorise patients as either low or medium-risk). This equates to 
approximately 78% of patients ‘screening positive’, therefore requiring pharmacist 
review (Table 51). Alternatively this can be interpreted as meaning that the MOAT 
permits identification of the 22% of patients least likely to experience an MSP MRP. 
Using the higher decision threshold (separating medium and high-risk patients), the 
sensitivity was 66.2%, which equates to 50% of patients requiring review (Table 52). 
The time taken to apply the MOAT was assessed by four volunteers: three pharmacists 
and one clinical pharmacy technician (one band 6 pharmacist, two band 7 pharmacists, 
and one band 6 clinical pharmacy technician). The median time required to obtain the 
required information and calculate the risk score was 2 minutes 18 seconds per patient 
(range 1 minute 28 seconds to 5 minutes 4 seconds; IQR 1 minute 41 seconds to 3 
minutes 12 seconds). 
A potential improvement for the MOAT was suggested by one volunteer. This was to 
move the two risk factors that require laboratory results (serum creatinine and white 
cell count) next to each other to prevent the need to ‘skip ahead when using the tool’. 
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10.3.3 Clinical implication of false negative predictions  
Sixty-one patients experienced an MSP MRP despite being categorised as ‘low-risk’ 
(Table 51). The predicted risk probability for these ‘false negative’ patients is given in 
Appendix A10.6, together with brief details of the MSP MRPs experienced. This shows 
that the patients’ predicted probability of experiencing an MSP MRP ranged from 
12.2% to 25.2% and the number of MSP MRPs experienced per patient ranged from 
one to five (median 1, IQR 1 to 2). The median severity rating of the MSP MRPs 
experienced by these patients was 3.25 (IQR 3.0 to 3.5). There were no obvious trends 
in the type of MSP MRPs identified. 
The ‘true positive’ patients (i.e. those patients correctly identified by the MOAT as being 
at risk of experiencing an MSP MRP) had predicted probabilities of experiencing an 
MSP MRP between 25.3% and 86.2%. The number of MSP MRPs per patient ranged 
from one to ten (median 1, IQR 1 to 2), and the median severity rating was 3.25 (IQR 
3.0 to 3.75). 
Despite the median severity rating of MSP MRPs being the same for the false negative 
and true positive patients, there was weak evidence for a statistically significant 
difference (p = 0.046). Similarly, despite the median number of MSP MRPs 
experienced per patient being the same in both groups, there was strong evidence for 
a difference (p = 0.0021).  
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10.4 Discussion 
Key findings 
The research presented in this chapter suggests that the MOAT was perceived as 
clinically credible and usable by practising pharmacy professionals. Additionally, the 
workload implications, based on the time taken to apply the MOAT compared to 
potential time saved by deprioritising low-risk patients, was considered to be 
reasonable. The results also suggest that patients who experienced an MSP MRP 
despite being categorised as low-risk (false negatives) may experience fewer MSP 
MRPs that are of lower severity, compared to patients categorised as medium or high-
risk. A number of potential improvements were also identified, together with additional 
points to consider prior to implementation of the MOAT.   
Interpretation  
This research highlights the value of using expert opinion to guide future development 
of the MOAT, with a number of suggestions offered by participants to further improve 
the presentation and interpretability of the MOAT. While the MOAT will require external 
validation, plus impact and implementation studies prior to routine use, this assessment 
suggests that the MOAT has clinical credibility, which provides evidence to justify 
further development. 
Strengths and limitations 
Strengths of the research presented in this chapter include the: 
 use of a standardised method (the NGT) to obtain consensus opinions on the 
MOAT; 
 inclusion of pharmacists and clinical pharmacy technicians in the assessments 
(with varying levels of seniority) so increasing diversity; 
 use of objective methods to calculate the workload implications, and clinical 
implications of false negative predictions.  
Limitations include: 
 the potential impact of selection and volunteer bias caused by the recruitment of all 
participants from the same study site, and the use of volunteers rather than random 
selection; as a result the participants may not be representative of all pharmacy 
staff at the study site, or those at other hospitals. This was necessary for pragmatic 
reasons, and the impact may be countered by the diversity within the assessors in 
terms of profession role and seniority; 
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 a risk of moderator bias, with myself acting as facilitator for the NGT meetings; to 
address this I endeavoured to maintain an objective approach throughout, providing 
facts and clarification (where needed) rather than personal opinions. The questions 
posed during the NGT meetings were also selected from previous literature, with 
the aim of minimising the potential that question bias may influence panellists’ 
responses. Reporting bias was minimised by verbatim reporting of panellists’ 
written comments.  
Implications for development of the MOAT and future research 
It will be necessary to repeat the clinical credibility and workload assessments following 
external validation of the MOAT to take account of predictive accuracy in a new group 
of patients. Given the limitations identified above, ideally this should involve a more 
diverse group of pharmacy staff, and an impartial facilitator. 
The work presented in this chapter has provided valuable user-feedback, guiding future 
development of the MOAT in terms of its presentation and usability (as detailed in 
sections 10.3.1 and 10.3.2). Opinions varied on the inclusion of additional risk factors, 
specifically anticoagulants and anti-diabetic medication; work will therefore be required 
to investigate this further prior to implementation (on the basis that inclusion would 
have minimal impact on patients’ risk scores, but may increase clinical confidence in 
the MOAT). 
This initial workload assessment suggests the MOAT has the potential to increase the 
efficiency of clinical pharmacy services, but this will depend on how the MOAT is 
applied in practice. For example, if scored manually (using the electronic scoring 
system) it may not be feasible, or beneficial, to rescore every patient every day. 
Research will be required to investigate this further, but one possibility would be to 
‘MOAT score’ patients on hospital admission to determine the level of review required, 
for example to indicate if medicines reconciliation is required, and/or to allocate team 
members appropriately based on their knowledge and skills. Subsequent prioritisation 
decisions could then be guided by professional judgement, or MOAT scores could be 
recalculated if there is a significant change in risk, for example due to the initiation of 
high-risk medicines, resulting in escalation or de-escalation as appropriate.  
Further research may also permit potential efficiency savings to be quantified. For 
example, if the MOAT were used to select patients for pharmacy-led medicines 
reconciliation  (with medicines reconciliation undertaken for medium and high-risk 
patients only) it may be possible to save approximately 12.5 minutes of pharmacy staff 
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time for all low-risk patients (based on the estimate that a medicines reconciliation 
takes an average of 15 minutes209, and the median time to apply the MOAT is 2 
minutes 18 seconds). If applied to all low-risk patients (i.e. 22% of admissions), this 
may lead to a significant and positive impact on workload.  
Further work will also be required to establish the clinical acceptability of this type of 
approach to prioritisation. The nominal group members expressed some unease over 
the potential for patients to be ‘overlooked’ by pharmacy services, as illustrated by the 
comment ‘don’t wish to be in acute [the acute assessment wards] when all low-risk 
patients are not seen at all by pharmacy’. One possibility, as discussed by the group, 
may be to develop guidelines on the level of pharmacy input required dependent on 
risk categorisation. This could range from a simple face-to-face discussion with low-risk 
patients to more intensive interventions for patients in higher risk categories (such as 
medicines reconciliation and medication review). As discussed in chapter 5, it may also 
be possible to combine the MOAT with other triggers for pharmacy review; for example, 
patients with swallowing difficulties, those receiving end of life care, or those at risk of 
MRPs post discharge. Potentially the MOAT could then be used by ward-based 
pharmacy staff as part of a suite of tools, permitting prioritisation of patients, and 
appropriate allocation of workload between team members based on their skills and 
expertise. The development of these types of implementation strategies may also 
address patients’ views of safety; the medical view of patient safety often focusses on 
outcomes and avoidance of harm210, whereas patients tend to focus on what makes 
them ‘feel safe’, including processes of care, and interpersonal dynamics with care 
providers211 212. The MOAT inherently fits a medical view of safety, with attention on 
‘risk reduction’; incorporation of the MOAT into an holistic system offering some level of 
pharmacy input to all patients, including those categorised as ‘low-risk’, may therefore 
help provide a sense of safety for all patients. 
Clinical acceptability may also be dependent on the choice of decision thresholds used 
to categorise patients, as this will impact on both workload and the false negative rate; 
acceptance may therefore depend on workforce capacity and aversion to risk within 
organisations or clinical teams. Research may therefore be warranted to explore this 
further, with the potential to develop flexible thresholds that could be tailored either to 
organisational need, or to fluctuating staffing levels.  
Finally, an additional area of potential future research would be the development of an 
automated scoring system that is fully integrated into the relevant electronic data 
Chapter 10: Assessment of the MOAT’s clinical credibility 
 
268 
 
 
sources. This would permit risk assessments in ‘real-time’, further supporting 
implementation. 
10.5 Conclusion 
Standardised and objective methods were used to assess the MOAT’s clinical 
credibility, and to identify implications for future development and implementation. The 
results suggest that the MOAT is clinically credible, minor modifications were also 
identified that have the potential to further improve usability. Further research will be 
required to establish generalisability and clinical effectiveness. 
The next chapter will summarise the research presented in this thesis by way of an 
overall discussion. 
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Chapter 11: Overall discussion 
Since starting the research presented in this thesis, medication safety has continued to 
be high on international and national agendas. In 2017 the World Health Organization 
published their Global Patient Safety Challenge: Medication Without Harm7, which 
outlines their global initiative to reduce the level of severe, avoidable medication-
related harm by 50% over five years. This was driven by the recognition that ‘unsafe 
medication practices and medication errors are a leading cause of injury and avoidable 
harm in health care systems across the world’, with an estimated global cost of $42 
billion United States dollars annually7. In England, the Department of Health and Social 
Care commissioned a review of the prevalence and economic burden of medication 
errors in the English NHS, resulting in publication of a report by the Policy Research 
Unit in Economic Evaluation of Health and Care Interventions (EEPRU) in February 
2018213. This report received ministerial attention, informing an article in the Daily 
Telegraph by the Secretary of State Jeremy Hunt, and resulting in significant media 
interest214; national headlines included ‘NHS medication errors contribute to as many 
as 22,000 deaths a year’215, and ‘Drug mistakes killing up to 22,300 patients a year’216. 
While the majority of medicine use occurs in primary care, the safe use of medicines in 
secondary care, and at transitions of care, continue to be areas of attention7 213, 
together with ongoing calls for hospital pharmacy services to operate more efficiently 
and safely36. The work presented in this thesis therefore remains as topical and 
relevant as when first proposed in 2015. 
A summary of the key findings of this research are described below, together with a 
high level comparison with previous literature, a summary of the overall strengths and 
limitations, and the implications for practice and for further research. 
11.1 Summary of key findings 
The aim of this research was to develop a prediction tool, the Medicines Optimisation 
Assessment Tool (MOATTM), to target patients most in need of pharmacists’ input while 
in hospital; this was driven by a desire to increase the efficiency of hospital pharmacy 
services, reduce risks and improve patient outcomes.  
One hundred and eighteen potential prognostic factors, also known as candidate 
predictors, were identified from previous research and an expert survey, and 18 pre-
selected for MOAT development. Among 1,503 eligible patient admissions, 894 
(59.5%) experienced at least one medication related problem (MRP), with 610 (40.6%) 
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experiencing the study’s outcome event, namely at least one moderate or severe 
preventable MRP (MSP MRP). A prognostic model was developed using multivariable 
logistic regression to determine the relationship between candidate predictors and 
patients with an outcome event, and used to develop an electronic clinical decision aid, 
the MOAT. The predictive performance of the MOAT was fair (concordance index 
0.66), and calibration was good. Three risk groups were created to categorise patients 
as low, medium or high-risk of experiencing an MSP MRP. The decision threshold for 
‘low’ and ‘medium-risk’ patients has a sensitivity of 90% (specificity 30%); the 
sensitivity for the threshold between ‘medium’ and ‘high-risk’ patients is 66% (specificity 
61%). Decision curve analysis suggests that the MOAT has potential to be clinically 
useful across a wide range of predicted risk probabilities (from approximately 15% to 
70%). The MOAT was assessed in terms of content validity, ease of use, acceptability 
of the time taken to use the tool, and acceptability of the false negative rate; results 
suggest the MOAT is clinically credible, and has potential to increase the efficiency of 
hospital pharmacy services by identifying the 22% of patients least likely to experience 
an MSP MRP. 
11.2 Comparison with previous literature  
The literature review performed for this study (chapter 3) found that no 
methodologically sound prognostic model to target hospital patients based on their risk 
of MSP MRPs currently exists. Twelve prediction tools for adverse medication-related 
outcomes were reviewed; five were developed using consensus methods46 48-51, and of 
the seven statistically derived tools, three predict adverse drug reactions (ADRs)41 42 43, 
two predict adverse drug events (ADEs)44 45, one predicts medication errors (MEs)47, 
and one predicts MRPs52. The prognostic models developed by Nguyen et al47 and 
Urbina et al52, designed to target patients at risk of MEs and MRPs respectively, are 
potentially the most similar to the present study in terms of outcome event (given that 
MEs are a subset of MRPs). Despite this, key differences exist in terms of the 
modelling strategies used, which limit direct comparison with the present study. Clinical 
usefulness, assessed using decision curve analysis, was not reported for any of the 
existing statistically derived tools. 
The MRP prevalence for the present study was found to be 59.5%, which is consistent 
with previous research (52% to 81%72 78 90). While no estimation of the prevalence of 
MSP MRPs exists, Blix et al78 reported that 49.6% of MRPs identified during their study 
were ‘extremely important or major’. Although the severity grading system used by Blix 
et al is not directly comparable with the present study, the proportion of MRPs that may 
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be considered to be ‘clinically significant’ is broadly comparable, with 44.2% of MOAT 
MRPs being found to be ‘moderate or severe’ (overall prevalence of MSP MRPs 
40.6%). 
11.3 Strengths and limitations 
A strength of this research has been adherence with recommendations of the 
PROGnosis RESearch Strategy (PROGRESS) partnership53 55, Transparent Reporting 
of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) 
statement94, and CHecklist for critical Appraisal and data extraction for systematic 
Reviews of prediction Modelling Studies (CHARMS)60, at all stages of MOAT 
development, from initial study design to statistical analysis and assessment of model 
performance. Other strengths include the: 
 inclusion of two study sites with markedly different patient demographics, 
potentially increasing the generalisability of the MOAT; 
 use of MSP MRPs as the outcome event for the MOAT, so aligning the MOAT with 
pharmaceutical care practice, enhancing clinical credibility, clinical relevance, and 
feasibility of implementation in terms of workload for pharmacists; 
 inclusion of 1,503 study admissions with 610 outcome events, resulting in 18 
‘events per variable’ (EPV), which is significantly above the ‘rule of thumb’ of at 
least 10 EPV (to address the risk of model overfitting92);  
 robustness of definitions and data collection procedures for the outcome event and 
candidate predictors, increasing reliability and reproducibility94; 
 use of internal validation and adjustment for optimism, improving potential 
predictive accuracy of the MOAT when used in a new group of patients70 94; 
 development of an electronic decision aid to simplify use, and indicate a course of 
action70 94; 
 creation of two decision thresholds for the MOAT, permitting flexible prioritisation 
based on clinical risk and workforce capacity; 
 use of ‘expert opinion’ to inform selection of candidate predictors, validate and 
severity rate MRPs, select decision thresholds for the MOAT’s risk categories, and 
assess clinical credibility of the MOAT. 
A limitation of the study is the possible underestimation of the prevalence of MRPs. As 
discussed in chapter 7, pharmacists at the study sites identified approximately 85% of 
MRPs as part of a simulated MRP identification assessment exercise. While a 
percentage agreement of 80% may be considered acceptable in health research164, 
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identification of less than 100% of outcome events may be subject to criticism, 
highlighting the need for robust external validation of the MOAT, including the possible 
need for updating or recalibratation94. 
Other limitations include the: 
 exclusion of predictors that are not routinely measured / recorded in clinical 
practice, have low prevalence, or potential measurement error (due to the potential 
for inaccurate results60 63 95). For example, it was not possible to model ‘non-
compliance with medication’ as this is not routinely assessed or recorded, and has 
potential for measurement error. Similarly, high-risk medicines, such as cytotoxics, 
could not be included as an individual category due to infrequent use. While it may 
be appropriate to omit predictors if their effect cannot be reliably estimated70, data 
on which predictors were excluded from the analysis will need to be shared with 
MOAT users to inform implementation; 
 observational nature of the study, meaning data collection was not carried out 
under strict trial conditions. While this may have impacted on the robustness of 
data collection, it permitted the MOAT to reflect clinical practice in terms of MRP 
identification, and ensured use of routinely recorded predictor data; 
 presence of missing predictor data, and subsequent use of multiple imputation. 
While this is a potential source of bias, a sensitivity analysis suggested data were 
missing at random (MAR), therefore multiple imputation was less likely to introduce 
selection bias than complete-case analysis94 148, in addition to being statistically 
more efficient62; 
 use of simplified categorisation of predictors. This prevented detailed analysis (for 
example of individual classes of medicines such as insulins) but was necessary to 
reduce the risk of overfitting (associated with the use of high numbers of variables 
in model development60 62 94);  
 trade-off between sensitivity and specificity of the MOAT217. To achieve a sensitivity 
of 90% (i.e. the decision threshold between ‘low’ and ‘medium-risk’ patients) the 
MOAT’s has a relatively low specificity (30%). The specificity for the threshold 
between ‘medium’ and ‘high-risk’ patients is higher (61%), but at the expense of 
lower sensitivity (66%). While no predictive model is perfectly accurate217, further 
work will be required to investigate the acceptability of the MOAT’s false negative 
rate, and the impact on clinical confidence; 
 need for external validation to establish generalisability, both within the United 
Kingdom and more widely. 
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11.4 Interpretation  
This research was successful in meeting it proposed objectives, culminating in 
development of the MOAT, and assessment of its predictive performance and clinical 
credibility. To the best of my knowledge, the MOAT is the first evidence-based clinical 
prioritisation tool to identify patients most in need of pharmacists’ input in terms of their 
risk of MSP MRPs. Results suggest the predictive accuracy, clinical usefulness and 
clinical credibility of the MOAT are acceptable, providing evidence to justify further 
development. 
Given the above limitations, subsequent research may be able to improve on the 
present study through use of alternative data collection methods that increase the 
identification rate for MRPs, and reduce the occurrence of missing predictor data. The 
inclusion of a larger study sample may also permit use of more complex categorisation 
of predictors. 
11.5 Implications for practice  
It is not possible to advocate routine use of the MOAT prior to completion of external 
validation; impact and implementation studies will also be needed206. Subject to 
completion of this work, the MOAT has potential to be applicable to adult hospitalised 
medical patients (general, acute, and elderly medicine), irrespective of age. Given the 
diverse characteristics of the sample population (section 6.4.2), the MOAT has 
potential applicability to a wide range of patients in terms of age, ethnicity, 
comorbidities and presenting medical conditions.   
As discussed in chapter 10, introduction of the MOAT may require the development of 
implementation strategies regarding the level of pharmacy input required by patients 
dependent on their risk categorisation. This may have implications for hospital 
pharmacy managers and others, who will need to consider the approach to risk 
management and governance that may be needed.  
11.6 Implications for further research  
Extensive external validation, involving prospective validation in a new cohort, will be 
required to further assess accuracy and generalisability before routine use of the 
MOAT could be recommended55. External validation will also provide opportunity to 
refine the MOAT in terms of improving the accuracy such as by updating the model55 
218, and/or simplifying the scoring system.  
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Following external validation, impact and implementation studies will be required to 
establish whether the MOAT has advantages over current practice, is compatible with 
(and can easily be incorporated into) practice, has the potential to change pharmacists’ 
behaviour, has a positive impact on patient outcomes, and is cost effective206. In terms 
of compatibility with practice, various potential implementation strategies were 
discussed in chapter 10. These include use of the MOAT to determine the level of 
pharmacy review required by individual patients, and combining the MOAT with other 
triggers for pharmacy review, for example, swallowing difficulties, end of life care, or 
risk of MRPs post discharge; potentially the MOAT could then be used as part of a 
suite of tools, permitting prioritisation of patients, and appropriate allocation of workload 
between team members based on skills and expertise. 
Other potential future developments for the MOAT include: 
 development of separate risk prediction tools that are specific to different stages of 
a ‘patient stay’ in hospital (as discussed in chapter 8); 
 integration of the MOAT into automated systems such as electronic health records 
systems. This could result in the ability to perform accurate, automated risk 
assessments in ‘real-time’, which would further support implementation into clinical 
environments; 
 assessment of the transportability of the MOAT (i.e. the ability to produce accurate 
predictions among people drawn from different but plausibly related populations219, 
such as surgical patients, or patients in care homes). This may require model 
adjustment, or development of new prognostic models. 
11.7 Overall conclusion  
Overall this thesis has extended current knowledge in the field of clinical prioritisation 
through development of a methodologically sound prognostic model, the MOAT, to 
target hospital patients most in need of pharmacists’ input. To my knowledge, this is 
the first prognostic model to identify hospitalised medical patients at risk of MSP MRPs.  
In addition, this research has created knowledge that may inform future studies in this 
field, including: 
 identification of potential risk factors associated with the occurrence of MRPs in 
hospitalised patients, using both theoretical knowledge and expert opinion; 
 the prevalence of MRPs and MSP MRPs in hospitalised UK patients; 
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 quantification of the potential variability in MRP identification by hospital 
pharmacists; 
 consensus views of practising pharmacy clinicians on the requirements of a 
predictive tool, including presentation and usability. 
Extensive external validation, involving prospective validation in a new cohort, will be 
required to further assess accuracy and generalisability of the MOAT before routine 
use can be recommended. Further research will also be required in terms of impact 
and implementation studies to assess the extent to which use of the MOAT may affect 
decision making, improve efficiency or improve health outcomes. 
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Appendices 
Appendix A2.1: Waterlow score 
                           
 
Waterlow J. Waterlow Pressure Ulcer Prevention/Treatment Policy 2005 [Available from: http://www.judy-
waterlow.co.uk/downloads/Waterlow%20Score%20Card-front.pdf]  
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Appendix A3.1: CHARMS guidance on key items to guide the 
framing of the review aim, search strategy, and study inclusion 
and exclusion criteria 
        
Moons KGM, de Groot JAH, Bouwmeester W, Vergouwe Y, Mallett S, et al. (2014) Critical Appraisal and 
Data Extraction for Systematic Reviews of Prediction Modelling Studies: The CHARMS Checklist. PLOS 
Medicine 11(10): e1001744. https://doi.org/10.1371/journal.pmed.1001744 
Copyright: © 2014 Moons et al. This is an open-access article distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original 
author and source are credited. 
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Appendix A3.2: Search strategy for EMBASE 
Search performed August 2015: 
Adverse medication-related outcomes 
1. EMBASE; "med* related problem*".ti,ab; 555 results 
2. EMBASE; "drug related problem*".ti,ab; 1752 results 
3. EMBASE; exp ADVERSE DRUG REACTION/; 353726 results 
4. EMBASE; "med* harm".ti,ab; 78 results 
5. EMBASE; 1 OR 2 OR 3 OR 4; 355474 results 
Prognostic factors/prediction tools 
6. EMBASE; "clinical dec* rule*".ti,ab; 804 results 
7. EMBASE; "clinical dec* tool*".ti,ab; 114 results 
8. EMBASE; "predict* tool*".ti,ab; 4094 results 
9. EMBASE; "predict* rule*".ti,ab; 2134 results 
10. EMBASE; "prognos* model*".ti,ab; 3650 results 
11. EMBASE; "prognos* tool*".ti,ab; 3354 results 
12. EMBASE; exp RISK FACTOR/; 693724 results 
13. EMBASE; "risk model*".ti,ab; 4977 results 
14. EMBASE; "risk tool*".ti,ab; 301 results 
15. EMBASE; "prognos* factor".ti,ab; 40678 results 
16. EMBASE; "predict* variable*".ti,ab; 9659 results 
17. EMBASE; 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16; 
755086 results 
18. EMBASE; 5 AND 17; 15569 results 
Hospital 
19. EMBASE; hospital*.ti,ab; 1240321 results 
20. EMBASE; 18 AND 19; 2033 results 
 
Additional search performed November 2015 to include medication errors:  
Medication error terms 
1. EMBASE; exp MEDICATION ERROR/; 14068 results. 
2. EMBASE; "prescrib* error*".ti,ab; 893 results. 
3. EMBASE; "drug* error*".ti,ab; 461 results. 
Prognostic factors/prediction tools 
4. EMBASE; exp RISK FACTOR/; 714881 results. 
5. EMBASE; "predict* model*".ti,ab; 24866 results. 
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6. EMBASE; "risk model*".ti,ab; 5253 results. 
7. EMBASE; "predict* tool*".ti,ab; 4305 results. 
8. EMBASE; "clinical dec* tool".ti,ab; 77 results. 
9. EMBASE; "clinical dec* rule".ti,ab; 490 results. 
10. EMBASE; "predict* rule*".ti,ab; 2195 results. 
11. EMBASE; "prognos* model*".ti,ab; 3854 results. 
12. EMBASE; "prognos* tool*".ti,ab; 3548 results. 
13. EMBASE; "risk tool*".ti,ab; 324 results. 
14. EMBASE; "prognos* factor*".ti,ab; 99002 results. 
14. EMBASE; "predict* variable*".ti,ab; 9985 results. 
15. EMBASE; 1 OR 2 OR 3; 14693 results. 
16. EMBASE; 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14; 
848238 results. 
17. EMBASE; 16 AND 17; 691 results. 
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Appendix A3.3: QUIPS risk of bias assessment tool 
        
Hayden JA, van der Windt DA, Cartwright JL, et al. ASsessing bias in studies of prognostic factors. Annals 
of Internal Medicine 2013;158(4):280-86. doi: 10.7326/0003-4819-158-4-201302190-00009* 
* Permission to use this image obtained from Annals of Internal Medicine   
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Appendix A3.4: CHARMS checklist for critical appraisal and 
data extraction for systematic reviews of prediction modelling 
studies 
 
Moons KGM, de Groot JAH, Bouwmeester W, Vergouwe Y, Mallett S, et al. (2014) Critical Appraisal and 
Data Extraction for Systematic Reviews of Prediction Modelling Studies: The CHARMS Checklist. PLOS 
Medicine 11(10): e1001744. https://doi.org/10.1371/journal.pmed.1001744 
Copyright: © 2014 Moons et al. This is an open-access article distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original 
author and source are credited. 
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Appendix A3.5: Literature review – table of study 
characteristics 
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Continued from previous page… 
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Appendix A3.6: Risk of bias assessment for prognostic factor 
studies using QUIPS tool 
Source Domains Ratings 
Bates et al. 
(1999)
76
 
 
Study 
participation 
Moderate  
 (Intensive care units intentionally oversampled which may 
skew data; no explanation of how the 2 study sites selected) 
Study attrition Low 
Prognostic 
factor 
measurement 
Moderate 
(Cut-points / categorisation used for laboratory results; 
proportion of patients with missing data not reported) 
Outcome 
measurement 
Low 
Study 
confounding 
N/A (exploratory study) 
Statistical 
analysis & 
reporting 
Low 
Van den 
Bemt et al. 
(2000)
77
 
 
Study 
participation 
Moderate 
 (Relatively small sample; no description of included versus 
excluded wards, or reasons for selecting the 2 study sites) 
Study attrition Low 
Prognostic 
factor 
measurement 
Moderate 
(Age and number of medicines categorised during data 
collection; timing of data collection in relation to admission 
not stated; proportion of patients with missing data not 
reported) 
Outcome 
measurement 
Moderate 
 (Outcome data collected from spontaneous reports from 
doctors & nurses, & from interviews with patients - therefore 
may not be comprehensive (in terms of reliability of 
spontaneous reporting, & ability of patients to correctly 
identify ADEs). This is shown by limited overlap (11%) 
among all 3 sources; no information given regarding the 
number of patients unable to be interviewed due to 
communication difficulties) 
Study 
confounding 
N/A (exploratory study) 
Statistical 
analysis & 
reporting 
Low 
Blix et al. 
(2004)
78
 
 
Study 
participation 
Moderate  
(Relatively small sample; no description of included versus 
excluded wards) 
Study attrition Low 
Prognostic 
factor 
measurement 
Moderate 
(A number of prognostic factors were considered together as 
‘clinical / pharmacological’ factors therefore the impact of 
individual factors cannot be assessed; timing of data 
collection in relation to admission not stated; cut-points used 
for quantitative data; proportion of patients with missing data 
not reported) 
Outcome 
measurement 
Low 
Study N/A (exploratory study) 
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confounding 
Statistical 
analysis & 
reporting 
Moderate 
(Limited data presented to assess the adequacy of the 
analytic strategy) 
Evans et al. 
(2005)
79
 
 
Study 
participation 
Low 
Study attrition Low 
Prognostic 
factor 
measurement 
Moderate 
(Cut-points used for renal function; timing of data collection 
for ‘concomitant drugs’ unclear in relation to admission; 16% 
of data missing – imputed using multiple regression 
imputation) 
Outcome 
measurement 
Moderate 
(Retrospective study over a 10-year period therefore data not 
collected for study purpose which may affect the reliability of 
outcome data (i.e. only pharmacist verified ADEs included in 
the analysis, but no information provided on the number of 
ADE alerts generated but not pharmacist verified) 
Study 
confounding 
N/A (exploratory study) 
Statistical 
analysis & 
reporting 
Moderate 
(Continuous variables only categorised if linearity not 
supported – but unclear how categories selected) 
Johnston et 
al. (2006)
80
 
 
Study 
participation 
Low 
Study attrition Low 
Prognostic 
factor 
measurement 
Moderate 
(Categorisation used for age; timing of data collection in 
relation to admission not stated; proportion of patients with 
missing data not reported) 
Outcome 
measurement 
Moderate 
(Data collected using voluntary reporting & analysed 
retrospectively, which may limit reliability of data collection; 
reports excluded if patient unidentifiable, or insufficient details 
provided – no information provided on the number excluded 
for these reasons) 
Study 
confounding 
N/A (exploratory study) 
Statistical 
analysis & 
reporting 
Moderate 
(Limited data presented to assess the adequacy of the 
analytic strategy; 93 prognostic factors identified for initial 
analysis & recursive partitioning used to reduce number prior 
to conducting regression analysis; authors acknowledge that 
‘drugs not included in the study may have proven to be good, 
if not better, indicators of the outcome’) 
Zopf et al 
(2008)
81
 
 
Study 
participation 
Moderate  
 (Relatively small sample; no explanation of how the 2 study 
sites selected; no description of dates / duration of data 
collection) 
Study attrition Low 
Prognostic 
factor 
measurement 
Moderate 
(Prognostic factor data collected at admission therefore does 
not account for changes during the admission; unclear 
definition for ‘number of drugs during hospital stay’; 
proportion of patients with missing data not reported) 
Outcome 
measurement 
Low 
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Study 
confounding 
N/A (exploratory study) 
Statistical 
analysis & 
reporting 
Moderate 
(Prognostic factors selected for the multivariable regression 
based on univariable analysis) 
Davies et al. 
(2009)
82
 
 
Study 
participation 
Low 
Study attrition Low 
Prognostic 
factor 
measurement 
Low 
 
Outcome 
measurement 
Low 
Study 
confounding 
N/A (exploratory study) 
Statistical 
analysis & 
reporting 
Moderate 
(Prognostic factors selected for the Cox regression based on 
univariable analysis; multivariable analysis carried out for 
10% of patients (i.e. 374)) 
Zaal et al. 
(2010)
83
 
 
Study 
participation 
Moderate  
(Relatively small sample; no description of included versus 
excluded wards) 
Study attrition Low 
Prognostic 
factor 
measurement 
Moderate 
(Cut-point used for renal function; unclear definition for 
‘number of medication orders during hospital stay’; timing of 
data collection in relation to admission not stated; proportion 
of patients with missing data not reported) 
Outcome 
measurement 
Moderate 
(Only prescribing and transcribing errors recorded as 
outcomes for this study; inappropriate drug choices not 
actively assessed & only included were obvious)  
Study 
confounding 
N/A (exploratory study) 
Statistical 
analysis & 
reporting 
Moderate 
(Study compared medication errors that ‘cause harm’ with 
those that ‘do not cause harm’, but only limited conclusions 
could be drawn due to the limited power for errors leading to 
harm; prognostic factors selected for the multivariable 
regression based on univariable analysis) 
Munoz-
Torrero et al. 
(2010)
84
 
 
Study 
participation 
Moderate  
 (Relatively small sample; no description of included versus 
excluded wards; no explanation of how the 2 study sites 
selected) 
Study attrition Low 
Prognostic 
factor 
measurement 
Moderate 
(Cut-points used for number of drugs, number of drugs with 
interaction, & serum albumin; timing of data collection in 
relation to admission not stated; proportion of patients with 
missing data not reported) 
Outcome 
measurement 
Low 
Study 
confounding 
N/A (exploratory study) 
Statistical 
analysis & 
reporting 
Moderate 
(Cut-point used to assess impact of a change in renal 
function during hospitalisation (>20%); prognostic factors 
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selected for the multivariable regression based on univariable 
analysis) 
Dequito et al. 
(2011)
85
 
 
Study 
participation 
Moderate  
 (Relatively small sample; no description of included versus 
excluded wards; no explanation of how the 2 study sites 
selected) 
Study attrition Low 
Prognostic 
factor 
measurement 
Moderate 
(Timing of data collection in relation to admission not stated; 
unclear definition for ‘number of medication orders’; 
proportion of patients with missing data not reported) 
Outcome 
measurement 
Low 
Study 
confounding 
N/A (exploratory study) 
Statistical 
analysis & 
reporting 
Moderate 
(Prognostic factors selected for the multivariable regression 
based on univariable analysis) 
Ben-Yehuda 
et al. 
(2011)
86
 
 
Study 
participation 
Moderate  
 (Relatively small sample with cases matched 1:1 with 
controls; no description of included versus excluded wards) 
Study attrition Low 
Prognostic 
factor 
measurement 
Moderate 
(Data on ‘number of medications’ collected at admission 
therefore does not account for changes during the admission; 
comorbidity score & number of medications categorised; 
proportion of patients with missing data not reported) 
Outcome 
measurement 
Moderate 
(Outcomes identified during twice weekly routine review of 
patients’ charts & nurses’ notes by investigators. This could 
result in missing data e.g. due to patient discharges, events 
that occur between scheduled review visits, or poor 
documentation in nursing records) 
Study 
confounding 
N/A (exploratory study) 
Statistical 
analysis & 
reporting 
Moderate 
(Prognostic factors selected for the multivariable regression 
based on univariable analysis) 
Beckett et al. 
(2012)
87
 
 
Study 
participation 
Moderate  
 (Relatively small sample with cases matched 1:1 with 
controls; controls randomly selected (i.e. matched based on 
severity of medication error only); no description of included 
versus excluded hospitals) 
Study attrition Low 
Prognostic 
factor 
measurement 
Moderate 
(Cut-points used for quantitative data; timing of data 
collection in relation to admission variable; proportion of 
patients with missing data not reported) 
Outcome 
measurement 
High 
(Outcome data collected from voluntary reporting system) 
Study 
confounding 
N/A (exploratory study) 
Statistical 
analysis & 
reporting 
Moderate 
(Prognostic factors selected for the multivariable regression 
based on univariable analysis; only factors with ‘sufficient 
entries in the data categories’ were included in the analysis) 
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O’Connor et 
al. (2012)
88
 
 
Study 
participation 
Moderate  
 (Relatively small sample) 
Study attrition Low 
Prognostic 
factor 
measurement 
Low 
Outcome 
measurement 
Low 
Study 
confounding 
N/A (exploratory study) 
Statistical 
analysis & 
reporting 
Moderate 
(Prognostic factors selected for the multivariable regression 
based on univariable analysis; age, renal function & liver 
disease categorised for analysis) 
Sikdar et al. 
(2012)
89
 
 
Study 
participation 
Low 
Study attrition Low 
Prognostic 
factor 
measurement 
Moderate 
 (Data on the ‘number of drugs’ not available for analysis as 
drug data not recorded in hospital database, therefore only 
descriptive analysis of drugs causing outcome available; 
comorbidity score categorised) 
Outcome 
measurement 
High 
(Outcomes obtained from hospital coding data (i.e. external 
causes of injury associated with the use of drug) therefore 
reliant on the quality of coding; study focussed on the most 
severe outcomes, which represent a small proportion of 
overall ADRs)  
Study 
confounding 
N/A (exploratory study) 
Statistical 
analysis & 
reporting 
Moderate 
(Categorisation used for age ranges) 
Wilmer et al. 
(2015)
90
 
 
Study 
participation 
High 
(Very small sample (131 patients); no description of included 
versus excluded wards; no inclusion / exclusion criteria 
given) 
Study attrition Low 
Prognostic 
factor 
measurement 
Moderate 
(Cut-points used for quantitative data; timing of data 
collection in relation to admission not stated; proportion of 
patients with missing data not reported) 
Outcome 
measurement 
High 
(Method to identify outcomes not stated; outcome 
assessments performed by different physicians / pharmacists 
due to organisational limitations) 
Study 
confounding 
N/A (exploratory study) 
Statistical 
analysis & 
reporting 
Moderate 
(Limited data presented to assess the adequacy of the 
analytic strategy) 
Ashcroft et 
al. (2015)
91
 
 
Study 
participation 
Low 
Study attrition N/A (patient follow-up not required) 
Prognostic 
factor 
Moderate 
(Proportion of patients with missing data not reported) 
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measurement 
Outcome 
measurement 
Low 
Study 
confounding 
N/A (exploratory study) 
Statistical 
analysis & 
reporting 
Moderate 
(Limited data presented to assess the adequacy of the 
analytic strategy) 
Ayalew et al. 
(2015)
72
 Study 
participation 
Moderate  
 (Small sample; no details of number/details of patients who 
refused to participate; patients excluded if length of stay 
under 48 hours) 
Study attrition Low 
Prognostic 
factor 
measurement 
Moderate 
(Limited data on definitions used; number of medicines 
categorised during data collection; timing of data collection in 
relation to admission not stated; proportion of patients with 
missing data not reported) 
Outcome 
measurement 
Moderate 
(MRPs identified remotely by researchers using standard 
reference databases i.e. not identified by routine care team;  
no description of clinical relevance of MRPs e.g. drug 
interactions accounted for 48% of all MRPs – unclear if these 
were restricted to those that are clinically relevant)  
Study 
confounding 
N/A (exploratory study) 
Statistical 
analysis & 
reporting 
Moderate 
(Limited data presented to assess the adequacy of the 
analytic strategy) 
Lenssen et 
al. (2016)
73
 
 
Study 
participation 
Moderate  
 (Relatively small sample; no description of included versus 
excluded wards; unclear if all consecutive admissions 
included) 
Study attrition Low 
Prognostic 
factor 
measurement 
Moderate 
(Unclear definition used for ‘number of drugs’; timing of data 
collection in relation to admission not stated; proportion of 
patients with missing data not reported) 
Outcome 
measurement 
Moderate 
(Outcomes only recorded if action taken by healthcare team 
to implement advice (i.e. 77% of recommendations)) 
Study 
confounding 
N/A (exploratory study) 
Statistical 
analysis & 
reporting 
Low 
N/A = not applicable   
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Appendix A3.7: Risk of bias assessment for prognostic model 
studies using CHARMS tool 
The CHARMS assessment for each prognostic study is shown below: 
Domain Key items Onder et al.41 
DATA 
SOURCE 
Source of data  Retrospective cohort 
P
A
R
T
IC
IP
A
N
T
S
 
Participant eligibility 
and recruitment 
method  
Patients receiving at least 1 medication during hospital stay. 
Patients receiving anticancer medication excluded (total 61). 
Written consent required (no details given on patients who 
refused to consent). 
Participant 
description 
65 years and over; community & university-based hospitals 
throughout Italy (part of the GIFA database). 
Study dates September-October 1993, 1995 & 1997. 
O
U
T
C
O
M
E
(S
) 
T
O
 B
E
 P
R
E
D
IC
T
E
D
 
Definition and 
method for 
measurement of 
outcome 
Outcome & method for measurement clearly defined.  
Definite & probable ADRs (using Naranjo algorithm, score 5-
12 points).  
All wards visited daily by study physicians, who spoke to 
nurses & doctors, & examined medical & nursing records. 
Verification of ADEs not discussed. 
Same outcome 
definition (and 
measurement) 
used in all patients? 
Definition the same, but details of inter-rater reliability among 
study physicians not stated.  
No further consensus validation. 
Type of outcome  Single endpoint (ADR). 
Blinding used? 
Assume not, as all data (outcomes and predictors) collected 
by study physicians. 
Predictors part of 
outcome? 
No 
Time of outcome 
occurrence  
During admission 
C
A
N
D
ID
A
T
E
 P
R
E
D
IC
T
O
R
S
 
Number and type of 
predictors  
Data collected on medication use (but individual drug classes 
not included in the modelling), diagnoses, anaemia, renal  
function, nutritional status, activity of daily living disability, 
falls, history of ADRs, number of comorbid conditions, heart 
failure, & liver disease.  
Definition and 
method for 
measurement of 
candidate 
predictors 
Unclear how nutritional status scored (assessed by 
measuring body mass index & serum albumin).  
No details of definition used for comorbid conditions, heart 
failure or liver disease.  
Details of inter-rater reliability among study physicians not 
stated.  
Drugs classified according to ATC system. 
Timing of predictor 
measurement  
Not stated 
Blinding used? 
Assume not for development study as all data (outcomes and 
predictors) collected by study physicians.  
Validation study: all data collected by study physicians, but 
'physicians not informed regarding variables entered in risk 
score'. 
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Handling of 
predictors in the 
modelling  
Categorisation used for number of medicines, with '≤5', & '5-
7' used (i.e. overlap between categories). 
Dichotomisation used for all other variables (anaemia, renal 
failure, activity of daily living disability, falls, number of 
comorbid conditions, heart failure, liver disease, & previous 
ADRs). 
S
A
M
P
L
E
 
S
IZ
E
 
Number of 
participants & 
outcomes / events 
Development study: 5936 participants; 383 outcomes (6.5%). 
Events Per Variable 
(EPV) 
Unable to determine as the number of candidate predictors, 
indicator variables, transformations, and interaction terms not 
stated. EPV appears to be >10. 
M
IS
S
IN
G
 D
A
T
A
 
Number of 
participants with 
any missing value  
Not stated 
Number of 
participants with 
missing data for 
each predictor 
Not stated 
Handling of missing 
data 
Not stated 
M
O
D
E
L
 D
E
V
E
L
O
P
M
E
N
T
 
Modelling method  Logistic regression 
Modelling 
assumptions 
satisfied 
Binary dependent variable used, & observations independent 
(i.e. no paired data), but no details regarding potential 
multicollinearity.  
Not stated if continuous variables checked for linearity.                                                                                                              
Method for 
selection of 
predictors for 
inclusion in 
modelling  
Univariable analysis used; variables added & retained in 
model if  P≤0.1 
Method for 
selection of 
predictors during 
modelling  
Stepwise logistic regression (not stated if forward or 
backwards selection), predictors added & retained if P≤0.1 
Shrinkage used? Not performed 
M
O
D
E
L
 
P
E
R
F
O
R
M
-
A
N
C
E
 Calibration and 
Discrimination   
Calibration not assessed. Discrimination reported as the area 
under the ROC curve.   
Area under ROC curve 0.71 (95% CI 0.68-0.73). 
Classification 
measures 
Internal validation: sensitivity 68%, specificity 65% using a 
cut-point score between 3 & 4 (not selected a priori). 
M
O
D
E
L
 
E
V
A
L
U
A
T
IO
N
  Method used for 
testing model 
performance 
Prospective validation study of 483 patients from 4 university 
hospitals in Europe, September-December 2008.  
Exclusion criteria <65 years & refused consent.  
Outcome frequency 11.6% (i.e. 56 outcomes). 
Area under ROC curve 0.70 (95% CI 0.63-0.78). 
In case of poor 
validation, model 
adjusted? 
N/A 
R
E
S
U
L
T
S
 
Final and other  
multivariable 
models  
Odds ratios and confidence intervals given for variables 
retained in multivariable analysis.  
Regression equation not given.   
Appendices 
 
311 
 
 
ADR = adverse drug reaction, GIFA = Gruppo Italiano di Farmacoepidemiologia nell'Anziano 
(Italian Group of Pharmacoepidemiology in the Elderly), ROC = receiver-operating 
characteristic, ATC = Anatomical Therapeutic Chemical, CI = confidence interval, N/A = not 
applicable 
 
  
Any alternative 
presentation of the 
final prediction 
models? 
Sum score developed, with risk score assigned to each 
variable based on odds ratio.  
Final risk score based on 6 factors: ≥ 4 comorbid conditions, 
heart failure, liver disease, number of drugs (≤5, 5-7, ≥8), 
previous ADR, & renal failure.  
Scoring varies with factor. 
Comparison of the 
distribution of 
predictors for 
development and 
validation datasets 
Frequency / distributions not given, but in the discussion it 
states that the validation group were 'sicker' i.e. 'older, had 
more comorbid conditions, and had a higher rate of ADRs'. 
IN
TE
R
P
R
ET
A
TI
O
N
 A
N
D
 
D
IS
C
U
SS
IO
N
 
Interpretation of 
presented models  
Further studies needed to validate tool in different 
populations & settings. 
Comparison with 
other studies, 
discussion of 
generalizability, 
strengths and 
limitations. 
Results compared with other prognostic studies.  
Strength: first study to identify high-risk patients; size of 
database used; assessment of ADRs done by study 
personnel during hospital stay.  
Limitations: data on preventability not recorded; results not 
generalisable to younger adults, or persons living in the 
community; prescribing patterns & disease burden differ by 
country; data collected between 1993 & 1997. 
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Domain Key items Tangiisuran et al.42 
DATA 
SOURCE 
Source of data  Prospective cohort 
P
A
R
T
IC
IP
A
N
T
S
 
Participant eligibility 
and recruitment 
method  
All patients 'systematically enrolled' therefore assume 
consecutive admissions.  
Excluded when self-poisoning suspected, patient transferred 
to another ward during weekend, admitted & discharged 
during weekend, died within 24 hours of admission, or 
medical notes not available for further investigation.  
Written consent required (no details on patients who refused 
to consent). 
256 excluded from final analysis as younger than 65, 111 as 
discharged or died before end of study period (no mention of 
other exclusions). 
Participant 
description 
Patients 65 years and over admitted to 4 care of the elderly 
wards (2 elderly care, 2 stroke). 
Study dates January-March 2007 & January-March 2008. 
O
U
T
C
O
M
E
(S
) 
T
O
 B
E
 P
R
E
D
IC
T
E
D
 
Definition and 
method for 
measurement of 
outcome 
Outcome & method for measurement clearly defined. 
Patients reviewed by primary investigator using trigger tool. 
Data collected from procedure & emergency department 
notes, physician progress notes, laboratory reports, 
medication records, nursing flow sheets, hospital discharge 
records, & multidisciplinary progress notes. Additionally, 
reports from healthcare providers & incident reports included 
for further review.  
All ADRs discussed with attending physician & hospital 
pharmacist to confirm interpretation.  
Causality determined by review by investigator & 
independent reviewer using Hallas algorithm (categorised as 
definite, probable, possible or unlikely.  
Likert scale also used to assess confidence of relationship.  
Events classified as definite, probable or possible, with >50% 
confidence rating were classified as ADR cases. 
Same outcome 
definition (and 
measurement) 
used in all patients? 
Yes (definition same, all ADR data collected by principal 
investigator & verified with physician & pharmacist, & 
causality confirmed by consensus). 
Type of outcome  Single endpoint (ADR). 
Blinding used? 
Assume not, as all data (outcomes and predictors) collected 
by primary researcher. 
Predictors part of 
outcome? 
No 
Time of outcome 
occurrence  
During admission 
C
A
N
D
ID
A
T
E
 
P
R
E
D
IC
T
O
R
S
 
Number and type of 
predictors  
Data collected on demographics (age, gender, ethnic origin) 
diagnosis, details of previous admissions, length of stay, 
social setting (living alone, smoking, alcohol), disability 
(Barthel Index), cognitive status (Abbreviated Mental Test 
Score), biological markers, drug history, & comorbidities 
(using ICD-10 codes). 
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Definition and 
method for 
measurement of 
candidate 
predictors 
Definition only given for renal failure, disability, & cognitive 
status only. 
Timing of predictor 
measurement  
Obtained within 48 hours of admission. 
Blinding used? No (all data collected by researcher). 
Handling of 
predictors in the 
modelling  
Dichotomisation used for all variables. 
S
A
M
P
L
E
 S
IZ
E
 Number of 
participants & 
outcomes / events 
690 participants; 86 outcomes (12.5%). 
Events Per Variable 
(EPV) 
Unable to determine as the number of candidate predictors, 
indicator variables, transformations, and interaction terms not 
stated, but appears to be significantly <10 EPV. 
M
IS
S
IN
G
 D
A
T
A
 
Number of 
participants with 
any missing value  
Not stated 
Number of 
participants with 
missing data for 
each predictor 
Not stated 
Handling of missing 
data 
Not stated 
M
O
D
E
L
 D
E
V
E
L
O
P
M
E
N
T
 
Modelling method  Logistic regression 
Modelling 
assumptions 
satisfied 
Binary dependent variable used, & observations independent 
(i.e. no paired data).  
Selected variables assessed for multicollinearity (none 
found). Not stated if continuous variables checked for 
linearity.  
Method for 
selection of 
predictors for 
inclusion in 
modelling  
Univariable analysis used, predictors included in model if 
P<0.05. In addition, variables identified as being important in 
other studies with P<0.25 included.  
Variables present in <5% of study population omitted from 
analysis. 
Method for 
selection of 
predictors during 
modelling  
Backwards elimination with removal criteria set at P=0.1. 
Process then repeated with forward selection procedure. 
Shrinkage used? Not performed 
M
O
D
E
L
 
P
E
R
F
O
R
M
A
N
C
E
 
Calibration and 
Discrimination   
Hosmer-Lemeshow test to assess overall fit (found to be 
satisfactory) & effect size measured using Nagelkerke R
2 
(low, indicating small effect size).  
Discrimination reported as the area under the ROC curve.  
Area under ROC curve 0.74 (95% CI 0.68-0.79). 
Classification 
measures 
Internal validation: sensitivity 80%, specificity 55%. Cut-point 
score >1 (not selected a priori). 
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M
O
D
E
L
 E
V
A
L
U
A
T
IO
N
  
Method used for 
testing model 
performance 
Prospective validation study of 483 patients from 4 European 
centres (September 2008-December 2008).  
Exclusion criteria identical to development dataset, plus 
patients receiving chemotherapy.  
Naranjo algorithm rather than Hallas criteria.  
Only events classified as definite or probable (score ≥5) 
considered to be drug related.  
Pair assessment not conducted.  
Outcome frequency 11.6% (i.e. 56 outcomes). 
Sensitivity 84%, specificity 43% with cut-point score >1 
Area under ROC curve 0.73 (95% CI 0.66-0.80). 
In case of poor 
validation, model 
adjusted? 
N/A 
R
E
S
U
L
T
S
 
Final and other  
multivariable 
models  
Intercept, regression coefficients, odds ratios and confidence 
intervals given for variables retained in multivariable analysis.  
Any alternative 
presentation of the 
final prediction 
models? 
Results compared with other prognostic studies.  
Strength: first study to identify high-risk patients; size of 
database used; assessment of ADRs done by study 
personnel during hospital stay.  
Limitations: data on preventability not recorded; results not 
generalisable to younger adults, or persons living in the 
community; prescribing patterns & disease burden differ by 
country; data collected between 1993 & 1997. 
Comparison of the 
distribution of 
predictors for 
development and 
validation datasets 
Given for length of stay (12 versus 10 days), number of 
medicines (rather than ≥8 medicines), & hyperlipidaemia 
(12.2 versus 28%). Not given for white cell count. 
IN
TE
R
P
R
ET
A
TI
O
N
 A
N
D
 D
IS
C
U
SS
IO
N
 
Interpretation of 
presented models  
Model validated across continental Europe, showing it is a 
reasonable robust, & may be applied to patients from other 
geographical locations & perhaps different healthcare 
systems with similar demographics.  
Need to establish if clinical judgement alone is more 
accurate, also need to test usability, & if use of the model 
would improve safety, & whether they are any humanistic & 
cost implications. 
Comparison with 
other studies, 
discussion of 
generalizability, 
strengths and 
limitations. 
Discrimination comparable to Onder, sensitivity better, 
specificity lower, but Onder's model only considers definite & 
probable ADRs, whereas Tangiisuran included possible 
ADRs.  
Previous research identified age, previous ADR, gender, 
heart failure, prior bleeding on admission, renal impairment, 
use of certain drug classes, abnormal laboratory results as 
prognostic, but these not retained in their model.  
Strengths: Model simple to use, acceptable goodness of fit & 
good discrimination, good sensitivity, validation performed. 
Limitations: low specificity, length of stay is a posteriori 
observation, different casualty tool used for development & 
validation, may not be applicable to countries outside of 
Europe, risk of information bias. 
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Domain Key items Kiguba et al.43 
DATA 
SOURCE 
Source of data  Prospective cohort 
P
A
R
T
IC
IP
A
N
T
S
 
Participant eligibility 
and recruitment 
method  
Systematic random sampling procedure; 3 new admissions 
per day on long-stay wards, 6 per day on short stay wards. 
Eligibility criteria not stated.  
Written consent required (no details given on patients who 
refused to consent). 
Participant 
description 
18 years & over; 3 medical & 1 gynaecology ward. 
Study dates December 2013-April 2014. 
O
U
T
C
O
M
E
(S
) 
T
O
 B
E
 P
R
E
D
IC
T
E
D
 
Definition and 
method for 
measurement of 
outcome 
Outcome & measurement clearly defined.  
Possible and probable ADRs (using Naranjo algorithm, 
although cut-scores not stated). Possible ADRs included 
possible, probable & definite ADRs, probable included 
probably & definite.  
Data collected daily by 4 research teams (comprising doctor, 
pharmacist & nurse, who received training prior to study). 
Data captured from clinical notes, clinical examination & 
patient interviews.  
Consensus agreement on ADR causality reached by 
committee including principal author. 
Same outcome 
definition (and 
measurement) 
used in all patients? 
Partly (definition same, & ADRs verified with physician & 
pharmacist, & causality confirmed by consensus, but unclear 
whether inter-rater reliability checked among research 
teams). 
Type of outcome  Single endpoint (ADR). 
Blinding used? 
Assume not, as all data (outcomes and predictors) collected 
by research teams. 
Predictors part of 
outcome? 
No  
Time of outcome 
occurrence  
During admission 
C
A
N
D
ID
A
T
E
 P
R
E
D
IC
T
O
R
S
 
Number and type of 
predictors  
No details given on predictor data collected. 
Final models included age, gender, number of conventional 
medicines, Charlson's comorbidity index, preadmission 
herbal medicines use, HIV-positive serostatus, hospitalisation 
in previous 3 months & gynaecology ward.  
Data on drug use collected, and analysed to identify drug 
classes associated with ADRs, but do not appear to have 
been used in model development. 
Definition and 
method for 
measurement of 
candidate 
predictors 
No definitions given. 
Timing of predictor 
measurement  
Not stated 
Blinding used? No (all data collected by research teams). 
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Handling of 
predictors in the 
modelling  
Cut-points used for number of conventional medicines and 
comorbidity score.  
Interaction assessed for HIV status and the 6 categorical 
variables - interaction between Charlson's index & HIV 
retained in model for possible ADRs. 
S
A
M
P
L
E
 S
IZ
E
 
Number of 
participants & 
outcomes / events 
762 participants; 194 possible ADRs (25.5%), 87 probable 
ADRs (11.4%). 
Events Per Variable 
(EPV) 
Sample size calculated based on incidence of ADRs & 5% 
confidence interval.  
Unable to determine EPV as the number of candidate 
predictors not stated. If it is assumed that only the predictors 
included in the final model were used (i.e. 9 variables), EPV 
for possible ADRs = 21.5, EPV for probably ADRs = 9.7 
(assuming no indicator variables, transformations, and 
interaction terms used). 
M
IS
S
IN
G
 D
A
T
A
 
Number of 
participants with 
any missing value  
Not stated 
Number of 
participants with 
missing data for 
each predictor 
Not stated 
Handling of missing 
data 
Low frequency missing data for binary categorical variables 
set to 'no'. 
M
O
D
E
L
 D
E
V
E
L
O
P
M
E
N
T
 
Modelling method  Logistic regression 
Modelling 
assumptions 
satisfied 
Binary dependent variable used, & observations independent 
(i.e. no paired data), but no details regarding potential 
multicollinearity.   
Limited information on checks for linearity. They state that 
'results obtained for linearity were compared with those using 
categorisation by comparing log-likelihoods for regressors in 
logistic regression for natural logarithms of the odds on 
having experienced possible or probable ADR', but no results 
presented.  
Models stratified by HIV serostatus to assess for interaction 
with the 6 categorised predictors (significance level set at 1% 
level). 
Method for 
selection of 
predictors for 
inclusion in 
modelling  
Not stated 
Method for 
selection of 
predictors during 
modelling  
Not stated 
Shrinkage used? Not performed 
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HIV = human immunodeficiency virus, N/A = not applicable 
  
M
O
D
E
L
 
P
E
R
F
O
R
M
A
N
C
E
 
Calibration and 
Discrimination   
Not performed 
Classification 
measures 
Not stated 
M
O
D
E
L
 
E
V
A
L
U
A
T
IO
N
 Method used for 
testing model 
performance 
None 
In case of poor 
validation, model 
adjusted? 
N/A 
R
E
S
U
L
T
S
 
Final and other  
multivariable 
models  
Two regression models developed (for probable ADRs, and 
possible ADRs).  
Intercept, odds ratios and confidence intervals given for 
variable included in multivariable analysis.  
Basic regression equation given for both models.  
Final models included age, gender, number of conventional 
medicines, Charlson's comorbidity index, preadmission 
herbal medicines use, HIV-positive serostatus, hospitalisation 
in previous 3 months & gynaecology ward (despite not all 
being statistically associated).  
Statistical significant predictors of probable ADRs = use of ≥ 
6 conventional medicines & self-reported herbal medicine 
use. Statistical significant predictors of possible ADRs = use 
of ≥6 conventional medicines & self-reported herbal medicine 
use, hospitalisation in 3 months prior to admission, and 
gynaecology ward. 
Any alternative 
presentation of the 
final prediction 
models? 
No 
Comparison of the 
distribution of 
predictors for 
development and 
validation datasets 
N/A 
IN
TE
R
P
R
ET
A
TI
O
N
 
A
N
D
 D
IS
C
U
SS
IO
N
 
Interpretation of 
presented models  
More research needed to validate model. 
Comparison with 
other studies, 
discussion of 
generalizability, 
strengths and 
limitations. 
Limitations: 'number of conventional medicines' may include 
medicines received after ADR occurred, suggest could have 
used Cox proportional hazards to track daily changes; clinical 
examination (rather than laboratory investigations) used as 
main method to identify ADRs. 
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Domain Key items McElnay et al.44 
DATA 
SOURCE 
Source of data  Prospective cohort 
P
A
R
T
IC
IP
A
N
T
S
 
Participant eligibility 
and recruitment 
method  
Consecutive admissions.  
Inclusion criteria: unplanned admission, written consent, 
receiving medication at time of admission.  
72 patients did not meet eligibility criteria - but further details 
not given. 
Participant 
description 
65 years and over; medical, surgical, cardiology & geriatric 
wards. 
Study dates Not stated 
O
U
T
C
O
M
E
(S
) 
T
O
 B
E
 P
R
E
D
IC
T
E
D
 
Definition and 
method for 
measurement of 
outcome 
Outcome described as definite & probable ADEs based on 
Naranjo algorithm (amended to include compliance 
assessment) with a score of 4 or more, although unclear how 
compliance assessed.  
Not clear who collected study data - but data collected using 
chart review, search of patient's computerised hospital 
records & structured patient interview.  
50.2% of study group & 41.7% of validation group 
interviewed.  
Verification of ADEs not discussed. 
Same outcome 
definition (and 
measurement) 
used in all patients? 
Partly (definition same, but unclear who collected the study 
data & whether ADEs verified, or inter-rater reliability 
checked). 
Type of outcome  
Combined endpoint (ADE i.e. ADR plus compliance) - 
frequency of individual component not given. 
Blinding used? 
Unclear who collected study data, therefore unable to 
assess. 
Predictors part of 
outcome? 
No  
Time of outcome 
occurrence  
During admission 
C
A
N
D
ID
A
T
E
 P
R
E
D
IC
T
O
R
S
 Number and type of 
predictors  
Not clear who collected study data - but data collected using 
same methods as outcome assessment.  
Variables included demographic, patient history, laboratory 
tests, clinical examination & medication use.  
47 predictors listed, plus medication (classified by 
pharmaceutical class), serum drug concentrations' & 
individual medical problems.  
Total number of variables investigated not stated. 
Definition and 
method for 
measurement of 
candidate 
predictors 
No definitions given. Drugs classified according to 
pharmacological class. 
Timing of predictor 
measurement  
Timing for 'number of medicines', physical examination & 
laboratory results not stated. 
Blinding used? 
As with outcome, unclear who collected study data, therefore 
unable to assess. 
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Handling of 
predictors in the 
modelling  
Not stated, but potassium & glucose levels dichotomised in 
univariable results. 
S
A
M
P
L
E
 S
IZ
E
 Number of 
participants & 
outcomes / events 
929 participants; number of outcomes not stated, but ADEs 
(all scores) recorded in 16% of patients, therefore ADEs with 
score of ≥4 lower than 148. 
Events Per Variable 
(EPV) 
Unable to determine as the number of candidate predictors, 
indicator variables, transformations and interaction terms not 
stated, but as 22 variables had P≤0.05 (i.e. lower than value 
for model inclusion) the EPV <7 
M
IS
S
IN
G
 D
A
T
A
 
Number of 
participants with 
any missing value  
Not stated 
Number of 
participants with 
missing data for 
each predictor 
Not stated.  
Percentage of patients interviewed is given, but not which 
predictors collected by this method, or how missing data 
handled during analysis. 
Handling of missing 
data 
Not stated 
M
O
D
E
L
 D
E
V
E
L
O
P
M
E
N
T
 
Modelling method  Logistic regression 
Modelling 
assumptions 
satisfied 
Binary dependent variable used, & observations independent 
(i.e. no paired data).  
Variables assessed for multicollinearity (pairwise interaction 
terms for the model evaluated with entry set at P=0.05) but 
results not reported.  
Not stated if continuous variables checked for linearity. 
Method for 
selection of 
predictors for 
inclusion in 
modelling  
Univariable analysis used, predictors included in model if 
P<0.25 & occurred in >5% of study population. In addition all 
drug classes included in modelling. 
Method for 
selection of 
predictors during 
modelling  
Backwards elimination with removal criteria set at P=0.15 
then P=0.05 
Shrinkage used? Not performed 
M
O
D
E
L
 
P
E
R
F
O
R
M
A
N
C
E
 
Calibration and 
Discrimination   
Not performed 
Classification 
measures 
Not stated 
M
O
D
E
L
 E
V
A
L
U
A
T
IO
N
  
Method used for 
testing model 
performance 
Prospective validation study of 204 patients (inclusion criteria 
as above). Number of outcomes not stated. 
Profile of the validation group was similar to that recorded for 
phase 1 study group.  
Study site & dates not stated.  
Sensitivity 40.5%, specificity 69%, overall accuracy 63% 
(when cut-point set to model-predicted probability of 0.3, 
selected to produce optimal sensitivity & specificity in 
validation group - i.e. not selected a priori). 
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ADE = adverse drug event  
In case of poor 
validation, model 
adjusted? 
No 
R
E
S
U
L
T
S
 
Final and other  
multivariable 
models  
Intercept, regression coefficients, odds ratios and confidence 
intervals given for variable retained in multivariable analysis. 
Final model based on 7 factors: antidepressants, digoxin, 
gastrointestinal problems, abnormal serum potassium, ‘thinks 
drugs were responsible for hospitalisation’, angina, & 
congestive obstructive pulmonary disease.  
Scoring system not stated. 
Any alternative 
presentation of the 
final prediction 
models? 
No 
Comparison of the 
distribution of 
predictors for 
development and 
validation datasets 
Not stated 
IN
TE
R
P
R
ET
A
TI
O
N
 
A
N
D
 D
IS
C
U
SS
IO
N
 Interpretation of 
presented models  
Sensitivity indicates model is not a satisfactory predictor of 
ADEs. 
Comparison with 
other studies, 
discussion of 
generalizability, 
strengths and 
limitations. 
Not discussed 
Appendices 
 
322 
 
 
Domain Key items Trivalle et al.45 
DATA 
SOURCE 
Source of data  Prospective cohort 
P
A
R
T
IC
IP
A
N
T
S
 
Participant eligibility 
and recruitment 
method  
Consecutive admissions.  
Patients excluded if they were in the intervention group of the 
original study (54), or not present during all 4 weeks of the 
study (17).  
Not stated if written consent required. 
Participant 
description 
65 years and over; 16 geriatric centres. 
Study dates Not stated 
O
U
T
C
O
M
E
(S
) 
T
O
 B
E
 P
R
E
D
IC
T
E
D
 
Definition and 
method for 
measurement of 
outcome 
Outcome clearly defined, but standardised system (Naranjo 
or Hallas) not used.  
ADEs identified using a standardised checklist (32 items, e.g. 
sleepiness, fall, vomit, diarrhoea) by nurses & a weekly 
review of all charts by investigators.  
Nurses & residents asked to report incidents to investigators. 
Investigators visited each unit weekly.  
Instructions given on how to complete data collection forms. 
Investigators reviewed all charts weekly.  
Standardised method used by group of reviewers to classify 
ADEs (either not ADE or probable ADE).  
Same outcome 
definition (and 
measurement) 
used in all patients? 
Partly (definition same, & consensus group used to verify 
ADEs, but not clear if inter-rater reliability checked among 
investigators). 
Type of outcome  Single endpoint (ADE). 
Blinding used? 
Assume not, as data collected by nurses & investigators (who 
also reviewed patients' charts weekly). 
Predictors part of 
outcome? 
No 
Time of outcome 
occurrence  
During admission 
C
A
N
D
ID
A
T
E
 P
R
E
D
IC
T
O
R
S
 Number and type of 
predictors  
Specific details of predictors other than those identified by 
univariable analysis (cardiovascular disease, respiratory 
disease, recent VTE, antihypertensives, & antidepressants), 
or included in final model (number of medicines, 
antipsychotics, & recent anticoagulation) not given, although 
some mentioned in discussion (e.g. heart failure, liver 
disease, renal failure, number of diseases, number of 
comorbidities & age not associated with ADEs). 
Definition and 
method for 
measurement of 
candidate 
predictors 
No information on which data collected.  
Medicines classified using ATC system, no other definitions 
given. 
Timing of predictor 
measurement  
All risk factor data collected as of date of the ADE, unclear 
when data collected for patients who did not experience an 
ADE.  
Blinding used? No details of who collected this data, but assume 
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investigators. As data collected as of date of ADE assume 
that not blinded. 
Handling of 
predictors in the 
modelling  
Categorisation used for number of medicines. 
S
A
M
P
L
E
 S
IZ
E
 
Number of 
participants & 
outcomes / events 
526 participants included an original study, & 223 outcomes 
identified (39%).  
For this study 54 patients (from original intervention group) 
excluded, plus 17 patients not present during all 4 weeks, 
therefore assume 455 participants. 152 outcomes (33.4%) 
Events Per Variable 
(EPV) 
Number of predictors included in modelling not stated 
therefore unable to assess. 
M
IS
S
IN
G
 D
A
T
A
 
Number of 
participants with 
any missing value  
Not stated 
Number of 
participants with 
missing data for 
each predictor 
Not stated 
Handling of missing 
data 
Not stated 
M
O
D
E
L
 D
E
V
E
L
O
P
M
E
N
T
 
Modelling method  Logistic regression 
Modelling 
assumptions 
satisfied 
Binary dependent variable used, & observations independent 
(i.e. no paired data).  
Correlations between potential risk factors assessed, & highly 
correlated variables analysed in separate models.  
Linear trend checked for number of medications, no other 
details given. 
Method for 
selection of 
predictors for 
inclusion in 
modelling  
Univariable analysis used, predictors included in model if 
P<0.05 with a prevalence of at least 5%. 
Method for 
selection of 
predictors during 
modelling  
Stepwise logistic regression (not stated if forward or 
backwards selection).  
Variables retained if P≤0.05 
Shrinkage used? Not performed 
M
O
D
E
L
 
P
E
R
F
O
R
M
A
N
C
E
 
Calibration and 
Discrimination   
Calibration not assessed.  
Discrimination reported as the area under the ROC curve. 
Area under ROC curve 0.70 (95% CI 0.65-0.74). 
Classification 
measures 
Not stated 
M
O
D
E
L
 
E
V
A
L
U
A
T
IO
N
  Method used for 
testing model 
performance 
The area under the ROC curves were 'calculated and 
bootstrapped', but no further details given. 
In case of poor 
validation, model 
adjusted? 
N/A 
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N/A = not applicable 
 
  
R
E
S
U
L
T
S
 
Final and other  
multivariable 
models  
Odds ratios and confidence intervals given for variables 
retained in multivariable analysis.  
Regression equation not given.  
Any alternative 
presentation of the 
final prediction 
models? 
Sum scored developed with each item weighted in proportion 
to its regression coefficient.   
Final risk score based on 3 factors: number of drugs, 
antipsychotics, & recent anticoagulation. Scoring varies with 
factor.  
Risk groups not created, but risk of ADE estimated by 
bootstrapping. A score of <6 gives an ADE risk of 12% (95% 
CI 8-15%), score of 7-12 ≡ 28% (95% CI 19-36%), score 13-
18 ≡ 35% (95% CI 28-43%), & >18 out of maximum 34 gives 
as estimated risk of ADE of 52% (95% CI 40-62%). 
Comparison of the 
distribution of 
predictors for 
development and 
validation datasets 
N/A 
IN
TE
R
P
R
ET
A
TI
O
N
 A
N
D
 
D
IS
C
U
SS
IO
N
 
Interpretation of 
presented models  
Future studies needed to validate score in other settings & 
countries. 
Comparison with 
other studies, 
discussion of 
generalizability, 
strengths and 
limitations. 
Results compared with other prognostic studies, 
discrimination similar to Onder.  
Strengths: multicentre trial; standardised data collection; 
results analysed by multidisciplinary team.  
Limitations: sample size; results cannot be extrapolated to 
community; prescribing may be specific to country; geriatric 
units may have better prevention of ADEs, underestimating 
occurrence. 
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Domain Key items Nguyen et al.47 
DATA 
SOURCE 
Source of data  Prospective cohort 
P
A
R
T
IC
IP
A
N
T
S
 
Participant eligibility 
and recruitment 
method  
Assume consecutive admissions (all patients included during 
study period).  
Eligibility criteria & number of excluded patients not stated. 
Consent not required. 
Participant 
description 
17 years & over; 21 hospital units (4 surgical & 17 medical). 
Study dates 1-31 April 2014. 
O
U
T
C
O
M
E
(S
) 
T
O
 B
E
 P
R
E
D
IC
T
E
D
 
Definition and 
method for 
measurement of 
outcome 
At least 1 clinically relevant ME during hospital stay (verified 
by a physician & pharmacist, who also classified clinical 
relevance using a European adaptation of NCC MERP index, 
disagreements resolved by third evaluator).  
Outcome & measurement clearly defined.  
Wards visited by 1 of 15 pharmacists, all trained in 
standardised medicine reconciliation, prescription analysis & 
ME reporting. 
Same outcome 
definition (and 
measurement) 
used in all patients? 
Partly (definition same, & consensus group used to verify 
ADEs, but not clear if inter-rater reliability checked among 
pharmacist who collected data). 
Type of outcome  Single endpoint (medication error). 
Blinding used? Assume not, as data collected by clinical pharmacists. 
Predictors part of 
outcome? 
No   
Time of outcome 
occurrence  
During admission 
C
A
N
D
ID
A
T
E
 P
R
E
D
IC
T
O
R
S
 
Number and type of 
predictors  
Data collected on age, sex, admission details, admission type 
(medical versus surgical), previous hospitalisation in 30 day, 
hour & day of admission,  number of prescribed drugs, drug 
class, treatment initiated before admission, medication 
history available. 
Definition and 
method for 
measurement of 
candidate 
predictors 
Admission details', 'number of prescribed drugs' & ' treatment 
initiated before entrance' not defined.  
Details of inter-rater reliability among pharmacists not stated.  
Drugs classified according to ATC system. 
Timing of predictor 
measurement  
Not stated 
Blinding used? No details of who collected this data, or if blinding used. 
Handling of 
predictors in the 
modelling  
Continuous predictors (age & number of drugs) treated as 
continuous data in final model.  
Quadratic & cubic terms used for age (to account for non-
linear relationship with outcome). 
S
A
M
P
L
E
 
S
IZ
E
 Number of 
participants & 
outcomes / events 
1408 participant; 365 outcomes (25.9%). 
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Events Per Variable 
(EPV) 
Unable to determine as the number of candidate predictors, 
indicator variables, transformations and interaction terms) not 
stated. 
M
IS
S
IN
G
 D
A
T
A
 
Number of 
participants with 
any missing value  
Not stated 
Number of 
participants with 
missing data for 
each predictor 
Not stated 
Handling of missing 
data 
Not stated 
M
O
D
E
L
 D
E
V
E
L
O
P
M
E
N
T
 
Modelling method  Logistic regression 
Modelling 
assumptions 
satisfied 
Binary dependent variable used, & observations independent 
(i.e. no paired data).  
No information on whether variables assessed for 
multicollinearity.  
Multiple fractional polynomials analysis used to take account 
of non-linearity of continuous variables. 
Method for 
selection of 
predictors for 
inclusion in 
modelling  
Univariable analysis used, predictors included in model if 
P<0.5 
Method for 
selection of 
predictors during 
modelling  
Selection method not stated, but alpha risk threshold set at 
P<0.3 
Shrinkage used? Bootstrapping used to correct optimistic performance. 
M
O
D
E
L
 
P
E
R
F
O
R
M
A
N
C
E
 
Calibration and 
Discrimination   
Calibration plot presented, & discrimination reported as the c-
statistic.  
Calibration: reported as 'good' (intercept equal to zero & 
slope equal to 1) but slight over-estimation of high 
probabilities;  
C-statistic 0.718 (95% CI: 0.689-0.748). 
Classification 
measures 
Not stated 
M
O
D
E
L
 E
V
A
L
U
A
T
IO
N
  
Method used for 
testing model 
performance 
Internal validation performed using bootstrapping.                                                                                            
To evaluate the impact of the model in clinical practice they 
conducted a series of simulated randomised controlled trials 
to compare strategies for pharmaceutical intervention (using 
the model compared with age) using different levels of 
pharmacy coverage. In all coverage scenarios pharmacists 
more likely to identify MEs using model. 
In case of poor 
validation, model 
adjusted? 
Intercept and regression coefficients corrected following 
bootstrapping.   
Corrected c-statistic 0.707, 95% CI not given. 
R
E
S
U
L
T
S
 
Final and other  
multivariable 
models  
Intercept, odds ratios and confidence intervals given for 
variables retained in multivariable analysis.  
Basic formula for regression equation given. Model includes 
11 predictors.  
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ME = medication error, NCC MERP = National Coordinating Council for Medication Error 
Reporting and Prevention, N/A = not applicable 
 
  
Medication error significantly associated with current 
treatment before admission, number of prescribed drugs & 
increasing age. Admission to surgical ward, admission within 
30 days & psycholeptics almost achieved statistical 
significance. Other informative predictors also included in 
model (best possible medication history available, blood 
substitutes & perfusion solutions, admission from emergency 
room, admission time (day versus night), admission from 
outside institution). 
Any alternative 
presentation of the 
final prediction 
models? 
No 
Comparison of the 
distribution of 
predictors for 
development and 
validation datasets 
N/A 
IN
TE
R
P
R
ET
A
TI
O
N
 
A
N
D
 D
IS
C
U
SS
IO
N
 Interpretation of 
presented models  
Requires external validation & evaluation of concrete clinical 
outcomes. 
Comparison with 
other studies, 
discussion of 
generalizability, 
strengths and 
limitations. 
Discrimination comparable to Onder, Tangiisuran, Trivalle, & 
Urbina. Strengths: used TRIPOD guidelines, adjusted for 
optimism & assessed impact on practice; limitations: model 
does not consider biological markers, diagnostic categories 
or comorbidities. 
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Domain Key items Urbina et al.52 
DATA 
SOURCE 
Source of data  Prospective cohort 
P
A
R
T
IC
IP
A
N
T
S
 
Participant eligibility 
and recruitment 
method  
Assume consecutive admissions.  
Patients excluded if 18 years or less (1128), admitted directly 
to critical care unit (733), or to emergency department without 
hospital admission / units without CPOE (1853).  
NB numbers excluded include development & validation 
samples.  
Consent not required. 
Participant 
description 
Patients 18 years or less excluded; medical, surgical, & 
maternity wards. 
Study dates January-August 2009. 
O
U
T
C
O
M
E
(S
) 
T
O
 B
E
 P
R
E
D
IC
T
E
D
 
Definition and 
method for 
measurement of 
outcome 
MRPs detected through pharmacy warning system integrated 
in computerised medical history.  
When prescription issued the programme generated a series 
of alerts (causes of possible MRPs) based on drug 
information introduced & each patient's demographic 
characteristics & laboratory data.  
Alerts and prescriptions reviewed daily by team of 
pharmacists & detected MRPs that are considered clinically 
relevant & proposed intervention reported to prescriber.  
Data collected on causes of potential MRPs detected by 
pharmacy warning system & its classification (using PCNE 
classification system).  
Not clear whether all alerts used as outcomes, or just those 
verified by pharmacists.  
NB prescription errors due to incorrect use of the CPOE 
system accounted for 23.9% of outcomes (highest of all 
categories of events). 
Same outcome 
definition (and 
measurement) 
used in all patients? 
Assume yes, is they are simply the alerts from the pharmacy 
warning system. 
Type of outcome  
Combined endpoint (MRPs) - frequency of individual 
component given (using PCNE classification). 
Blinding used? Appears to be automated alerts from system, therefore yes. 
Predictors part of 
outcome? 
No 
Time of outcome 
occurrence  
During admission 
C
A
N
D
ID
A
T
E
 
P
R
E
D
IC
T
O
R
S
 
Number and type of 
predictors  
Data collected on demographics (age, sex), type of 
admission (urgent or elective), major diagnostic category, 
admitting department (surgical or medical), Charlson 
comorbidity index, diagnosis-related groups weight, obesity, 
cachexia, glomerular filtration rate, liver failure, number of 
distinct drugs received during admission, readmission related 
to prior admission, drugs classified according to ATC system. 
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Definition and 
method for 
measurement of 
candidate 
predictors 
No definition for liver failure, number of drugs received during 
admission, obesity, cachexia.  
Details of inter-rater reliability among study physicians not 
stated.  
Timing of predictor 
measurement  
Not stated 
Blinding used? No details of who collected these data, or if blinding used. 
Handling of 
predictors in the 
modelling  
Charlson index, obesity, cachexia, renal failure & liver 
disease categorised. 
S
A
M
P
L
E
 S
IZ
E
 Number of 
participants & 
outcomes / events 
Development study: 8713 admissions; 2425 outcomes 
(27.8%). 
Events Per Variable 
(EPV) 
Not stated in text, but 34 variables listed in univariable results 
table giving 71 EPV (assuming no indicator variables, 
transformations and interaction terms used). 
M
IS
S
IN
G
 D
A
T
A
 
Number of 
participants with 
any missing value  
Not stated 
Number of 
participants with 
missing data for 
each predictor 
Not stated 
Handling of missing 
data 
Not stated 
M
O
D
E
L
 D
E
V
E
L
O
P
M
E
N
T
 
Modelling method  Logistic regression 
Modelling 
assumptions 
satisfied 
Binary dependent variable used, but not all observations 
independent (i.e. 8,713 admissions, 7,202 patients).  
No details regarding potential multicollinearity.  
Not stated if continuous variables checked for linearity.       
Method for 
selection of 
predictors for 
inclusion in 
modelling  
Univariable analysis used, predictors included in model if 
P<0.1 
Method for 
selection of 
predictors during 
modelling  
Variables whose exclusion did not significantly change 
model's verisimilitude or the coefficients of remaining 
variables were excluded. 
Shrinkage used? Not performed 
M
O
D
E
L
 
P
E
R
F
O
R
M
A
N
C
E
 
Calibration and 
Discrimination   
Hosmer-Lemeshow test to assess calibration.  
Discrimination reported as the area under the ROC curve. 
Results of Hosmer-Lemeshow test not stated.  
Area under ROC curve 0.778 (95% CI 0.768-0.789) 
Classification 
measures 
Not stated 
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MRP = medication related problem, PCNE = Pharmaceutical Care Network Europe, CPOE = 
computerised physician order system, N/A = not applicable 
 
  
M
O
D
E
L
 
E
V
A
L
U
A
T
IO
N
  Method used for 
testing model 
performance 
Prospective validation study of 4058 consecutive admissions 
from same centre, September-December 2009.  
Outcome frequency 21.6% (i.e. 876 outcomes). 
Area under ROC curve 0.776 (95% CI 0.759-0.792). 'Model 
not significant' according to Hosmer Lemeshow's test 
(P=0.131). 
In case of poor 
validation, model 
adjusted? 
N/A 
R
E
S
U
L
T
S
 
Final and other  
multivariable 
models  
Intercept, regression coefficients, odds ratios and confidence 
intervals given for variable retained in multivariable analysis. 
Basic regression equation given.  
Any alternative 
presentation of the 
final prediction 
models? 
Sum score developed using variables retained in model, with 
risk score assigned to each variable based on odds ratio. 
Final risk score based on 14 factors: age >60 years, Charlson 
index =2, number of drugs >10, 6 ‘major diagnostic category 
(MDC) groups; 5 ATC groups.  
Scoring varies with factor.  
Age & number of medicines categorised using cut-points with 
highest sensitivity and specificity. 
Comparison of the 
distribution of 
predictors for 
development and 
validation datasets 
Not stated 
IN
TE
R
P
R
ET
A
TI
O
N
 A
N
D
 D
IS
C
U
SS
IO
N
 Interpretation of 
presented models  
Not stated 
Comparison with 
other studies, 
discussion of 
generalizability, 
strengths and 
limitations. 
Results compared with other prognostic studies.  
Strength: first study to design & validate a predictive score to 
detect  MRPs in hospitalised patients; CPOE warning system 
includes information on drugs, diagnostic, & laboratory tests, 
allowing extensive & automatic patient monitoring & routine 
updating; large sample sizes.  
Limitations: comparison with other studies limited by 
definitions & outcomes used in other studies; results may not 
be reproducible to other hospitals as CPOE designed, & 
model validated, in staff at their centre. 
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Appendix A3.8: Risk of bias assessment for consensus studies 
Roten et 
al. (2010)
50
 
Summary of study: Development of an electronic screening tool to identify 
patients at risk of MRPs. 
Study method: Six ‘electronic queries’ were formulated based on a literature 
review, clinical pharmacists’ experience, a list if queries used at Brigham and 
Women’s Hospital, Boston USA, and programming feasibility. 
Expert group: Clinical pharmacists at Hôpital du Valais. No further details given 
regarding number, experience of participants, or process used. 
Testing/validation: Prospective observational study of 501 patients to compare 
identification of patients using the electronic flags to a manual check by 
pharmacists. Sensitivity 85.1%, specificity 60.4%. 
Cottrell et 
al. (2013)
48
 
Summary of study: Development of an automated electronic screening tool 
using data from an electronic prescribing system to assist pharmacists target 
patients in greatest need. 
Study method: Initial priority criteria identified through discussions with clinical 
pharmacy team at University Hospital Ayr, and an initial scoring system 
developed to categorise patients as low, medium, or high-risk. This was refined 
during a 15-week evaluation period through weekly meetings of the pharmacist 
leading the project and a minimum of four clinical pharmacists. Feedback was 
also obtained from members of the clinical pharmacy team (who used the 
screening tool within their day-to-day work), resulting in ad hoc amendment (with 
contentious changes requiring the consensus of the clinical teams). 
Expert group: Iterative process involving the clinical pharmacy team members 
from medical and surgical specialities within University Hospital Ayr. 
Testing/validation: ‘Testing phase’ reported (no details given). Patients scored 
by algorithm as ‘high-risk’ compared to those identified by ‘traditional ward round’. 
Match reported
71
. 
Falconer 
et al. 
(2014)
49
 
Summary of study: Development of a software-based tool, the Assessment of 
Risk Tool (ART) to prioritise inpatients for ADE prevention. 
Study method: The system was designed with 38 risk ‘flags, identified from the 
literature. Each flag was assigned a score by senior pharmacists at Middlemore 
Hospital using a group consensus process. Each patient’s scores from all 
triggered flags are then summed to categorise patient as low, medium or high-risk 
for MEs and ADEs. Allocation of scores to risk groups was on the basis of staffing 
constraints, so that the top 10% (by ART score) would be categorised at high-risk, 
those in the next 15
th
 percentile were medium-risk, and the remainder were low-
risk.  
Expert group: Senior pharmacists at Middlemore Hospital. No further details 
given regarding number, experience of participants, or process used. 
Testing/validation: None reported 
Kaufmann 
et al. 
(2015)
38
 
Summary of study: Expert panel to gather risk factors for MRPs. 
Study method: Triangulation process using a mixed method approach to identify 
risk factors for MRPs. This included the nominal group technique (NGT), literature 
review, and a two-round Delphi survey.  
Expert group: Two hospital physicians, one emergency physician, one general 
practitioner, one clinical pharmacologist, one clinical pharmacist, one registered 
nurse, one home care nurse, and two community pharmacists. The expert panel 
were selected to reflect different settings and professional roles, and all 10 
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members had at least 5 years of professional experience, held senior positions, 
and undertook regular clinical duties. 
Testing/validation: N/A 
Saedder et 
al. (2016)
46
 
Summary of study: Development of ‘medicines risk score’ (MERIS) to identify 
patients at increased risk of MEs.  
Study method: Literature search to identify variables, followed by two-round 
Delphi process to categorise medicines, and drug interactions as low, medium or 
high-risk
220
. Various scoring algorithms constructed, using theoretical weighting 
(which involved assigning importance to the various elements in the algorithm). 
Statistical testing used to compare the accuracy, sensitivity and specificity of 
various versions of the algorithm in three historic datasets, with adjustments made 
following each assessment. Final score validated in a prospective study of 53 
patients. ‘Detection limit’ for each algorithm (i.e. the score to identify high-risk 
patients) was selected retrospectively to give the highest precision. Categorisation 
used for all variables in the risk score, but it is unclear how these categories were 
selected. Datasets ranged in size from 50 to 146 patients, providing 9-33 outcome 
events per group. The groups also differed in age, with two groups restricted to 
adults over the age of 65 years, whereas two included adult of all ages. There 
were also differences in: the number of medicines prescribed (those prescribed ≥ 
8 medicines ranged from 40% to 92%); average number of MEs (from 0.2 to 1.1 
per patient), and number of patients who experienced an ME (from 18% to 62%). 
Expert group: Panel of 36 experts (physicians and pharmacists) appointed by 
Danish Medical Societies, Danish Health and Medical Agency and the Danish 
Society of Pharmacists (no further details given). Survey administered 
electronically
220
. 
Testing/validation: Final algorithm sensitivity 64%, specificity 75%, area under 
ROC curve 0.76 (95% CI 0.62-0.89). 
Hickson et 
al. (2016)
51
 
Summary of study: Assessment of a ‘pharmaceutical assessment screening 
tool’ (PAST), developed to assign a ‘patient acuity level’ (PAL) to patients (level 1, 
2 or 3). 
Study method: Tool developed by consultant pharmacist in medication safety, 
based on similar tools in the literature
48 221 222
 (including Cottrell’s), but also 
includes patient-level
223 224
 and medication-based risk factors based on high-risk 
medications known to cause serious harm
225
. A team of pharmacists piloted the 
tool to confirm face validity. Agreement on final tool and PAL sought using 
consensus methodology (no further details provided). 
Expert group: Junior and senior pharmacists from medical and surgical 
specialities within study site (900-bed teaching hospital in England). No further 
details given. 
Testing/validation: Quasi-experimental service evaluation to quantify agreement 
among pharmacist-documented and per-guidance PAL, no other testing or 
evaluation reported.  
MRP = medication related problem, ME = medication error, ROC = receiver-operating 
characteristic, CI = confidence interval, N/A = not applicable 
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Appendix A5.1: Expert survey 
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STOPP = Screening Tool of Older People's potentially inappropriate Prescriptions   
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Appendix A6.1: Comparison of comorbidity scales 
S
y
s
te
m
 
Modified Cumulative Illness 
Rating Scale (CIRS)128 
Charlson 
index129 
Elixhauser 
system130 
C
a
rd
ia
c
 
Cardiac (heart only)  
Includes: coronary arteries dx, heart 
failure, valvular heart dx, endocardities, 
miocardities, pericarditis, arrhythmias 
(extrasystoles, bundle branch blocks, 
AF, PMK placement),  past MI, angina, 
acute coronary syndrome 
Myocardial infarct  
Excludes AF, 
valvular disease, 
arrhythmias & 
angina 
Excluded: old 
myocardial infarction 
H
e
a
rt
 f
a
il
u
re
 
Included in cardiac Congestive heart 
failure 
Congestive heart 
failure 
Includes: rheumatic 
heart disease, various 
causes of heart failure, 
cardiomyopathy, left 
ventricular failure 
A
rr
h
y
th
m
ia
s
 
Included in cardiac Excluded Cardiac arrhythmias 
Includes: heart block, 
arrhythmias 
(tachycardia, atrial 
fibrillation, 
bradycardia, 
ventricular fibrillation, 
cardiac pacemaker 
V
a
lv
u
la
r 
d
is
e
a
s
e
 
Included in cardiac Excluded Valvular disease 
Includes: 
cardiovascular 
syphilis, rheumatic 
valve diseases 
P
u
lm
o
n
a
ry
 v
a
s
c
u
la
r 
d
is
o
rd
e
rs
 
Included in vascular-haematopoietic Not included Pulmonary vascular 
disorders 
Includes: pulmonary 
embolism, pulmonary 
hypertension, 
pulmonary heart 
disease 
W
a
rf
a
ri
n
 Not included Use of warfarin 
(additional 
component to 
predict cost) 
Not included 
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S
y
s
te
m
 
Modified Cumulative Illness 
Rating Scale (CIRS)  
Charlson index Elixhauser system 
V
a
s
c
u
la
r 
Vascular-haematopoietic 
Artery disease: carotid atherosclerosis, 
peripheral arteries disease, aneurysms 
Venous disease: venous insufficiency, 
varices , deep vein thrombosis, 
pulmonary embolism, pulmonary 
hypertension 
Haematopoietic: anaemia, leucopenia, 
thrombocytopenia, haematological 
malignancy 
Lymphopoietic disease: chronic 
lymphatic oedema, lymphoma, spleen & 
thymus disease 
Immunologic disease: systemic lupus 
erythematosus, systemic sclerosis, 
sarcoidosis, hypersensitivity 
Peripheral 
vascular disease 
Peripheral vascular 
disorders 
Includes: 
atherosclerosis, 
aneurysms, peripheral 
vascular disease, 
cardiac & vascular 
implants 
H
y
p
e
rt
e
n
-s
io
n
 
Hypertension  Hypertension 
(additional 
component to 
predict cost) 
Hypertension 
C
e
re
b
ro
-
v
a
s
c
u
la
r 
Included in neurological Cerebrovascular 
disease  
Includes: 
cerebrovascular 
accident, transient 
ischaemic attack 
Not included 
D
e
m
e
n
ti
a
 Included in psychiatric / behavioural  Dementia Included in specific 
comorbidities 
R
e
s
p
ir
a
to
ry
 
Respiratory 
Includes: COPD, asthma, emphysema, 
restrictive pulmonary interstitial lung 
disease, malignancies of lung & pleura, 
pneumonia, smoking status 
Chronic 
pulmonary 
disease 
Chronic pulmonary 
disease 
Includes: pulmonary 
heart disease, 
bronchitis, 
emphysema, chronic 
obstructive pulmonary 
disease, asthma, 
bronchiectasis, 
pneumoconiosis 
E
a
r,
 n
o
s
e
 &
 
th
ro
a
t 
Ear, nose, throat, larynx 
Includes: glaucoma, cataracts, macular 
degeneration, otitis, dizziness, hearing 
impairment, rhinitis, pharyngitis, nasal 
polyps, sinusitis, dysphonia, laryngitis, 
malignancies 
Not included Not included 
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S
y
s
te
m
 
Modified Cumulative Illness Rating 
Scale (CIRS) 
Charlson index Elixhauser system 
U
p
p
e
r 
G
I 
Upper gastrointestinal (GI) 
Includes: intestinal tract from 
oesophagus to duodenum, & pancreatic 
tree (dysphagia, gastroesophageal 
reflux disease, hiatus hernia, 
oesophageal diverticula, gastritis, 
gastric / duodenal ulcer, pancreatitis, 
malignancies) 
Excludes diabetes 
Ulcer disease 
Excludes GI 
bleeding 
Peptic ulcer disease 
Includes: gastric, 
duodenal & 
gastrojejunal ulcer 
L
o
w
e
r 
G
I 
Lower GI  
Includes: from small bowel to anus 
(Whipple’s disease, diverticulosis, 
irritable bowel, malignancies, 
constipation) 
Excludes 
inflammatory bowel 
disease 
Excludes inflammatory 
bowel disease 
L
iv
e
r 
Hepatic 
Includes: liver, gallbladder, biliary trees, 
portal system, hepatitis, cirrhosis, portal 
hypertension, malignancies 
Liver disease  Liver disease 
Includes: viral & 
alcoholic hepatitis, 
varices, fatty liver, 
cirrhosis, hepatic 
failure, chronic liver 
disease 
E
n
d
o
c
ri
n
e
 /
 d
ia
b
e
te
s
 
Endocrine-metabolic  
Includes: diabetes, obesity, 
dyslipidaemia, thyroid disease; 
parathyroid disease, adrenal 
pathologies, hypogonadism, 
hypopituitarism, breast, malignancies of 
these glands. Also, electrolyte 
disorders, sepsis, systemic infections 
(tuberculosis, syphilis, AIDS), and 
poisonings (chronic by metals or acute 
by pesticides or carbon monoxide) 
Diabetes / 
diabetes with end 
organ damage 
Excludes 
hypopituitarism, 
adrenal 
insufficiency, 
recurrent acidosis 
Diabetes 
(uncomplicated & 
complicated scored 
separately) 
Includes: insulin 
dependent, non-insulin 
dependent, 
ketoacidosis, renal, 
ophthalmic, 
neurological, 
circulatory 
complications 
T
h
y
ro
id
 Included in endocrine-metabolic  Not included Hypothyroidism 
P
a
ra
ly
s
is
 Included under specific systems Hemiplegia Paralysis 
Includes: paraplegia, 
hemiplegia  
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y
s
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m
 
Modified Cumulative Illness Rating 
Scale (CIRS) 
Charlson index Elixhauser system 
R
e
n
a
l 
Renal  
Includes: kidney stones, renal failure, 
glomerulonephritis, nephrotic 
syndrome, pyelonephritis, nephropathy, 
carcinoma 
Moderate / severe 
renal disease 
Renal failure 
Includes: renal failure, 
chronic kidney 
disease’ dialysis, renal 
transplant 
T
u
m
o
u
r Included under specific systems Any tumour Solid tumour without 
metastasis 
L
e
u
k
a
e
-
m
ia
 
Included in vascular-haematopoietic Leukaemia Included under 
lymphoma 
L
y
m
p
h
-
o
m
a
 
Included in vascular-haematopoietic Lymphoma Lymphoma 
M
e
ta
s
ta
t-
ic
 c
a
n
c
e
r Included under specific systems Metastatic solid 
tumour 
Metastatic cancer 
A
ID
S
 /
 
H
IV
 
Included in endocrine-metabolic AIDS / HIV AIDS / HIV 
N
e
u
ro
lo
g
ic
a
l 
Neurological  
Includes: stroke, neurodegenerative 
diseases (Parkinson’s disease, multiple 
sclerosis, amyotrophic lateral sclerosis 
etc), myelopathies, trauma with 
neurological outcomes, epilepsy, 
neuropathies, primary tumours, 
migraines, insomnia 
Excludes dementia 
Excludes 
Parkinson’s 
disease, seizures, 
syncope 
Other neurological 
disorders 
Includes: Huntington 
disease, cerebellar 
ataxia, motor neurone 
disease, Parkinson’s 
disease, multiple 
sclerosis, epilepsy, 
encephalopathy 
Excludes: 
cerebrovascular 
disease 
 
  
Appendices 
 
347 
 
 
Continued from previous page… 
S
y
s
te
m
 
Modified Cumulative Illness Rating 
Scale (CIRS) 
Charlson index Elixhauser system 
M
u
s
c
u
lo
s
k
e
le
ta
l 
Musculoskeletal-intergumentary 
Includes: osteoarthritis, osteoporosis, 
bone fracture, neoplasm, rheumatoid 
arthritis, polymyalgia rheumatic, 
muscular injuries, pressure sores, 
dermatological disease 
Connective tissue 
disease 
Rheumatoid arthritis 
/ collagen vascular 
diseases 
Includes: scleroderma, 
rheumatoid arthritis, 
ankylosing spondylitis, 
systemic lupus 
erythematosus, 
polymyositis, Sjögren 
syndrome, polymyalgia 
rheumatic, ankylosing 
spondylitis 
Excludes: 
osteoarthritis 
S
k
in
 
Included in musculoskeletal-
intergumentary 
Skin ulcers / 
cellulitis (additional 
component to 
predict cost) 
Excluded 
C
o
a
g
u
lo
p
a
th
y
 
Included in vascular-haematopoietic Excluded Coagulopathy 
Includes: defibrination 
syndrome, factor VIII & 
IX, XI deficiency, 
thrombophilia, 
Idiopathic 
thrombocytopenic 
purpura, 
thrombocytopenia 
O
b
e
s
it
y
 Included in endocrine-metabolic Not included Obesity 
W
e
ig
h
t 
lo
s
s
 
Not included Not included Weight loss 
F
lu
id
 &
 e
le
c
tr
o
ly
te
s
 
Included in endocrine-metabolic Not included Fluid & electrolyte 
disorders 
Includes: dehydration, 
hypovolaemia, hypo-
osmolality and 
hyponatraemia, 
acidosis, alkalosis, 
hyperkalaemia, 
hypokalaemia, fluid 
overload 
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S
y
s
te
m
 
Modified Cumulative Illness Rating 
Scale (CIRS) 
Charlson index Elixhauser system 
A
n
a
e
m
ia
 
Included in vascular-haematopoietic Not included Blood loss anaemia 
Included in vascular-haematopoietic Not included Deficiency anaemia 
Includes: iron 
deficiency anaemia, 
vitamin B12 deficiency 
anaemia, folate 
deficiency anaemia, 
other megaloblastic 
anaemia 
A
lc
o
h
o
l 
a
b
u
s
e
 Not included Not included Alcohol abuse 
Includes: harmful 
alcohol use, and 
complications of 
alcohol abuse (e.g. 
polyneuropathy) 
D
ru
g
 
a
b
u
s
e
 Not included Not included Drug abuse 
P
s
y
c
h
ia
tr
ic
 
Psychiatric / behavioural  
Includes dementia, depression, anxiety, 
agitation / delirium, psychosis 
Not included Psychoses 
Includes: 
schizophrenia, 
delusional disorder, 
schizoaffective 
disorder, bipolar 
affective disorder 
D
e
p
re
s
s
-
io
n
 
Included in psychiatric / behavioural Depression 
(additional 
component to 
predict cost) 
Depression 
G
e
n
it
o
-
u
ri
n
a
ry
 Other genitourinary  
Includes: ureters, bladder, urethra, 
prostate, genitals, uterus, ovaries 
 
Not included Not included 
AIDS = acquired immunodeficiency syndrome, HIV = human immunodeficiency virus 
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Appendix A6.2: Grouping used for MOAT comorbidity count 
Grouping of comorbidities (based on the categories used in the Modified Cumulative 
Illness Rating Scale)
128
 
Cardiac  
1. Ischaemic heart disease (including old myocardial infarction, angina pectoris, 
aortocoronary bypass graft, presence of coronary angioplasty implant and graft) 
2. Arrhythmias (including atrial fibrillation, presence of electronic cardiac devices, ventricular 
fibrillation, heart block) 
3. Heart failure 
4. Valvular heart disease 
5. Other (including. septal defects, cardiomyopathy, cardiomegaly, myocarditis) 
Hypertension  
6. Hypertension 
Vascular-haematopoietic  
7. Artery disease (including atherosclerosis, peripheral arteries disease) 
8. Aneurysms 
9. Venous disease (including venous insufficiency, oesophageal varices , deep vein 
thrombosis, pulmonary embolism, pulmonary hypertension) 
10. Haematopoietic (including anaemia, leucopenia, thrombocytopenia)  
11. Lymphopoietic disease (including lymphadenitis, lymphoedema, diseases of spleen)  
12. Immunologic disease (including systemic lupus erythematosus, systemic sclerosis, 
sarcoidosis) 
13. Raynaud syndrome 
Respiratory  
13. Chronic obstructive pulmonary disease 
14. Asthma 
15. Interstitial lung disease 
16. Other (including sleep apnoea, absence of part of lung) 
Eye, ear, nose & throat  
17. Glaucoma 
18. Retinal disease (including blindness, retinopathy, macular degeneration) 
19. Disorders of balance (including Meniere’s disease, vertigo) 
20. Chronic sinusitis 
Upper gastrointestinal (GI) 
21. Oesophageal (including gastro-oesophageal reflux disease, oesophagitis) 
22. Stomach / duodenum (including gastritis, duodenitis) 
23. Pancreatic tree (including pancreatitis, diseases of pancreas excluding diabetes) 
24. Dyskinesia of oesophagus 
25. Other (including absence of part of stomach, tracheo-oesophageal fistula) 
Lower GI  
26. Inflammatory bowel disease 
27. Coeliac disease / diverticulitis / irritable bowel syndrome 
28. Other (including Meckel diverticulum, vesicointestinal fistula) 
Hepatic 
29. Liver (including hepatitis, hepatic failure, cirrhosis) 
30. Gall bladder (including cholecystitis, obstruction of bile duct, biliary cirrhosis) 
31. Portal hypertension 
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Renal  
32. Anatomical (including absence of kidney, cysts, calculus) 
33. Functional (including chronic kidney disease, renal failure) 
34. Other (including hydronephrosis, nephrotic syndrome, pyonephrosis) 
Other genitourinary  
35. Prostatic hypertrophy 
36. Bladder (including calculus, cystocele) 
37. Ovaries / uterus (including leiomyoma, polycystic ovary disease) 
Musculoskeletal-intergumentary 
38. Osteoarthritis (including arthrosis, spondylosis, spinal stenosis) 
39. Rheumatoid arthritis / fibromyalgia / psoriasis / pemphigoid / myasthenia gravis 
40. Gout / crystal arthropathies 
41. Muscular dystrophy 
42. Nummular dermatitis 
43. Osteogenesis imperfect 
44. Osteoporosis 
45. Ehlers-Danlos syndrome 
Neurological  
46. Stroke 
47. Parkinson’s disease 
48. Other degenerative diseases (including  multiple sclerosis, motor neurone disease) 
49. Neuropathies 
50. Epilepsy 
51. Myelopathy / dorsalgia / sciatica 
52. Paralysis 
53. Hydrocephalus 
54. Huntington disease 
55. Neuropathic arthropathy 
Endocrine-metabolic  
56. Diabetes 
57. Thyroid disorders 
58. Dyslipidaemia 
59. Parathyroid disorders 
60. Adrenal disease 
61. Systemic infectious diseases (human immunodeficiency virus, syphilis) 
62. Disorders of pituitary gland 
63. Breast disorders 
64. Syndrome of inappropriate secretion of antidiuretic hormone 
65. Paget’s disease 
66. Obesity 
Psychiatric / behavioural  
67. Dementia 
68. Depression / anxiety / bipolar affective disorder / panic disorder 
69. Psychosis / schizophrenia 
70. Agoraphobia / eating disorders 
71. Autism 
72. Developmental disorders 
73. Postviral fatigue syndrome / somataform disorder 
Tumours / malignancies 
74. Benign neoplasms 
75. Malignant neoplasm 
76. Leukaemia / lymphoma 
Appendices 
 
351 
 
 
Appendix A6.3: Conventions for medicine data collection 
Scenario 
Hospital A 
(electronic prescribing 
records) 
Hospital B 
(handwritten prescribing 
records) 
Medicine prescribed regularly, 
but as intravenous or oral  
Record as ‘IV or oral’ As Hospital A 
Medicine prescribed regularly, 
but patient ‘refused’  
Record on the spread sheet 
irrespective of whether doses 
actually administered (i.e. the 
medicine had been 
prescribed) 
As Hospital A 
Variable doses prescribed (e.g. 
codeine 30mg or 60mg)  
Only list once As Hospital A 
Intravenous fluids Record as ‘IV FLUIDS’ (i.e. 
not individually) i.e. binary 
variable (yes/no) 
As Hospital A  
If a medicine is prescribed by 
infusion – this needs to be 
recorded separately, e.g. 
omeprazole & aminophylline 
are always given by infusion 
Intravenous / subcutaneous 
fluids given once only  
Treat as ‘once only’ dose 
therefore don’t include 
As Hospital A 
Medicine prescribed then 
stopped & re-prescribed the 
same day (different dose) 
 
Only list once As Hospital A 
Medicine prescribed but no 
doses given 
Record (i.e. the medicine 
had been prescribed) 
 
As Hospital A  
If only partly prescribed (i.e. 
‘crossed off’ before fully 
prescribed) assume 
prescriber changed their mind 
before finishing the 
prescription - & do not record 
Medicine ‘suspended’ (i.e. 
prescribed but withheld) 
Record (i.e. the medicine 
had been prescribed) 
As Hospital A  
 
Drug prescribed to start on a 
date after the patient was 
discharged  
Ignore As Hospital A  
 
Medicine prescribed twice 
(different frequency, route, 
formulation / administration 
device or dose) 
Record both  As Hospital A  
 
Start date on day after the first 
full day of admission, but at 
8am  
Include in medicine count as 
prescribed on first day of 
admission 
As Hospital A  
 
Bedtime snack Ignore As Hospital A  
Medicines prescribed on day 
after first day of admission but 
‘once only’ dose was 
prescribed on the first day 
Include in medicine count as 
prescribed on first day of 
admission 
As Hospital A  
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Appendix A6.4: Diagnoses included in MOAT categories for 
primary diagnosis 
MOAT 
category 
Diagnoses included 
Cardiovascular 
system 
Valvular disease; hypertension; angina; myocardial infarction; ischaemic heart 
disease; atherosclerotic heart disease; aneurysm; pericarditis; arrhythmias; 
cardiac arrest; heart failure; atherosclerosis of extremities; phlebitis; varicose 
veins; oesophageal varices; orthostatic hypotension; pulmonary embolism; 
primary pulmonary hypertension; tachycardia; bradycardia; haematopoietic 
disorders (e.g. anaemia, haematological malignancies); lymphopoietic disease 
(e.g. lymphoma, enlarged lymph nodes); immunologic disease (e.g. 
hypergammaglobulinaemia). 
Respiratory 
system 
Tracheitis; pneumonia; bronchitis; emphysema; chronic obstructive pulmonary 
disease; asthma; bronchiectasis; pneumonitis; interstitial pulmonary disease; 
pyothorax; pneumothorax; respiratory failure; pulmonary infections (e.g. 
tuberculosis, mycobacteria); neoplasms; mesothelioma of pleura; haemoptysis; 
dyspnoea. 
Gastrointestinal 
system 
Diseases of tongue; tonsillitis; oesophagitis; achalasia of cardia; gastro-
oesophageal reflux disease; ulcers of gastrointestinal tract; gastritis / duodenitis; 
obstruction; appendicitis; hernias; inflammatory bowel disease; gastroenteritis; 
paralytic ileus; diverticular disease; constipation; haemorrhoids; peritonitis; liver 
disease; disease of gallbladder and bile ducts; pancreatic disease; 
hematemesis; enteritis / enterocolitis; intestinal viral infections; tuberculosis of 
intestines; stomatitis; neoplasms; dysphagia. 
Genitourinary 
system 
Nephritis; renal failure; pyonephrosis; calculus (kidney & urinary); cystitis; urinary 
tract infection; hyperplasia of prostate; diseases of testis, uterus, ovaries, vagina; 
haematuria; urine retention; neoplasms. 
Musculoskeletal
-intergumentary 
systems 
Rheumatoid arthritis; arthropathies; gout; painful joints; spondylosis; 
myelopathies; cervicalgia; sciatica; neoplasm of bone; neoplasms of skin; 
abscess / carbuncle; cellulitis; lichen simplex chronicus; nail disorders; psoriasis; 
urticaria; skin ulcers. 
Endocrine-
metabolic 
diseases 
Diabetes; thyroid disorders; parathyroid disease; syndrome of inappropriate 
secretion of antidiuretic hormone; pituitary disease; adrenal disease; electrolyte 
disorders; disorders of plasma-protein metabolism; systemic infections (sepsis, 
malaria); breast cancer; neoplasms. 
Nervous system 
and mental 
disorders 
Meningitis / encephalomyelitis; Parkinson’s disease; Alzheimer’s disease; 
degenerative diseases of nervous system; multiple sclerosis; epilepsy; migraine; 
cluster headaches; amnesia; transient ischaemic attack; Bell's palsy; 
neuropathies; encephalopathy; myelopathies; other dementias / delirium / 
cognitive disorders; brain / nervous system related pathologies (e.g. infections 
and neoplasms); stroke; paraesthesia; depression; anxiety; bipolar disorder; 
eating disorders somatoform disorders. 
Other Varicella; infectious mononucleosis; mesothelioma / neoplasms (where site not 
specified); amyloidosis; effects of alcohol use / abuse; eye and vestibular 
disorders; poisoning; allergy / anaphylaxis; non-specific symptoms (e.g. 
abnormal investigative findings, cough, precordial / chest pain, abdominal pain, 
nausea and vomiting, dizziness, fever, headache, malaise and fatigue, 
somnolence, disorientation, epistaxis); non-specific findings (e.g. haemorrhage - 
site not specified, difficulty walking, tendency to fall, syncope, localised swelling, 
collapse, volume depletion); superficial injuries (fractures, traumatic injuries). 
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Appendix A6.5: Medication related problem data collection form 
 
 
MRP = medication related problem, Meds Rec = medicines reconciliation, 
TTA = discharge prescription (“To Take Away”),  
MMPT = medicines management pharmacy technician   
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IV = intravenous, SR = sustained release, CD = controlled drug,  
TDM = therapeutic drug monitoring, INR = International Normalised Ratio,  
NOAC = novel oral anticoagulant, PV = per vagina, PR = per rectum,  
ADR = adverse drug reaction, UTI = urinary tract infection, BD = bis in die (twice daily),  
QDS = quarter die sumendum’ (four times daily) 
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Appendix A6.6: Breakdown of missing data by study variable 
Variable 
Admissions with missing data 
Hospital A 
(admissions = 
1,006) 
n (% of 
admissions) 
Hospital B 
(admissions = 
497) 
n (% of 
admissions) 
All patients  
(admissions = 
1,503) 
n (% of 
admissions) 
Medicines reconciliation completed*  0 0 0 
Age  0 0 0 
Gender* 0 0 0 
Socioeconomic status  3 (0.3) 3 (0.6) 6 (0.4) 
Ethnic origin*  62 (6.2) 34 (6.8) 96 (6.4) 
Previous allergy  1 (0.1) 0 1 (0.07) 
Body mass index  257 (25.6) 84 (16.9) 341 (22.7) 
Number of hospital admissions in 
previous 6 months  
0 0 0 
Primary diagnosis  0 0 0 
Number of comorbidities  0 0 0 
History of dementia  0 0 0 
Length of hospital stay*  0 0 0 
Number of medicines  0 0 0 
High-risk medicines use 0 0 0 
Parenteral administration route 0 0 0 
Renal function  6 (0.6) 3 (0.6) 9 (0.6) 
Liver disease  0 0 0 
Serum albumin  7 (0.7) 19 (3.8) 26 (1.7) 
Serum potassium  20 (2.0) 10 (2.0) 30 (2.0) 
Serum sodium  3 (0.3) 0 3 (0.2) 
White cell count  5 (0.5) 1 (0.2) 6 (0.4) 
Platelet count 6 (0.6) 2 (0.4) 8 (0.5) 
* Data collected for descriptive purposes and not included in the regression analyses to 
develop the MOAT 
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Appendix A6.7: Characteristics of admissions with missing 
values and completely observed data 
Characteristic 
Admissions with 
missing data = 
449 
n (% of admissions 
with missing data) 
Admissions with 
complete data = 
1,054 
n (% of admissions 
with complete data) 
p value 
(test for difference 
between admissions 
with and without 
missing data) 
Medication related problem (MRP) occurrence*  
Number of admissions with outcome 
event (at least one moderate or 
severe preventable MRP)  
140 (31.2) 470 (44.6) <0.0001
 
(Chi-square) 
Patient related 
Age (years) Median: 71 
IQR: 56-83 
Median: 77 
IQR: 60-86 
<0.001
 
(Mann-Whitney) 
Gender (female)  179 (39.9) 514 (48.8) 0.0015
 
(Chi-square) 
Socioeconomic status
†‡ Median: 50.6 
IQR: 27.6-78.0 
Median: 49.5 
IQR: 31.2-80.0 
0.384
 
(Mann-Whitney) 
Ethnic origin (White)
†
 292 (83.0) 915 (86.8) 0.075
 
(Mann-Whitney) 
Body mass index
†
 (kg/m
2
)  
Median: 26.8 
IQR: 22.5-29.5 
Median: 24.7 
IQR: 21.4-29.0 
0.029
 
(Mann-Whitney) 
Number of hospital admissions in 
previous 6 months 
Median: 0 
IQR: 0-1 
Median: 0 
IQR: 0-1 
<0.001
 
(Mann-Whitney) 
Number of comorbidities Median: 3 
IQR: 1-4 
Median: 4 
IQR: 2-6 
<0.001
 
(Mann-Whitney) 
History of dementia  54 (12.0) 107 (10.2) 0.282
 
(Chi-square) 
Length of hospital stay (days) Median: 3 
IQR: 1-6 
Median: 7 
IQR: 3-15 
<0.001
 
(Mann-Whitney) 
Medicines related 
Number of medicines  Median: 6 
IQR: 4-10 
Median: 8 
IQR: 5-11 
<0.001
 
(Mann-Whitney) 
Parenteral administration  253 (56.3) 755 (71.6) <0.001
 
(Mann-Whitney) 
Laboratory results 
Renal function
†
 - estimated 
glomerular filtration rate
§
 ≥ 60 
ml/min/1.73m
2
 
313 (71.1) 690 (65.5) 0.0334
 
(Chi-square) 
Serum albumin within standard 
reference
 †
 
201 (47.5) 420 (39.9) 0.0069
 
(Chi-square) 
Serum potassium within standard 
reference range
†
  
372 (88.8) 928 (88.3) 0.692
 
(Chi-square) 
Serum sodium within standard 
reference range
†
  
377 (84.5) 868 (82.4) 0.305
 
(Chi-square) 
White cell count within standard 
reference range
†
  
274 (61.9) 618 (58.6) 0.237
 
(Chi-square) 
Platelet count within standard 
reference range
†
  
385 (87.3) 900 (85.4) 0.332
 
(Chi-square) 
*
  
MRPs considered by expert panel to be true MRPs 
† For patients without missing data (further details provided in Appendix A6.6) 
‡ Ranked using English Indices of Deprivation 2015 – Index of Multiple Deprivation
149
. Deprivation 
rank based on patients’ postcode, shown as the ranked position as a percentage of all 
neighbourhoods in England (where 1 is the most deprived) 
§ Glomerular filtration rate estimated using modified Modification of Diet in Renal Disease (MDRD) 
equation
121
. Glomerular filtration rate cut-off of < 60 ml/min/1.73m
2
 used as an indicator of chronic 
kidney disease
125
 
IQR = interquartile range 
Bonferroni adjusted p value used to judge statistical significance 0.0028 (based on 18 statistical tests)  
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Appendix A7.1: Medication charts used for pharmacist 
medication related problem identification exercise  
Medication chart 1*: 
 
 
 
* Actual paperwork used was A4 
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Medication chart 2: 
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Medication chart 3: 
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Medication chart 4: 
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Appendix A9.1: High-risk medicines included in development of 
the MOAT  
High-risk medicines 
category 
Medicines included 
Anticoagulants / direct 
oral anticoagulants 
Apixaban; edoxaban; dabigatran; rivaroxaban; warfarin 
 
Therapeutic heparin Dalteparin; enoxaparin; fondaparinux; tinzaparin 
Anti-diabetic 
medication 
Acarbose; alogliptin; glibenclamide; gliclazide; glimepiride; insulin; 
linagliptin; metformin; nateglinide; pioglitazone; repaglinide; saxagliptin; 
sitagliptin; vildagliptin  
Opiates (excluding 
codeine, tramadol, 
meptazinol & 
dihydrocodeine) 
Buprenorphine; diamorphine; fentanyl; methadone; morphine; 
oxycodone; tapentadol 
Aminoglycosides & 
glycopeptides 
Amikacin; gentamicin; teicoplanin; vancomycin  injection 
Systemic 
antimicrobials 
(excluding 
aminoglycosides & 
glycopeptides) 
Aciclovir; amoxicillin; atovaquone; azithromycin; aztreonam;  
benzylpenicillin; caspofungin; cephalexin; cefotaxime;  
ceftriaxone; ciprofloxacin; clarithromycin; clindamycin; co-amoxiclav; 
colistimethate; co-trimoxazole; dapsone; daptomycin; demeclocycline; 
doxycycline; ertapenem; erythromycin; ethambutol; famciclovir; 
flucloxacillin; fluconazole; fosfomycin; isoniazid; itraconazole; 
levofloxacin; linezolid; meropenem; metronidazole; moxifloxacin; 
oseltamivir; penicillin V; piperacillin with tazobactam; posaconazole; 
riamet; rifampicin; rifater; sodium fusidate; temocillin; terbinafine; 
tigecycline; trimethoprim 
Epilepsy medicines Carbamazepine; gabapentin; lamotrigine; levetiracetam; phenobarbital; 
phenytoin; pregabalin; primidone; sodium valproate; topiramate; 
valproate semisodium; zonisamide; lacosamide 
Antipsychotics Amisulpride; aripiprazole; chlorpromazine; clozapine; flupentixol; 
haloperidol; levomepromazine; olanzapine; quetiapine; risperidone; 
sulpiride; trifluoperazine; zuclopenthixol 
Antiarrhythmics Adenosine; amiodarone; digoxin; dronedarone; flecainide; verapamil 
Antidepressants Amitriptyline; citalopram; clomipramine; dosulepin; doxepin; duloxetine; 
escitalopram; fluoxetine; mirtazapine; nortripyline; paroxetine; sertraline; 
trazodone; venlafaxine  
Other   Anti-retrovirals: atripla; darunavir; raltegravir; ritonavir; truvada; 
tenofovir   
 Theophylline & aminophylline 
 Cytotoxics: axitinib; capecitabine; erlotinib; hydroxycarbamide; 
methotrexate; osimertinib   
 Immunosuppressants (excluding corticosteroids): azathioprine; 
ciclosporin; leflunomide; mycophenolate mofetil; tacrolimus; 
adalimumab 
 Lithium  
 Medicines for Parkinson’s disease: co-beneldopa; co-careldopa; 
orphenadrine; pramipexole; ropinirole; rotigotine; selegiline; stalevo; 
trihexphenidyl 
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Appendix A9.2: Range for candidate predictor values before 
and after multiple imputation   
Candidate predictor 
Original / 
imputed 
data 
Minimum 
value 
Maximum  
value 
Socioeconomic status, ranked using English 
Indices of Deprivation 2015 – Index of Multiple 
Deprivation
149
 
Original 0 100 
Imputed 0 100 
Body mass index (kg/m
2
) 
Original 10.6 40.6 
Imputed 10.6 47.6 
Renal function - estimated glomerular filtration 
rate
‡
 (ml/min/1.73m
2
) 
Original 3 161 
Imputed 3 190 
Serum albumin (g/L)  
Original 20 55 
Imputed 14.9 55 
Serum potassium (mmol/L) 
Original 2.3 5.9 
Imputed 2.3 6.3 
Serum sodium (mmol/L) 
Original 111 170 
Imputed 111 170 
White cell count (10
9
/L) 
Original 0.3 20.7 
Imputed 0.3 20.9 
Platelet count (10
9
/L) 
Original 50 490 
Imputed 50 570 
‡ Glomerular filtration rate estimated using modified Modification of Diet in Renal Disease 
(MDRD) equation
121
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Appendix A9.3: Comparison of multivariable regression 
coefficients for complete-case and multiply imputed datasets 
(excluding body mass index) 
Predictor 
Complete-cases 
 (observations = 1,440*) 
Multiple imputation 
 (observations = 1,503) 
Regression 
coefficient
†
 
Standard 
error 
p 
value
‡
 
Regression 
coefficient
†
 
Standard 
error 
p 
value
‡
 
Demographic 
Age 0.0324 0.042 0.438 0.0425 0.041 0.298 
Socioeconomic status  0.0430 0.021 0.040 0.0450 0.021 0.029 
Patient related 
Previous allergy 0.265 0.121 0.028 0.260 0.118 0.028 
Number of hospital 
admissions in previous 
6 months  
0.0254 0.076 0.738 0.0257 0.075 0.732 
Primary diagnosis: 
Endocrine and 
metabolic 
Base category 
0.035 
Base category 
0.020 
Nervous system and 
mental disorders 
0.274 0.306 0.319 0.303 
Cardiovascular system -0.211 0.283 -0.227 0.282 
Respiratory system -0.354 0.281 -0.318 0.278 
Gastrointestinal 
system 
-0.673 0.319 -0.660 0.317 
Genitourinary system -0.085 0.302 -0.058 0.300 
Musculoskeletal-
intergumentary  
0.036 0.333 0.033 0.329 
All other categories -0.083 0.289 -0.0085 0.286 
Number of 
comorbidities  
0.137 0.033 <0.001 0.137 0.033 <0.001 
History of dementia  -0.226 0.196261 0.249 -0.259 0.193 0.181 
Medicines related     
Number of medicines  0.0239 0.018 0.185 0.0230 0.018 0.195 
Use of high-risk medicines: 
Anticoagulants 0.102 0.156 0.516 0.106 0.153 0.489 
Therapeutic heparin 0.279 0.181 0.122 0.266 0.179 0.137 
Anti-diabetic 
medication 
0.151 0.154 0.329 0.217 0.151 0.151 
Opiates 0.0414 0.198 0.834 0.0138 0.197 0.944 
Aminoglycosides and 
glycopeptides 
0.400 0.229 0.081 0.330 0.225 0.143 
Other antimicrobials 0.334 0.150 0.026 0.361 0.147 0.014 
Epilepsy medicines 0.445 0.167 0.008 0.478 0.165 0.004 
Antipsychotics 0.131 0.238 0.583 0.164 0.236 0.487 
Antiarrhythmics -0.0809 0.204 0.692 -0.0578 0.201 0.773 
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Continued from previous page… 
Predictor 
Complete-cases 
 (observations = 1,440*) 
Multiple imputation 
 (observations = 1,503) 
Regression 
coefficient
†
 
Standard 
error 
p 
value
‡
 
Regression 
coefficient
†
 
Standard 
error 
p 
value
‡
 
Antidepressants 0.209 0.139 0.134 0.203 0.138 0.140 
Other high-risk 
medicines 
0.139 0.218 0.525 0.123 0.215 0.566 
Parenteral 
administration  
-0.0194 0.152 0.899 0.0408 0.149 0.784 
Laboratory results     
Estimated glomerular 
filtration rate 
-0.0417 0.020 0.038 -0.0358 0.020 0.071 
Liver disease  -0.0709 0.195 0.717 -0.0962 0.194 0.620 
Serum albumin 0.00036 0.012 0.975 0.00051 0.012 0.965 
Serum potassium -0.123 0.102 0.226 -0.128 0.100 0.204 
Serum sodium -0.0079 0.011 0.490 -0.0063 0.011 0.575 
White cell count 0.0262 0.015 0.086 0.0225 0.015 0.136 
Platelet count 0.0019 0.007 0.781 0.0029 0.007 0.665 
* Following inclusion of values determined using common sense solutions
182
  
† Relationship between the independent and dependent variable (amount of increase in 
predicted log odds of the outcome event that would be predicted by a one unit increase 
in the independent variable) 
‡ Values with a significance level of p<0.157 shown in bold 
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Appendix A9.4: Univariable and multivariable association 
between predictors and outcome events 
Predictor 
Univariable 
analysis 
Multivariable 
analysis 
Odds ratio
†
 
(95% CI) 
p 
value
‡
 
Odds ratio
†
 
(95% CI) 
p 
value
‡
 
Demographic     
Age/10 (years) 
1.18  
(1.12 to 1.25) 
<0.001 
1.04 
(0.96 to 1.13) 
0.352 
Socioeconomic status/10, ranked 
using English Indices of Deprivation 
2015 – Index of Multiple 
Deprivation
149
* 
1.04 
(1.00 to 1.08) 
0.044 
1.05 
(1.00 to 1.09) 
0.034 
Patient related     
Previous allergy 
1.67 
(1.35 to 2.06) 
<0.001 
1.30 
(1.02 to 1.67) 
0.035   
Body mass index (kg/m
2
) 
1.01 
(0.99 to 1.03) 
0.610 
0.100  
(0.97 to 1.02) 
0.810 
Number of hospital admissions in 
previous 6 months  
1.19 
(1.05 to 1.35) 
0.008 
1.02 
(0.88 to 1.191) 
0.757 
Primary diagnosis:     
Endocrine and metabolic 
1.34 
(0.81 to 2.2) 
0.260 
1.01 
(0.57 to 1.78) 
0.977 
Nervous system and mental 
disorders 
1.40 
(0.92 to 2.1) 
0.113 
1.40 
(0.88 to 2.21) 
0.158 
Cardiovascular system 
1.19 
(0.84 to 1.67) 
0.329 
0.80 
(0.54 to 1.20) 
0.279 
Respiratory system 
1.17 
(0.83 to 1.65) 
0.359 
0.73 
(0.48 to 1.10) 
0.137 
Gastrointestinal system 
0.64 
(0.41 to 0.99) 
0.048 
0.52 
(0.31 to 0.87) 
0.013 
Genitourinary system 
1.53 
(1.01 to 2.33) 
0.046 
0.95 
(0.59 to 1.55) 
0.847 
Musculoskeletal-intergumentary 
systems 
1.67 
(1.03 to 2.71) 
0.036 
1.05 
(0.61 to 1.81) 
0.859 
All other categories Base category Base category 
Number of comorbidities  
1.24 
(1.18 to 1.30) 
<0.001 
1.15 
(1.07 to 1.24) 
<0.001 
History of dementia  
1.05 
(0.75 to 1.46) 
0.779 
0.76 
(0.52 to 1.14) 
0.182 
Laboratory results 
Estimated glomerular filtration 
rate/10
*
 (ml/min/1.73m
2
) 
0.92 
(0.89 to 0.95) 
<0.001 
0.96 
(0.93 to 1.00) 
0.076 
Liver disease  
0.90 
(0.65 to 1.26) 
0.548 
0.90 
(0.61 to 1.33) 
0.609 
Serum albumin  (g/L) 
0.97 
(0.95 to 0.99) 
<0.001 
1.00 
(0.98 to 1.02) 
0.958 
Serum potassium (mmol/L) 
1.09 
(0.91 to 1.29) 
0.358 
0.88 
(0.72 to 1.08) 
0.213 
Serum sodium (mmol/L) 
0.99 
(0.97 to 1.01) 
0.257 
0.99 
(0.97 to 1.02) 
0.583 
White cell count (10
9
/L) 
1.03 
(1.00 to 1.05) 
0.021 
1.02 
(0.99 to 1.06) 
0.143 
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Continued from previous page… 
Predictor 
Univariable 
analysis 
Multivariable 
analysis 
Odds ratio
†
 
(95% CI) 
p 
value
‡
 
Odds ratio
†
 
(95% CI) 
p 
value
‡
 
Platelet count/10 (10
9
/L) 
1.00 
(0.99 to 1.01) 
0.682 
1.00 
(0.99 to 1.02) 
0.677 
Medicines related 
Number of medicines  
1.10 
(1.07 to 1.13) 
<0.001 
1.02 
(0.99 to 1.06) 
0.194 
Use of high-risk medicines:     
Anticoagulants 
1.50 
(1.16 to 1.92) 
0.002 
1.12 
(0.82 to 1.52) 
0.479 
Therapeutic heparin 
1.32 
(0.99 to 1.76) 
0.057 
1.31 
(0.92 to 1.89) 
0.139 
Anti-diabetic medication 
1.71 
(1.33 to 2.21) 
<0.001 
1.25 
(0.92 to 1.70) 
0.151 
Opiates 
1.37 
(0.97 to 1.93) 
0.073 
1.01 
(0.69 to 1.50) 
0.951 
Aminoglycosides and glycopeptides 
1.74 
(1.17 to 2.59) 
0.006 
1.40 
(0.89 to 2.20) 
0.147 
Other antimicrobials 
1.71 
(1.38 to 2.13) 
<0.001 
1.44 
(1.07 to 1.95) 
0.018 
Epilepsy medicines 
1.92 
(1.44 to 2.55) 
<0.001 
1.63 
(1.14 to 2.31) 
0.007 
Antipsychotics 
1.28 
(0.84 to 1.95) 
0.255 
1.18 
(0.74 to 1.89) 
0.492 
Antiarrhythmics 
1.40 
(1.00 to 1.96) 
0.053 
0.94 
(0.63 to 1.41) 
0.775 
Antidepressants 
1.50 
(1.18 to 1.90) 
0.001 
1.23 
(0.93 to 1.63) 
0.148 
Other high-risk medicines 
1.33 
(0.91 to 1.94) 
0.143 
1.13 
(0.73 to 1.73) 
0.585 
Parenteral administration  
1.46 
(1.17 to 1.83) 
<0.001 
  1.04 
(0.77 to 1.40) 
0.790 
* Deprivation rank based on patients’ postcode, shown as the ranked position as a 
percentage of all neighbourhoods in England (where 1 is the most deprived) 
† Measure of association between exposure and outcome event (the odds that an 
outcome will occur given a particular exposure, compared to the odds of the outcome 
occurring in the absence of exposure)  
‡ Test for difference between admissions with and without occurrence of outcome event. 
Obtained from regression modelling  
Age, socioeconomic status, estimated glomerular filtration rate, and platelet count analysed as 
deciles to aid interpretability (i.e. after dividing the actual value by ten) 
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Appendix A10.1: Participant information sheet (MOAT 
assessment) 
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Appendix A10.2: Participant consent form (MOAT assessment) 
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Appendix A10.3: Consensus score sheet (MOAT assessment) 
Assessment of Medicines Optimisation Assessment 
Tool (MOAT) - consensus score sheet 
 
Name of participant:………………………………………………….. 
 Listed below are five statements. Please review each statement and indicate 
the extent to which you agree or disagree. A score of one indicates total 
disagreement, and nine indicates total agreement 
 A nine-point scale has been used to permit responses to be categorised, 
with scores of 1-3 representing disagreement, scores of 4-6 representing an 
equivocal response, and scores of 7-9 representing agreement 
 Please circle a score, and give brief reason(s) for your score in the space 
provided 
 
1. The choice of risk factors is appropriate. 
Disagreement Equivocal Agree 
1 2 3 4 5 6 7 8 9 
Reason(s) for score: 
 
 
 
2. The presentation of the MOAT is reasonable. 
Disagreement Equivocal Agree 
1 2 3 4 5 6 7 8 9 
Reason(s) for score: 
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3. The MOAT has the potential to be ‘usable’ in clinical practice: 
 3a. The MOAT is simple to interpret. 
Disagreement Equivocal Agree 
1 2 3 4 5 6 7 8 9 
Reason(s) for score: 
 
 
 
3b. The time it takes to use the MOAT is reasonable.  
Disagreement Equivocal Agree 
1 2 3 4 5 6 7 8 9 
Reason(s) for score: 
 
 
 
4. The proposed ‘decision thresholds’ for the creation of risk groups (as 
discussed during the meeting) are appropriate. 
Disagreement Equivocal Agree 
1 2 3 4 5 6 7 8 9 
Reason(s) for score: 
 
 
 
 
 
Thank-you for your participation 
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Appendix A10.4: Workload implication (MOAT assessment) 
 
Assessment of Medicines Optimisation Assessment 
Tool (MOAT) – time taken to apply the MOAT 
 
Name of participant:………………………………………………….. 
 Please use the MOAT to calculate a risk score (probability of experiencing a 
moderate or severe preventable medication related problem) for 5 patients  
 Ideally these patients should have been recently admitted to hospital (i.e. all 
data should be unknown to you prior to the assessment) 
 Record the actual time taken to complete the task, that is, please do not 
count travel time to or from wards, or distractions experienced (e.g. 
responding to queries from ward staff) 
 Ideally, use a stopwatch, which can be paused if necessary, and record the 
time taken (minutes and seconds) 
 Where data collection is performed for all patients together, (e.g. ICE results, 
and JAC information) please record the total time, then split as appropriate) 
 It is not necessary to record patient identifying details  
 
Please note, you will need to obtain the following data: 
Number of comorbidities A count of the number of comorbidities recorded 
Number of ‘regular’ medicines 
prescribed 
All regular medicine on the first full day of admission 
Exclude ‘when required’ and ‘once only’ medicines, dietary 
products, non-medicated topical products (e.g. emollients), 
wound dressings, oxygen 
Age  At admission 
Serum creatinine First result following admission 
Gender Male or female 
Ethnicity Black or non-black (used to calculate eGFR) 
White cell count First result following admission 
Documented allergy YES/NO 
Whether patient treated with 
systemic aminoglycosides or 
glycopeptides 
i.e. gentamicin or vancomycin 
YES/NO 
Whether patient treated with 
other systemic antimicrobial(s) 
i.e. other than aminoglycosides & glycopeptides 
YES/NO 
Whether patient treated with 
‘epilepsy medicines’ 
YES/NO 
Primary diagnosis 
i.e. Whether admission related to: 
 Nervous system or mental disorder 
 Respiratory system 
 Gastrointestinal system 
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Patient Time taken (minutes and seconds) 
1 
 
 
 
 
2 
 
 
 
 
3 
 
 
 
 
4 
 
 
 
 
5 
 
 
 
 
 
 
ICE = Sunquest Integrated Clinical Environment™ (laboratory data electronic reporting 
system), JAC = electronic prescribing record system, eGFR = estimated glomerular 
filtration rate 
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Appendix A10.5: Written comments from consensus meetings 
Statement 1 – The choice of risk factors is appropriate 
Comments (meeting 1): 
 I agree with the risk factors, as more we add, the more time it would take to 
complete & may put people off. 
 Understood rationale for risk factors, however would like anticoagulants included. 
 If the data can be pulled across electronically then more risk factors should be 
added e.g. socioeconomic. 
 Having considered the options, I still feel anticoagulants & insulins should be on the 
drug section. 
 Lacking risk factors (e.g. anticoagulants) will be captured by co-morbidities data. 
 Discussed the reason for not including high-risk drugs / conditions that are not a 
significant representation of patients → the focus is on co-morbidities which if noted 
properly would indicate associated drug groups to be used. 
 Those risk factors I thought would be in there have been shown not to significantly 
increase risk. 
Comments (meeting 2): 
 There is room to add more if required, since it’s electronic it will be very easy to 
amend data. 
 The information that anticoagulants etc do not make a significant difference should 
be communicated so we feel confident in using the system without these 
categories. 
 I’m still of the opinion that insulin and anticoagulants should be added even though 
I know I will make little difference to the scoring. 
 Increased score to 8 due to capability of the tool to include anticoagulants / anti-
diabetics if deemed appropriate. 
 I have not changed my score as although other risk factors have been found not to 
be significant I feel adding anti-diabetics / anticoagulants would make others “trust” 
the score more + feel happier about using this tool. 
 OK as it was if explain why some risk factors excluded before people use tool, need 
to draw line somewhere. Don’t want it to be too onerous to use to start with (may 
put people off).  
Statement 2 – The presentation of the MOAT is reasonable 
Comments (meeting 1): 
 All the information is on one screen. 
 Generally, I really like the presentation. Appears to be easy to use & easy to read, 
Needs a few minor adjustments as discussed within the group. I like the green 
colour scheme. 
 Keep the box (MOAT scoring screen) on top of other screens when clicking on 
other screens. 
 Like the information buttons. Some concern over ‘race’ button (i.e. may not be able 
to establish race by ‘looking’ at a patient). All on one screen. Put in ability to 
increase size of screen. Colour – I like it! ‘Units’ for creatinine – able to choose 
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option (i.e. add ‘mg/dl’ as an alternative option). Get rid of Excel background. 
Colour blindness! 
 Easy to use. Clear & legible. Remove Excel background. Simplified → colour 
scoring system + percentage score (good visuals). Hassle free. Restricted options 
allowing for ease of use without complicating matters. Room for improvement: 
submit button → can this calculate eGFR + risk automatically; risk category writing 
→ BOLDER + BIGGER. 
 “Green” low score – how will it show up on green background. 
Comments (meeting 2): 
 Higher resolution and size. Tool will grow with lots more data or function buttons. 
 After using the MOAT tool I found the presentation really easy to use. All changes 
we have discussed are easily made. 
Statement 3a – The MOAT is simple to interpret 
Comments (meeting 1): 
 Anyone should be able to use, provided they have the right training / information. 
 Really easy to follow. Jess made a good point regarding explanation of “Probability 
%”. 
 Very easy to interpret. Easy to use. Give ranges for risk scoring – explanation 
buttons. 
 Intention is fantastic to save time focus on those most high-risk / vulnerable patient 
→ clear colour system → + % score to further rationalise which patients to see. 
Can further improve by adding a key → explaining the scoring system / categories 
(how high / medium / low-risk). 
 Statement for what % is actually showing, Key for what high / med / low means + 
what the cut offs are. 
Comments (meeting 2): 
 No change to score 
Statement 3b – The time it takes to use the MOAT is reasonable 
Comments (meeting 1): 
 Obtaining information electronically should not take long, via patient or notes may 
take a bit longer. 
 Difficult to answer until it’s been tested on the wards. Think the benefits will 
outweigh the time taken as it will save time later → help prioritise high-risk patients. 
 Not sure, have to complete bedplans, pharmacy friend, board round. If this tool gets 
added on it may slow our work rate down? 
 This is the part that causes me most concern. 
 Reasonable for an area with lower levels of new patients, may not be in acute 
setting. 
 Theoretical time taken to complete the tool would be beneficial as it would allow 
you to spend your time more wisely on the ward to high-risk groups. In practise → 
too time consuming on acute e.g. 21 new patients daily??? 
 Unsure until put into practise. May be more useful on one ward than another. 
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Comments (meeting 2): 
 As before, should not take long provide you have access to all the info. 
 3 mins using tool beats 20 mins medicines reconciliation. 
 Changed score after using – very quick i.e. only if don’t need to use patients notes. 
Statement 4 – The proposed ‘decision thresholds’ for the creation of risk 
groups (as discussed during the meeting) are appropriate 
Comments (meeting 1): 
 Current gap appropriate, more can be added in future. 
 Low-risk should still be seen during their inpatient stay. Understood rationale 
behind risk groups. 
 I feel the % are more important but the thresholds do help & allow flexibility. 
 The ‘have to see’ is useful. I like the % scoring – I can make my decision based on 
this. 
 Good prioritisation tool + scoring system to further allow you to focus on patients 
within categories. 
 Need to try out to see how this works in practise – will be saturated with “Red” 
patients. Able to use % rather than categories to re-prioritise. Don’t wish to be in 
‘acute’ (the acute assessment wards) when all low-risk patients are not seen at all 
by pharmacy. 
Comments (meeting 2): 
 Still think people will use percentage risk over groups. 
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Appendix A10.6: Moderate or severe preventable medication 
related problems (MSP MRPs) experienced by ‘low-risk’ 
patients 
Study 
code 
Predicted 
risk 
probability 
(%) 
Details of moderate or severe preventable medication related 
problems (MSP MRPs) experienced 
W0104 12.2 Subtherapeutic dose of prophylactic enoxaparin (based on weight) 
W0374 13.1 
No prescription chart written - therefore patient's regular felodipine 
not prescribed 
No prescription chart written - therefore patient's regular morphine 
liquid (10mg/5ml) not prescribed 
No prescription chart written - therefore patient's regular omeprazole 
not prescribed 
Patient recently prescribed apixaban, advised to review whether 
aspirin still indicated 
W0353 14.6 Medicines reconciliation discrepancy - ramipril not prescribed 
W0126 14.9 
Prescribed full dose paracetamol (patient jaundiced & liver function 
impaired) 
W0322 15.1 
Venous thromboembolism (VTE) assessment not completed - 
unclear if prophylaxis required 
M0948 15.2 
Medicines reconciliation discrepancy - beclometasone inhaler not 
prescribed 
W0451 15.9 
Medicines reconciliation discrepancy - oral contraceptive pill not 
prescribed 
Co-amoxiclav 1.2g three times daily prescribed orally - had intended 
parenteral 
M0914 16.0 
Dexamethasone prescribed as 8mg twice daily for 14 days only - 
had intended to prescribe as a reducing regimen 
M0609 16.4 
Medicines reconciliation discrepancy - ivabradine not prescribed 
Medicines reconciliation discrepancy - clopidogrel not prescribed 
M0344 16.6 Medicines reconciliation discrepancy - olanzapine not prescribed 
M0513 17.1 Medicines reconciliation discrepancy - bisoprolol dose too low 
W0445 17.3 Medicines reconciliation discrepancy - levothyroxine not prescribed 
M0299 17.5 
Medicines reconciliation discrepancy - fluticasone inhaler not 
prescribed 
M1098 17.8 Medicines reconciliation discrepancy - bisoprolol not prescribed 
M0987 18.0 
Medicines reconciliation discrepancy - sertraline not prescribed 
Medicines reconciliation discrepancy - morphine sulphate modified 
release tablets not prescribed 
Medicines reconciliation discrepancy - morphine liquid (10mg/5ml) 
not prescribed 
Medicines reconciliation discrepancy - gabapentin not prescribed 
Medicines reconciliation discrepancy - omeprazole not prescribed 
(patient also takes naproxen) 
M0577 18.0 
Incorrect rate of aminophylline infusion prescribed (40 mg/hour 
instead of 20mg/hour) 
M0004 18.3 Medicines reconciliation discrepancy - mirtazapine not prescribed 
W0101 18.8 
Medicines reconciliation discrepancy - citalopram not prescribed 
Subtherapeutic dose of prophylactic enoxaparin (based on weight) 
W0299 18.9 Warfarin prescribed but administration time not specified  
W0303 19.2 Medicines reconciliation discrepancy - amlodipine not prescribed 
M0227 19.3 
Patient prescribed sliding scale insulin - regular long-acting insulin 
not prescribed 
W0177 19.4 Medicines reconciliation discrepancy - quetiapine not prescribed 
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Continued from previous page… 
Study 
code 
Predicted 
risk 
probability 
(%) 
Details of MSP MRP 
M0709 19.6 
Prophylactic penicillin V not prescribed on discharge prescription (to 
restart after current course of co-amoxiclav) 
M0017 19.6 
Fondaparinux not discontinued (acute coronary syndrome diagnosis 
excluded) 
M0812 19.7 
Prescribed amlodipine on discharge prescription, not prescribed an 
inpatient (was wrong patient) 
M0238 20.2 Reason for admission recurrent eye infection - no treatment initiated 
W0337 20.3 
VTE assessment completed - patient high-risk but no prophylactic 
heparin prescribed 
M0230 20.6 
Medicines reconciliation discrepancy - sertraline not prescribed 
Medicines reconciliation discrepancy - aspirin not prescribed 
Medicines reconciliation discrepancy - lansoprazole not prescribed 
(patient on high-dose prednisolone) 
W0439 20.9 
Chlordiazepoxide prescribed - no plan for reducing dose over 
weekend  
M0983 21.3 
Provisional diagnosis  of stroke - only 1 antiplatelet prescribed 
Medicines reconciliation discrepancy - lansoprazole not prescribed 
(patient has gastro-oesphageal reflux disease) 
W0264 21.4 
VTE assessment completed - patient high-risk but no prophylactic 
heparin prescribed 
M0894 21.4 No maximum frequency prescribed for 'as required' midazolam 
M0690 21.7 No stop date specified for filgrastim  
M0453 22.0 
Medicines reconciliation discrepancy - amlodipine not prescribed 
Medicines reconciliation discrepancy - mirtazapine not prescribed 
M0942 22.0 
Medicines reconciliation discrepancy - ramipril not prescribed 
Medicines reconciliation discrepancy - metformin not prescribed 
M0587 22.1 Medicines reconciliation discrepancy - trimethoprim not prescribed 
W0369 22.2 Medicines reconciliation discrepancy - flupentixol not prescribed 
M0835 22.3 
Medicines reconciliation discrepancy - amlodipine not prescribed 
Medicines reconciliation discrepancy - resource thickener not 
prescribed 
W0391 22.4 
VTE assessment completed - patient high-risk but no prophylactic 
heparin prescribed 
M0825 22.5 
Medicines reconciliation discrepancy - citalopram not prescribed 
Medicines reconciliation discrepancy - memantine not prescribed 
W0276 22.5 Paracetamol prescribed as 'regular' and 'as required' 
M0416 22.5 
Sando K not discontinued despite potassium level now above 
standard reference range 
M0715 22.8 
Meropenem prescribed for patient with documented meropenem 
allergy. Appears allergy status incorrect - therefore corrected 
W0297 22.8 VTE assessment not completed - unclear if prophylaxis required 
W0075 22.9 
Morphine liquid (10mg/5ml) prescription not legible (poor 
handwriting and units not stated) 
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Continued from previous page… 
Patient 
reference 
Predicted 
risk 
probability 
(%) 
Details of MSP MRP 
M0355 23.1 
Medicines reconciliation discrepancy - sertraline not prescribed 
Medicines reconciliation discrepancy - quetiapine not prescribed 
Sub-therapeutic dose of prophylactic heparin (not increased 
following improvement in renal function) 
W0316 23.1 
Medicines reconciliation discrepancy - pilocarpine eye drops not 
prescribed 
Medicines reconciliation discrepancy - Azopt eye drops not 
prescribed 
Medicines reconciliation discrepancy - Lumigan eye drops not 
prescribed 
Medicines reconciliation discrepancy - finasteride not prescribed 
M0516 23.2 
Medicines reconciliation discrepancy - latanoprost/timolol eye 
drops not prescribed 
M0132 23.3 Allergy status not recorded 
M0698 23.5 
Originally on clopidogrel - admitted with 'non-ST-elevation 
myocardial infarction'. Could be clopidogrel non-responder - 
switch to ticagrelor 
M0030 23.7 
Prescribed ciprofloxacin for 'spontaneous bacterial peritonitis' 
prophylaxis (long term) - suspended during admission whilst on 
alternative antibiotic treatment but not re-prescribed on discharge 
prescription 
W0135 23.7 
Medicines reconciliation discrepancy - enalapril not prescribed 
Prophylactic enoxaparin not prescribed  
W0437 23.8 Dose of prophylactic enoxaparin too high (based on weight) 
M0845 24.0 Teicoplanin dose too high (based on weight) 
W0350 24.1 
Medicines reconciliation discrepancy - dose of doxazosin too low 
Medicines reconciliation discrepancy - ramipril not prescribed 
M0336 24.4 
Medicines reconciliation discrepancy - amlodipine not prescribed 
Medicines reconciliation discrepancy - losartan not prescribed 
M0055 24.5 Medicines reconciliation discrepancy - letrozole dose too high 
W0418 24.8 
Patient transferred wards, medication (quetiapine) not transferred 
with patient 
W0040 24.9 
Patient's weight recorded incorrectly so prophylactic heparin 
dose prescribed incorrectly 
M0309 24.9 
Filgrastim dose too low (prescribed 250mcg daily, usual dose 
300mcg OD) 
M0769 25.2 
Medicines reconciliation discrepancy - bimatoprost eye drops not 
prescribed 
Medicines reconciliation discrepancy - salbutamol inhaler not 
prescribed 
Patient has 'chronic pulmonary obstructive disease' - but only 
treatment prescribed is salbutamol - review required 
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